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Abstract 
Spinal muscular atrophy (SMA) is a debilitating genetic disorder, characterised by homozygous 
loss of the survival of motor neuron 1 (SMN1) gene, resulting in insufficient levels of 
ubiquitously expressed survival of motor neuron (SMN) protein. The traditional picture of SMA 
as a neuromuscular disease is slowly being changed by the findings of systemic pathology in 
SMA patients. This is also one of the reasons why therapeutic strategies aimed at increasing 
the levels of functional SMN protein are not completely effective, since they would often 
target neuromuscular pathology only. Here, the research was focused on identifying and 
characterising new disease pathways in SMA that could potentially be used as therapeutic 
targets in SMA. In the first results chapter, six proteins, lamin A/C, UBA1, ANXA2, GAPDH, 
NCAM and GAP43, identified previously in a multi-study comparison as having consistent 
direction of differential expression across three proteomic studies of SMA, were investigated 
in SMA tissues and cells using western blotting. Of these, lamin A/C, UBA1, ANXA2 and GAPDH 
showed widespread dysregulation across a range of tissues from severe Taiwanese mouse 
model of SMA and in fibroblast cells from SMA patients, suggesting that each one of these 
proteins might have a role in SMA disease pathways. Selection of drugs that can target these 
proteins proved to be very challenging, and further efforts are needed to identify appropriate 
therapeutic strategies. In the second results chapter, the potential role for lamin A/C in SMA 
disease pathways was further highlighted by findings of mechanistic link between lamin A/C 
and UBA1, a known SMA modifier. Lamin A/C dysregulation might be especially relevant in 
the context of heart pathology, where increased levels of lamin A/C would likely stiffen the 
cardiomyocytes and impair normal heart function. In the third results chapter, multi-study 
comparison of published proteomic studies of amyotrophic lateral sclerosis (ALS) identified 
core protein changes in ALS tissues and cells, and biochemical investigation of two proteins, 
xiv 
 
ALDOA and GAPDH, highlighted defects in cell metabolism as an important disease mechanism 
in ALS. Of these, fifteen proteins were also differentially expressed across at least two 
proteomic studies of SMA, however, when investigated biochemically in SMA and ALS mouse 
spinal cords, these proteins showed very little evidence that two diseases converge on the 
same molecular mechanisms. When taken together, results presented here show that 
published proteomic studies contain a wealth of information that often get overlooked when 
examined in isolation. These datasets were exploited here to identify core proteins and 
molecular mechanisms that drive disease pathogenesis in SMA and ALS. Knowledge of general 
disease mechanisms may allow development of therapies that can systemically target 
peripheral pathology in SMA. For example, systemic restoration of lamin A/C levels might 
prove useful for correcting defects in a range of tissues, with an emphasis on stiff tissues like 
the heart and muscles, and when combined with an SMN-targeted approach, it might bring 
greater therapeutic benefit to SMA patients compared to SMN-targeted approach alone. In 
conclusion, several proteins identified in a multi-study comparison, including lamin A/C, 
GAPDH and ALDOA, were linked to different SMA and ALS disease pathways, providing 
evidence that multi-study comparison has the power to identify core disease-related protein 
changes. This thesis also opened a range of new questions that need to be addressed in the 
future work, including the selection of drugs that can restore defects in the expression or 
activity or target proteins. Many other proteins, identified in multi-study comparisons, could 
not be investigated here in more detail. These proteins may help to further expand the 
knowledge of SMA and ALS disease pathways and therefore demand further experimental 
attention.  
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1.1. Spinal muscular atrophy 
Spinal muscular atrophy (SMA) is debilitating neuromuscular disorder, genetically 
characterised by functional loss of the survival of motor neuron 1 (SMN1) gene (Wirth et al., 
1999), and the most common genetic cause of infantile death that shows the autosomal 
recessive mode of inheritance (Wirth, Brichta and Hahnen, 2006; D’Ydewalle and Sumner, 
2015). SMA is characterised by the loss of alpha motor neurons in anterior horn of the lumbar 
spinal cord, leading to progressive weakening and atrophy of voluntary muscles of the limbs 
and trunk (Monani, 2005). With an incidence of 1:6000 to 1:10000 births, and a carrier 
frequency between 1:35 to 1:60, SMA is one of the most frequent autosomal recessive 
disorders (Ogino et al., 2002; Prior, 2010). Homozygous functional loss of SMN1 gene is SMA 
determining factor (Lefebvre et al., 1995), however,  disease severity is modulated by the 
number of copies of survival of motor neuron 2 (SMN2) gene (Feldkötter et al., 2002; Wirth et 
al., 2006).  
The most significant clinical symptoms in SMA are tremor of fingers and hands, absence of 
deep tendon reflex, hyporeflexia, fasciculation of the tongue muscle, hypotonia and 
symmetrical muscle weakening (Simic, 2008). Weakness is usually first expressed in proximal 
voluntary muscles of limbs. Distal voluntary muscles of limbs and eventually the entire trunk 
gets affected during disease progression, while the diaphragm and extraocular muscles 
remain spared until the late stages of disease (Simic, 2008). Patients are usually divided into 
four groups (SMA I-IV) based on age of disease onset and motor function (Dubowitz, 1995; 
Zerres, Klaus; Rudnik-Schöneborn, 1995). There is one additional group, the most severe type 
(SMA 0) (Dubowitz, 1999), with disease onset at neonatal stage. Movement impairments in 
those patients can be detected even in prenatal stage, and if untreated, do not survive beyond 
first month (Mercuri, Bertini and Iannaccone, 2012; D’Ydewalle and Sumner, 2015). 
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Approximately 50% of the patients have severe type I SMA (Werdnig-Hoffmann disease) 
(Wirth, Brichta and Hahnen, 2006; Lunn and Wang, 2008). In the natural history of disease 
progression, symptom onset is usually before 6 months and death around the age of 2. The 
term “floppy infant” is often used for clinical description of these children because of 
generalized muscle weakness and hypotonia (Wirth, Brichta and Hahnen, 2006). Children are 
never able to sit or walk, have problems with breathing (paradoxical breathing) and feeding. 
Airway impairment increases incidence of respiratory infections, an important cause of death 
in type I SMA patients (Wirth, Brichta and Hahnen, 2006; Lunn and Wang, 2008). In type II 
SMA (intermediate form), the first symptoms appear between 6-18 months (Lunn and Wang, 
2008; Mercuri, Bertini and Iannaccone, 2012). Children can sit but are never able to walk, often 
develop kyphoscoliosis and tremors, and have problems with swallowing and breathing. In the 
natural history of disease progression death usually occurs in adolescence or early adulthood 
due to respiratory failure (Lunn and Wang, 2008; Mercuri, Bertini and Iannaccone, 2012). In 
SMA III (Kugelberg-Welander disease) lifespan is not reduced (Wirth, Brichta and Hahnen, 
2006). All patients can sit and walk, but motor function capabilities differ between two 
subgroups (IIIa and IIIb). In SMA type IIIa symptom onset is before the age of 3, and less than 
50% of the patients can still walk at the age of 20. In SMA type IIIb symptom onset is after the 
age of 3, and around 90% of the patients can still walk at the same age (Wirth, Brichta and 
Hahnen, 2006). Type IV SMA (adult form) has later onset, around the age of 30. Patients 
express mild motor problems, but retain ability to walk and do not have reduced lifespan 
(Lunn and Wang, 2008). 
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1. 2. SMA determining gene: survival of motor neuron (SMN) 
In 1990, the location of the SMA determining gene was linked to chromosome 5 by two 
separate groups, Gilliam’s (Gilliam et al., 1990) in New York and Melki’s (Melki et al., 1990) in 
Paris. Five years later, an inverted duplication in 5q13 was identified, leading to isolation and 
characterization of SMN gene (Lefebvre et al., 1995; Bürglen et al., 1996). The SMN gene is 
highly conserved across species, however, duplication of about 500 kb long sequence 
containing SMN gene is specific for primates, where humans only developed two different 
SMN copies (SMN1 and SMN2) (Rochette, Gilbert and Simard, 2001). While SMN1 gene (SMNT) 
is present in one copy and located at the telomeric part of the sequence, the number of copies 
of centromeric SMN2 (SMNC) gene varies (Wirth, Garbes and Riessland, 2013). SMN genes are 
highly homologous, contain ten exons and code for the same 294 amino acid protein (Lefebvre 
et al., 1995; Bürglen et al., 1996). Several point mutations have been identified in SMN2 gene 
that distinguish it from SMN1 gene (Singh and Singh, 2018), however, only C to T substitution 
at the position six in exon seven is in the coding region of the gene (Lorson et al., 1999). 
Although the mutation is translationally silent, it leads to splicing defects and production of 
SMN transcripts lacking exon seven (SMNΔ7) (Lunn and Wang, 2008). Consequently, protein 
products are truncated, non-functional and prone to fast degradation. Only 10% of the spliced 
SMN2 transcripts code for the full-length functional SMN protein (Lunn and Wang, 2008) 
(Figure 1.1A). 
 
In healthy individuals, contribution of the SMN2 gene in protein production is minor, however, 
when SMN1 is depleted low levels of functional SMN protein become essential for prenatal 
development and regulation of disease severity (Taylor et al., 1998). An inverse correlation 
between the number of SMN2 copies and disease severity is usually observed (Feldkötter et 
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al., 2002; Wirth et al., 2006). Thus, patients with neonatal onset SMA (SMA 0) carry one SMN2 
copy, type I SMA patients usually carry two copies, type II SMA patients three copies, type III 
SMA patients three or four copies and type IV SMA patients four to six copies of SMN2 (Wirth, 
Garbes and Riessland, 2013) (Figure 1.1B). 
 
Figure 1. 1. Genomic structure of SMN genes and genome-phenotype correlation. (A) C to T mutation in exon 
seven of the SMN2 gene causes alternative splicing of the pre-mRNA and skipping of exon 7. Truncated SMNΔ7 
proteins are unstable, non-functional and prone to degradation. (B) SMN2 copy number inversely correlates 
with disease severity in SMA. Image created with BioRender.com. 
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1.2.1. Splicing mechanism in SMN transcripts 
Correct splicing of SMN transcript is regulated by a large number of specific transcript 
sequences (cis elements), that can be stimulating, exonic splicing enhancers (ESEs) and 
intronic splicing enhancers (ISEs), and inhibitory, exonic splicing silencers (ESSs) and intronic 
splicing silencers (ISSs) (Wirth, Brichta and Hahnen, 2006). Cis elements get recognised by 
splicing factors (trans elements), including the serine-arginine-rich (SR) proteins and 
heterogeneous nuclear ribonucleoproteins (hnRNPs). SR protein SF2/ASF, for example, 
recognises SE1, an important ESE that is localized at the 5' end of SMN exon seven (Wirth, 
Brichta and Hahnen, 2006). An early study, using ESE motif-prediction tools, proposed that 
the C to T mutation in SMN2 exon seven is located within the heptamer sequence of the SE1, 
which disrupts binding of the SF2/ASF splicing factor to ES1 (Cartegni and Krainer, 2002). 
Consequently, exon seven is not recognised by the splicing machinery which results in 
generation of SMNΔ7 transcripts (Cartegni and Krainer, 2002). Soon after that, it has become 
clear that SF2/ASF is not responsible, at least not solely, for SMN2 exon seven skipping. For 
example, depletion of SF2/ASF splicing factor in DT40-ASF cells had no effect on exon 7 splicing 
in either SMN1 or SMN2 transcripts (Kashima and Manley, 2003). The same study proposed 
the idea that C to T mutation in SMN2 exon seven generates specific ESS for hnRNP1 A1, a 
strong splicing inhibitor, that is responsible for SMN2 exon seven skipping (Kashima and 
Manley, 2003). Indeed, incubation of Hela nuclear extracts with purified 5’ half RNA fragments 
of SMN1 and SMN2 exon 7 resulted in selective binding of hnRNP A1 to the exon seven of the 
SMN2 transcript (Kashima and Manley, 2003). In addition, inhibition of hnRNP A1, hnRNP A2 
and hnRNP A1/A2 in combination enhanced inclusion of SMN2 exon seven into messenger 
ribonucleic acid (mRNA) in Hela cells, but did not affect splicing efficiency of SMN1 exon seven 
(Kashima and Manley, 2003). Further studies identified several hnRNP A1/A2 binding sites that 
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have a role in SMN2 exon 7 splicing, including one in intron 6 (between nucleotide 41 to 55) 
(Hua et al., 2008) and one in intron seven (between nucleotide 10 and 24) named ISS-N1 (Singh 
et al., 2006; Hua et al., 2008). For example, deletion of ISS-N1 region in Neuro-2a, NSC-34, SK-
N-SH, P-19 and HEK293 cell lines induced SMN2 exon seven inclusion in mRNA (Singh et al., 
2006). In addition, simultaneous deletion of ISS-N1 and abrogation of one of the stimulatory 
cis elements, including intronic element 2, Tra2-ESE, Conserved tract and a critical guanosine 
residue at the first position of exon 7, promoted SMN2 exon seven inclusion into mRNA, thus 
showing the critical role for ISS-N1 in SMN2 exon seven splicing defects (Singh et al., 2006). In 
line with this, antisense oligonucleotide against ISS-N1 increased SMN2 exon seven inclusion 
into mRNA (Singh et al., 2006), which is also the mechanism of action of an approved antisense 
oligonucleotide drug nusinersen (described in more detail in section 1.5.1.1) (Ottesen, 2017). 
Other SMN2 splicing regulators have been described including, for example, splicing inhibitor 
Sam68 that was shown to bind the C to T mutation site in exon seven in HEK293T cells (Pedrotti 
et al., 2010). Indeed, mutations that affect RNA binding activity of Sam68 induced SMN2 exon 
seven inclusion into mRNA in HEK293T cells and SMA patient fibroblasts, and SMN protein 
production in SMA patient fibroblasts (Pedrotti et al., 2010). In addition, positive splicing 
factors, Htra2-β1 (Hofmann et al., 2000) and hnRNP M (Cho et al., 2014), were shown to 
promote SMN2 exon seven inclusion by binding to the ESE region in SMN exon seven. Other 
positive splicing factor, including hnRNP G, TDP-43 and SRp30c were shown to promote SMN2 
exon seven inclusion by direct interaction with other factors like Htra2-β1 (Hofmann and 
Wirth, 2002; Young et al., 2002; Bose et al., 2008). A schematic diagram, showing SMN exon 
seven splicing regulation, is presented in Figure 1.2. 
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Figure 1. 2. SMN2 exon 7 splicing regulation. Schematic diagram showing known cis and trans splicing factors, 
within (A) exon seven and (B) introns six and seven, that modulate SMN2 exon 7 splicing. Positive (+) and 
negative (-) splicing elements are indicated, together with exonic (upper case) and intronic (lower case) 
sequences. C to T (C to U) mutation at position six of exon seven is indicated by black arrow. Additional SMN2-
specific single nucleotide substitutions are indicated by red arrow (Singh and Singh, 2018). 
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1.2.2. Functions of the SMN protein 
SMN controls different aspects of RNA metabolism including transcription, pre-mRNA splicing, 
snRNP assembly, mRNA trafficking, telomerase activity and translation [reviewed in (Singh et 
al., 2017)]. 
 
1.2.2.1. SnRNP assembly 
SMN has well established function in assembly of small nuclear ribonucleoproteins (snRNPs) 
that are involved in splicing of pre-mRNA (Morris, 2008). SnRNAs are synthesised in the 
nucleus and transported to the cytoplasm where they interact with SMN complex. SMN 
complex is comprised of SMN, gemin proteins (2-8) and unr interacting protein (unrip) (Baccon 
et al., 2002; Carissimi et al., 2006; Battle et al., 2007). In an adenosine triphosphate (ATP)-
dependent manner, SMN complex attaches snRNA to heptameric ring of Smith (Sm) proteins 
to assemble the snRNPs (Raker et al., 1999). After assembly, SMN complex transports snRNPs 
to the nucleus, where they get released into the Cajal bodies (CB, coiled bodies) for further 
modification (Narayanan et al., 2004). The interaction between coilin, an essential protein of 
CBs, and SMN complex seems to be involved in snRNP release into the CB, and consequent 
release and recycling of the SMN complex to the cytoplasm (Hebert et al., 2001). 
 
The efficiency of SnRNP assembly strongly correlates with disease severity and survival in SMA 
mice, where spinal cords from the most severe mice showed the lowest capacity for snRNP 
assembly compared to less severe SMA mice or healthy controls (Workman et al., 2009). 
Dysregulation of snRNP assembly caused splicing defects in a range of tissues including spinal 
cord, brain and kidney from SMA mice (Gabanella et al., 2007; Zhang et al., 2008, 2013; 
Bäumer et al., 2009; Huo et al., 2014). In addition, these changes seem to be tissue/cell type 
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specific (Zhang et al., 2008, 2013), and correlate with disease severity (Gabanella et al., 2007; 
Bäumer et al., 2009). For example, motor neurons and glial cells from SMA mice both showed 
widespread dysregulation of mRNA levels, however, very few dysregulated transcripts were 
common to both cell types (Zhang et al., 2013). 
 
Defective snRNP assembly was proposed as one of the explanations for selective lower motor 
neuron vulnerability. It was suggested that motor neurons are more sensitive to defects in 
snRNP assembly, and consequent pre-mRNA splicing, because of their size and higher energy 
demands (Battaglia et al., 1997). However, other large, high energy demanding cells, like 
cortical motor neurons and sensory neurons, do not show the same vulnerability, which 
makes this theory questionable (Monani, 2005). Tissue specific splicing changes, especially in 
the minor spliceosome snRNAs, may thus provide an alternative view of how defects in SMN 
housekeeping role can lead to specific motor neuron pathology. It has been suggested that 
motor neurons may preferentially use minor spliceosomes in a greater manner then other 
cells, which would make them more vulnerable in an environment of decreased SMN (Tu et 
al., 2017). Indeed, reduction of minor spliceosome snRNAs, including U11, U12, and U4atac, 
was identified in the brain, spinal cord and heart tissue from SMA mice, while in skeletal 
muscles and kidneys, the same snRNAs stayed unaffected (Zhang et al., 2008). 
 
1.2.2.2. Axonal specific role of SMN 
Other studies, showing SMN expression in neurites, growth cones, and filopodia-like 
structures in neuronal and glial cells, proposed a motor neuron specific function for SMN 
(Sharma et al., 2005). Zhang et al. demonstrated cytoskeleton-dependent bidirectional 
transport of SMN granules in neurites and axonal processes of rat spinal cord and chick 
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forebrain cultured neurons, and showed colocalization of SMN and ribosomal RNAs in growth 
cones of rat spinal cord cultured neurons (Zhang et al., 2003). A number of RNA-binding 
proteins were shown to interact with SMN, all of which have a known role in transport of 
axonal mRNAs (Rossoll et al., 2003; Akten et al., 2011; Fallini et al., 2011; Hubers et al., 2011). 
Correct localization and rapid translation of axonal mRNAs is necessary for regulation of axon 
growth and function. For example, a role for heterogeneous nuclear ribonucleoproteins R 
(hnRNP R) in the regulation of β-actin dynamics was identified in PC12 cells, where hnRNP R 
overexpression resulted in accumulation of β-actin mRNA in the growth cones of PC12 cells, 
whereas β-actin mRNA localization to growth cones was completely abolished in PC12 cells 
expressing mutant hnRNP R (Rossoll et al., 2003). In addition, reduced accumulation of both 
hnRNP R and β-actin was identified in motor neurons from a mouse model of SMA,  suggesting 
that interaction between SMN and hnRNP R might be necessary for the transport and 
localization of β-actin mRNA to growth cones (Rossoll et al., 2003). Indeed, overexpression of 
SMN and hnRNP R lead to substantial accumulation of β-actin mRNA in growth cones of PC12 
cells and increase in neurite growth (Rossoll et al., 2003). Other RNA-binding proteins, 
including HuD, have shown direct interaction with SMN in mouse motor neurons and motor 
neuron-derived MN1-cells (Akten et al., 2011; Fallini et al., 2011; Hubers et al., 2011). HuD 
protein and poly(A) mRNA were both reduced in axonal compartment of mouse motor 
neurons following SMN knockdown (Fallini et al., 2011). Cpg15 mRNA, for example, was shown 
to interact directly with both SMN and HuD in mouse cortical neurons (Akten et al., 2011). 
Reduction of cpg15 mRNA was identified in SMN-deficient mouse cortical neurons, and 
overexpression of cpg15 partially rescued axonal growth defects in zebrafish model of SMA 
(Akten et al., 2011). All the evidence suggests that SMN might be involved in axonal mRNA 
trafficking by regulating assembly and transport of axonal RNPs. Although this proposed 
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function strongly correlates with a function in snRNP assembly, an essential snRNP 
component, Sm ring, is not present in axonal SMN granules, thus indicating that nucleus-
specific and axon-specific functions of SMN are independent (Fallini, Bassell and Rossoll, 
2012).  
 
1.3. Clinical manifestation of SMA 
1.3.1. Neuromuscular pathology 
Neuromuscular pathology in SMA has been associated with intrinsic muscle and motor neuron 
defects. For example, axonal terminals from SMNΔ7 mouse model of SMA failed to develop 
proper terminal branching, and appeared swollen with accumulation of neurofilament (NF) 
from a pre-symptomatic stage of the disease (Kariya et al., 2008). In addition, defects in 
acetylcholine receptor (AChR) clustering have been identified in diaphragm from embryonic 
SMNΔ7 mice, suggesting neuromuscular junction (NMJ) maturation defects (Kariya et al., 
2008). Similar defects were observed in a zebrafish model of SMA, where animals presented 
with shorter axons that had abnormal branching (Mcwhorter et al., 2003). A reduction in 
synaptic vesicle protein 2 (SV2), which is found in presynaptic vesicles, was observed in SMA 
zebrafish, suggesting that SMN reduction also affects synaptic transmission (Boon et al., 
2009). Restoration of SMN protein levels rescued motor axon and NMJ defects (Boon et al., 
2009; Hao et al., 2013), and increased zebrafish survival when introduced early during 
development (Hao et al., 2013). Kariya et al. generated transgenic mouse model of SMA 
(SMN2;CreER;SmnF7/-) carrying floxed SMN allele (SmnF7) that can be inactivated following Cre-
mediated recombination (Kariya et al., 2014). This was done to examine the consequences of 
SMN depletion in different timepoints of mouse postnatal development (Kariya et al., 2014). 
Early SMN depletion induced severe SMA phenotype and NMJ defects, whereas SMN 
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depletion in adult animals delayed SMA pathology, thus replicating disease spectra in SMA 
patients. In addition, SMA pathology in adult mice was further ameliorated following focal 
NMJ injury (Kariya et al., 2014). These observations indicate that high levels of SMN protein 
during early postnatal development are necessary for NMJ maturation, after which 
requirements for SMN drastically decreases, and in adulthood SMN is necessary for the 
maintenance and repair of NMJs (Kariya et al., 2014). Interestingly, tissue specific reduction 
of SMN levels results in different phenotypes in mouse models (Frugier et al., 2000; Cifuentes-
Diaz et al., 2001). For example, motor neuron specific depletion of SMN levels resulted in both 
motor neuron degeneration and muscle atrophy (Frugier et al., 2000). Depletion of SMN levels 
specifically in skeletal muscles resulted in severe muscle dystrophy phenotype, evidenced by 
necrotic muscle fibers and infiltration of connective tissue with mononuclear cells, however, 
no evidence of motor neuron pathology was observed in these mice (Cifuentes-Diaz et al., 
2001). This suggests that muscle atrophy is not purely a product of motor neuron 
degeneration, and intrinsic muscle defects contribute to impairment of motor functions in 
SMA (Cifuentes-Diaz et al., 2001). 
 
1.3.2. Systemic pathology 
Although SMA is traditionally classified as neuromuscular disorder, it is becoming more 
evident that SMN depletion influences a variety of different cells and tissue types (Shababi, 
Lorson and Rudnik-Schöneborn, 2014). Indeed, a review study, looking at the health insurance 
claims from SMA patents, confirmed that many SMA patients experience non-neuromuscular 
problems, in cardiovascular, gastrointestinal, metabolic, reproductive and skeletal system, 
even before the symptom onset (Lipnickid et al., 2019). SMA-associated pathologies are 
presented in Figure 1.3.  
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1.3.2.1. Pathological changes in the brain and non-motor neuron cells 
Brain 
SMN was highly expressed in the developing foetal brain (Briese et al., 2006), rat spinal cord 
and chick forebrain during embryonic development (Zhang et al., 2003), so it would seem 
logical that other parts of nervous system, besides motor neurons, should be affected by its 
depletion. Indeed, morphological changes in brain regions that express high levels of SMN, 
including hippocampus and hippocampal dentate gyrus, have been identified from pre-
symptomatic stage of the disease in severe mouse model of SMA (Wishart et al., 2010). The 
size of hippocampus and hippocampal dentate gyrus was significantly reduced in SMA mice 
compared to controls (Wishart et al., 2010). Decreased size of SMA mice hippocampus was 
associated with lower number of proliferating cells (Wishart et al., 2010). This was also 
confirmed by quantitative proteomics, showing dysregulation of proteins connected to cell 
proliferation, migration and development in the hippocampus from late-symptomatic SMA 
mice (Wishart et al., 2010). Furthermore, degeneration of thalamus was observed by magnetic 
resonance (MR) imaging in severe SMA patient (Ito et al., 2003), and by neuropathological 
examination in five type I SMA patients  (Harding et al., 2015). 
 
Sensory neurons 
Degenerative changes were also reported in sensory neurons from type I SMA patients 
(Harding et al., 2015), and reduction in the number of proprioceptive-motor neuron synapses 
was identified in SMA mouse spinal cords from an early stage of the disease (Ling et al., 2010; 
Mentis et al., 2011). At the molecular level, defects in sensory-motor neuron connectivity have 
been connected to the ubiquitin-like modifier activating enzyme 1 (UBA1)- glycine-tRNA ligase 
(GARS) pathway (Shorrock et al., 2018). Reduced levels of UBA1 were previously identified in 
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zebrafish and mouse models of SMA, and in induced pluripotent stem cell (iPSC)-derived 
motor neurons from patients with type I SMA (Wishart et al., 2014; Powis et al., 2016), and 
pharmacological or genetic suppression of UBA1 was sufficient to induce an SMA-like 
phenotype in zebrafish, thus demonstrating that UBA1 directly contributes to SMA disease 
pathways (Wishart et al., 2014). In a study by Shorrock et al., upregulation of GARS levels was 
identified in spinal cord tissues from a severe mouse model of SMA (Shorrock et al., 2018). 
Interestingly, upregulation of GARS levels was restricted to dorsal root ganglia (DRG) that 
contain sensory neuron bodies (Shorrock et al., 2018), and mutations in GARS are known to 
cause Charcot-Marie-Tooth disease Type 2D (CMT2D) that is typically characterised by sensory 
impairment (Antonellis et al., 2003). Quantitative analysis of mouse spinal cord sections 
revealed reduction in the number of sensory neurons in DRG from SMA mice, and 
overexpression of UBA1 was sufficient to restore GARS levels in DRGs and correct sensory 
neuron defects in SMA mice (Shorrock et al., 2018). It was proposed that dysregulation of 
UBA1/GARS pathways is responsible, at least in part, for disrupted sensory neuron fate and 
altered sensory-motor connectivity in SMA mice (Shorrock et al., 2018). 
 
Schwann cells 
An increased number of unmyelinated intercostal nerves, and intercostal nerves with thinner 
myelin sheet was identified in ‘severe’ (Smn-/-; SMN2tg/tg) and Taiwanese (Smn-/-; SMN2tg/0) 
mouse models of SMA, and this morphology was evident at early symptomatic stage of the 
disease in Taiwanese mice (Hunter et al., 2014). In addition, immature Schwann cells from 
SMA mice failed to respond to differentiating clues in vitro (Hunter et al., 2014). Myelination 
defects were corrected in vitro in murine Schwann cells (Hunter et al., 2014), and in vivo in a 
mouse model of SMA (Hunter et al., 2016) by overexpression of wild type SMN. Mass 
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spectrometry analysis revealed widespread defects in the proteome of Schwann cells derived 
from SMA mice, with a number of dysregulated proteins being linked to ubiquitination 
pathways (Aghamaleky Sarvestany et al., 2014). For example, reduction of UBA1 levels was 
confirmed by immunostaining in cultured Schwann cells from SMA mice, and pharmacological 
inhibition of UBA1 in murine Schwann cells was sufficient to disrupt the expression of myelin 
protein zero (MPZ), an important regulator of myelination process (Aghamaleky Sarvestany et 
al., 2014).   
 
Astrocytes  
Astrocytes are specialised glial cells that regulate central nervous system (CNS) blood flow, 
provide nutrient and oxygen supply for neurons, participate in the maintenance of synapses 
and modulate synaptic transmission. Astrocytes too have been implicated in SMA 
pathogenesis. For example, restoration of SMN levels specifically in astrocytes improved 
survival and motor functions in severe (SMNΔ7) and intermediate (smn2B-) mouse models of 
SMA (Rindt et al., 2015). Interestingly, an increased number of fully innervated NMJs and 
improved sensory-motor neuron connectivity were identified in SMA mice following 
restoration of SMN levels, however, the total number of spinal cord motor neurons did not 
change (Rindt et al., 2015). This suggested that restoration of SMN levels in astrocytes acts by 
stabilising functions of remaining motor neurons rather than stopping motor neuron death 
(Rindt et al., 2015). 
Activated astrocytes were identified in spinal cord from SMA patients (Rindt et al., 2015) and 
SMNΔ7 mouse model of SMA (Rindt et al., 2015; Ohuchi et al., 2019), indicating that SMN-
deficient astrocytes might contribute to SMA pathogenesis by promoting inflammation. 
Indeed, increased expression of proinflammatory cytokines, including interleukin 1 beta (IL-
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1β), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNFα), was identified in the spinal 
cord from SMA patients and SMNΔ7 mouse model of SMA, (Rindt et al., 2015), and restoration 
of SMN levels specifically in astrocytes decreased the expression of both IL-1β and IL-6 in SMA 
mouse spinal cord (Rindt et al., 2015). Consistent with this finding, increased expression and 
secretion of another modulator of immune response, microRNA (miR)-146a, was detected in 
iPSC-derived astrocytes from type I SMA patients and in spinal cord from SMNΔ7 mice (Sison 
et al., 2017). Treatment of healthy iPSC-derived motor neurons with synthetic miR-146 or 
conditioned medium from SMA patient iPSC-derived astrocytes was sufficient to induce motor 
neuron loss, which was blocked by addition of miR-146a inhibitor (Sison et al., 2017). 
 
1.3.2.2. Skeletal system abnormalities 
Skeletal problems such as the scoliosis, pelvic obliquity and hip dislocation were commonly 
reported among type I-III SMA patients (Bach, 2007; Fujak et al., 2013). In addition, a high 
frequency of bone fractures was reported in SMA patients (Fujak et al., 2010; Vai et al., 2015; 
Wasserman et al., 2017), which coincided with decreased bone mineral density (BMD) (Khatri 
et al., 2008; Vai et al., 2015; Wasserman et al., 2017). Indeed, negative regression observed 
between two bone metabolism markers, where 25-OH vitamin D showed decreased and 
parathyroid hormone (PTH) increased levels, confirmed these findings (Vai et al., 2015). 
Decreased levels of 25-OH vitamin D negatively influence bone metabolism by increasing the 
expression of PTH, which in turn increases bone resorption (Vai et al., 2015). In addition, 
increased levels of bone resorption marker CTx were identified in type II and III SMA patients 
in two separate studies (Vai et al., 2015; Baranello et al., 2019), and increased osteoclast 
activity and bone resorption, and decreased osteoblast differentiation were identified in 
vertebrae from a severe mouse model of SMA (Shanmugarajan et al., 2009). These studies 
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suggest that SMA patients are at higher risk of osteopenia, osteoporosis and fractures, and 
further studies are clearly warranted to elucidate the precise molecular mechanism of bone 
metabolism dysregulation in SMA. This would allow identification of novel therapeutic targets 
and better management of bone fragility in SMA (Baranello et al., 2019).  
 
1.3.2.3. Cardiovascular defects 
A systematic review of the literature in 2017 found 58 studies that reported on a total of 264 
SMA patients with cardiac abnormalities (Wijngaarde et al., 2017). Common findings among 
the 77 patients with the most severe type of SMA were structural pathology, observed mainly 
in the septum and/or cardiac outflow tract, and electrocardiogram (ECG) abnormalities, the 
most common of which was bradycardia (Wijngaarde et al., 2017). All of the 63 type II SMA 
patients identified in the literature search had ECG abnormalities, while the 124 patients with 
Type III SMA had cardiac rhythm disorders and/or structural abnormalities. Structural heart 
abnormalities have also been identified in severe and intermediate mouse models of SMA, 
including thinning of ventricle walls and interventricular septum (Shababi et al., 2010; Maxwell 
et al., 2018) and dilation of ventricles (Heier et al., 2010; Bogdanik et al., 2015; Maxwell et al., 
2018). In addition, cardiac fibrosis was frequently reported in SMA patients and mouse models 
of SMA (Wijngaarde et al., 2017), and it was detected at a pre-symptomatic stage of the 
disease in severe and intermediate mouse models of SMA (Shababi et al., 2010; Cobb et al., 
2013). All of these defects mimic dilated cardiomyopathy, the functional consequence of 
which is systolic heart failure where the heart cannot pump blood properly (Maxwell et al., 
2018). This would be evidenced by decreased ejection fraction and blood pooling in ventricles, 
both of which were identified in SMA mice (Heier et al., 2010; Shababi et al., 2012; Bogdanik 
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et al., 2015; Maxwell et al., 2018) and SMA patients (Yasuma, Kuru and Konagaya, 2004; Roos 
et al., 2009; Iwahara et al., 2015). 
 
At the cellular level, cardiomyocytes from SMA mice were highly disorganised, meaning they 
failed to develop typical spiral organization of the middle heart muscle layer that is necessary 
for transduction of electrical impulse and ventricle contraction (Maxwell et al., 2018). In 
addition, trabeculae, that form during embryonic development to increase surface area for 
nutrient uptake, failed to compact in the SMA heart which is necessary to increases the mass 
of the heart muscle (Maxwell et al., 2018). Disorganisation of cardiomyocytes was connected 
to defects in the basement membrane, evident by decreased and non-uniform collagen IV 
staining (Maxwell et al., 2018). In addition, increased oxidative stress, identified at pre- and 
early-symptomatic stages of the disease in two severe mouse models of SMA (Shababi et al., 
2010; Maxwell et al., 2018), was connected to cardiomyocyte apoptosis, that was observed at 
early symptomatic stage of the disease in the heart from severe Taiwanese mice (Maxwell et 
al., 2018). Another factor that is likely contributing to cardiomyocyte death in SMA hearts is 
decreased microvasculature that was evident at early-symptomatic stage of the disease in 
Taiwanese SMA mice (Maxwell et al., 2018).  
 
Another group observed vascular defects in proximal skeletal muscles and spinal cord in two 
severe mouse models (Taiwanese and SMNΔ7), and in proximal skeletal muscles of SMA I and 
SMA II patients (Somers et al., 2016). The rate of vascularization increases with age in 
unaffected control muscles, however, SMA muscles do not show the same developmental 
pattern. For example, patient muscles showed a 10-fold decrease in the rate of vascularization 
at the age of three compared to their respective controls, and a 50% decrease in 
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vascularization was observed in muscles from two severe mouse models of SMA at late-
symptomatic stage of the disease (Somers et al., 2016). The same developmental defects in 
vascularization were observed in spinal cords from two severe mouse models of SMA, and 
vascular defects, accompanied by hypoxia, were detected at an early symptomatic stage of 
the disease in Taiwanese SMA mice (Somers et al., 2016). In addition, impaired vasculature is 
thought to be responsible for necrosis of the fingers and toes in severe type I SMA patients 
(Rudnik-Schöneborn et al., 2010). 
 
1.3.2.4. Altered metabolism 
A progressive decrease in the number of insulin producing β cells and a parallel increase in the 
number of glucagon producing α cells was reported in the pancreas of Smn2B/- mouse model 
of SMA, starting from pre-symptomatic stage of the disease (Bowerman et al., 2012). Similar 
findings were observed in type I SMA patients, where pancreatic islets contained 
predominantly glucagon producing α cells (Bowerman et al., 2012). In addition, hyperglycemia 
and hyperglucagonemia were identified at pre- and early symptomatic stages of the disease 
in Smn2B/- mouse model, which by the end stage of the disease resulted in glucose intolerance, 
suggesting developmental problems in the pancreas (Bowerman et al., 2012).  
 
Abnormal fatty acid metabolism was observed in severe SMA patients (Tein et al., 1995; 
Crawford et al., 1999; Deguise et al., 2019) and in a mouse model of SMA (Deguise et al., 
2019). The increased levels of abnormal fatty acid metabolites, identified in type I and II SMA 
patient plasma and urine (Tein et al., 1995; Crawford et al., 1999), were associated with 
compromised activity of several enzymes involved in fatty acid metabolism, including L-3-
hydroxyacyl-CoA dehydrogenase (SCHAD), long-chain L-3-hydroxyacyl-CoA dehydrogenase 
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(LCHAD), acetoacetyl-CoA thiolase and 3-ketoacyl-CoA thiolase (Tein et al., 1995). In addition,  
accumulation of fat in the liver (steatosis) was identified in type I SMA patients and in SMNΔ7 
and Smn2B/- mouse models of SMA (Deguise et al., 2019). Morphological examination of the 
liver from Taiwanese SMA mice showed disorganisation of sinusoids, accumulation of 
immature red blood cells (RBC) within the sinusoids and  iron deposition, all of which indicate 
developmental liver problems (Szunyogova et al., 2016). In addition, an increased number of 
megakaryocytes was identified in the liver from SMA mice, which resulted in accumulation 
and clumping of platelets in the liver (Szunyogova et al., 2016). All evidence suggest that SMN 
is required for normal liver development, since SMN depletion resulted in abnormal fatty acid 
metabolism and persistent haematopoiesis, which is typical for embryonic liver (Szunyogova 
et al., 2016).  
 
1.3.2.5. Compromised renal function 
Pathological changes were detected in kidney tissue from type I SMA patients, including 
tubular injury, calcifications and fibrosis, and calcifications were accompanied by T-cell and 
macrophage accumulations, indicating inflammatory response (Nery et al., 2019). In addition, 
type I SMA patients showed decreased serum creatinine, cystatin C (CysC) and sodium levels, 
high glucose and calcium levels, and granular casts and amorphous crystals in the urine, all of 
which indicate renal tubular dysfunction (Nery et al., 2019). Renal abnormalities, including 
decreased circulating creatinine, blood urea nitrogen, albumin, calcium and chloride, were 
also observed in Smn2B/− mice at a symptomatic stage of the disease, thus showing that renal 
dysfunction in conserved pathology in SMA (Nery et al., 2019). 
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1.3.2.6. Immune system dysregulation 
Compromised spleen development was identified in severe (Taiwanese and SMN-/-; SMN2) 
and intermediate (Smn2B- ) mouse models of SMA, as evidenced by the failure of the spleen to 
grow and develop mature morphology (Deguise et al., 2017; Khairallah et al., 2017; Thomson 
et al., 2017). During normal postnatal development, homogenous spleen tissue differentiates 
into distinct red and white pulp, and the spleen develops defined capsule and trabeculae 
(Thomson et al., 2017). In contrast, spleens from SMA mice maintained homogenous 
morphology throughout development, with no segregation between red and white pulp 
(Deguise et al., 2017; Khairallah et al., 2017; Thomson et al., 2017), and failed to develop 
defined capsule and trabeculae (Thomson et al., 2017). Pathological changes in the spleen 
were also confirmed in approximately 50% of type I SMA patients (Thomson et al., 2017). 
Morphological abnormalities in the thymus have been observed in the symptomatic stage of 
the disease in severe (SMN-/-; SMN2) and intermediate (Smn2B- ) mouse models of SMA, 
including decreased size, thinner cortex, reduced cell content, and increased number of 
apoptotic bodies and tangible body macrophages (Deguise et al., 2017). Molecular analyses 
revealed reduced numbers and altered localization of B- lymphocytes in the spleen from 
intermediate Smn2B/- (Deguise et al., 2017) and severe Taiwanese (Thomson et al., 2017) 
mouse models of SMA, and a general reduction in the number of circulating lymphocytes was 
identified in the blood from severe SMA mice (Thomson et al., 2017). Diffuse distribution and 
expression pattern of T cells was also evident in the spleen from Smn2B/- mice (Deguise et al., 
2017). 
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Figure 1. 3. Systemic SMA pathology. Depletion of SMN causes structural and functional defects in a range of 
organs and organ systems. Image created with BioRender.com. 
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1.4. SMA models 
Several animal models have been used in SMA research, including Caenorhabditis elegans, 
Drosophila melanogaster, zebrafish, mice (Edens et al., 2015) and pigs (Holm, Alstrup and Luo, 
2016).  
 
1.4.1. Caenorhabditis elegans 
The nematode, Caenorhabditis elegans, carries one SMN gene, SMN-1, whose protein product 
shows 36% homology with the human SMN ortholog (Bertrandy et al., 1999). A nematode 
model of SMA was created by deletion of SMN-1 allele (ok355), where an otherwise lethal 
mutation is rescued by the presence of maternal SMN-1 protein (Briese et al., 2009). Mutant 
nematodes develop up to late larval stage when maternal SMN-1 protein levels decrease 
below critical levels, leading to developmental arrest, motoric defects and early death at late 
larval stage (Briese et al., 2009). Created mutants cannot completely mimic the SMA 
phenotype, but they can be used to study the response of different tissues to decreased SMN-
1 levels, or as a platform for drug screening studies (Briese et al., 2009). Sleight et al., for 
example, created a less severe nematode model of SMA by introducing a point mutation in 
exon 2 of the SMN-1 gene (Sleigh et al., 2011). The SMN-1 (cb131) mutant nematodes 
presented with the same pathology, however, disease progression was slower and resulted in 
longer survival (Sleigh et al., 2011). This model was then used to screen 1040 chemical 
compounds as potential drugs for SMA, six of which were chosen for further validation studies. 
Three drugs, including 4-aminopyridine, gaboxadol hydrochloride and N-acetylneuraminic 
acid rescued at least one aspect of SMN-1 phenotypic dysfunction, including increase in the 
lifespan (Sleigh et al., 2011), thus showing that nematode model is a good platform for big 
drug screening studies. 
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1.4.2. Drosophila melanogaster 
D. melanogaster has one SMN gene whose protein product shows 41% homology with the 
human ortholog (Miguel-Aliaga et al., 2000). Like C. elegans, maternal SMN protein is 
expressed during early embryogenesis, and is responsible for the rescue and early 
development of the Drosophila mutants carrying lethal SMN alleles, SMN73Ao and SMNB (Chan 
et al., 2003). As maternal Smn protein decreases, motor abnormalities start to develop, 
resulting in paralysis and death in late larval stage; a phenotype that can be completely 
rescued by delivery of the wild type Smn protein to both neurons and muscles (Chan et al., 
2003). Both mutants showed defects in NMJs (Chan et al., 2003), confirming findings 
previously observed in a mouse model of SMA (Cifuentes-Diaz et al., 2002). Short life cycle 
and easy genetic manipulation make Drosophila a valuable research tool (Muqit and Feany, 
2002). Indeed, Drosophila has been used in genetic screening for identification of SMN 
modifiers (Chang et al., 2008; Dimitriadi et al., 2010; Sen et al., 2013). 
 
1.4.3. Danio rerio 
Zebrafish (Danio rerio) has numerous advantages that make it an excellent model organism 
for neuromuscular research (Edens et al., 2015). It has relatively simple, but conserved and 
well-characterized organization of the nervous system. Transparency of the zebrafish embryos 
allows easy in vivo manipulation and imaging of motor neurons. In addition, easy manipulation 
of the genome allows creation of transgenic animals, making it a desirable model in SMA 
research (Edens et al., 2015). The zebrafish SMN gene encodes for the protein that shows 52% 
homology with the human ortholog (Bertrandy et al., 1999). Consistent with previously 
described models, early development of the zebrafish SMN mutants is rescued by maternal 
SMN, with the death occurring at larval stage (Boon et al., 2009). Motor neuron defects, 
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including axonal truncation and abnormal branching have been described in several zebrafish 
models of SMA  (Mcwhorter et al., 2003; Winkler et al., 2005; McWhorter et al., 2008; Hao et 
al., 2013), together with abnormal NMJs (Boon et al., 2009), thus proving that zebrafish is a 
good model to study motor neuron defects in SMA. 
 
1.4.4. Mus musculus 
The mouse SMN gene shows 83% homology with the human ortholog (Bertrandy et al., 1999). 
Contrary to previously described models, mouse embryos do not have maternal SMN, and so 
homozygous deletion of SMN gene is embryonically lethal (Schrank et al., 1997). Easy genetic 
manipulation and higher physiological similarity to humans (compared to previously described 
models) make mice models preferable for exploring SMA pathogenesis (Sleigh, Gillingwater 
and Talbot, 2011). The first severe mouse model of SMA was created by introduction of human 
SMN2 gene into mouse SMN knockdown (Smn-/-; SMN2) (Hsieh-Li et al., 2000; Monani et al., 
2000). Smn-/-;SMN2 mice, carrying low number of SMN2, showed remarkable phenotypical 
resemblance to type I SMA patients. They were indistinguishable from control animals in the 
first two days after birth, after which motoric function defects developed, leading to death 
before postnatal day 7 (P7) (Hsieh-Li et al., 2000; Monani et al., 2000). Growth defects, 
decreased movement, decreased or lack of suckling, laboured breathing, tremors in the limbs 
and motor neuron degeneration, starting from P3, are all consistent with SMA I phenotype 
(Monani et al., 2000). Moreover, high copy number Smn-/-;SMN2 mice did not show any 
symptoms, thus mimicking less severe SMA phenotype (Hsieh-Li et al., 2000; Monani et al., 
2000). Introduction of human SMN cDNA lacking exon 7, SMNΔ7 transgene, into severe mouse 
model resulted in creation of severe SMNΔ7 model (Smn-/-/SMN2/SMNΔ7) (Le et al., 2005). It 
was initially created to assess SMNΔ7 toxicity, but instead was shown to increase lifespan from 
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6 to 13 days. Improvement of the phenotype is thought to be due to the complex formation 
between SMN and SMNΔ7 proteins which stabilizes SMNΔ7 turnover (Le et al., 2005). 
Introduction of other SMN1 transgenes, containing point mutations A2G (Monani et al., 2003) 
or A111G (Workman et al., 2009), into severe mouse model of SMA (Smn-/-/SMN2) resulted in 
further increase of the lifespan. It was proposed that A2G transgene is able to form partially 
functional SMN complexes in the presence of low levels of full length SMN, which results in a 
mouse model with mild SMA (SMN A2G;SMN2;Smn-/-) that mimics SMA type III (Monani et al., 
2003). SMN (A111G) transgene, on the other hand, rescued the SMA phenotype, which was 
associated with the ability of the A111G allele to participate in snRNP assembly (Workman et 
al., 2009). The intermediate SMA mouse model (Smn2B/-) carries a three nucleotide 
substitution in ESE sequence of exon 7 (Didonato et al., 2001). Mimicking SMN2 splicing 
defects, this change results in production of Δ7SMN transcripts, leading to death by the age 
of 1 month (Didonato et al., 2001).  
 
1.4.5. Sus scrofa 
Lorson et al. started developing a porcine model of SMA in 2011, by first creating heterozygous 
SMN knockout animals (SMN+/-) (Lorson et al., 2011). Pigs, out of all animal models, show most 
similarities with humans, and creation of a porcine model of SMA may thus provide a valuable 
platform for evaluation of drug efficiency and toxicity (Lorson et al., 2011). In 2016, Holm et 
al. reported that splicing pig model of SMA ( Smn+/-/SMN2) has been successfully created and 
is being evaluated for the use in drug studies (Holm, Alstrup and Luo, 2016). Another pig model 
of SMA was developed by intrathecal administration of self-complimentary adeno-associated 
virus serotype-9- short hairpin RNA (scAAV9-shRNA) vector into five day old piglets (Duque et 
al., 2015). Knockdown of SMN expression in motor neurons resulted in SMA-like phenotype, 
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including motor neuron loss and progressive muscle weakness (Duque et al., 2015).  
Neuromuscular pathology was rescued by introduction of scAAV9-SMN 24 hours after the 
knockdown (Duque et al., 2015). 
 
Animal models of SMA generated valuable knowledge on molecular mechanisms underlying 
SMA pathology and have been extensively used in SMA therapy design (Foust et al., 2010; Hua 
et al., 2011; Ling et al., 2012), however, translation of these findings into clinics was often 
shown to be challenging. For example, treatment with the histone deacetylase inhibitor 
(HDACi) valproic acid (VPA) improved neuromuscular pathology and motor functions in 
intermediate mouse model of SMA, however, type II and III SMA patients treated with VPA 
showed little or no improvement in motor functions (Swoboda et al., 2010; Darbar et al., 2011; 
Kissel et al., 2011, 2014). Although SMN has a highly conserved function in RNA metabolism 
(Bertrandy et al., 1999), homology differences in SMN gene exist between species (Bertrandy 
et al., 1999) and could explain some discrepancies between animal and clinical studies. In 
addition, the SMN2 gene is specific to primates only (Lefebvre et al., 1995), while some species 
like Caenorhabditis, Drosophila and zebrafish have maternal SMN that can rescue early 
embryonic development (Chan et al., 2003; Boon et al., 2009; Briese et al., 2009). Although 
pigs show most similarities to humans, development of porcine transgenic animal models is 
expensive and time-consuming (Prather et al., 2013). All these problems raise a need for a 
simpler and genetically similar model system that would complement research utilising animal 
models of SMA. 
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1.4.6. In vitro models of SMA 
Human skin fibroblasts are easily accessible, and easy to grow and maintain in cell culture 
(Ebert and Svendsen, 2010), and SMA patient fibroblasts showed reduced levels of SMN at the 
protein and mRNA level (Wadman et al., 2016). A correlation between SMN protein levels and 
SMN2 copy number was observed in fibroblast cells from SMA patients, which makes them a 
desirable in vitro model for the study of SMA disease mechanisms (Wadman et al., 2016). For 
example, Custer and Androphy have reported accumulation of early autophagosomes, and 
protein p62, which is degraded exclusively by autophagy, in SMA patient fibroblasts and motor 
NSC-34 cells, indicating that autophagy is dysregulated in SMN-deficient cells (Custer and 
Androphy, 2014). Fibroblasts have also been used extensively as a platform for testing and 
optimization of potential therapeutics (Mohseni et al., 2016; Woll et al., 2016). For example, 
increased expression of SMN mRNA and protein levels was identified in SMA patient 
fibroblasts after the treatment with HDACis, suberoylanilide hydroxamic acid (SAHA) and 
Dacinostat (Mohseni et al., 2016), thus showing that patient fibroblasts can serve as a good 
platform for in vitro drug screening studies. 
 
Another useful in vitro model for SMA research are induced pluripotent stem cells (iPSCs) that 
are reprogrammed from adult somatic cells by viral transduction (Takahashi et al., 2007) or 
episomal plasmid (Sareen et al., 2012). Pluripotency of generated iPSCs allows generation of 
any human cell type that can be studied in vitro, which in the case of SMA means motor 
neurons to study their selective vulnerability (Fuller et al., 2016). Indeed, iPSC-derived motor 
neurons have been successfully generated from SMA patient fibroblasts (Corti et al., 2012; 
Sareen et al., 2012; Fuller et al., 2016). They showed selective death compared to control cells, 
thus mimicking in vivo motor neuron degeneration (Corti et al., 2012; Sareen et al., 2012), and 
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widespread dysregulation of the proteome compared to control cells (Fuller et al., 2016). In 
addition, Yoshida et al. successfully co-cultured SMA patient iPSC-derived motor neurons with 
murine myoblasts to study NMJs in vitro, and found neurofilament (NF) accumulation in axon 
terminals and AChR clustering defects that were previously observed in animal models 
(Yoshida et al., 2015). This model was also used to assess therapeutic potential of two drugs 
that increase SMN expression: valproic acid (VPA) and phosphorodiamidate morpholino 
oligonucleotides (PMOs). For example, VPA rescued AChR defect but did affect NF 
accumulation, while PMOs improved both AChR clustering and NF accumulation, implicating 
that in vitro models using patient cells are a useful system for evaluation of therapeutic 
efficiency (Yoshida et al., 2015). 
 
1.5. SMA therapies 
There is no cure for SMA, but the last few years have seen significant progress in the 
development of therapies aimed at alleviating symptoms by raising full-length SMN protein 
levels (Sumner and Crawford, 2018). Nusinersen (SpinrazaTM), an antisense oligonucleotide 
drug, is now widely available for children and young adults with SMA, and most recently, 
ZolgensmaTM (previously known as AVXS-101), an adeno-associated virus-based gene 
replacement therapy, was given approval by The Food and Drug Administration (FDA) for 
the treatment of SMA children under 2 years of age (Sumner and Crawford, 2018). Other 
therapeutic approaches, employing both SMN-dependent and SMN-independent strategies, 
have been developed over the years, and are summarised below and in Figure 1.4. 
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1.5.1. SMN-targeted therapies: 
SMN-targeted therapies employ one of the two approaches to raise the levels of full length 
SMN protein: a) by promoting SMN2 expression (Brichta et al., 2003; Andreassi et al., 2004; 
Riessland et al., 2006, 2010; Avila et al., 2007; Garbes et al., 2009; Schreml et al., 2012; 
d’Ydewalle et al., 2017) or correct splicing (Finkel et al., 2017; Mercuri et al., 2018), and b) by 
replacing the defective SMN1 gene (Mendell et al., 2017). 
 
1.5.1.1. Increasing the efficiency of SMN2 splicing 
Nusinersen (SpinrazaTM) 
Nusinersen, an antisense oligonucleotide (ASO) therapy, was approved by the FDA in 
December 2016 as the first available treatment for SMA (Hensel, Kubinski and Claus, 2020). 
Nusinersen in administrated intrathecally, four times within the first three months (12 mg on 
day 0, 14, 28 and 63), after which  the treatment is repeated every four months (Finkel et al., 
2016). Nusinersen targets the intronic splicing silencer (ISS)-N1 to promote SMN2 exon 7 
inclusion into the transcript and production of full length SMN protein (Ottesen, 2017). 
Indeed, a phase two clinical study on type I SMA patients identified increased SMN levels in 
spinal cord and brain tissue following nusinersen treatment (Finkel et al., 2016). Nusinersen 
improved motor milestones in 51% of patients with the most severe type of SMA, 22% of 
which achieved full head control, 10% were able to roll over, 8% were able to sit and 1% were 
able to stand (Finkel et al., 2017). The treatment also improved event-free survival, meaning 
it reduced the risk of death or the use of permanent assisted ventilation in SMA patients by 
47% compared to untreated group (Finkel et al., 2017). In the group of type II and III SMA 
patients, nusinersen treatment improved motor milestones in 57% of patients, measured as 
an increase of at least three points from the baseline in the Hammersmith Functional Motor 
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Scale– Expanded (HFMSE) score (Mercuri et al., 2018). In both studies younger patients 
showed greater improvement in motor functions, however, some patients, especially those 
with a more advanced stage of the disease, showed no or little change in motor functions or 
even a decline with disease duration (Finkel et al., 2017; Mercuri et al., 2018). This shows the 
existence of a critical “time window” when SMN-targeted therapies can bring maximal benefit 
to SMA patients (Chiriboga et al., 2016; Finkel et al., 2016). Indeed, all patients enrolled in 
these trials were symptomatic, and so it is possible that treatment was delivered too late in 
some patients (Chiriboga et al., 2016; Finkel et al., 2016). Clinical trial on pre-symptomatic 
type I and II SMA patients confirmed these findings, since all 25 patients were able to sit 
without support after 2.9 years of the treatment, 92% were able to walk with assistance and 
88% were able to walking independently (De Vivo et al., 2019). The delivery route is another 
consideration to think about when treating older SMA patients, since a growing body of 
evidence suggests the involvement of other organs in SMA pathogenesis (summarised in 
section 1.3.2), and so nervous system specific delivery of SMN may not be sufficient to 
completely rescue SMA phenotype. 
 
Branaplam (LMI070) and Risdiplam (RG7916) 
Branaplam and risdiplam are orally administrated small drugs that increase the efficiency of 
SMN2 exon7 inclusion into the transcript (Poirier et al., 2018). For example, ten daily doses of 
risdiplam increased the levels of full length SMN protein in the brain, spinal cord, muscle, 
heart, skin and blood from SMA mice, thus showing that orally administrated drug can 
systemically rescue SMN levels (Poirier et al., 2018). In a phase I clinical trial on 25 healthy 
subjects, a single oral dose of risdiplam (0.6- 18 mg) was safe and well tolerated, which was 
prerequisite for phase II and III clinical trials on type I, II and III SMA patients (currently under 
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investigation) (Sturm et al., 2019). Preliminary data from FIREFISH study indicate that type 1 
SMA infants treated with risdiplam achieve better motoric milestones compared to the 
natural history of disease development 1, and risdiplam is currently under review by the FDA 
as a treatment for all types of SMA2. 
 
A daily dose of Branaplam improved body weight and survival in SMNΔ7 mouse model of SMA, 
which was accompanied by increased levels of the full length SMN protein in the brain 
(Palacino et al., 2015). A phase I clinical trial on 13 type I SMA patients was conducted initially 
over the course of 13 weeks, with weekly dosage of branaplam, to assess safety and 
tolerability of the drug, and was then extended to 13 months (Charnas et al., 2017). Adverse 
effects were mild but manageable, and some SMA patients showed improvement in motor 
functions (Charnas et al., 2017). 
 
1.5.1.2. Regulation of SMN2 gene expression 
Several histone deacetylase inhibitors (HDACi), including valproic acid (VPA) (Brichta et al., 
2003), phenylbutyrate (Andreassi et al., 2004), suberoylanilide hydroxamic acid (SAHA) 
(Riessland et al., 2010), trichostatin A (TSA) (Avila et al., 2007), benzamide M344 (Riessland et 
al., 2006), hydroxamic acid LBH589 (Garbes et al., 2009) and Dacinostat (Mohseni et al., 2016) 
were shown to increase SMN mRNA and protein levels in in vitro an in vivo models of SMA. 
HDAC inhibitors promote expression of SMN2 gene by blocking the activity of HDACs, known 
suppressors of gene expression (Mohseni, Zabidi-Hussin and Sasongko, 2013). Some of these, 
 
1https://www.prnewswire.com/news-releases/risdiplam-rg7916-pivotal-firefish-study-demonstrated-
statistically-significant-improvement-in-infants-with-type-1-spinal-muscular-atrophy-300991624.html 
2https://smanewstoday.com/2019/11/25/risdiplam-potential-oral-therapy-all-sma-types-under-fda-priority-
review/ 
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like SAHA (Riessland et al., 2010) and TSA (Avila et al., 2007), improved NMJ defects and motor 
functions, and increased survival of severe mouse models of SMA, however, only two HDACi 
were tested in clinical trials. For example, oral daily doses of phenylbutyrate over the course 
of a week increased the levels of full length SMN transcript in the blood of six type II and III 
SMA patients, and improved motor functions and muscle strength (Brahe et al., 2005). 
However, a larger study on 103 type II SMA patients, where phenylbutyrate was taken orally 
for 13 weeks by using an intermittent schedule (7 days on/7 days off), found no difference in 
motor functions between the phenylbutyrate and placebo treated group (Mercuri et al., 
2007). Another clinical study on type I and II SMA patients has been completed, however, it is 
not clear whether phenylbutyrate treatment improved motor functions is those SMA 
patients3. The first VPA clinical trial on type I, II and III SMA patients showed good safety and 
tolerability, however, increased body weight, identified in some SMA patients, was associated 
with the decline in motor functions (Swoboda et al., 2009). VPA was administrated orally, 
every day for 12 months. The majority of SMA patients that showed improvement in motor 
functions were under the age of 5, thus indicating that VPA treatment might not be 
appropriate for all SMA patients (Swoboda et al., 2009). Indeed, subsequent clinical studies, 
using similar experimental design, showed that VPA does not improve muscle strength and 
motor function in older SMA patients, while some improvement can be observed in younger 
population of SMA patients (Swoboda et al., 2010; Darbar et al., 2011; Kissel et al., 2011, 
2014). Once again, the critical ‘time window’ for effectiveness of SMN-targeted therapies was 
emphasised here, suggesting that alternative approaches are necessary for older SMA 
patients.  
 
3https://clinicaltrials.gov/ct2/show/results/NCT00528268?term=phenylbutyrate&cond=spinal+muscular+atrop
hy&draw=2&rank=1 
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1.5.1.3. Replacement of the defective SMN1 gene  
ZolgensmaTM (Onasemnogene Abeparvovec) 
Zolgensma, a single dose gene therapy that relies on self-complementary adeno-associated 
virus 9 (scAAV9) delivery of functional SMN gene, was approved by the FDA in 2019 for the 
treatment of SMA children under the age of 2 (Hensel, Kubinski and Claus, 2020). The scAAV9 
vector carrying SMN gene does not integrate into the genome, which greatly reduces the risk 
of insertional mutagenesis, and it crosses the blood-brain barrier thus allowing systemic drug 
delivery (Al-Zaidy and Mendell, 2019). Only one study to date, a phase I clinical trial, has been 
published and included 15 infants with type I SMA (Mendell et al., 2017). All patients, enrolled 
in low dose (n = 3) or high dose cohort (n = 12), were alive at the age of 20 months, did not 
require permanent ventilation and showed improvement in motor milestones, which is in 
stark contrast with the natural history of disease development. Of the 12 patients who had 
received the high dose of gene therapy, 11 achieved head control, 11 were able to sit 
unassisted, 9 were able to roll over, 11 were able to speak and swallow independently, and 2 
were able to crawl, stand and walk independently (Mendell et al., 2017). Four patients had 
increased levels of liver enzymes that were attenuated by prednisolone treatment (Mendell 
et al., 2017). Similar to nusinersen treatment, SMA children treated at a younger age achieved 
better motor milestones (Mendell et al., 2017). There are no published studies on older SMA 
patients, however, a study on type I SMA patients (Mendell et al., 2017), and previous 
experiences with nusinersen (Finkel et al., 2017; Mercuri et al., 2018) and valproic acid 
(Swoboda et al., 2009, 2010; Darbar et al., 2011; Kissel et al., 2011, 2014) suggest that the 
beneficial effect of gene therapy is likely to be reduced in older SMA patients. 
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Though undoubtedly an enormous step forward, none of the two strategies (i.e. nusinersen 
and zolgensma) that have been approved for the treatment of SMA show complete 
efficiency (Finkel et al., 2017; Mendell et al., 2017; Mercuri et al., 2018; Sumner and Crawford, 
2018). Coupled with uncertainties around long-term effectiveness and the extremely high 
price of both strategies, there is keen interest to find alternative therapeutic strategies that 
could, in combination with SMN-targeted therapy, offer maximal therapeutic benefit to all 
SMA patients (Bowerman, 2019).  
 
1.5.2. Non-SMN-targeted therapies 
Molecular pathways downstream of SMN (reviewed below) have been identified as crucial in 
the regulation of SMA pathogenesis, and as such present attractive targets that can 
complement SMN-targeted therapies. 
 
1.5.2.1. Neuroprotection 
Regulation of mitochondrial stability 
Olesoxime is small cholesterol–oxime that binds to the components of the mitochondrial 
permeability pore and stops excessive permeability under stress conditions, and it showed 
neuroprotective effect in vitro and in vivo models (Bordet et al., 2010). For example, 
Olesoxime treatment delayed cell death in rat embryonic cortical neurons treated with a 
deoxyribonucleic acid (DNA) damaging agent Camptothecin (Gouarné et al., 2013), and 
reduced astrogliosis, microglial activation, and motor neuron death in SOD1G93A mouse model 
of ALS (Sunyach et al., 2012). The efficiency of Olesoxime was assessed in type II and III SMA 
patients, where patients received daily oral doses of Olesoxime for 24 months (Bertini et al., 
2017). Treatment was safe and well tolerated, and motor functions stayed preserved in 
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Olesoxime-treated group, which is in contrast with a natural decline in motor functions 
observed in placebo-treated group (Bertini et al., 2017). However, another study, looking at 
the long-term effectiveness and safety of Olesoxime in type II and III SMA patients, showed 
deterioration of motor functions after 18 months of treatment, and so development of 
Olesoxime was stopped at this point 4.  
 
Activation of PI3K-Akt-mTOR pathway 
The phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K-Akt-
mTOR) pathway controls different aspects of cellular function including, for example, cell 
signalling, apoptosis, neuronal  polarity, proliferation and cytoskeletal protein expression 
(Godena and Ning, 2017). Downregulation of phosphatase and tensin homolog (PTEN), a 
negative regulators of PI3K-Akt-mTOR pathway, improved axonal growth and cell survival in 
SMN-deficient and healthy mouse motor neurons (Ning et al., 2010). This phenotype was 
associated with increased phosphorylation of the proteins involved in PI3K-Akt-mTOR 
pathway, including Akt, I-kappa-B kinase (IKK) and Bcl2-associated agonist of cell death (Bad), 
and with restoration of β-actin protein levels (Ning et al., 2010). Depletion of PTEN levels in 
levator auris longus (LAL) muscle at postnatal day one increased the number of functional 
NMJs in SMNΔ7 mouse model of SMA, and systemic depletion of PTEN levels increased the 
survival rate of SMNΔ7 mice by three-fold and improved their motor functions (Little et al., 
2015). Another inhibitor of PI3K-Akt-mTOR pathway, a specific microRNA, miR-183, was found 
upregulated in SMN-knockdown neurons, patient-derived fibroblasts, and spinal cord and 
sciatic nerve from SMNΔ7 mice (Kye et al., 2014). Binding of miR-183 to mTOR mRNA was 
 
4 https://www.curesma.org/roche-releases-community-statement-on-olesoxime-program/ 
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shown to be directly responsible for decreased translation of mTOR in SMN-deficient neuron 
cultures, which was restored upon miR-183 knockdown (Kye et al., 2014). Knockdown of miR-
183 improved axonal growth defects in SMN-depleted neuron cultures, and spinal motor 
neuron-specific depletion of miR-183 levels in SMNΔ7 mice resulted in a modest improvement 
of motor functions and survival (Kye et al., 2014). All studies indicate that modulation of PI3K-
Akt-mTOR pathway may have important implications in neuroprotection.  
 
Restoration of actin dynamics  
Neuronal growth is dependent on dynamic rearrangements of the actin cytoskeleton, which 
is controlled by different proteins including Rho GTP-ases, transforming protein RhoA (RhoA), 
CDC42 small effector protein 1 (Cdc42) and Ras-related C3 botulinum toxin substrate 1 (Rac1) 
(Bowerman, Shafey and Kothary, 2007). Of these, when in an active state, RhoA-GTP has an 
inhibitory effect on neuronal outgrowth and differentiation, while both Cdc42-GTP and Rac1-
GTP were shown to induce neuronal outgrowth and differentiation (Bowerman, Shafey and 
Kothary, 2007). Perturbations in actin cytoskeleton were identified in SMN-deficient PC12 
cells, including mis-localization of F-actin and dysregulation of GTP-ases. For example, total 
RhoA and RhoA-GTP levels were increased in SMN-knockdown PC-12 cell line, while the levels 
of Cdc42-GTP decreased compared to control cells (Bowerman, Shafey and Kothary, 2007). In 
the Smn2B/- mouse model of SMA, total RhoA protein levels stayed unchanged, however, 
RhoA-GTP levels  were significantly increased in spinal cord tissue at pre-symptomatic stage 
of the disease (Bowerman et al., 2010). Activated RhoA activates its downstream effector Rho-
associated protein kinase 1 (ROCK), and subsequent activation of other members of the RhoA 
pathway results in inhibition of neuronal growth and differentiation (Bowerman, Shafey and 
Kothary, 2007). Indeed, pharmacological inhibition of ROCK increased muscle fiber size, 
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improved NMJ defects and survival of Smn2B/- mice, thus showing that activation of RhoA 
pathways and defective actin cytoskeleton play important role in motor neuron defects in 
SMA (Bowerman et al., 2010). In addition, profilin IIa, a known regulator of actin dynamics and 
ROCK binding partner, was upregulated at the mRNA and protein level, suggesting that 
increased formation of RhoA-ROCK-profilin IIa might be driving neuronal growth defects 
(Bowerman et al., 2010). 
 
PLS3 (plastin 3) is an another protein involved in actin filament organization and actin 
stabilization (Bowerman et al., 2009). It was found highly expressed in the human foetal brain 
and adult spinal cord, and is significantly increased during neuronal differentiation in rat PC12 
cells (Oprea et al., 2008). PLS3 was reduced in the spinal cord and brain tissue from Smn2B/- 
mice, and this pattern of expression was directly linked to dysregulation of profilin IIa levels, 
since knockdown of profilin II in Smn2B/- mice increased PLS3 levels (Bowerman et al., 2009). 
PLS3 was identified as a key protective modifier in asymptomatic female patients carrying 
homozygous deletion of SMN1 gene (Oprea et al., 2008). In addition, higher expression of PLS3 
was identified in some SMA I and III patients, and in this group of patients, a milder phenotype 
was observed only in female patients, suggesting that PLS3 protective effect may be gender-
specific (Oprea et al., 2008). Since PLS3 has a role in actin filament organization, the 
relationship between monomeric G-actin and filamentous F-actin was examined. Increased 
levels of PLS3 in asymptomatic females, and type I and III SMA patients correlated with 
upregulation of F-actin level, suggesting that protective effect of PLS3 is exacerbated through 
stabilization of actin filament organization and axonal growth (Oprea et al., 2008). Indeed, 
knockdown of PLS3 in PC12 cells impaired neurite growth, while overexpression of PLS3 in 
PLS3-knockdown zebrafish and severe mouse model of SMA rescued neurite growth defects, 
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increased muscle fiber size and axon number per endplate, improved maturation of NMJs and 
improved survival (Oprea et al., 2008; Ackermann et al., 2013). In addition, upregulation of 
PLS3 levels, in combination with SMN-targeted therapy (SMN-ASO), increased the survival rate 
of severe SMNΔ7 mouse model of SMA compared to SMN-ASO treatment alone, thus showing 
that combinatorial approach may bring greater therapeutic benefit to SMA patient (Kaifer et 
al., 2017). 
 
Regulation of endocytosis 
Neurocalcin-delta (NCALD) overexpression in primary olfactory neuron cultures previously 
demonstrated a negative effect on axonal growth (Yamatani et al., 2010), and interestingly, 
decreased NCALD levels were identified in asymptomatic individuals carrying homozygous 
deletion of SMN1 gene, indicating that low levels of NCALD might have a neuroprotective 
action in SMA (Riessland et al., 2017). Indeed, retinoic acid-induced differentiation of NSC34 
cells led to a steady reduction of NCALD levels over time, and NCALD knockdown was sufficient 
to induce motor neuron differentiation and axonal growth in NSC34 cells (Riessland et al., 
2017). In addition, NCALD knockdown rescued axonal growth defects in cultured motor 
neurons from SMA mice, and ameliorated neuromuscular defects in a zebrafish, C. elegans 
and mouse models of SMA (Riessland et al., 2017; Torres-Benito et al., 2019). Dysregulation 
of endocytosis was proposed as a mechanism of NCALD action in SMA, where NCALD binds to 
clathrin, an important pre-synaptic vesicle protein, and inhibits vesicle recycling at the NMJs 
(Riessland et al., 2017). Indeed, endocytosis was impaired in SMA patient fibroblasts, SMN-
deficient NSC34 cells and in NMJs from a mouse model of SMA, and knockdown of NCLAD 
levels rescued endocytosis defects in NSC34 cells and SMA mice (Riessland et al., 2017). In 
addition, ASO directed against NCALD, in combination with an SMN-targeted therapy, at a pre-
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symptomatic stage of the disease ameliorated neuromuscular pathology in Taiwanese SMA 
mice (Torres-Benito et al., 2019). Improvement in neuromuscular pathology using a 
combinatorial approach was greater compared to SMN-ASO treatment alone, suggesting once 
again that additional therapies, in combination with SMN approach, are necessary to preserve 
motor neuron health in SMA (Torres-Benito et al., 2019).  
  
1.5.2.2. Muscle-enhancing strategies 
Therapies aimed at improving muscle size and fatigue are also being developed in SMA and 
include compounds like Reldesemtiv and SRK-015 (Shorrock, Gillingwater and Groen, 2018). 
Reldesemtiv (CK-2127107) is fast skeletal muscle troponin binding protein that slows calcium 
release, and leads to increased force output following motor neuron stimulation in animals 
and humans (Hwee et al., 2015).  A phase II clinical trial evaluated safety, tolerability and 
effectiveness of daily oral administration of Reldesemtiv in 70 patients with type II, III and IV 
SMA. At the half point (four weeks) and completion of the study (eight weeks), SMA patients 
in both treatment groups (150 and 450 mg dose) showed improvement in muscle fatigue 
(measured by Six Minute Walk Distance test) and increased strength of respiratory muscles 
compared to placebo group, and the drug was safe and well tolerated5. This drug showed 
promising results for preserving muscle strength in SMA patients, and other studies, possibly 
in combination with SMN strategy, are anticipated in the near future. 
In a recent study using the SMNΔ7 mouse model of SMA, SRK-015P, a monoclonal antibody 
which specifically inhibits myostatin, a negative regulator of muscle mass, showed promising 
results in combination with SMN2 splicing modifier (Long et al., 2019). When compared to 
 
5https://www.curesma.org/cytokinetics-presents-data-from-the-phase-2-clinical-trial-of-reldesemtiv-ck-
2127107-in-patients-with-sma-at-the-2018-annual-sma-conference/ 
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SMN-targeted therapy alone, the combinatorial approach increased body and skeletal muscle 
weight, increased the percentage of large muscle fibers, and improved motor functions in SMA 
mice (Long et al., 2019). An optimised variant of SRK-015P, SRK-015, is currently being 
evaluated in a phase II clinical study, to assess safety, tolerability and efficiency of the 
treatment in type II and III SMA patients 6. 
 
1.5.2.3. Other therapeutic approaches 
Systemic restoration of IGF levels 
IGF-1 (insulin-like growth factor-1), hormone that regulates cellular growth, proliferation, 
differentiation and survival, has been studied as a potential therapeutic approach in SMA 
(Murdocca et al., 2012; Tsai et al., 2012, 2014). Reduced levels of endogenous IGF-1 were 
identified in the blood from SMNΔ7 mice (Murdocca et al., 2012). Nervous system targeted 
delivery of human IGF-1 reduced motor neuron death in intermediate mouse model of SMA, 
but did not rescue NMJ defects or improve motor functions (Tsai et al., 2012). Perinatal 
treatment of SMNΔ7 mice with IPLEX (IGF-1/IGFBP-3 complex), where IGFBP-3 (IGF-1 binding 
protein 3) increases half-life of circulating IGF-1, had mild effect on motor neuron 
degeneration and motor function improvement, but did not improve survival or body weight 
of SMA mice (Murdocca et al., 2012). On the other hand, systemic administration of AAV1- 
IGF-1 on P1 in severe mouse model of SMA increased IGF-1 protein levels in spinal cord, brain, 
muscles and heart (Tsai et al., 2014). Treated animals showed a decrease in motor neuron 
degeneration and NMJ defects, decreased muscle and heart atrophy and improved motor 
functions and lifespan, once again showing the necessity for systemic approach in SMA 
 
6https://clinicaltrials.gov/ct2/show/NCT03921528?term=SRK-
015&cond=Spinal+Muscular+Atrophy&draw=2&rank=1 
43 
 
therapy design (Tsai et al., 2014). However, type II and III SMA patients treated with daily 
doses of somatotropin, growth hormone that induces IGF-1 expression, for three months 
showed no significant change in motor functions compared to untreated patients (Kirschner 
et al., 2014). 
 
Restoration of the proteasomal pathway 
Ubiquitin-like modifier activating enzyme 1 (UBA1) is the first member of the ubiquitin 
proteasome pathway (UPP) which has a well-established role in regulation of protein 
homeostasis by control of their degradation (Lecker, Goldberg and Mitch, 2006). Mutations in 
the UBA1 gene cause X-linked infantile SMA (SMAX2) (Ramser et al., 2008), and in SMN-
dependent SMA, decreased UBA1 expression was identified across a range of tissues in severe 
and Taiwanese mouse models of SMA, including spinal cord, skeletal muscles, heart, liver, lung 
and kidney (Wishart et al., 2014; Powis et al., 2016), in  zebrafish embryos, and in iPSC-derived 
motor neurons from type I SMA patients (Fuller et al., 2016; Powis et al., 2016). In addition, 
UBA1 was completely absent from motor neuron cytoplasm of Taiwanese SMA mice at early 
symptomatic stage of the disease, indicating defects in subcellular distribution of the UBA1 
(Wishart et al., 2014). A direct role for UBA1 in SMN-dependent disease pathways was 
established in zebrafish embryos, where genetic and pharmacological suppression of UBA1 
levels resulted in axonal branching defects, thus mimicking motor neuron defects previously 
observed in SMN-deficient zebrafish (Wishart et al., 2014). Restoration of UBA1 levels 
increased motor performance in zebrafish and mouse models of SMA, as well as increased 
survival and improved systemic pathology in SMA mice (Powis et al., 2016). The efficiency of 
UBA1- directed approach remains to be investigated in clinical settings. 
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In summary, it has been shown here that SMA is not exclusively a motor neuron disease, and 
other pathologies, affecting skeletal, cardiovascular, immune and endocrine system, have 
been identified in SMA patients. Although very successful in improving motor functions in 
young and especially pre-symptomatic SMA patients, the antisense oligonucleotide approach 
nusinersen showed limited benefit in older population of SMA patients, and was not able to 
rescue systemic pathology. The gene therapy zolgensma, though administrated systemically, 
was also more successful in improving motor functions in younger population of SMA patients. 
Both of these examples show that therapies aiming to increase the levels of functional SMN 
may not be sufficient to completely abolish all the downstream effects of SMN loss in SMA 
patients. Other therapeutic approaches that target different SMA disease pathways, including 
proteasomal degradation, actin cytoskeleton dynamics and pathways involved in muscle 
growth, are currently under development. In combination with SMN-targeted approaches 
Figure 1. 4. Overview of potential therapeutic strategies in SMA. Most therapies currently under development 
target SMN levels, however, additional approaches are being explored and include drugs designed to enhance 
muscle function, provide neuroprotection and/or target systemic pathology. Combinations of these approaches 
will be necessary to provide robust rescue of all SMA-associated phenotypes. NCALD- neurocalcin delta, PLS3 
plastin-3, SMA-spinal muscular atrophy, SMN-survival motor neuron, UBA1-ubiquitin-like modifier activating 
enzyme 1 (Shorrock, Gillingwater and Groen, 2018). 
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they may prove useful in abolishing both neuromuscular and systemic pathology, thus 
bringing greater therapeutic benefit to all SMA patients. 
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The aim of this thesis was to identify and characterise new SMA disease pathways that could 
potentially be targeted therapeutically, and to determine the shared molecular fingerprint 
between SMA and amyotrophic lateral sclerosis (ALS). 
Specific objectives were as follows: 
a) To determine the molecular overlap between proteins and genes that were 
differentially expressed in SMA cells and tissues across at least two omics studies of 
SMA, so that appropriate therapeutic strategies, that can target molecules on the gene 
and/or protein levels, can be selected. To establish the pattern of differential 
expression of six protein targets in SMA tissues and cells, including UBA1, lamin A/C, 
GAPDH, ANXA2, NCAM and GAP43, and identify pharmaceutical compounds that have 
the potential to change their expression and test them in patient fibroblasts. 
b) To investigate the molecular mechanism of lamin A/C dysregulation in SMA tissues and 
cells and determine the functional consequences of lamin A/C dysregulation in SMA 
patient fibroblasts. This knowledge can then be used in the development of therapies 
that can restore lamin A/C expression to normal levels. Considering that lamin A/C 
dysfunction has important implications for the heart health, it was important too to 
determine whether other changes to the proteome can be identified in the heart from 
SMA mice. 
c) To identify conserved protein changes in ALS tissues and cells by comparison of 
published proteomic studies of ALS, and to compare these to the list of conserved 
protein changes in SMA tissues and cells. The aim here was to identify shared 
molecular overlap between SMA and ALS that can expand the knowledge of common 
disease pathways, so that the same therapy can be designed for treatment of SMA and 
ALS patients. 
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CHAPTER 2: Materials & Methods 
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2.1. Experimental models 
2.1.1. Cell lines 
Fibroblast cells from SMA patients (n = 3) and age/gender matched healthy controls (n = 3) 
were obtained from the Coriell Institute for Medical Research (NIGMS Human Genetic Cell 
Repository). Fibroblast cells from healthy older individuals (n = 5) were obtained from the 
Newcastle Biobank. Specifications for each cell line are provided in Table 2.1. 
Mouse embryonic fibroblast cells (MEFs) from lamin A/C knockout (LMNA KO) (Sullivan et al., 
1999) and wild type mouse were obtained from Prof Colin L Stewart (Institute of Medical 
Biology, Singapore). 
HEK293 cells were obtained from European Collection of Authenticated Cell Cultures. HEK293 
cell culture and knockdown (KD) of ubiquitin-like modifier-activating enzyme 1 (UBA1) were 
performed by Dr Hannah K. Shorrock and Prof. Thomas H. Gillingwater (University of 
Edinburgh)  as previously described (Shorrock et al., 2018). 
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Table 2. 1. Fibroblast cell lines derived from SMA patients and healthy controls 
Disease phenotype, SMN2 copy number, age of the donor, and biopsy source and tissue type are listed for each 
cell line. 
 
2.1.2. Mouse models of SMA and ALS 
The Taiwanese mouse model of severe SMA (original strain purchased from Jackson 
Laboratories, No.005058), heterozygous for the SMN2 transgene on Smn null background 
(Smn−/−;SMN2tg/+) (Hsieh-Li et al., 2000) and age-matched phenotypically normal controls 
(Smn+/-; SMN2tg/o) were maintained in specific-pathogen-free (SPF) facilities at the University 
of Edinburgh. Breeding, genotyping using standard polymerase chain reaction (PCR) protocols, 
and tissue collection were performed by Dr Hannah K. Shorrock and Prof. Thomas H. 
Gillingwater (University of Edinburgh) as previously described (Riessland et al., 2010). Tissue 
was harvested at a symptomatic time point, postnatal day 8 (P8).  
ID Phenotype SMN2 copy 
number 
Gender/Age Biopsy source/ 
Tissue type 
Supplier 
GM00302 Healthy 
control 
NA Male/10 
months 
Unspecified/skin Coriell Cell 
Repository 
GM00498 Healthy 
control 
NA Male/3 years Unspecified/skin Coriell Cell 
Repository 
GM05659 Healthy 
control 
NA Male/1 year Chest/skin Coriell Cell 
Repository 
F152 Healthy 
control 
NA Female/27 
years 
Unspecified Newcastle Biobank 
F154 Healthy 
control 
NA Female/34 
years 
Unspecified Newcastle Biobank 
F008 Healthy 
control 
NA Male/39 years Unspecified Newcastle Biobank 
F011 Healthy 
control 
NA Female/45 
years 
Unspecified Newcastle Biobank 
F067 Healthy 
control 
NA Female/66 
years 
Unspecified Newcastle Biobank 
GM00232 SMA I 2 SMN2 copies Male/7 months Unspecified Coriell Cell 
Repository 
GM09677 SMA I 3 SMN2 copies Male/2 years Eye/lens Coriell Cell 
Repository 
GM03813 SMA II 3 SMN2 copies Male/3 years Arm/skin Coriell Cell 
Repository 
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The SOD1G93A mouse model of ALS (Gurney et al., 1994), and age/gender-matched wild type 
(WT) littermates were obtained from the University of Oxford. Breeding, genotyping using 
standard PCR protocols, and tissue collection were performed by Dr Melissa Bowerman (Keele 
University) as previously described (Bowerman et al., 2015). Tissue was harvested at late 
symptomatic (20 weeks) and early symptomatic (12 weeks) time points. 
 
2.2. Aseptic cell culture 
Sterile conditions were maintained at all time during cell culture.  
 
2.2.1. Thawing of cells 
After removal from the liquid nitrogen (N2; -196°C), fibroblast cells and MEFs were first placed 
in the freezer (-80°C) for half an hour and then allowed to thaw either at room temperature 
(RT) or in a water bath (37°C). The thawed cell suspension was transferred to a universal tube 
(25mL) containing 10 mL of complete medium [High glucose Dulbecco's Modified Eagle 
Medium (DMEM; 31966021; Gibco), 10% fetal bovine serum (FBS; 10270098; Gibco) for 
fibroblasts or 15% FBS for MEFs, 1% non-essential amino acids (MEM-NEAA; 11140035; Gibco) 
and 1 % penicillin-streptomycin (PEN-STREP; 17-603E; Lonza)], in a drop-wise manner, and 
centrifuged on 365xg for 6 minutes (4K15; Sigma). Following centrifugation, the supernatant 
was carefully removed, and cell pellet was resuspended in complete medium. 
 
2.2.2. Cell viability and cell count  
Cell viability was assessed by using the trypan blue exclusion test. This test is based on the 
principle that live cells poses intact membranes that exclude certain dyes such as trypan blue 
(Strober, 2001). Dead cells would, therefore, stain blue while life cells remain transparent. For 
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this, 20-50 μL of cell suspension was mixed with an equal volume of 0.4% trypan blue (T6146; 
Sigma), incubated for 3 minutes and pipetted on to a haemocytometer. Cells in four corner 
squares of the haemocytometer were counted to assess the percentage of viable cells in the 
suspension, and cell concentration (number of viable cells per mL of medium) using following 
calculations: 
Cell viability (%) = (number of live cells/ total number of cells) x 100 
Cell concentration (cells/mL) = [(N/4) x d] x 10000 
 
,where N/4 represents average number of viable cells across four corner squares of the 
haemocytometer, and d represents trypan blue dilution factor. 
 
2.2.3. Monolayer cell culture and cell harvesting 
According to calculations of the cell concentration, human fibroblasts and MEFs were seeded 
in tissue culture flasks (Sarstedt) containing complete medium at a density of 5x103 cells/cm2 
and maintained in humidified incubator (Leec) at 37°C and 5% carbon dioxide (CO2). Cells were 
grown up to 70% confluency, after which the media was removed from the flask, and the cells 
were incubated with trypsin/0.25 % ethylenediaminetetraacetic acid (EDTA) (25200056; 
Gibco) for 5 minutes at 37°C. Gentle tapping was applied to help detachment of cells from the 
culture flask. Trypsin activity was neutralised by addition of an equal volume of the complete 
medium, after which the cells were centrifuged at 365xg for 6 minutes. Supernatant was 
discarded, and the cells were either resuspended in a fresh volume of complete medium and 
reseeded, as described above, or resuspended in cold phosphate buffered saline [PBS; 0.02 M 
Sodium phosphate dibasic dodecahydrate (Na2HPO4x12H2O; 71649; Sigma) and 0.15 M 
Sodium Chloride (NaCl; BP359; Fisher Scientific); pH 7.2 adjusted with phosphoric acid (H3PO4; 
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P-6560; Sigma)] and centrifuged at 365xg for 6 minutes. The PBS was then discarded, and the 
tubes were left upside-down to allow the cell pellet to dry completely. Tubes were wrapped 
in parafilm to prevent cell pellets from getting wet and stored on -80°C until further 
processing.  
 
For immunocytochemistry analysis, cells were seeded in complete medium on glass coverslips 
(22mmx22mm) at a density of 2.5x104 per coverslip and maintained in humidified incubator 
at 37°C and 5% CO2. After reaching 70% confluency, the medium was removed, and cells were 
washed twice in cold PBS. The PBS was removed, and the cells were fixed in acetone (67-64-
1; Fisher Scientific): methanol (67-56-1; Fisher Scientific) solution at a 50:50 ratio for 10 
minutes. After removing the solution, coverslips were left to air dry, wrapped in parafilm and 
stored on -80°C until further processing.  
 
2.2.4. Cryopreservation 
Cells were trypsinized as explained above, and the supernatant was discarded following 
centrifugation at 365xg for 6 minutes. Cells were resuspended in a mixture of FBS and dimethyl 
sulfoxide (DMSO; BP231-100; Fisher Scientific) at 90:10 ratio, and carefully pipetted into a 
cryovial tube (1 mL per tube). Cryovials were stored at -80°C overnight before moving them 
to long-term storage in N2. 
 
2.3. Biochemical analyses of protein expression and localization 
2.3.1. Quantitative western blotting 
Quantitative western blotting is an established technique for investigating protein abundance 
(Bass et al., 2017). Here, western blotting was used to investigate protein expression levels in 
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a range of tissues and cells from animal models and in human cells. These included spinal cord, 
brain, liver, muscle and heart from postnatal day 8 (P8) SMA mice (n = 5) and age-matched 
healthy controls (n = 5), spinal cord from 20-week (n = 5) and 12-week (n = 3) old ALS mice, 
and their respective age-matched healthy controls (n = 4), fibroblast cells from SMA patients 
(n = 3) and age/gender matched healthy controls (n = 3), UBA1 KD HEK cells (n = 3) and control 
HEK cells (n = 3), and LMNA KO MEFs (n = 3) and wild type MEFs (n = 3). 
 
2.3.1.1. Protein extraction 
Alongside chemical homogenization, mechanical disruption methods such as homogenization 
using pellet pestle and sonication were used to ensure complete protein extraction from the 
tissues (Bass et al., 2017). Tissues were homogenized in 2x modified RIPA buffer [2% nonidet 
P-40 (NP-40; 155942; ICN Biomedicals), 0.5% sodium deoxycholate (D6750; Sigma), 2mM 
ethylenediamine tetra-acetic acid (EDTA; 104245S, BDH), 300 mM NaCl (BP358; Fisher 
Scientific) and 100 mM Tris-HCl, pH 7.4 (Trizma base; T1503; Sigma)] with pellet pestle (30 
strokes), after which the samples were left on ice (4°C) for 10 minutes and sonicated at 5 
microns for 10 seconds (Sonicrep 150; MSE). The same process was repeated two more times 
to ensure sufficient homogenization of the tissue. Cell pellets were resuspended in 2x 
modified RIPA buffer, left on ice (4°C) for 10-15 minutes, and sonicated at 5 microns for 10 
seconds. Detergents NP-40 and sodium deoxycholate were used to improve extraction 
efficiency and protein solubilization (Dapic et al., 2017). EDTA was used for inhibition of 
metalloproteinases and serine/threonine (Ser/Thr) phosphatase interactions (Bass et al., 
2017). Protein extracts were then centrifuged at 13000 RPM (Micro Centaur MSB010.CX2.5; 
MSE; rotor radius- 4 cm) for 5 minutes at 4°C to pellet any insoluble material. 
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2.3.1.2. Protein quantification 
Protein concentration was determined using either Pierce™ 660nm Protein Assay Reagent 
(22660, Thermo Scientific) or PierceTM BCA protein assay kit (23227; Thermo Scientific). 
 
2.3.1.2.1. Bicinchoninic acid (BCA) protein assay 
Bicinchoninic acid (BCA) assay (Smith et al., 1985) was performed according to instructions 
outlined in the guideline (23227; Thermo Scientific). Colorimetric BCA assay is based on the 
ability of the bicinchoninic acid to form a purple complex with cuprous ions (Cu1+), which are 
generated under alkaline conditions by reaction of proteins with cupric ions (Cu2+) (Smith et 
al., 1985). The intensity of the colour is therefore proportional to the concentration of the 
protein in the sample. 
Bovine serum albumin standards were prepared at an assay working range (0.125-2 mg/ml). 
Working reagent was prepared by mixing 50 parts of BCA reagent A with 1 part of BCA reagent 
B. 10 μL of each sample and standard was carefully pipetted into a well of 96-well plate, 
followed by addition of 200 μL of working reagent (sample to working reagent ratio = 1:20). 
All reactions were performed in triplicate to ensure accuracy. The plate was mixed on a plate 
shaker for 30 seconds, incubated at 37°C for 30 minutes, cooled to RT, and the absorbance 
was measured at 562nm using microplate reader (FLUOstar Omega; BMG Labtech). Samples 
that produced readings greater than the highest standard were further diluted and the 
absorbance was measured again (the dilution factor was taken into account during 
calculations). A standard curve was prepared in Excel by plotting average blank-corrected 
absorbance for each BSA standard vs. its concentration in mg/mL (example is shown in Figure 
2.1). A quadratic calibration model was used to determine protein concentration (x) for each 
sample according to formula: 
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x = (-b+SQRT(b2-4*a*(c-y)))/(2*a) 
(y represents average blank-corrected absorbance of the sample, and a, b and c represent 
three coefficients of the quadratic equation (y = ax2+bx+c)). 
  
 
2.3.1.2.2. Pierce™ 660nm Protein Assay Reagent 
660nm Protein Assay is colorimetric assay that relies on binding of the dye-metal complex 
(polyhydroxybenzenesulfoneph-thalein-type dye and a transition metal) to mainly basic 
amino acid residues in proteins (Antharavally et al., 2009). The binding of the complex to 
protein causes a shift in the absorption maximum from 450 to 660 nm, which causes a change 
in colour from reddish-brown to green. The colour is stable and increase proportionally with 
protein concentrations (Antharavally et al., 2009). 
Bovine serum albumine (BSA; A7906; Sigma) standards were prepared in 7 serial dilutions for 
the analysis in assay working range (0.05–2 mg/ml of protein). 10 μL of each diluted sample 
Figure 2. 1. Bovine serum albumine (BSA) standard curve. Average blank-corrected absorbance (562 nm) for 
each BSA standard was plotted against its concentration in mg/mL. Quadratic fit model (y = ax2+bx+c) was used 
to determine concentration of the samples. 
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and standard, containing 0.8% of Triton X-100 (9002-93-1; Sigma), was carefully pipetted into 
a well of 96-well plate, following addition of 150 μL of 660nm protein assay reagent. All 
reactions were performed in triplicate to ensure accuracy. The plate was incubated at RT for 
5 minutes, and the absorbance was measured at 660nm using microplate reader. Protein 
concentration in each sample was determined as described in section 2.3.1.2.1. 
 
2.3.1.3. Sodium dodecylsulfate -polyacrylamide gel electrophoresis (SDS-PAGE) 
The results from the protein assay were used to ensure equal loading for quantitative western 
blotting. Protein extracts were mixed with 2X SDS sample buffer [4% sodium dodecylsulfate 
(SDS; AM9823; Invitrogen), 10% 2-mercaptoethanol (M3148; Sigma), 20% glycerol (G9012; 
Sigma), 0.125 M Tris-HCl (Trizma base; T1503; Sigma; pH 6.8) and bromophenol blue (B6896; 
Sigma)], in a ratio of 1:1, and heated for 3 minutes at 95°C on a block heater, after which the 
samples were subjected to SDS-PAGE (Laemmli, 1970). 2-mercaptoethanol is used in the 
buffer to break disulfide bonds between cysteine residues, and SDS to facilitate solubilization 
of hydrophobic proteins (Bass et al., 2017). Another important role of SDS is to overcome 
positive charge of the proteins in the sample (Bass et al., 2017). Negatively charged proteins 
are separated by their mass, on a polyacrylamide gel by application of electrical current (Bass 
et al., 2017). Samples and PageRuler™ Protein Ladder (26619; Thermo Scientific) were 
carefully loaded on Bolt™ 4-12% Bis-Tris Plus gel (NW04125BOX; Invitrogen) that was 
submerged in 1x SDS running buffers, MOPS (B0001; Invitrogen) or MES (B000202; Invitrogen), 
for separation of medium-large sized proteins or small-medium sized proteins respectively. 
Proteins in the sample were subject to electrophoresis at 140 V using a powerpack (PowerPac 
BASICTM; Biorad). 
 
57 
 
2.3.1.4. Protein transfer and immunoblotting 
A slice of the gel, that did not contain protein of interest, was excised and stained with 
Coomassie blue dye [0.2% Coomassie Brilliant Blue R (B-0149; Sigma), 10% glacial acetic acid 
(64-19-7; Fisher Scientific), 20% industrial methylated spirits (IMS; Genta Medical) and 70% 
dH20] for one hour or overnight, as an internal loading control for total protein. Coomassie 
staining is total protein loading control that showed higher linearity of protein detection 
compared to common housekeeping proteins such as glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (Welinder and Ekblad, 2010). Coomassie dye forms complexes with 
proteins by binding primarily to arginine and lysine residues (Sapan, Lundblad and Price, 
1999). After incubation in Coomassie blue, the gel was left in de-stain solution (10% glacial 
acetic acid, 20% IMS and 70% dH20) to remove the background staining. The remaining part 
of a gel was assembled into a sandwich (as shown in Figure 2.2.) and submerged into transfer 
buffer [192 mM glycine (G7126; Sigma) and 25 mM Trizma base (T1503; Sigma)] to allow for 
transfer of proteins onto a nitrocellulose membrane (10600041; Amersham). Protein transfer 
was done overnight at 100 mA using a powerpack (PowerPac BASICTM; Biorad). The system 
was kept cool by cold water constantly running through a pipe that was submerged into the 
transfer tank. 
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Following protein transfer, the membrane was incubated with 4% powdered milk (Marvel) in 
PBS for one hour to block non-specific protein binding. The membranes were incubated with 
an appropriate primary antibody (Table 2.2.) in western blot (WB) buffer [1% FBS, 1% horse 
serum (HS; 16050130; Gibco), 0.1% BSA and 0.05% Triton X-100/ in PBS] at RT for one or two 
hours, followed by incubation with HRP-labelled goat anti-rabbit Ig (P0448; DAKO) or HRP-
labelled goat anti-mouse Ig (P0260; DAKO) in WB buffer at 0.25 ng/mL,  for one hour at RT. 
Between each step membranes were washed three times with PBS for five minutes. 
Membranes were incubated with SuperSignalTM West Femto (34904; Thermo Scientific) or 
SuperSignalTM West Pico (34580; Thermo Scientific) chemiluminescent substrate for 5 minutes 
at RT and visualised using a Gel Image Documentation system (Biorad).
Figure 2. 2. Assembly of a sandwich for western blotting. Proteins from the gel were transferred onto a 
nitrocellulose membrane by assembling sandwich: sponge, filter paper, gel, nitrocellulose membrane, filter 
paper and sponge. The gel has to be on the negative side of the electrode to allow protein transfer onto the 
nitrocellulose membrane. Image created with BioRender.com. 
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Table 2. 2. Primary antibodies used in western blotting 
Antibody Supplier and catalog 
number 
Dilution Predicted mol. 
weight (kDa) 
Comment 
Mouse monoclonal 
anti-SMN 
MANSMA12 2E6 (Young 
et al., 2000) 
1:100 38  
Mouse monoclonal 
anti-lamin AC 
MANLAC1 4A7 (Manilal 
et al., 2004) 
1:100 71-66 For analyses of 
cell extracts 
Rabbit monoclonal 
anti-lamin AC 
ab169532; Abcam 1:1000-1:2000 74 For analyses of 
mouse tissues 
Mouse monoclonal 
anti-GAPDH 
NBP2-27103; Novus  1:1000-1:2000 36  
Rabbit monoclonal 
anti-UBA1 
NBP2-67816; Novus  1:500-1:1000 130  
Mouse monoclonal 
anti-ANXA2 
MAB3928; RD System 1:1000 40  
Rabbit monoclonal 
anti-NCAM 
701379; Invitrogen  1:500 94, 140, 180  
Rabbit polyclonal 
anti-GAP43 
ab16053; Abcam  1:2000 43-53  
Mouse monoclonal 
anti-active β-catenin 
05-665; Merc Millipore 1:500 92  
Mouse monoclonal 
anti-β-catenin 
610154; BD Trans. Lab. 1:1000-1:2000 92  
Mouse monoclonal 
anti-emerin 
MANEM1 5D10; 
(Manilal et al., 1996) 
1:100 34 For analyses of 
cell extracts 
Rabbit polyclonal 
anti-emerin 
Made in the house 1:200 34 For analyses of 
mouse tissues 
Rabbit polyclonal 
anti-ALDOA 
NBP1-87488; Novus  1:500 40  
Rabbit polyclonal 
anti-SOD1 
ab13498; Abcam  1:1000 18  
Rabbit polyclonal 
anti-CALR 
NB600-103SS; Novus 1:500 55  
Mouse monoclonal 
anti-GRP94 
sc-393402; Santa Cruz  1:50 94 Also known as 
HSP90B1 
Rabbit monoclonal 
anti-Neurofilament-L 
C28E10; Cell Signaling  1:1000 70  
Rabbit polyclonal 
anti-FAS ligand 
ab15285; Abcam  1:200 31  
Mouse monoclonal 
anti-3-nitrotyrosine 
sc-32757; Santa Cruz 1:50-1:200 NA  
Catalog number and supplier are listed for each primary antibody, together with the dilution, molecular weight 
of the protein target and sample type the antibodies were used on. NA-not applicable 
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2.3.1.5. Densitometry measurements of antibody reactive bands 
Densitometry measurements of antibody reactive bands were obtained using Fiji software 
(v1.51) (Schindelin et al., 2012). Before the analyses, images were converted to gray-scale 
images (Image → Type → 8-bit), and where necessary, contrast and brightness were adjusted 
uniformly across the gel and blot to decrease the background and enhance signal detection 
(Image → Adjust → Brightness/Contrast). 
A rectangular box of a fixed size was drawn around the band in the first lane and marked as 
selection one, using a CTR+1 command. The box was then moved to the next lane and marked 
as selection 2 using a CTR+2 command. The same was repeated for all consecutive lanes until 
all bands were labelled, and the CTR+3 command was then used to draw a profile plot of each 
lane. Profile plot represents the relative density of the contents of the rectangle selection, 
where the peak corresponds to the dark band. The straight-line selection tool was used to 
draw a line at the base of the peak to divide the background from the peak. The surface of the 
peak was measured using a wand selection tool. For analysis of Coomassie stained gel, a 
rectangular selection tool was drawn across all lanes, to include several bands in each sample, 
and analysed as described above. Densitometry measurements of antibody reactive bands 
were normalized to densitometry measurements of the Coomassie stained gel, after which all 
samples were normalised to the average of control. The workflow is presented in Figure 2.3.  
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2.3.2. Immunocytochemistry (ICC) 
Fibroblasts, MEFs and HEK cells were washed with PBS (3x for 5 min) and incubated with 
primary antibody (Table 2.3) in immunofluorescence (IMF) buffer (1% FBS, 1% HS and 0.1% 
BSA/ in PBS) for one or two hours. After washing with PBS (3x for 5 min), cells were incubated 
with goat anti-rabbit IgG Alexa Fluor 488 or 546 (A11034 or A11010; Life Technologies), or 
goat anti-mouse IgG Alexa Fluor 488 or 546 (A11029 or A11030; Life Technologies) in IMF 
buffer for one hour at 5 μg/mL. Cells were then washed with PBS (3x for 5 min), stained with 
4’,6-diamidino-2-phenylindole (DAPI; D9542; Sigma; 0.4 μg/mL) for 10 minutes, washed with 
Figure 2. 3. Densitometry measurements of protein expression. Densitometry measurements of (A) protein 
of interest and (B) Coomassie stained gel. Rectangular box of a fixed size was drawn around protein band in 
each lane and across all lanes in Coomassie gel. Profile plots were generated, where peaks correspond to dark 
bands in each selection. The surface under the peak is proportional to the quantity of the protein in the sample. 
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PBS again (3x for 5 min) and mounted using Hydromount mounting media (National 
diagnostics).  
 
Table 2. 3. Primary antibodies for immunocytochemistry analyses 
Catalog number and supplier are listed for each primary antibody used in immunocytochemistry analysis, 
together with the dilution and sample type the antibodies were used on. 
  
2.3.2.1. Imaging and quantitative analyses  
Images were obtained using Leica SP5 confocal microscope (Minsky, 1988), with 63× oil 
immersion objective and LAS AF software (Leica Microsystems CMS GmbH). Argon, HeNe 543 
and Diode 405 laser power were set to 10%, and they were used for detection of IgG Alexa 
Fluor 488 fluorophore, IgG Alexa Fluor 546 fluorophore and DAPI staining respectively. 
Imaging was performed in sequential scanning mode to avoid crosstalk between fluorophores. 
 
2.3.2.1.1. Nuclear morphology defects 
Control (GM00302, GM00498 and GM05659) and patient (GM00232, GM03813, GM09677) 
fibroblasts were examined for nuclear morphology defects based on the results from the 
previous study (van Tienen et al., 2019). These included donut and honeycomb-like structures, 
Antibody Supplier and catalog N° Dilution Comments 
Rabbit monoclonal anti-
UBA1 
NBP2-67816; Novus 1:100  
Mouse monoclonal anti-
lamin A 
sc-71481; Santa Cruz 1:50 For all other ICC analysis 
Mouse monoclonal anti-
lamin A/C 
MANLAC1 4A7; (Manilal et 
al., 2004) 
1:4 For analysis of lamin A/C staining 
in quercetin treated cells 
Rabbit polyclonal anti-
SMN 
Made in the house 1:50 For analysis of SMN staining in 
MEFs 
Mouse monoclonal anti-
SMN 
MANSMA1 11F3; (Young et 
al., 2000) 
1:4 For analysis of SMN staining in 
quercetin treated cells 
Mouse monoclonal anti-
FLAG 
F3165; Sigma 1:200  
Mouse monoclonal anti 
active β-catenin (ABC) 
05-665; Millipore 1:200  
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blebs, micronuclei and nuclear shape abnormalities (Figure 2.4). Only cells that were 
completely in the field of view were analysed. At least 100 cells were analysed for nuclear 
morphology defects in each primary cell, meaning that at least 300 cells were analysed in each 
group, control and SMA.   
 
 
2.3.3. Immunohistochemistry 
Lumbar spinal cord sections (25 μm) from P8 SMA mice and healthy littermates, and 20 week-
old ALS mice and WT littermates were permeabilised with 0.3% Triton X-100/ in PBS for ten 
minutes, washed with PBS (3x for 5 min) and blocked for one hour in blocking buffer (4% BSA, 
0.1% Triton X-100/ in PBS) or 10% goat serum (GS)/ in PBS. Sections were incubated with 
rabbit monoclonal anti-calreticulin (ab92516; Abcam; 1:250) (Figure 5.9), or rabbit polyclonal 
anti-Fas ligand (ab15285; Abcam; 1:100) and mouse monoclonal anti-calreticulin (NBP2-
50053; Novus; 1:100) (Figure 5.10A) in blocking buffer (with or without 1% GS) overnight at 
4°C, and washed with PBS (3x for 5 min). After incubation with goat anti-rabbit IgG Alexa Fluor 
488 or 546 (A11034 or A11010; Invitrogen) or goat anti-mouse IgG Alexa Flour 488 (A11029; 
Invitrogen) for one hour at 5 μg/mL, sections were washed with PBS (3x for 5 min), stained 
with DAPI (D9542; Sigma; 0.4 μg/mL) for 10 minutes, washed with PBS again (3x for 5 min) 
and mounted using Hydromount mounting media (National diagnostics). Images were 
obtained using Leica SP5 confocal microscope as described above. 
Figure 2. 4. Examples of nuclear morphology defects in SMA patient fibroblasts. N- normal fibroblast; BL-bleb; 
NSA-nuclear shape abnormality; D-donut-like structure; HC-honeycomb-like structure 
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2.3.3.1. Densitometry measurements of calreticulin staining using Fiji software 
Densitometry measurements of calreticulin staining in motor neurons of the anterior horn 
were performed using Fiji software (v1.51) (Schindelin et al., 2012). Calreticulin staining was 
assessed in two control and two SMA mice (P8), and in two control and two ALS mice (20 
weeks). A minimum of four sections from each mouse were used in the analysis. Two fields of 
view (left and right anterior horn) were selected from each section (where the quality of the 
section allowed this) and measurements of three distinct regions that contained alpha motor 
neurons were taken from each field of view. A minimum of 45 measurements were made from 
each experimental group. 
First, images were calibrated using a calibrated step tablet. A rectangular selection that filled 
most of the step without overlapping another one was created to measure mean grey value 
of the first step. The same rectangular selection was then used to measure the mean grey 
value of all the consecutive steps in the tablet. Measured values were plotted against standard 
measurements of optical density (OD) to create a calibration curve using a “Rodbard” function. 
OD of the negative control (IgG control) was then measured as described below. The colour 
(RGB) picture was converted into an 8-bit picture (Image→ Type→ 8-bit) and inverted (Edit→ 
Invert) for further analysis. A rectangular selection tool of fixed size was then used to measure 
OD of three regions of interest in each field of view. This protocol was used for measurements 
of all pictures, with an addition of one step. Prior to measurements of the OD, the mean OD 
of the negative control was subtracted from the picture to correct the background (Process→ 
Math→ Subtract). 
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2.3.4 Dot blotting 
The results from the protein assay (Section 2.3.1.2) were used to ensure equal protein loading 
for dot blot analyses. Dot blotting is an immuno-associated technique were protein extracts 
are loaded directly on the nitrocellulose membrane, and the membrane is developed in the 
same way that a regular western blotting would be (Salazar-Anton, Tellez and Lindh, 2012). 
GM05659 control and GM00232 patient fibroblast extracts were used to test antibodies raised 
against three SMN epitopes, including mouse anti-MANSMA12 2E6, mouse anti-MANSMA2 
8F7 and mouse anti-MANSMA3 8E1 (Young et al., 2000), and to test mouse anti-MANLAC1 
4A7 antibody raised against lamin A/C protein (Manilal et al., 2004). GM00302 control and 
GM00232 patient fibroblast extracts were used to test mouse anti-lamin A antibody (sc-
71481; Santa Cruz). Cell extracts were prepared in serial dilutions in concentration range 
between 1.5 mg/mL- 0.0468 mg/mL, and 2 μL of each prepared sample was carefully pipetted 
on to a nitrocellulose membrane in triplicates. After being left to dry for 5 minutes at RT, 
membranes were incubated with 4% powdered milk (Marvel) in PBS for one hour to block 
non-specific protein binding. Following incubation with an appropriate primary antibody 
(Table 2.4) in WB buffer for one hour at RT, the membranes were incubated with HRP-labelled 
goat anti-mouse Ig (P0260; DAKO) in WB buffer at 0.25 ng/mL, for one hour at RT. Between 
each step membranes were washed three times with PBS for five minutes. Membranes were 
incubated with SuperSignalTM West Femto (34904; Thermo Scientific) or SuperSignalTM West 
Pico (34580; Thermo Scientific) chemiluminescent substrate for 5 minutes at RT and visualised 
using a Gel Image Documentation system (Biorad). 
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Table 2. 4. Primary antibodies used in dot blotting 
Antibody Supplier and catalog N° Dilution Epitope 
Mouse monoclonal 
anti-SMN 
MANSMA2 8F7 (Young et al., 2000) 1:100 aa - ASL 
Mouse monoclonal 
anti-SMN 
MANSMA3 8E1 (Young et al., 2000) 1:100 Exon 5 aa- PSGP- - -P 
Mouse monoclonal 
anti-SMN 
MANSMA12 2E6 MANSMA3 8E1 
(Young et al., 2000) 
1:100 DDT-LI—Y--A 
Mouse monoclonal 
anti-lamin A 
sc-71481; Santa Cruz 1:250 Unknown 
Mouse monoclonal 
anti-lamin A/C 
MANLAC1 4A7; (Manilal et al., 2004) 1:100 aa477-485 
Catalog number and supplier are listed for each primary antibody, together with the dilution and target epitope. 
 
2.3.4.1. Densitometry measurements of antibody reactive dots using Fiji software 
Densitometry measurements of antibody reactive dots were obtained using Fiji software 
(v1.51) (Schindelin et al., 2012). Before the analyses, images were converted to gray-scale 
images (Image → Type → 8-bit), inverted (Edit → Invert), and where necessary, contrast and 
brightness or the background were adjusted uniformly across the membrane to enhance 
signal detection (Image → Adjust → Brightness/ Contrast or Process → Subtract Background). 
An oval selection tool of a fixed size was drawn around the first dot and integrated density of 
the selection was measured using CTR+M function. Oval selection was then moved to the next 
dot to measure integrated density, and the same was repeated for all consecutive dots on the 
membrane. The workflow is presented in Figure 2.5. R-squared (R2) value was calculated for 
serial dilutions of each sample to determine accuracy of the dot blot approach. Sensitivity of 
the dot blot was determined by calculating the average protein levels in SMA cell line relative 
to control in all consecutive dilutions and comparing them to western blot analysis. 
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2.3.5. Indirect enzyme-linked immunosorbent assay (ELISA) 
ELISA is an immunoassay that allows quantitative and qualitative analyses of different 
molecules including proteins (Sakamoto et al., 2018). In indirect ELISA, proteins are 
immobilised on the cell surface of the well and detected using a two-step antibody labelling. 
Protein extracts from control (GM00498) and patient (GM00232) fibroblasts were prepared 
at a concentration of 0.2 mg/mL to ensure equal protein loading. Seven serial dilutions of each 
cell extract were prepared, starting with 1:5 dilution, and a 100 μL of each dilution was 
carefully pipetted in ELISA 96-well plate in triplicates to allow protein immobilisation to the 
well surface. Following incubation with protein extracts for one hour at RT, proteins were 
Figure 2. 5. Workflow of dot blot analysis. Image was converted to gray-scale image and inverted, and the 
background was adjusted uniformly across the membrane to enhance signal detection. Oval selection tool of 
a fixed size (blue circle) was used to measure integrated density of each dot on the membrane. Example 
measurements are presented for the first row of the blot. 
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incubated with 4% powdered milk (Marvel) in PBS for one hour to block non-specific protein 
binding. After the incubation with mouse monoclonal anti-lamin A (sc-71481; Santa Cruz; 1: 
250) in WB buffer for one hour, proteins were incubated with HRP-labelled goat anti-mouse 
Ig (P0260; DAKO) in WB buffer at 0.25 ng/mL for one hour at RT and developed with 3,3',5,5'-
tetramethylbenzidine (TMB) substrate. Between each step wells were washed three times 
with PBS/0.1 % Triton X-100 for five minutes. In reaction with horseradish peroxidase, TMB 
substrate produces blue product with a maximum absorbance at 370 nm and 650 nm (Bos et 
al., 1981). The reaction is then stopped by addition of sulfuric acid, that causes a shift in colour 
to yellow with a maximum absorbance at 450 nm. Blue reaction product did not develop after 
the addition of TMB, and so the experiment was stopped at this point.  
 
2.4. Immunoprecipitation  
Immunoprecipitation was performed as described previously (Fuller et al., 2017). Anti-mouse 
Pan Ig-coated magnetic beads (50 μL) (11041; Invitrogen) were washed with 4% BSA/PBS (3x) 
to block the non-specific binding. In all steps, DynaMagTM spin magnet (12320D; Invitrogen) 
was used to separate the beads from the solution. Beads were then incubated with 50 μL of 
the appropriate antibody or PBS (negative control) for 1 hour at RT with gentle rolling. 
Antibodies were as follows: mouse anti-lamin A/C [MANLAC1 4A7; (Manilal et al., 2004); neat], 
mouse anti-SMN [MANSMA1 11F3; (Young et al., 2000); neat] and mouse-anti 3-nitrotyrosine 
(sc-32757; Santa Cruz; 1:5). The beads were then washed twice with 4% BSA/PBS and once 
with PBS, and incubated with RIPA extracts of human fibroblast cells (75 μL), mouse heart 
tissue (15μl) or mouse spinal cord tissue (20 μL) for 1 hour at RT on a roller. Following 
incubation, the supernatant was carefully removed and stored in fresh tubes as it represents 
the unbound part of the pulldown. The beads were washed once with RIPA buffer and 4x with 
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PBS, and the captured material was eluted from the beads by heating at 90°C for 3 minutes in 
1xSDS sample buffer (30 μL for heart and spinal cord pulldown, and 75 μL for fibroblast 
pulldown). 
Samples were then subjected to western blotting as described in section 2.3.1 to investigate 
potential interacting partners. Primary antibodies were as follows: mouse anti-SMN 
[MANSMA12 2E6 (Young et al., 2000)], mouse anti-lamin A/C [MANLAC1 4A7; (Manilal et al., 
2004)], rabbit anti-lamin AC (ab169532; Abcam), rabbit anti-UBA1 (NBP2-67816; Novus), 
mouse anti-β-catenin (610154; BD Transduction Laboratories), rabbit anti-ALDOA (NBP1-
87488; Novus) and mouse-anti 3-nitrotyrosine (sc-32757; Santa Cruz). 
 
2.5. Quantitative (real time) reverse transcription polymerase chain reaction 
(RT-qPCR) 
2.5.1. Extraction of total RNA 
Total RNA was extracted using RNeasy Plus Mini kit (74134; Qiagen) according to instructions 
outlined in the kit guidelines. Fibroblasts cells were lysed and homogenised in 350 μL of RTL 
buffer containing 1% 2-mercaptoethanol (M3148; Sigma) by repeated pipetting. 600 μL of RTL 
buffer/2-mercaptoethanol was added to the heart tissue, and the samples were lysed and 
homogenised using a GentleMACS Dissociator (Miltenyi Biotec) for 45 seconds. Guanidine 
Isothiocyanate in the RTL buffer and 2-mercaptoethanol were used to denature and inhibit 
RNAases to ensure isolation of intact RNA (Wagner, 2013). Homogenized lysates were 
transferred to a gDNA Eliminator spin column placed in a 2 ml collection tube and centrifuged 
for 30 seconds at 13000 RPM (Micro Centaur MSB010.CX2.5; MSE; rotor radius- 4 cm) to 
remove double-stranded DNA. The column was discarded, and 1 volume (350 or 600 μL) of 
70% ethanol was added to the flow-through to precipitate the RNA from the solution (Wagner, 
70 
 
2013). Samples were mixed by gentle pipetting, transferred to a RNeasy spin column and 
centrifuged for 15 seconds at 13000 RPM. In this step, total RNA binds to the membrane while 
down-stream contaminants, such as the ethanol, get discarded in the flow-through. RNeasy 
spin column with total RNA was then washed by centrifugation (13000 RPM) in RW1 buffer 
(700 μL) for 15 seconds, and twice in RPE buffer (500 μL), for 15 seconds and 2 minutes 
respectively. The RNeasy spin column was then transferred into the new collection tube and 
centrifuged on 13000 RPM for 1 minute to eliminate any possible carryover of buffer RPE. 
RNeasy spin column was placed into the new collection tube and total RNA was eluted from 
the column by centrifugation (13000 RPM) in 30 μL of RNase-free water for 1 minute. Total 
RNA was quantified with a NanoDrop ND- 1000 spectrophotometer (Thermo Fisher). 
Absorption ratio (OD260/OD280 nm) was used to verify the integrity of the RNA, where ratio of 
1.8-2.0 represented pure RNA. 
 
2.5.2. Synthesis of complementary DNA (cDNA) 
Total RNA was reverse transcribed using SuperScriptTM VILOTM cDNA Synthesis Kit (11754050; 
Invitrogen) according to instructions outlined in the guideline. Total RNA from fibroblast cells 
(2 μg) and heart tissue (1.5 μg) was prepared in 20 μL reactions, and subjected to cDNA 
synthesis using a Prime Thermal Cycler (Bibby Scientific) with parameters: 25°C for 10 min 
(primer annealing), 42°C for 60 min (reverse transcription) and 85°C for 5 min (enzyme 
inactivation). Enzyme mix contains reverse transcriptase, recombinant ribonuclease inhibitor 
to prevent RNA/DNA degradation, and a proprietary helper protein. VILO reaction mix 
contains random primers, MgCl2, and dNTPs.  
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cDNA reactions: 
x μL total RNA 
4 μL 5x VILO reaction mix 
2 μL 10x enzyme mix 
Make up to the final volume of 20 μL with RNase-free water 
 
2.5.3. Quantitative PCR (qPCR) 
Quantitative PCR (qPCR) for the LMNA gene was performed using a SYBR Green detection 
system (Ririe, Rasmussen and Wittwer, 1997), according to instructions outlined in the 
guideline (SYBRTM Select Master Mix; 4472903; Applied Biosystems). SYBR master mix 
contains: SYBR® GreenER Dye, AmpliTaq DNA polymerase, heat-labile Uracil-DNA glycosylase 
(UDG), ROX dye passive reference, dNTP blend containing dUTP/dTTP and optimized buffer 
components. In this system, fluorescent SYBR green dye forms complexes with double-
stranded DNA (dsDNA), and as its fluorescence increases it can be measured at the end of 
each amplification cycle of qPCR (Navarro et al., 2015). UDG prevents carryover and 
amplification of non-specific PCR products (contaminants) by removing any uracil 
incorporated into single- or double-stranded amplicons. The ROX dye passive reference 
provides an internal reference to which the reporter-dye signal can be normalized. PCR 
reactions were prepared to contain 3.75 ng of cDNA (fibroblast cells) or 2.8 ng of cDNA (heart 
tissue) in 20 μL reactions.  
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qPCR reactions: 
x μL DNA 
10 μL SYBR master mix (2X) 
300 nM Forward and 300 nM Reverse primers 
Make up to the final volume of 20 μL with RNase-free water 
 
All PCR reactions were performed in triplicates. Parallel wells with no cDNA were run for each 
gene to control for contamination. RNA Polymerase II Subunit J (POLR2J) and TATA-Box 
binding protein (TBP) were used as reference genes as they have previously demonstrated 
stable expression across tissues (Radonić et al., 2004), and their expression was not 
dysregulated in published transcriptomics studies of SMA. qPCR was performed using a 
QuantStudio 3 Real Time PCR system (Applied Biosystems) with the following parameters: 
50°C for 2 min (UDG activation), 95°C for 10 min (DNA polymerase activation), and 40 cycles 
of 95°C for 15 sec (denaturation) and 60°C for 1 min (anneal/extend faze). Amplification plots 
were generated by plotting cycles on the X axes against ΔRn on y-axes, where ΔRn is defined 
as normalized reporter value (Rn) of an experimental reaction minus the Rn value of the 
baseline signal generated by the instrument. The baseline and threshold values were 
automatically defined by the software. Baseline value represents background fluorescence 
that is not taken into account during calculations. Threshold value is placed in the region of 
the exponential faze of the amplification plot and is used to define cycle threshold (Ct) value 
for each sample (Figure 2.6A). Relative gene expression was quantified using Pfaffl method 
(Pfaffl, 2001). First the geometric mean of reference genes (POLRJ and TBP) was subtracted 
from the Ct value of lamin A giving the ΔCt value, after which raw gene expression was 
calculated using the equation: 2^-(ΔCt). Data was presented as average raw expression of the 
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group. Dissociation curves were obtained for each sample to control for amplification of non-
specific products and formation of primer- dimers (Navarro et al., 2015) (Figure 2.6B). 
 
Figure 2. 6. Example of quantitative RT-PCR. Representative images showing (A) amplification plots and (B) 
dissociation curves for LMNA, POLRJ and TBP genes in control and SMA fibroblasts. Three peaks, corresponding 
to LMNA, POLRJ and TBP, were identified in dissociation curves, indicating absence of non-specific products 
and primer- dimers formations. LMNA- lamin A/C; POLR2J- RNA Polymerase II Subunit J; TBP- TATA-Box binding 
protein; NTC-no template control 
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2.5.3.1. Primer design and primer efficiency  
Primer sequences for lamin A, POLR2J and TBP were designed using National Center for 
Biotechnology Information (NCBI) primer-BLAST tool (Ye et al., 2012). Primers were chosen 
based on the ability to produce PCR product of approximately the same size (between 70-150 
bp), to have similar melting temperatures (around 60°C). For the LMNA gene, primer pairs 
were also designed to recognise only lamin A isoform (exon 11 and 12). Primer sequences are 
listed in the Table 2.5. Efficiency of the primer pairs was determined by making serial dilutions 
of the cDNA and performing qPCR as described above. Log values of the cDNA were then 
plotted on the X axis against the Ct (cycle threshold) values on y axes to generate equation 
(Figure 2.7). Primer efficiency was calculated using a slope according to the equation: E = (10[–
1/slope]-1) x 100 (Pfaffl, 2001). The theoretical maximum of 100% indicates that the amount of 
PCR product doubles with each cycle. Primers with the efficiency between 90%-110% are 
considered optimal (Wagner, 2013), and were used here for qPCR. 
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Table 2. 5. Primer sequences for qPCR 
Target gene Species Sequence Size of the 
PCR product 
LMNA human F: CTCCTACCTCCTGGGCAACT 
R: AGGTCCCAGATTACATGATGCT 
74 bp 
LMNA mouse F: AGAGATGGGAATGACGGGGA 
R: CAGGCTCAGAAGCTGGGAAA 
71 bp 
TATA-Box Binding 
Protein (TBP) 
human F: GCATCACTGTTTCTTGGCGT 
R: AGAGCATCTCCAGCACACTC 
78 bp 
TATA-Box Binding 
Protein (TBP) 
mouse F: TCAGTTACAGGTGGCAGCAT 
R: GCAGGGTGATTTCAGTGCAG 
83 bp 
RNA Polymerase II 
Subunit J (POLR2J) 
human F: CTGGACCAAAGATCCGGGG 
R: GGTTTGCACACTTCTCTCCG 
70 bp 
RNA Polymerase II 
Subunit J (POLR2J) 
mouse F: GCTACAAAGTCCCTCACCCC 
R: TCCTGGGGACTGTAGTCTGG 
62 bp 
Forward and reverse primers for human and mouse lamin A, POLRJ and TBP genes are listed in the table, together 
with the size of the PCR product. 
 
 
Figure 2. 7. Assessing the efficiency of a primer pair. Log values of the sample quantity were plotted on the X 
axis against the Ct values on the y axes to generate equation. Slop (-3.447) was plotted in the equation: E = 
(10[–1/slope] -1) x 100 to calculate primer efficiency (95%). 
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2.6. Functional studies 
2.6.1. Cell proliferation 
Control (GM05659 P14, GM00498 P17, GM00302 P20) and SMA (GM00232, GM03813, 
GM09677 P13) fibroblasts were thawed and grown in complete medium as described 
previously in section 2.2. (The number after the cell ID (i.e. P14) indicates cell passage number. 
Passage number was not available/known for cell lines GM03813 and GM00232). After 
reaching 70% confluency, the cells were trypsinized and re-seeded in T25 culture flasks 
containing complete medium at a density of 30 000 cells/flask. Cells were maintained in 
humidified incubator (Leec) at 37°C and 5% CO2 for three days, after which the media was 
removed from the flask, and the cells were trypsinized and counted as described in section 
2.2. Each cell line was grown in three T25 flasks (technical replicates), and each technical 
replicate was counted four times, meaning that 12 measurements were done for each cell 
line. Doubling time (DT) for each cell was calculated using equation: 
DT= ln(2) * t/ (ln(C2) – ln(C1)) 
,where t represents culture duration in hours, C2 is the number of cells at the end of the culture 
and C1 is the number of seeded cells. 
 
The same protocol was used for the proliferation experiment in young (GM05659 P15, 
GM00498 P17, GM00302 P22) vs old (F011 P9, F067 P8, F154 P10) healthy fibroblasts. 
 
2.6.2. Trans-well migration assay 
Control (GM00498 P17) and SMA (GM03813) fibroblasts were thawed and grown in complete 
medium up to 70% confluency as described previously in section 2.2. Cells were trypsinized, 
carefully resuspended in media without the FBS and seeded on hanging cell culture inserts 
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(MCMP24H48; Millipore; 5 μm pore size) at a density of 20 000 cells/insert, that were placed 
into 24-well plates containing complete media (schematic diagram is shown in Figure 2.8). This 
was done to establish a nutrient gradient and induce migration of the cells through the 
membrane (Harada et al., 2014). Cells were maintained in humidified incubator (Leec) at 37°C 
and 5% CO2 for 6, 24, 48 and 72 hours to assess optimal incubation time. 
 
 
2.6.2.1. Immunocytochemistry 
Following incubation, the cells were washed with PBS (3x for 5 min), fixed in methanol (67-56-
1; Fisher Scientific) for 5 minutes and permeabilized in 0.5% Triton X-100/PBS for 5 minutes. 
After incubation with mouse anti-lamin A (sc-71481; Santa Cruz; 1:100) in IMF buffer at RT for 
1 hour, the cells were incubated with goat anti-mouse IgG Alexa Fluor 546 (A11030; 
Invitrogen; 5 μg/mL) in IMF buffer for one hour at RT, followed by incubation for 10 minutes 
with DAPI (D-9542; Sigma-Aldrich; 0.04 μg/mL). Between each step cells were washed with 
Figure 2. 8. Schematic diagram showing transwell migration assay. Cells were seeded on the apical side of the 
well insert to allow migration through a 5 μm well insert towards the media with FBS. Image created with 
BioRender.com. 
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PBS (3x for 5 minutes). The membrane was carefully cut from the insert and mounted with 
Hydromount, with apical side of the membrane facing up. 
 
2.6.2.2. Imaging and cell count using Fiji software 
Images were obtained using Leica SP5 confocal microscope with 63X oil immersion objective, 
using a Z-stack function. Z-stack function allows 3D reconstruction of the specimen (Kopecky 
et al., 2012), and here it was used to determine the number of cells on each side of the 
membrane (apical or dorsal). Apical and dorsal focal planes were defined in the begin and end 
boxes of the Z-stack panel in LAS AF software. The number of steps was defined to 15-40, and 
represents the number of pictures that were taken in each Z-stack. Cells were counted using 
Fiji software (v1.51) (Schindelin et al., 2012). The membrane was stained in blue with DAPI 
which served as a good guideline for the position of cells on the membrane. All pictures from 
one side of the membrane were uploaded into Fiji software and converted into a stack (Image 
→ Stacks → Images to stack). The stack was then converted into a single image with a Z-project 
function (Image → Stacks → Z Project), with projection type set to max intensity (Figure 2.9). 
Cells were counted using a multi-point tool. Cells on the left and bottom edge of the picture 
were counted if at least half of the cell was in the field of view. Cell on the top and right edge 
of the picture were excluded from the analysis. Results were expressed as percentage of 
migrated cells (MC) using formula: 
MC= D*100/T 
,where D represents number of cells on the dorsal side of the membrane and T represents 
total number of cells. 
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The same protocol was used to assess cell migration in control (GM05659 P13, GM00498 P16, 
GM00302 P20) vs SMA (GM00232, GM03813, GM09677 P14) fibroblasts, and young 
(GM05659 P13, GM00498 P115, GM00302 P20) vs old (F011 P7, F067 P6, F154 P8) healthy 
fibroblasts. Each cell line was grown in three technical replicates for 70 hours as described 
above, and three fields of view (Z-stacks) were taken from each technical replicate, meaning 
that nine fields of view were analysed in each cell.  
 
2.7. Transfection of MEFS with wild type lamin A using electroporation 
Transfection by electroporation relies on the use of high-voltage electric shocks to introduce 
DNA into the cell, and can be used both for transient and stable transfection of mammalian 
cells (Potter and Heller, 2003). LMNA KO MEFs were grown in cell culture up to 70% 
Figure 2. 9. Assessing cell migration through a 5 μm well insert. Cells on the apical and dorsal side of the 
membrane, and centre of the membrane are indicated on three consecutive figures (generated with stack 
function in Fiji). Image created with BioRender.com. 
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confluency, trypsinized, neutralised and centrifuged (as described in section 2.2). Following 
removal of supernatant, the cells were resuspended in F12 Ham medium to a concentration 
of 2x106 cells/mL, and 200 μL of cell suspension was gently mixed with 24 μg of pSVK3/lamin 
A WT plasmid. The pSVK3/lamin A WT plasmid was designed by Dr Ian Holt (Holt et al., 2003). 
The modified pSVK3 vector adds N-terminal FLAG tag to the lamin A/C protein. Cell/plasmid 
mix was added to electroporation cuvette with 2 mm gap (Biorad) and the cells were 
electroporated using Gene Pulser (Biorad) at 1.5 kV (resistance = 200 W; capacitance = 25 mF; 
time constant » 0.8). Cell viability and cell concentration were assessed as described 
previously in section 2.2.2. Following electroporation, around 60% of cells were viable, and 
these were seeded in tissue culture flasks (5x103 cells/cm2) and on glass coverslips (2.5x104 
cells) containing complete medium (with 20% FBS). Cells were maintained in humidified 
incubator (Leec) at 37°C and 5% CO2 for 48 hours to allow cell adhesion and expression of 
transfected plasmid. 
 
2.7.1. Western blotting and immunocytochemistry 
Cells were harvested for western blotting as described in section 2.2.3. Protein extraction and 
quantitative western blotting were done as described previously in section 2.3.1., using mouse 
monoclonal anti-lamin A/C [MANLAC1 4A7 (Manilal et al., 2004); 1:100], mouse monoclonal 
anti-SMN [MANSMA12 2E6 (Young et al., 2000); 1:100] and rabbit monoclonal anti-UBA1 
(NBP2-67816; Novus; 1:1000) antibodies. 
 
Cells seeded on glass coverslips were fixed in acetone: methanol solution as described in 
section 2.2.3. Immunocytochemistry analysis was done as described in section 2.3.2, using a 
mouse monoclonal anti-FLAG antibody (F3165; Sigma, 1:200). Fields of view were chosen to 
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capture at least 100 cells per coverslip. Three coverslips were analysed in each group, i.e. 
pSVK3/lamin A transfected and non-transfected cells, meaning that at least 300 cells were 
analysed in each group. Cells on the left and upper edge of the picture were included in the 
analysis if at least half of the cell was in the field of view. Results were expressed as average 
percentage of transfected cells (TC) using formula: 
TC= FP *100/T 
,where FP represents number of FLAG positive cells and T represents total number of cells. 
 
2.8. Drug studies on control and patient fibroblasts 
2.8.1. Cell culture and drug treatment  
Control and patient fibroblasts were grown in cell culture as described previously in section 
2.2. Briefly, the cells were seeded in tissue culture flasks containing complete medium at a 
density of 5x103 cells/cm2 and maintained in humidified incubator (Leec) at 37°C and 5% CO2 
until enough quantity of cells was generated for drug treatment. GM05659 control and 
GM00232 patient cell lines were used to investigate the effects of PDGF-BB and quercetin 
treatment, while GM00498 control and GM09677 patient cell lines were used to investigate 
the effect of trichostatin A (TSA) treatment. Cells were trypsinized and re-seeded in complete 
media in 6-well plates, at a concentration listed in table 2.6, for western blot analyses. For 
quercetin treatment, cells were also seeded on coverslips (25000 cells/coverslip) for 
immunocytochemistry analyses. To assess cell viability after TSA treatments, cells were 
seeded in 24-well plates at a concentration listed in table 2.6. Cells were maintained in 
humidified incubator (Leec) at 37°C and 5% CO2 until they reached appropriate confluency so 
that they can be treated with an appropriate concentration of the drug (details are listed in 
table 2.6). To do this, drugs were first dissolved in either DMSO (quercetin and TSA) or 4mM 
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HCl (PDGF-BB) according to instructions outlined in the guidelines, and diluted to the 
concentration that is 1000x higher than the one needed in experiment. Prepared drug 
concentrations were then mixed with complete media at 1:1000 dilution and sterile filtered 
to prevent microbial contamination. Cell culture media was carefully aspirated from the cells, 
and media containing appropriate concentration of the drug was carefully pipetted into the 
wells or on coverslips. Parallel wells, containing DMSO or 4 mM HCl (vehicle control), were 
prepared at 1:1000 dilution with complete media. This dilution was chosen to ensure that all 
drug and vehicle wells contained the same final concentration of the vehicle (i.e. 0.1%). Cells 
grown in complete media only served as untreated controls. Three technical replicates for 
each group, i.e. drug treatment, vehicle and untreated cells, were set up in 6-well plates and 
on coverslips. Two technical replicates were used in 24-well plates. The cells were maintained 
in humidified incubator (Leec) at 37°C and 5% CO2 (as listed in table 2.6). 
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Table 2. 6. Details of the drug treatment 
Drug Supplier and 
catalog N° 
Seeding density (time in culture) Drug treatment 
(concentration/ duration) 
Western blotting (6-well plates) 
PDGF-BB R&D Systems; 
220-BB 
CTR: 80000 cells/well (48 hours) 
SMA: 100000 cells/well (48 hours) 
0 and 100 ng/mL / 24 hours 
Quercetin Sigma- Aldrich; 
337951 
CTR: 80000 cells/well (24 hours) 
SMA: 100000 cells/well (24 hours) 
0, 6.25, 12.5, 25, 50 and 100 μM/ 
24 hours 
Trichostatin 
A  
Santa Cruz; SC-
3511 
50000 cells/well (72 hours) 
80000 cells/well (48 hours) 
50000 cells/well (72 hours) 
50000 cells/well (72 hours) 
0, 50 and 100 nM/ 4 hours 
0, 25, 50 and 100 nM/ 8 hours 
0, 25, 50 and 100 nM/ 16 hours 
0, 25, 50 and 100 nM/ 24 hours 
Cell viability (24-well plates) 
Trichostatin 
A 
Santa Cruz; SC-
3511 
10000 cells/well (48 hours) 
20000 cells/well (72 hours) 
15000 cells/well (72 hours) 
15000 cells/well (72 hours) 
0, 50 and 100 nM / 4 hours 
0, 25, 50 and 100 nM/ 8 hours 
0, 25, 50 and 100 nM/ 16 hours 
0, 25, 50 and 100 nM/ 24 hours 
Immunocytochemistry (coverslips) 
Quercetin Sigma Aldrich; 
337951 
25000 cells/well (24 hours) 0, 6.25 and 100 μM/ 24 hours 
Supplier and product code for each drug are listed in the table. Seeding density and time in the cell culture before 
the drug treatment are listed for each application, together with the concentration and duration of the drug 
treatment. The 0 concentration represent vehicle (DMSO or 4 mM HCl). 
 
2.8.2. Cell viability 
After the TSA and quercetin treatment, cell viability was assessed using trypan blue exclusion 
test as described in section 2.2.2. For TSA treatment, cells were seeded in duplicates in 24-
well plates and two cell viability assays were performed for each well, meaning that, in each 
treatment group, cell viability was assessed four times. For quercetin treatment, cells plated 
in triplicates in 6-well plates were also used for cell viability assay, meaning that, in each 
treatment group, cell viability was assessed three times. 
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2.8.3. Protein extraction and western blotting 
Cell treated with PDGF-BB and quercetin were harvested as described previously in section 
2.2.3. and proteins were extracted as described in section 2.3.1.1. Cells treated with TSA were 
washed twice in cold PBS, and lysed directly from the plate using 100 μL of 2X modified RIPA 
buffer. During this procedure the plate was kept on ice (4°C). RIPA buffer was carefully 
pipetted across the surface of the well multiple times to ensure complete protein extraction, 
followed by sonication at 5 microns for 10 seconds (Sonicrep 150; MSE). Protein extracts were 
then centrifuged at 13000 RPM (Micro Centaur MSB010.CX2.5; MSE; rotor radius- 4 cm) for 5 
minutes at 4°C to pellet any insoluble material. Cell extracts were subjected to protein assay 
using Pierce™ 660nm Protein Assay Reagent to determine sample protein concentration (as 
described in section 2.3.1.2.2). The samples were then subjected to quantitative western 
blotting as described in section 2.3.1, using mouse monoclonal anti-lamin A/C [MANLAC1 4A7 
(Manilal et al., 2004); 1:100], mouse monoclonal anti-SMN [MANSMA12 2E6 (Young et al., 
2000); 1:100], rabbit monoclonal anti-UBA1 (NBP2-67816; Novus; 1:500), mouse monoclonal 
anti-active β-catenin (05-665; Merc Millipore; 1:1000) and mouse monoclonal anti-β-catenin 
(610154; BD Trans. Lab.; 1:2000) antibodies. 
 
 2.8.4. Immunocytochemistry analysis of quercetin treated cells 
Following quercetin treatment, cells on glass coverslips were washed in cold PBS and fixed in 
acetone/methanol solution as described in section 2.2.3. Immunocytochemistry analyses 
were done as described in section 2.3.2, using mouse monoclonal anti-lamin A/C [MANLAC1 
4A7 (Manilal et al., 2004); 1:4], mouse monoclonal anti-SMN [MANSMA1 11F3 (Young et al., 
2000); 1:4], rabbit monoclonal anti-UBA1 (NBP2-67816; Novus; 1:100) and mouse monoclonal 
anti-active β-catenin (05-665; Merc Millipore; 1:200) antibodies. Images were obtained using 
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Leica SP5 confocal microscope, with 63× oil immersion objective, as described previously in 
section 2.3.2.1. 
 
2.8.4.1. GEM number 
Fields of view were chosen to capture at least 100 cells per coverslip. Three coverslips were 
analysed in each group, i.e. 0 μM (vehicle), 6.25 μM and 100 μM quercetin, meaning that at 
least 300 cells were analysed in each group. Only cells that were completely visible in the field 
of view were included in the analysis. SMN can be found both in the cytoplasm and nucleus, 
and nuclear SMN is located in structures called Gemini of the coiled bodies (GEMs) (Coovert 
et al., 1997) (Example is shown in Figure 2.10). Here, GEMs were counted in quercetin treated 
cells to determine the effect of a drug treatment on SMN levels. This was done because 
reduction in the number of GEMs was previously shown to corelate with disease severity in 
SMA (Coovert et al., 1997), meaning that number of GEMs decreases with reduction of SMN 
levels. 
 
Figure 2. 10. Representative immunocytochemistry images showing GEMs in healthy fibroblasts. GEMs are 
indicated by arrows. Scale bar = 7.5 μm. 
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2.8.4.2. Densitometry measurements of nuclear staining using Fiji software 
Fields of view were chosen to capture at least a 100 cells per coverslip. Three coverslips were 
analysed in each group, i.e. 0 μM (vehicle), 6.25 μM and 100 μM quercetin, meaning that at 
least 300 cells were analysed in each group. Densitometry measurements of nuclear lamin 
A/C, ABC and UBA1 staining were obtained using Fiji software (v1.51) (Schindelin et al., 2012). 
First, images were calibrated using a calibrated step tablet (as described in section 2.3.3.1). 
OD of the nuclear region was first measured on the negative control (IgG control) as described 
below. The split channels function (Image → Colour → Split Channels) was first used to 
separate blue and green channels which automatically converted them into gray-scale images 
for further analyses. Pixels on the green channel (LMNA, ABC and UBA1) were inverted (Edit 
→ Invert), while blue channel (DAPI) was used to define regions of interest. This was done by 
using one of the auto-threshold options, i.e. Huang or Huang2 (Image→ Adjust →Auto 
Threshold), where regions of interest are defined based on the intensity of staining. 
Measurement setting (Analyse→ Set Measurements) were defined as follows: integrated 
density, limit to threshold and redirect to green channel. This was done to ensure that 
integrated density is measured on the green channel and in the defined region of interest only. 
OD of the nuclear region was then measured using the analyse particles function (Analyse→ 
Analyse particles) with defined parameters: size (inch^2): 0.05-infinity, circularity: 0.00-1.00 
and exclude on edges (to exclude cells that are not completely visible in the field of view). This 
protocol was then used for measurements of all pictures, with an addition of one step. Prior 
to measurements of the OD, the mean OD of the negative control was subtracted from the 
green channel to correct the background, by using subtract function (Process→ Math→ 
Subtract). OD measurements from each field of view were normalised to the number of cells 
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in the field of view, and the average OD from each field of view was used in statistical analysis. 
The workflow is presented in Figure 2.11. 
 
Figure 2. 11. Workflow of densitometry measurements of nuclear protein staining. OD measurements of 
nuclear lamin A/C staining are presented, together with all corresponding steps. 
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2.9. Multi-study comparison of published ‘omics’ studies and bioinformatics 
analyses 
2.9.1. Identification and comparison of published transcriptomics studies of SMA  
PubMed searches were performed by Dr Heidi Fuller (Keele University). The search was 
conducted to include studies published up to April 2016, and published studies were 
considered eligible for inclusion if they had applied an unbiased transcriptomics approach to 
identify disease-specific gene expression patterns in SMA. Further selection of studies for 
comparison was done by me. Studies that utilised a targeted approach (i.e. seeking specific 
genes) for initial gene identification were excluded from comparison. Initially 15 studies were 
eligible for review, but four studies were further excluded from the list due to inaccessible or 
incomplete data (i.e. lack of access to complete article, only some results published or 
accessible), leaving 11 studies in total. 
 
All studies provided the list of genes in a standard format (i.e. official gene symbol), and so the 
use of DAVID gene ID conversion tool was not necessary here. Transcriptomics datasets were 
first extracted into a Microsoft Excel spreadsheet, and compared using Microsoft Excel’s ‘pivot 
table’ function (Grech, 2018) to identify genes that appeared in multiple studies. Pivot table 
function is a powerful tool that allows summary of a complex data (Grech, 2018). To do this, 
all transcriptomics studies were first listed in column A, together with the list of differentially 
expressed genes listed in column B. In the pivot table function (Insert → Pivot Table) the fields 
were dragged into the appropriate area, meaning that column A (‘Study’) was dragged into 
the column area, and column B (‘Gene’) was dragged into the row area, with the output 
measure (value) set to ‘count of genes’. The value of 1 suggested that the gene was identified 
as dysregulated in that specific study. 
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2.9.1.1. Bioinformatics analysis using DAVID and STRING 10 
Database for Annotation, Visualization and Integrated Discovery (DAVID) 
The Gene ontology (GO) analysis tool of the Database for Annotation, Visualization and 
Integrated Discovery (DAVID; version 6.8) platform (Huang, Sherman and Lempicki, 2009b, 
2009a) was used to investigate the likely function of genes that showed consistent direction 
of differential expression across at least three transcriptomic studies of SMA. In the GO 
analysis, genes/proteins are systematically mapped to biological annotations (gene ontology 
terms), including biological process (BP), molecular function (MF) and cellular component (CC) 
terms (Huang, Sherman and Lempicki, 2009b). This allows identification of biological 
processes that may have important role in the experimental model studied. The Fisher exact 
test is used to calculate the p-value, by measuring the gene/protein-enrichment in annotation 
terms (Huang, Sherman and Lempicki, 2009b). First, the number of genes/proteins that are 
associated with a specific GO term is determined from the reference dataset. The reference 
dataset is referred in DAVID as the ‘background’. The entire genome of the species that the 
data was derived from is usually set as a default background (Huang, Sherman and Lempicki, 
2009b). In this comparison, the background was set to Homo sapiens since data from both 
human and mouse samples was included in the comparison (Section 3, Table 3.1). The number 
of genes/proteins that are associated with the same GO term is then determined in the input 
dataset. If more genes/proteins are identified in the input dataset compared to the reference 
dataset, the specified term is significantly enriched in the input dataset (i.e. the association is 
not due to a chance) (Workflow is presented in Figure 2.12). Gene ontology (GO) analysis was 
conducted to include terms that had at least three annotated genes and a p-value ≤0.05. 
Following the analysis, redundant terms (those that were describing the same function and 
had identical matches, i.e. gene expression and regulation of gene expression) were combined 
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into one term to generate the final list of enriched GO terms. Data was presented as chord 
diagram using the circlize package in R software (Gu et al., 2014). 
 
 
Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) 10 
Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) 10 (Szklarczyk et al., 
2015) was used to identify statistically significant interactions between proteins, encoded by 
genes that showed consistent direction of differential expression across at least three 
transcriptomic studies of SMA. The STRING platform extracts data from multiple sources 
including KEGG Pathway Database, Reactome Pathway Database, The Biomolecular 
Interaction Network Database and many others7, thus integrating information about protein 
 
7 https://string-db.org/cgi/help.pl?sessionId=wxWRgx0N5sDs 
Figure 2. 12. Workflow of the enrichment analysis. If the overlap between genes/proteins in the input dataset 
and genes/proteins that are associated with a specific GO term is bigger compared to the reference dataset, 
the term is considered to be significantly enriched. 
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interactions from more than 2000 organisms (Szklarczyk et al., 2015). Protein interaction 
represents functional relationship between two proteins that is likely contributing to a 
common biological purpose (Szklarczyk et al., 2015). 
A list of proteins was uploaded into a tab: multiple proteins, with background set to Homo 
sapiens since data from both human and mouse samples was included in the comparison. 
Protein association network consist of nodes (input proteins), and edges which represent the 
predicted functional associations (Szklarczyk et al., 2015). Data was filtered to include protein 
associations identified with high confidence (0.700) interaction score to exclude false positive 
results. Confidence score is derived from seven types of evidence, each of which is scored 
separately (Szklarczyk et al., 2017). All evidence scores are then combined to give a final 
interaction score. Different types of evidence are presented with a different colour in 
association network. A red line represents fusion evidence, where proteins are given an 
interaction score if their orthologs have fused into a single, protein-coding gene in at least one 
organism. A green line represents neighbourhood evidence, where genes are given an 
association score if they are consistently observed in each other’s genome neighbourhood. A 
blue line represents co-occurrence evidence and assesses the phylogenetic distribution of 
orthologs of all proteins in a given organism.  Proteins are given an interaction score if their 
orthologs show a high similarity in the distribution, i.e. if they tend to be ‘present’ or ‘absent’ 
in the same subsets of organisms. A purple line represents experimental evidence, where 
proteins are given an interaction score if they were shown to interact experimentally. A light 
blue line represents database evidence, where proteins are given interaction score if 
information about their interaction was gathered from curated databases. A yellow line 
represents text-mining evidence, where proteins are given an interaction score if they are 
often mentioned together in PubMed abstracts and in other text collections. A black line 
92 
 
represents co-expression evidence, where proteins are given high association score if their 
expression patterns are consistently similar under a variety of conditions (Szklarczyk et al., 
2017).  
 
2.9.2. Comparison of the SMA proteome and transcriptome 
Differentially expressed genes, identified in the comparison of published transcriptomic 
studies of SMA (Chapter 3, Table 3.2), were compared with the differentially expressed 
proteins identified in a multi-study comparison of SMA proteomic studies (Fuller, Gillingwater 
and Wishart, 2016) using a Microsoft Excel’s ‘pivot table’ function (Grech, 2018) as described 
above. 
 
2.9.3. Identification of upstream regulators using Ingenuity pathway analysis (IPA)  
Upstream regulators of eight protein targets, SMN, lamin A/C, UBA1, GAPDH, ANXA2, GAP43, 
NCAM and COL6A3, were identified using a trial version of Ingenuity Pathway Analysis (IPA) 
(QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis). 
The upstream regulator function of the IPA enables identification of upstream regulators that 
have a known mechanism of action on target proteins/genes (Krämer et al., 2014). Upstream 
regulators include different molecules such as the transcription factors, miRNAs, drugs, 
growth factors etc. Two main values are generated in upstream regulators analysis, the p-
value of an overlap and the Z-score. The p-value is calculated by Fisher exact test (as described 
in section 2.9.1.1) by looking at the overlap between the genes/proteins in the input dataset 
and the genes from the literature that are known to be regulated by upstream regulators. Z-
score, on the other hand, gives a prediction of whether the upstream regulator is activated or 
inhibited based on the direction of expression change in the input dataset. This is done by 
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comparing the IPA database, which tells us what to expect when upstream regulator interacts 
with its downstream target, to the direction of differential gene/protein expression that was 
observed in the input dataset. Z-score of ≥2 represents the prediction of activation, while Z-
score ≤ -2 represents the prediction of inhibition.  
An Excel file, containing eight proteins of interest (expressed as official gene symbols) and 
their average fold changes across all proteomic studies, was uploaded into the IPA software 
(New → Core analysis → Upload), with column A defined as an ID column, and column B as an 
observation column. Core analysis were performed on the Expr fold change values to enable 
Z-score calculations. The Ingenuity Knowledge Base was defined as a reference dataset. Only 
experimentally determined, direct and indirect, upstream regulators were considered in the 
analysis. The analysis identified 307 upstream regulators that have a known mechanism of 
action on one or more protein targets, with a p-value ≤ 0.05. After removal of upstream 
regulators that were identified with just one downstream target, 78 upstream regulators were 
left that showed a known mechanism of action on at least two proteins. Of these, 20 upstream 
regulators were chemical or biological drugs that where considered for in vitro drug screening 
studies. After exclusion of toxic drugs (the ones that are used in cancer treatment), the list 
was reduced to eleven candidates. Drugs identified with two target proteins were further 
excluded from the list which left six potential drugs.   
 
2.9.4. Identification and comparison of published proteomic studies of ALS 
PubMed searches were performed initially by Joanne Stock (Keele University Masters 
student), and later updated by myself (DS) using combinations of the terms: “amyotrophic 
lateral sclerosis”, “Lou Gehrig’s disease” or “motor neuron disease” AND “proteomics” or 
“mass spectrometry”. The search was conducted to include studies published up to 1st July 
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2018, and published studies were considered eligible for inclusion if they had applied an 
unbiased proteomics approach to identify disease-specific protein patterns in ALS. Studies 
that utilised a targeted approach (i.e. seeking specific proteins) for initial protein identification 
were excluded. Initially 40 studies were eligible for review, but seven studies were further 
excluded from the list due to inaccessible or incomplete data (i.e. lack of access to complete 
article, only some results published or accessible), leaving 33 studies in total. Of these, 12 
studies examined proteome changes in biofluids from ALS patients and 21 studies examined 
proteome changes in cells and tissues from ALS models. 
 
The studies eligible for review applied a variety of strategies in data analysis and processing, 
and so it was necessary to establish a method of data selection for the comparison. First, only 
proteins changed in expression in ALS compared to healthy controls were considered for 
analysis. Proteins that were differentially expressed between ALS and diseased controls (e.g. 
Alzheimer disease), protein changes identified between different groups of ALS patients, 
and/or protein changes identified between different regions of the same tissue were 
disregarded. Results from studies that used multiple groups in proteomic comparison were 
filtered so that only proteins that showed differential expression between ALS and healthy 
controls were included in the comparison. Proteomic datasets were first extracted into a 
Microsoft Excel spreadsheet. To facilitate an achievable and accurate method for comparison 
between the studies the protein identifiers from each study were first converted to official 
gene symbols by using DAVID platform (Huang, Sherman and Lempicki, 2009b, 2009a). If 
protein identifiers were not provided, or if DAVID could not recognise the accession number, 
identifiers were assigned manually by searching for protein names using NCBI with the 
appropriate species filter to identify the corresponding accession number. Rarely, proteins 
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had been removed from the NCBI database and so were not included in the final analysis. 
Most studies presented changes in the protein expression as a fold change (FC) difference 
between ALS and controls, after having applied a cut-off value to identify proteins that were 
differentially expressed in ALS. In cases where the cut-off value for fold change was not 
applied, only proteins that showed at least 20% change in the expression were included in the 
comparison. (This value was chosen because it has been commonly used in other published 
proteomic studies to identify differentially expressed proteins e.g. (Mutsaers et al., 2013; 
Wishart et al., 2014; Chen et al., 2016)). The final lists of gene names were then compared 
using Microsoft Excel’s ‘pivot table’ function (Grech, 2018) to identify proteins that appeared 
in multiple studies, as described in section 2.9.1. 
 
2.9.4.1. Bioinformatics analysis 
Bioinformatics analyses were conducted on a list of proteins that showed consistent direction 
of differential expression across at least two proteomic studies of ALS, as described in section 
2.9.1.1. Gene ontology analysis, using DAVID platform (Huang, Sherman and Lempicki, 2009b, 
2009a), was conducted to include terms that had at least three annotated proteins and a p-
value ≤0.05, with background set to Homo sapiens. Redundant terms (i.e. those that were 
describing the same function and had identical matches, e.g. response to oxidative stress and 
removal of superoxide radicals) were combined into one term. Data was presented as chord 
diagram using circlize package in R tool (Gu et al., 2014). STRING 10 (Szklarczyk et al., 2015) 
was used to identify statistically significant interactions between proteins that showed 
consistent change in expression in ALS. Association network analysis was performed with high 
confidence (0.700) interaction score to exclude false positive results. 
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2.9.5. Comparison of SMA and ALS proteome changes 
Differentially expressed proteins identified in the comparison of ALS proteomic studies (Table 
5.4. and 5.5.) were compared with the list of differentially expressed proteins identified in the 
comparison of published proteomic studies of SMA proteomic (Fuller, Gillingwater and 
Wishart, 2016) to investigate common molecular patterns between the two diseases. Proteins 
with dysregulated expression in both SMA and ALS datasets were subjected to bioinformatics 
analysis using DAVID (Huang, Sherman and Lempicki, 2009b, 2009a) and STRING 10 (Szklarczyk 
et al., 2015) as described in section 2.9.4.1. 
 
2.10. GAPDH and ALDOA activity assays 
Aldolase fructose-bisphosphate A (ALDOA) and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) activity were measured in spinal cord extracts from 8-days old Taiwanese mice (n = 
3) and age-matched healthy controls (n = 3), 20-week old SOD1G93A mice (n = 3) and age-
matched healthy controls (n = 5 for ALDOA, and n = 3 for GAPDH), and 12-week old SOD1G93A 
mice (n = 4 for ALDOA, and n = 3 for GAPDH) and age-matched healthy controls (n = 3), 
according to instructions outlined in the guidelines. ALDOA (ab196994; Abcam) and GAPDH 
(ab204732; Abcam) are colorimetric activity assays that rely on the reaction between the 
developer and the product of the ALDOA or GAPDH activity. This reaction produces a coloured 
product that absorbs maximally at 450 nm, where the intensity of the colour is proportional 
to the enzyme activity levels. 
 
2.10.1. Protein extraction and quantification 
Spinal cord tissue was homogenized in ice-cold aldolase assay buffer with pallet pestle (30 
strokes), after which the samples were left on ice (4°C) for 10 minutes and sonicated at 5 
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microns for 10 seconds (Sonicrep 150; MSE). The same process was repeated two more times 
to ensure sufficient homogenization of the tissue. Protein extracts were then centrifuged at 
13000 RPM (Micro Centaur MSB010.CX2.5; MSE; rotor radius- 4 cm) for 5 minutes at 4°C to 
pellet any insoluble material, and supernatants were transferred to a fresh tube. Because of 
the compatibility between buffers of the two kits (in consultation with a technical team from 
Abcam), samples extracted in aldolase assay buffer were also used for measurements of 
GAPDH activity. Pierce™ 660nm Protein Assay was used to determine protein concentration 
of the samples (as described in section 2.3.1.2.2). The results from a protein assay were then 
used to ensure equal protein loading across all samples (1 mg/mL) that would allow accurate 
quantification of ALDOA and GAPDH activity. 
 
2.10.2. Measurements of ALDOA and GAPDH activity  
Nicotinamide adenine dinucleotide (NADH) standards, positive control and samples were 
prepared for the analysis in 96-well plates according to instructions outlined in the guidelines. 
All reactions were prepared in duplicates in the final volume of 50 μL. NADH standards were 
prepared from a 1.25 mM stock solution as described in Table 2.7, and 50 μL of the solution 
was carefully transferred into the well. Spinal cord extracts (1 mg/mL) were diluted to the final 
volume of 50 μL as shown in Table 2.8. Reaction and background wells were prepared for each 
sample in duplicates. Positive control wells were prepared at the same dilution as 
corresponding samples. 
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Table 2. 7. NADH standards 
NADH concentration (nmol/well) 0 2.5 5 7.5 10 12.5 
Volume of standard (μL) 0 5 10 15 20 25 
Volume of assay buffer (μL) 125 120 115 110 105 100 
Recipe for each standard is given in the table. 
 
Table 2. 8. Sample dilutions 
Sample Application and dilution 
ALS (20 weeks) ALDOA activity- 1:20 
GAPDH activity- 1:20 
ALS (12 weeks) ALDOA activity- 1:80 
GAPDH activity- 1:20 
SMA (8 days) ALDOA activity- 1:80 
GAPDH activity- 1:20 
Dilution factors used for each sample type and assay are listed. 
 
Reaction mix (50 μL) was then added to each standard, positive control and sample reaction 
well, and background mix to background sample wells (Table 2.9). Absorbance was measured 
at 450 nm using microplate reader (FLUOstar Omega; BMG Labtech), in a kinetic mode (every 
two minutes), for 1 hour at 37°C. 
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Table 2. 9. Reaction and background mix 
Component  Reaction mix (μL) Background mix (μL) 
Assay buffer 46 (GAPDH) 
44 (ALDOA) 
48 (GAPDH) 
46 (ALDOA) 
Substrate 2 0 
Developer 2 2 
Enzyme mix* 2 2 
Recipes for reaction and background mix are given. *Enzyme mix was added to the reaction and background mix 
only in ALDOA activity assay. 
 
2.10.3. ALDOA and GAPDH activity calculations 
First, the corrected absorbance was calculated for each NADH standard and sample, meaning 
that average absorbance of the blank (0 nmol/well) was subtracted from the average 
absorbance of samples and standards. Difference in absorbance (ΔOD) between the two time 
points was calculated for each sample according to formula: 
ΔOD= (A2-ABG2)- (A1-ABG1) 
(A1 represents corrected sample absorbance at time point 1, A2 corrected absorbance at time 
point 2, and ABG1 and ABG2 represent corrected background sample absorbance for each time 
point).  
Standard curve was created in Excel by plotting the corrected absorbance for each NADH 
standard vs. its concentration in nmol/well. Quadratic calibration model from the standard 
curve was then used to obtain the amount of the NADH (nmol) for the ΔOD value (B) according 
to formula: 
B = (-b+SQRT(b2-4*a*(c-ΔOD)))/(2*a) 
, where a, b and c represent three coefficients of the quadratic equation (y = ax2+bx+c). 
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Aldolase activity was calculated according to formula: 
Aldolase activity = [B/(T2-T1) x V)]*D 
(T1 and T2 represent time of the first (A1) and second (A2) absorbance reading in minutes, V is 
the sample volume added to reaction well (μL), and D is the sample dilution factor). 
 
2.11. Quantitative iTRAQ proteomics analysis 
Quantitative iTRAQ mass spectrometry analysis was performed as previously described (Fuller 
et al., 2014). Isobaric tags for relative and absolute quantification (iTRAQ) allows for the 
analysis of several samples in one experiment (Fuller and Morris, 2012). This eliminates the 
need to do multiple experiments, thereby reducing in-between experiment variations and 
overall analytical time. Isobaric tags covalently bind to all primary amines in the sample, 
meaning that all peptides are labelled (Fuller and Morris, 2012). Each isobaric label contains a 
unique reporter group, peptide reactive group, and a neutral balance group, and has an overall 
mass of a 145 Da (Fuller and Morris, 2012). Following peptide fragmentation, the unique 
reporter groups break off and produce distinct ions, i.e. m/z 114, 115, 116, 117 for four-plex 
iTRAQ, where the signal intensity form reporter ions corresponds to relative protein 
abundance in the sample (Fuller and Morris, 2012).  
 
2.11.1. Protein extraction 
Frozen hearts from postnatal day 8 (P8) Taiwanese mice (Smn−/−;SMN2tg/+) (Hsieh-Li et al., 
2000) (n = 5) and healthy littermate mice (n = 5) were homogenised in 4 volumes (w/v) of 
extraction buffer [6 M Urea (U0631; Sigma), 2 M thiourea (T8656; Sigma), 2% 3-[(3-
Cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate (CHAPS; C9426; Sigma) 
and 0.5% SDS (AM9823; Invitrogen)], as described in section 2.3.1.1. Urea is often used in 
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extraction buffers to facilitate protein denaturation and unfolding, while addition of 
detergents, such as SDS and CHAPS, improves solubilization of hydrophobic proteins (Dapic et 
al., 2017). Protein extracts were centrifuged at 13000 RPM (Micro Centaur MSB010.CX2.5; 
MSE; rotor radius- 4 cm) for 5 minutes at 4°C to pellet any insoluble material. Components of 
the extraction buffer can interfere with enzymatic digestion and mass spectrometry analysis, 
and have to be removed from the sample before downstream analysis (Dapic et al., 2017). To 
do this, supernatants were precipitated in 4 volumes of ice-cold acetone overnight at −20°C, 
and acetone precipitates were pelleted at 13000 RPM for 5 minutes at 4°C. The supernatant, 
containing interfering substances, was discarded, and pellets were resuspended in 200 μL of 
500 mM triethylammonium bicarbonate (TEAB, T7408; Sigma) in ultrapure water to dissolve 
the proteins. Dissolution of proteins after acetone precipitation can be challenging (Feist and 
Hummon, 2015), and so several strategies have been employed here to facilitate dissolution. 
These included addition of the SDS to TEAB solution, to a maximum of 0.05% (4352135, 
Applied biosystems), and mechanical homogenisation by repeated pipetting, vortexing, 
sonication and the use of pellet pestles. 
 
2.11.2. Protein quantification  
50 μL of protein extract from each sample (n = 5) were pulled into one tube to make two 
groups, i.e. control (CTR) and SMA. The remaining samples were stored on -80°C for 
downstream analysis. Protein concentration was determined using Bradford reagent (B6916; 
Sigma) according to instructions outlined in the guideline. Bradford assay (Coomassie brilliant 
blue assay) is rapid and simple colorimetric assay for quantification of protein concentration 
(Bradford, 1976). Principles of Bradford rely on the binding of Coomassie brilliant G-250 dye 
to the arginine and lysine residues of the protein (Sapan, Lundblad and Price, 1999). The 
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reaction is performed under acidic conditions, where the formation of dye-protein complexes 
results in a change of colour from brown to blue that absorbs at 595 nm (Sapan, Lundblad and 
Price, 1999). 
Bovine serum albumine standards were prepared in 8 serial dilutions for the analysis in assay 
working range (0.1–1.4 mg/ml of protein). 50 μL of each diluted sample and standard was 
added to the tube, following addition of 1 mL of Bradford reagent (sample to reagent ratio = 
1:20). Content of the tube was mixed by gentle pipetting, after which a 150 μL of the mixture 
was loaded in 96-well plate in triplicates. Each sample, i.e. CTR and SMA, was prepared as 
described in three separate tubes, meaning that each sample was analysed in nine technical 
replicates to ensure better accuracy (3 tubes x 3 replicates). The plate was incubated at RT for 
5 minutes, and absorbance was measured at 595 nm using microplate reader (FLUOstar 
Omega; BMG Labtech). Protein concentration in each sample was determined as described in 
section 2.3.1.2.1. The results were used to calculate the appropriate volume of the extract 
that had to be added to the tube to get 90 μg of total protein for iTRAQ labelling.   
 
2.11.3. Sample reduction, alkylation, digestion and labelling 
Samples were prepared for quantitative iTRAQ mass spectrometry analysis according to 
instructions outlined in the iTRAQ labelling kit (4352135, Applied biosystems). For this, 20 µL 
of dissolution buffer and 2 µL of reducing reagent (tris-(2-carboxyethyl) phosphine, TCEP) was 
added to each of the four samples containing 90 µg of total protein. SDS was not added in this 
step since the extracts already contained 0.05% SDS, and higher concentration could interfere 
with mass spectrometry analysis. The tubes were vortexed for a couple of seconds and 
incubated on 60°C for one hour to reduce proteins. SDS increases protein solubility, while 
TCEP breaks disulphide bonds between cysteine residues, both of which reduce proteome 
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complexity for downstream analysis (Padula et al., 2017). Reduction of disulphide bonds 
produces thiol groups that have to be blocked to prevent reforming of disulphide bonds 
(Padula et al., 2017). 1 µL of cysteine blocking reagent was added to samples, after which the 
samples were mixed and incubated at RT for 10 minutes to allow cysteine alkylation. 
Sequencing grade modified trypsin (Promega, V511A) was then added to samples in a ratio 1 
µg trypsin/ 10 µg of protein, and the proteins were digested at 37°C overnight. iTRAQTM 
tagging reagents were reconstituted with 70 µL of ethanol at RT and each tag was added to 
appropriate sample group as follows: 114-control (P8), 115-SMA (P8). Tubes were vortexed 
and incubated at RT for one hour to allow the labelling, after which contents of all tubes were 
combined into one tube. The sample was dried with centrifugal vacuum concentrator at 41°C, 
and the remaining pellet was stored at -80°C until further analysis.  
 
2.11.4. Data analysis 
Mass spectrometry analysis were performed by Dr Sally L. Shirran and Dr Silvia A. Synowsky 
(University of St Andrews) as described (Šoltić et al., 2019). Raw mass spectrometry data files 
were analysed by ProteinPilot software, version 5.0.1.0 (Applied Biosystems) with the 
ParagonTM database search and Pro GroupTM Algorithm using the UniProtKB/Swiss-Prot 
FASTA database. The general Paragon search analysis parameters were: type ‘iTRAQ4plex 
(Peptide Labeled)’, cysteine alkylation ‘MMTS’, digestion ‘trypsin’ as the cleavage enzyme, 
instrument ‘TripleTOF, and species ‘Mouse’ for sample parameters; processing parameters 
were specified as ‘quantitative’, ‘bias correction’, ‘background correction’; ‘thorough ID’ and 
‘biological modifications’. Proteins that showed a Protein Threshold > 5 were used for the Pro 
Group Algorithm to calculate the relative quantification of the protein expression, generating 
an error factor and p-value. A false discovery rate (FDR) analysis was performed using the 
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Proteomics System Performance Evaluation Pipeline (PSPEP). This approach identified 3105 
proteins in total of which 2479 were identified with a 5% local false-discovery rate. For reliable 
quantification, proteins identified from just a single peptide were removed, after which, 
differentially expressed proteins were identified by removal of proteins with an expression  
change of less than 25%, and finally, exclusion of proteins with a p-value of >0.05 assigned to 
their fold changes. 
 
2.11.5. Bioinformatics analysis 
Bioinformatics were performed as described in section 2.9.1.1. GO analysis using DAVID 
platform (Huang, Sherman and Lempicki, 2009b, 2009a) was performed separately for 
upregulated and downregulated proteins, and included terms with at least two annotated 
proteins and p-value ≤ 0.05. Differentially expressed proteins were also analysed using the 
STRING 10 (Szklarczyk et al., 2015) to identify statistically significant interactions between 
them. Association network analysis was performed with high confidence (0.700) interaction 
score for upregulated and with highest confidence (0.900) interaction score for 
downregulated proteins to exclude false positive results. In both cases the background was 
set to Mus musculus.  
 
2.12.  Statistical analyses 
All statistical analyses were performed in GraphPad Prism version 8.0.1 for Windows, 
GraphPad Software, San Diego, California USA, www.graphpad.com. The Shapiro-Wilk test 
was first used to assess the distribution of the data. The unpaired two-tailed t-test was used 
for parametric data, and a Mann-Whitney U test for a non-parametric data, when comparing 
two datasets. One-way ANOVA with Dunnett’s multiple comparison test was used for 
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parametric data, and Kruskal-Wallis test for a non-parametric data, when comparing three or 
more datasets. Results from dot blot analyses (Figure 3.11. and 3.12) were subjected to linear 
regression analysis and R2 value was extrapolated from the graph to assess linear regression 
fit. Multiple t-tests with Holm-Sidak multiple comparison test was used to determine whether 
the difference in lamin A/C expression between control and SMA sample is statistically 
significant across serial dilutions (Figure 3.12). All data are presented as mean ± standard 
deviation (SD). Statistical significance was considered to be p ≤ 0.05 for all analyses. 
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CHAPTER 3: Results 
Selection of multi-target drugs that can change the 
expression of core differentially expressed proteins in 
SMA 
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3.1. Introduction 
Two SMN-targeted therapeutic strategies, Nusinersen (SpinrazaTM) and ZolgensmaTM, are 
available to SMA patients, but neither of them show complete efficiency in alleviating 
disease symptoms in all patient populations (Finkel et al., 2017; Mendell et al., 2017; Mercuri 
et al., 2018; Sumner and Crawford, 2018). Coupled with uncertainties around long-term 
effectiveness and extremely high price of both strategies, there is keen interest to find 
alternative therapeutic strategies that could, in combination with SMN-targeted therapy, offer 
maximum therapeutic benefit to all SMA patients (Bowerman, 2019). 
Identification of novel therapeutic targets is very challenging due to high complexity of 
biological systems, and even greater complexity of pathological mechanisms in SMA. For 
example, over a 100 potential interacting partners of SMN have been identified, and 
considering that each one of these proteins also has its own “interactome”, it is highly likely 
that SMN loss would affect a wide range of proteins and pathways in different cells and tissues 
(Fuller, Gillingwater and Wishart, 2016). Selection of proteins to be investigated in SMA 
disease pathways can therefore be difficult. 
 
3.1.1. Untangling the complexity of SMA pathogenesis 
An attempt to uncover the mechanism of SMA pathology has put “omics” technologies in the 
centre of SMA research. Unbiased, quantitative comparisons of the whole proteome (Wishart 
et al., 2010; Aghamaleky Sarvestany et al., 2014; Fuller et al., 2016), transcriptome (Oprea et 
al., 2008; Zhang et al., 2013) or spliceosome (Zhang et al., 2008, 2013) can identify conserved 
disease-related molecular changes downstream of SMN in variety of different SMA models. 
For example, comparison of the transcriptome profile of asymptomatic females carrying 
homozygous deletion of SMN1 and their SMA-affected siblings, led to discovery of two 
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protective modifiers in SMA, plastin 3 (Oprea et al., 2008) and neurocalcin delta (Riessland et 
al., 2017). Both proteins were subsequently studied in in vitro and in vivo models of SMA were 
they showed neuroprotective potential that could potentially be used in a therapy design for 
SMA patients (summarised in chapter 1, section 1.5.2.1). Two separate proteomics studies, 
using Schwann cells (Aghamaleky Sarvestany et al., 2014) and hippocampus synaptosomes 
(Wishart et al., 2014) from severe mouse models of SMA, identified dysregulation of ubiquitin-
proteasome pathway which was found to be important regulator of SMA disease pathways 
(described in chapter 1, section 1.5.2.3). In addition, proteome comparison of the SMA patient 
fibroblasts with genetically matched iPSC-derived motor neurons revealed differential 
response of the two cell types to SMN depletion (Fuller et al., 2016). When compared to their 
respective controls, SMA iPSC-derived motor neurons showed a higher number of 
dysregulated proteins then genetically matched fibroblasts, which suggests that different 
tissues/cells have different requirements for SMN levels. In addition, only seven of these 
proteins were common to both cell types, which confirms previous findings that different 
tissues/cells respond differently to dysregulation of SMN levels (Fuller et al., 2016). All of these 
examples demonstrate the valuable contribution of omics technologies in investigation of 
complex SMA disease pathways.   
 
3.1.1.1 Limitations of proteomics approach 
Although proteomics technologies usually generate a wealth of new knowledge, two main 
limitations have to be considered when examining the data. First, proteomic studies utilise a 
variety of different experimental models and sample types to investigate disease mechanism 
(Fuller, Gillingwater and Wishart, 2016). This could unavoidably result in identification of 
model/tissues-specific pathogenic patterns that cannot be isolated or distinguished from core 
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molecular mechanisms in SMA pathogenesis (Fuller, Gillingwater and Wishart, 2016). 
Translation of these findings into other experimental models or clinical research can therefore 
be very challenging, and demands careful examination and selection of targets from a long list 
of protein changes (Wishart et al., 2014). The amount of information generated using this 
approach represents the second challenge. Proteomics technologies usually generate 
extensive lists of differentially expressed proteins, of which, very few protein candidates get 
further experimental attention (Fuller, Gillingwater and Wishart, 2016). This process usually 
involves selection of proteins with the biggest fold change difference, or selection of proteins 
that are of specific interest to the research group, where potentially important changes might 
be overlooked (Fuller, Gillingwater and Wishart, 2016). Public availability of these proteomic 
datasets, however, represents the opportunity to systematically examine this information, to 
generate new knowledge of SMA disease pathways.  
 
3.1.2. Comparison of published proteomic studies of SMA identified conserved 
protein response in SMA cells and tissues 
One recent study used a comparative approach to interrogate a range of datasets from 
published proteomic studies of SMA, and successfully identified core molecular changes in 
SMA tissues and cells (Fuller, Gillingwater and Wishart, 2016). Nine proteomic studies, 
investigating proteome alterations in in vitro and in vivo models of SMA and in SMA patient 
samples, were included in the comparison. These included cells from SMA patients and SMA 
mice at different stages of differentiation, SMN depleted NSC34 cells, different tissues from 
SMA mice and plasma from SMA patients (Fuller, Gillingwater and Wishart, 2016). The analysis 
identified 66 proteins that showed differential expression across at least two proteomic 
studies of SMA, of which 29 showed consistent direction of differential expression, meaning 
that their expression levels were either increased or decreased in SMA samples compared to 
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control in all proteomic studies (Fuller, Gillingwater and Wishart, 2016). Of these, seven 
proteins showed consistent direction of differential expression across three proteomic studies 
of SMA, including ubiquitin-like modifier-activating enzyme 1 (UBA1), whose implication in 
SMA disease pathways has already been described in chapter 1, section 1.5.2.3. Identification 
of proteins that have already been implicated in SMA disease pathways is highly relevant, and 
indicates the validity of this approach to identify core pathological mechanisms in SMA. This 
also suggested the potential role for the remaining six proteins, lamin A/C (LMNA), 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), annexin A2 (ANXA2), neural cell 
adhesion molecule 1 (NCAM), neuromodulin (GAP43) and collagen type VI alpha 3 chain 
(COL6A3), in SMA disease pathways.  
 
3.1.3. Multi-target therapies 
The seven proteins identified in the multi-study comparison of published proteomic studies 
(Fuller, Gillingwater and Wishart, 2016) represent potential therapeutic targets in SMA, and 
in theory could be targeted either individually or simultaneously. Given the complexity of the 
SMN interactome and the potential number of SMA disease pathways (Fuller, Gillingwater and 
Wishart, 2016), manipulation of individual proteins is unlikely to completely alleviate disease 
symptoms in SMA patients. However, by targeting multiple proteins at the same time it might 
be possible to restore several disease pathways, and when combined with SMN-targeted 
therapies, this strategy could bring greater therapeutic benefit to SMA patients. There are 
three different approaches in the design of multi-target therapies (Hopkins, 2008). The first 
strategy involves a combination of different drugs, and it has been successfully used, for 
example, for the treatment of HIV infections (Freeman et al., 2004). However, a major safety 
issue in the use of several drugs are drug-drug interactions (DDIs) that can cause severe 
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adverse reactions (Hopkins, 2008). DDIs can, for example, change pharmacokinetic properties 
of the drug, by altering its distribution, absorption or metabolism, and pharmacodynamic 
profile, where one drug can have additive or antagonistic effect on the other drug (Moore, 
Pollack and Butkerait, 2015). This issue can be resolved by designing multicomponent drugs, 
meaning that several active ingredients are formulated in one delivery system such as the 
capsule or inhaler (Hopkins, 2008). Pharmacokinetics and bioavailability of different 
substances can, however, pose a significant challenge in therapy design, and so 
multicomponent medicines may not always be a viable solution (Hopkins, 2008). A third 
strategy involves the design of a single compound that can simultaneously affect several 
targets (Hopkins, 2008). This strategy has advantage over the other two approaches, in terms 
of the safety (no drug-drug interactions) and easier management of the pharmacokinetics and 
bioavailability of the drug. In addition, single compounds face less barriers during approval 
process (Hopkins, 2008).  
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The aim of this chapter was to investigate the differential expression of core molecules in SMA 
tissues and cells, and to determine the best strategy for the selection of multi-target drugs. 
The specific objectives were as follows: 
a) To conduct a multi-study comparison of published transcriptomics studies of SMA to 
determine whether conserved changes to the proteome can be tracked back to the 
aberrant transcriptional regulation. 
b) To investigate the differential expression of six protein targets identified in a multi-
study comparison of published proteomic studies, including UBA1, lamin A/C, GAPDH, 
ANXA2, NCAM and GAP43, in tissues from a severe mouse model of SMA and in SMA 
patient fibroblast cells. 
c) To identify different pharmaceutical compounds that have been associated with 
several protein targets listed above, and to test their ability to change the expression 
of target proteins in SMA patient fibroblasts. 
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3.2. Results 
3.2.1. Multi-study identification of molecular overlap between proteomic and 
transcriptomic studies of SMA 
Fuller, Gillingwater and Wishart have recently showed that comparison of published 
proteomic studies of SMA can identify core protein changes in SMA tissues/cells that might 
be implicated in disease pathways (Fuller, Gillingwater and Wishart, 2016). Here, a similar 
approach was undertaken to identify core changes to the transcriptome in SMA tissues and 
cells. The result of the analysis were then compared to the result of a multi-study comparison 
of published proteomic studies of SMA (Fuller, Gillingwater and Wishart, 2016) to identify 
whether protein changes in SMA are driven by aberrant transcriptional regulation. This is 
important question for future work, as it would help to determine whether targeting of 
molecules at the protein and/or gene level would be necessary to maximise the effect of 
therapeutic approach in SMA.  
 
3.2.1.1. Multi-study comparison of published transcriptomic studies of SMA identifies 28 
genes with consistent direction of differential expression across three studies 
First, the analysis of SMA transcriptomics datasets had to be conducted to determine core 
molecular changes in SMA on the gene level (as described in chapter 2, section 2.9.1). 
Comparison of eleven published transcriptomic studies of SMA (Table 3.1) identified 608 
genes that were differentially expressed across two or more studies in a range of 
neuromuscular tissues/cells from SMA patients and animal models of SMA (data not shown). 
Only 28 of the genes showed conserved change in one direction across three or more separate 
studies of SMA, of which 17 showed decreased expression and 11 showed increased 
expression (Table 3.2). Among these where genes already linked to SMA pathogenesis, 
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including chondrolectin (CHODL) (Sleigh et al., 2014), doublecortin (DCX) (Wishart et al., 2010), 
cyclin dependent kinase inhibitor 1A (CDKN1A) (Staropoli et al., 2015) and complement c1q b 
chain (C1QB) (Zhang et al., 2013), adding support that this is a valid approach to identify 
disease-related molecular changes in SMA. The remaining genes represent a molecular 
response to decreased levels of SMN that may have been previously overlooked. 
 
Table 3. 1. Overview of SMA transcriptomics studies 
Model/sample type Differentially 
expressed genes 
Reference 
Mouse (severe) at P1 (pre-symptomatic) and P5 (late 
symptomatic)/Spinal cord 
162 (Murray et al., 2010) 
SMN knockdown/ mouse motor neurons 3412 (Saal et al., 2014) 
Mouse (severe) at P3 (early symptomatic)/ Lumbar spinal 
cord 
166 (Huo et al., 2014) 
Mouse (Intermediate)/ Spinal cord and kidney 279 (Zhang et al., 2008) 
Mouse (severe) at P1 (pre-symptomatic)/ Motor neurons 
and glial cells 
459 (Zhang et al., 2013) 
SMN knockdown/ rat motor neurons 748 (Wertz et al., 2016) 
Mouse (severe) at P1 (pre-symptomatic), P7 (early 
symptomatic) and P14 (late symptomatic)/ Spinal cord 
178 (Bäumer et al., 2009) 
Mouse (severe)/ ESC-derived motor neurons 269 (Maeda et al., 2014) 
Mouse (intermediate)/ Motor neurons (SMAv, SMAr) 565 (Murray et al., 2015) 
Muscles from type I and III SMA patients 88 (Millino et al., 2009) 
Myoblasts from type II SMA patients 62 (Anderson et al., 2004) 
SMA studies included in the transcriptomics comparison are listed in table, together with SMA model and sample 
type used in each study. Number of differentially expressed genes identified in each study is listed in column 
two. SMAv - vulnerable (abdominal) motor neurons; SMAr- less vulnerable (cranial) motor neurons.
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Table 3. 2. Genes differentially expressed across three or more transcriptomic studies of 
SMA 
Gene name 
(Official Gene Symbol) 
SMA model  References 
Decreased expression   
Survival of Motor Neuron 1, 
Telomeric (SMN1) 
 
Mouse ESC-derived motor neurons  
Mouse spinal cords  
Rat motor neurons  
Mouse kidney  
Mouse motor neurons and glial cells  
Mouse spinal cord  
(Maeda et al., 2014) 
(Murray et al., 2010) 
(Wertz et al., 2016) 
(Zhang et al., 2008) 
(Zhang et al., 2013) 
(Bäumer et al., 2009) 
Chondrolectin (CHODL) 
 
 
Rat motor neurons  
Mouse spinal cord 
Mouse motor neurons  
Mouse spinal cord  
(Wertz et al., 2016) 
(Zhang et al., 2008) 
(Zhang et al., 2013) 
(Bäumer et al., 2009) 
Collagen Type XII Alpha 1 Chain 
(COL12A1) 
Mouse spinal cords  
Mouse motor neurons  
Rat motor neurons  
Mouse motor neurons 
(Murray et al., 2010) 
(Saal et al., 2014) 
(Wertz et al., 2016) 
(Zhang et al., 2013) 
Protein Regulator of Cytokinesis 1 
(PRC1) 
Mouse spinal cords  
Mouse motor neurons  
Mouse spinal cord and kidney  
Mouse spinal cord  
(Murray et al., 2010) 
(Saal et al., 2014) 
(Zhang et al., 2008) 
(Bäumer et al., 2009) 
PCNA Clamp Associated Factor 
(PCLAF) 
Mouse spinal cords 
Mouse motor neurons  
Mouse spinal cord  
(Murray et al., 2010) 
(Saal et al., 2014) 
(Huo et al., 2014) 
Anti-Silencing Function 1B Histone 
Chaperone (ASF1B) 
Mouse spinal cords  
Mouse motor neurons  
Mouse kidney  
(Murray et al., 2010) 
(Saal et al., 2014) 
(Zhang et al., 2008) 
Cyclin A2 (CCNA2) Mouse spinal cords  
Mouse motor neurons  
Mouse spinal cord and kidney  
(Murray et al., 2010) 
(Saal et al., 2014) 
(Zhang et al., 2008) 
Cell Division Cycle Associated 7 
(CDCA7) 
Mouse spinal cords  
Mouse motor neurons  
Mouse glial cells 
(Murray et al., 2010) 
(Saal et al., 2014) 
(Zhang et al., 2013) 
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Doublecortin (DCX) Mouse ESC-derived motor neurons  
Mouse motor neurons  
Mouse motor neurons  
(Maeda et al., 2014) 
(Murray et al., 2015) 
(Saal et al., 2014) 
Eukaryotic Translation Initiation 
Factor 1 (EIF1) 
Mouse SMN-knockdown motor neurons  
Rat motor neurons  
Mouse spinal cord  
(Saal et al., 2014) 
(Wertz et al., 2016) 
(Huo et al., 2014) 
EPH Receptor A5 (EPHA5) Mouse ESC-derived motor neurons  
Mouse motor neurons  
Rat motor neurons  
(Maeda et al., 2014) 
(Saal et al., 2014) 
(Wertz et al., 2016) 
Lumican (LUM) Mouse spinal cords 
Mouse spinal cord 
Mouse spinal cord  
(Murray et al., 2010) 
(Zhang et al., 2008) 
(Bäumer et al., 2009) 
NUF2, NDC80 Kinetochore 
Complex Component (NUF2) 
Mouse motor neurons  
Mouse kidney 
Mouse spinal cord  
(Saal et al., 2014) 
(Zhang et al., 2008) 
(Huo et al., 2014) 
PDZ Binding Kinase (PBK) Mouse spinal cords  
Mouse motor neurons  
Mouse spinal cord  
(Murray et al., 2010) 
(Saal et al., 2014) 
(Bäumer et al., 2009) 
Retrotransposon Gag Domain 
Containing 4 (RGAG4) 
Mouse ESC-derived motor neurons 
Rat motor neurons  
Mouse glial cells  
(Maeda et al., 2014) 
(Wertz et al., 2016) 
(Zhang et al., 2013) 
Solute Carrier Family 8 Member 
A1 (SLC8A1) 
Mouse motor neurons  
Rat motor neurons  
Mouse kidney  
(Saal et al., 2014) 
(Wertz et al., 2016) 
(Zhang et al., 2008) 
X-Box Binding Protein 1 (XBP1) Mouse motor neurons  
Rat motor neurons  
Mouse glial cells  
(Saal et al., 2014) 
(Wertz et al., 2016) 
(Zhang et al., 2013) 
Increased expression   
Cyclin Dependent Kinase Inhibitor 
1A (CDKN1A) 
Mouse motor neurons  
Mouse kidney  
Mouse motor neurons and glial cells  
Mouse spinal cord  
(Murray et al., 2015) 
(Zhang et al., 2008) 
(Zhang et al., 2013) 
(Bäumer et al., 2009) 
B-cell CLL/Lymphoma 11A 
(BCL11A) 
Mouse motor neurons  
Rat motor neurons  
Mouse motor neurons  
(Saal et al., 2014) 
(Wertz et al., 2016) 
(Zhang et al., 2013) 
Complement C1q B Chain (C1QB) Mouse motor neurons 
Mouse motor neurons  
Mouse spinal cord  
(Saal et al., 2014) 
(Zhang et al., 2013) 
(Bäumer et al., 2009) 
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C-C Motif Chemokine Ligand 3 
(CCL3) 
Mouse motor neurons  
Mouse glial cells  
Mouse spinal cord  
(Saal et al., 2014) 
(Zhang et al., 2013) 
(Bäumer et al., 2009) 
Ectodysplasin A2 Receptor 
(EDA2R) 
Mouse spinal cords  
Mouse kidney  
Mouse spinal cord  
(Murray et al., 2010) 
(Zhang et al., 2008) 
(Bäumer et al., 2009) 
FK506 Binding Protein 5 (FKBP5) Mouse spinal cord and kidney  
Mouse motor glial cells  
Mouse spinal cord  
(Zhang et al., 2008) 
(Zhang et al., 2013) 
(Bäumer et al., 2009) 
Metallothionein 2A (MT2A) Mouse spinal cords  
Mouse glial cells  
Mouse spinal cord 
(Murray et al., 2010) 
(Zhang et al., 2013) 
(Bäumer et al., 2009) 
Paternally Expressed 3 (PEG3) Mouse motor neurons  
Rat motor neurons  
Mouse kidney  
(Murray et al., 2015) 
(Wertz et al., 2016) 
(Zhang et al., 2008) 
Sphingosine-1-Phosphate 
Phosphatase 2 (SGPP2) 
Mouse motor neurons  
Mouse motor neurons 
Mouse spinal cord  
(Saal et al., 2014) 
(Zhang et al., 2013) 
(Zhang et al., 2008) 
Small Nuclear Ribonucleoprotein 
Polypeptide A' (SNRPA1) 
Mouse spinal cords  
Mouse motor neurons  
Mouse spinal cord  
(Murray et al., 2010) 
(Zhang et al., 2013) 
(Bäumer et al., 2009) 
Zinc Finger Protein 750 (ZNF750) Mouse motor neurons 
Mouse motor neurons 
Mouse spinal cord  
(Murray et al., 2015) 
(Zhang et al., 2013) 
(Bäumer et al., 2009) 
Genes with a consistent change in expression across three or more transcriptomics studies of SMA are shown. 
Gene name is given, followed by the official gene symbol in brackets. Genes are listed according to direction of 
differential expression (genes with decreased expression are listed first, followed by genes with increased 
expression). SMA model and sample type used in each study are listed (studies are listed in the reference 
column). 
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GO analysis, using DAVID platform (Huang, Sherman and Lempicki, 2009b, 2009a), was 
conducted on the 28 genes that showed consistent direction of differential expression across 
three transcriptomics studies of SMA, as described in Methods chapter 2.9.1.1. The analysis 
revealed enrichment in terms connected to biological process, among which were nervous 
system development, gene expression, RNA metabolism and intracellular signalling (Figure 
3.1A). STRING 10 software (Szklarczyk et al., 2015) was next used to identify statistically 
significant associations between proteins that are encoded by the 28 genes (as described in 
chapter 2.9.1.1). The analysis identified association between seven of the 28 proteins (Figure 
3.1B), that are connected to biological process terms like regulation of gene expression and 
RNA metabolism. 
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Figure 3. 1. Bioinformatics analyses of the 28 genes that were differentially expressed in the same direction 
across three or more transcriptomic studies of SMA. (A) Top eight enriched terms from GO biological process 
domain are shown in the chord diagram, together with the genes annotated to each term. (B) STRING 10 analysis 
of proteins that are encoded by 28 genes were performed with high confidence (0.700) interaction score. The 
analysis identified significant asocciations between seven of these proteins. The type of association between 
proteins is indicated by the colour (pink: experimentally determined interactors; light blue: interactors from 
curated database; yellow: text-mining; black: co-expression). 
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Although the initial number of genes, identified as being differentially expressed across two 
or more transcriptomic studies of SMA, was high, very few genes followed the same direction 
of differential expression across at least three transcriptomic studies of SMA. The 28 genes 
that showed consistent direction of differential expression were associated with functions like 
gene expression, RNA metabolism and nervous system development. 
 
3.2.1.2 Multi-study comparison of published proteomics and transcriptomics studies of SMA 
identified little overlap between differentially expressed genes and proteins 
The 608 genes that showed differentially expression across at least two transcriptomic studies 
of SMA were then compared to the list of proteins that showed differentially expression across 
at least two proteomic studies of SMA (Fuller, Gillingwater and Wishart, 2016). The analysis 
identified seven molecules that were differentially expressed at both the gene and protein 
level across at least two omics studies of SMA (Table 3.3). Of these, annexin A2 (ANXA2) was 
consistently increased at the protein level and consistently decreased at the gene level across 
all omics studies, while the remaining six proteins, including neural cell adhesion molecule 1 
(NCAM1), glutamic-oxaloacetic transaminase 2 (GOT2), collagen type I alpha 1 chain (COL1A1), 
collagen type VI alpha 1 chain (COL6A1), caldesmon 1 (CALD1) and aldolase, fructose-
bisphosphate A (ALDOA) showed different directions of differential expression across studies.
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Table 3. 3. Seven molecules that showed dysregulated expression at protein and gene level in SMA omics studies 
Protein/gene name (Official gene symbol) Omics study 
(Direction of expression change) 
SMA model/sample References 
Annexin A2 (ANXA2) Proteomics (Up) 
Proteomics (Up) 
Proteomics (Up) 
Transcriptomics (Down) 
Transcriptomics (Down) 
Type I patient motor neurons 
Mouse Schwann cells 
Mouse muscle 
Mouse spinal cord 
Mouse spinal cord 
(Fuller et al., 2016) 
(Aghamaleky Sarvestany et al., 2014) 
(Mutsaers et al., 2013) 
(Murray et al., 2010) 
(Zhang et al., 2008) 
Aldolase, Fructose-Bisphosphate A (ALDOA) Proteomics (Up) 
Proteomics (Up) 
Proteomics (Down) 
Transcriptomics (Down) 
Transcriptomics (Down) 
Mouse Schwann cells 
Mouse hippocampus synaptosomes 
Mouse hippocampus 
Mouse motor neurons 
Rat motor neurons 
(Aghamaleky Sarvestany et al., 2014) 
(Wishart et al., 2014) 
(Wishart et al., 2010) 
(Murray et al., 2015) 
(Wertz et al., 2016) 
Neural Cell Adhesion Molecule 1 (NCAM1) Proteomics (Down) 
Proteomics (Down) 
Proteomics (Down) 
Transcriptomics (Up) 
Transcriptomics (Down) 
Type I patient motor neurons 
Mouse hippocampus 
Type I, II and III patient plasma 
Rat motor neurons 
Mouse motor neurons 
(Fuller et al., 2016) 
(Wishart et al., 2010) 
(Kobayashi et al., 2013) 
(Wertz et al., 2016) 
(Saal et al., 2014) 
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Caldesmon 1 (CALD1) Proteomics (Up) 
Proteomics (Up) 
Proteomics (Down) 
Transcriptomics (Up) 
Transcriptomics (Down) 
Type I patient motor neurons 
Mouse Schwann cells 
Type I patient skin fibroblast 
Mouse motor neurons 
Mouse motor neurons 
(Fuller et al., 2016) 
(Aghamaleky Sarvestany et al., 2014) 
(Fuller et al., 2016) 
(Murray et al., 2015) 
(Saal et al., 2014) 
Glutamic-Oxaloacetic Transaminase 2 (GOT2) Proteomics (Up) 
Proteomics (Down) 
Transcriptomics (Down) 
Transcriptomics (Up) 
Mouse muscle 
Type I patient motor neurons 
Rat motor neurons 
Mouse motor neurons 
(Mutsaers et al., 2013) 
(Fuller et al., 2016) 
(Wertz et al., 2016) 
(Saal et al., 2014) 
Collagen Type I Alpha 1 Chain (COL1A1) Proteomics (Up) 
Proteomics (Up) 
Transcriptomics (Up) 
Transcriptomics (Down) 
Transcriptomics (Up) 
Type I patient motor neurons 
Mouse Schwann cells 
Mouse motor neurons 
Mouse spinal cord 
Mouse motor neurons and glial cells  
(Fuller et al., 2016) 
(Aghamaleky Sarvestany et al., 2014) 
(Murray et al., 2015) 
(Murray et al., 2010) 
(Zhang et al., 2013) 
Collagen Type VI Alpha 1 Chain (COL6A1) Proteomics (Up) 
Proteomics (Up) 
Transcriptomics (Down) 
Transcriptomics (Up) 
Type I patient skin fibroblast 
Type I, II and III patient plasma 
Mouse spinal cord 
Mouse glial cells 
(Fuller et al., 2016) 
(Kobayashi et al., 2013) 
(Murray et al., 2010) 
(Zhang et al., 2013) 
Seven molecules that were differentially expressed at both the gene and protein level. Protein/gene name is given, followed by official gene symbol in brackets. Type of proteomic study, 
direction of differential protein/gene expression, and model and sample type are listed for each study (studies are listed in column four). 
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The aim here was to determine whether changes in the protein expression, identified 
previously in multi-study comparison of published proteomic studies of SMA (Fuller, 
Gillingwater and Wishart, 2016), are driven by transcriptional defects, as this could aid 
selection of appropriate therapies for SMA. The very few molecules that showed differential 
expression at both the gene and protein levels do not seem to follow the same pattern of 
differential expression, suggesting that changes in protein expression in SMA tissues are most 
likely posttranscriptional. Further research efforts where therefore focused on dysregulated 
proteins in SMA since they represent functional units of cellular pathways. 
 
3.2.2. Liver tissue extracts from SMA mice showed widespread dysregulation of 
protein expression, while SMA mouse muscles showed very few consistent changes 
in protein expression compared to controls  
Proteins that showed consistent direction of differential expression across three proteomic 
studies of SMA (Fuller, Gillingwater and Wishart, 2016) were given priority, as they may have 
important role in SMA disease pathways across a range of tissues. The expression of six protein 
targets, UBA1, lamin A/C, GAPDH, ANXA2, NCAM and GAP43, was studied in the heart, spinal 
cord, brain, liver and muscle tissue from late-symptomatic (P8) Taiwanese SMA mice 
(Smn−/−;SMN2tg/+), and in fibroblast cells from two type I SMA patients and one type II SMA 
patient (details are provided in Table 2.1) using quantitative western blotting. COL6A3 levels 
could not be measured reliably in patient and control fibroblasts using western blotting, due 
to the high background and the presence of multiple bands in the sample (data not shown), 
and so COL6A3 levels were not investigated biochemically in other tissues from a mouse 
model of SMA. The workflow for the quantitative western blotting is presented in Figure 3.2 
(in all analyses a Coomassie stained gel was used as an internal, total protein loading control). 
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The levels of SMN were first determined in tissues from 8 days old control and severe 
Taiwanese mice, and in control and SMA patient fibroblast cells, and they served as positive 
control and reference (Figure 3.3). As expected, all SMA tissues and cells showed significant 
reduction of SMN levels when compared to healthy controls. Liver and muscle tissue from 
SMA mice showed the greatest reduction of SMN levels (94%, p < 0.001), followed by the heart 
(92%, p < 0.001), brain (91%, p < 0.001) and spinal cord (88%, p < 0.001) tissue from SMA mice, 
and patient fibroblast cells (71%, p = 0.0013).  
 
Figure 3. 2. Schematic diagram showing workflow of quantitative western blot analysis. Total protein extracts 
from human fibroblast cells and mouse tissues were subjected to SDS-PAGE. A part of the gel was stained with 
Coomassie blue as an internal, total protein loading control. Proteins from the remaining part of the gel were 
transferred to nitrocellulose membrane and developed with the appropriate antibody. Quantification of 
protein levels was performed by normalising densitometry measurements of antibody reactive bands to 
densitometry measurements of Coomassie stained gel. Image created with BioRender.com 
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Figure 3. 3. SMN protein levels in tissues from late-symptomatic SMA mice (P8) and in patient fibroblast cells. 
A) Representative western blots showing SMN levels in the heart, spinal cord, brain, liver and muscle tissue 
extracts from SMA mice (n=5) and age-matched healthy controls (n=5), and in SMA patient fibroblast cells (n=3) 
and age-matched healthy controls (n=3). Coomassie stained gel was used as internal, total protein loading 
control. Fibroblast cells are listed in this order from left to the right: GM00498, GM05659, GM00302, GM03813, 
GM09677, GM00232. (B) Densitometry measurements of SMN reactive bands were first normalised to 
densitometry measurements of Coomassie stained gel, after which all samples were normalised to the average 
of control. The graph is presented as average protein levels (expressed relative to control), with error bars 
showing standard deviation from the mean. ** p<0.01; ***p<0.001 
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UBA1 levels were significantly reduced in the heart (76%, p = 0.0002) and liver extracts (66%, 
p = 0.0002) from SMA mice (Figure 3.4). A 59% reduction of UBA1 levels in muscles from SMA 
mice was not statistically significant, likely due to the large variability in protein expression 
between the samples in both control and SMA groups. Spinal cord and brain tissue from SMA 
mice, and fibroblast cells from SMA patients did not show a significant change in UBA1 levels 
compared to controls (Figure 3.4). The unchanged levels of UBA1 in SMA mouse spinal cord 
and brain tissue extracts are in contrast with proteomic studies, where UBA1 showed 
decreased expression across neuronal tissues, including Schwann cells and hippocampus 
synaptosomes from SMA mice, and iPSC-derived motor neurons from SMA patients (Fuller, 
Gillingwater and Wishart, 2016).  
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Figure 3. 4. UBA1 protein levels in tissues from late-symptomatic SMA mice (P8) and in patient fibroblast 
cells. (A) Representative western blots showing UBA1 levels in the heart, spinal cord, brain, liver and muscle 
tissue extracts from SMA mice (n=5) and age-matched healthy controls (n=5), and in SMA patient fibroblast 
cells (n=3) and age-matched healthy controls (n=3). Coomassie stained gel was used as internal, total protein 
loading control. Fibroblast cells are listed in this order from left to the right: GM00498, GM05659, GM00302, 
GM03813, GM09677, GM00232. (B) Densitometry measurements of UBA1 reactive bands were first 
normalised to densitometry measurements of Coomassie stained gel, after which all samples were normalised 
to the average of control. The graph is presented as average protein levels (expressed relative to control), with 
error bars showing standard deviation from the mean. ns- not significant; ***p<0.001 
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Widespread dysregulation of both lamin A and lamin C levels was observed in tissues from a 
mouse model of SMA and SMA patient fibroblasts (Figure 3.5A). A statistically significant 
reduction of lamin A levels was seen in SMA patient fibroblasts compared to those from 
healthy controls (84%, p = 0.0438), while a statistically significant upregulation of lamin A 
levels was found in the brain (25%, p = 0.0434), liver (52%, p = 0.0026) and heart (69%, P = 
0.0007) tissue from SMA mice (Figure 3.5B). Spinal cord extracts from SMA mice did not show 
a significant change in lamin A expression compared to controls, but they did show a 
significant increase in the levels of lamin C (43%, p = 0.0078), as did the liver (42%, p = 0.0075), 
brain (43%, p= 0.0116) and heart (91%, P = 0.0079) (Figure 3.5B). Increased levels of lamin C 
in spinal cord from SMA mice are in line with proteomic studies of SMA, where increased lamin 
A/C expression was identified in Schwann cells from a mouse model of SMA (Aghamaleky 
Sarvestany et al., 2014) and in SMA patient motor neurons (Fuller et al., 2016). Patient 
fibroblast cells and skeletal muscles from SMA mice showed no significant change in lamin C 
expression compared to the healthy controls (Figure 3.5B). In contrast, a 45% reduction of 
lamin A levels in skeletal muscle extracts from SMA mice was not statistically significant, likely 
due to the large variability in protein expression between the samples (Figure 3.5B). This, 
however, is in contrast with the proteomic study of SMA where increased lamin A/C 
expression was identified in muscles from P5 SMA mice (Mutsaers et al., 2013).  
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Figure 3. 5. Lamin A/C protein levels in tissues from late-symptomatic SMA mice (P8) and in patient 
fibroblast cells. (A) Representative western blots showing lamin A/C levels in the heart, spinal cord, brain, liver 
and muscle tissue extracts from SMA mice (n=5) and age-matched healthy controls (n=5), and in SMA patient 
fibroblast cells (n=3) and age-matched healthy controls (n=3). Coomassie stained gel was used as internal, 
total protein loading control. Fibroblast cells are listed in this order from left to the right: GM00498, GM05659, 
GM00302, GM03813, GM09677, GM00232. (B) Densitometry measurements of lamin A and lamin C reactive 
bands were first normalised to densitometry measurements of Coomassie stained gel, after which all samples 
were normalised to the average of control. In the liver extract, the lower band was presumed to be lamin C, 
and the upper two bands were presumed to be lamin A isoforms and were consequently measured together 
to give a single value. The graph is presented as average protein levels (expressed relative to control), with 
error bars showing standard deviation from the mean. The dashed line represents protein levels across healthy 
control tissues. ns- not significant; *p<0.05; **p<0.01; ***p<0.001 
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The expression of GAPDH was significantly reduced in the liver (49%, p = 0.0087) and heart 
(41%, p = 0.0034) tissue from SMA mice compared to age-matched healthy controls (Figure 
3.6). Spinal cord, brain and muscle tissue from SMA mice, and SMA patient fibroblast cells, on 
the other hand, showed no significant change in GAPDH expression when compared to 
controls (Figure 3.6). The direction of expression change in heart and liver tissue followed the 
same trend as observed in proteomic studies of SMA. Once again, however, biochemical 
studies on mouse spinal cord and brain tissue showed different results compared to proteomic 
studies, where decreased GAPDH levels were identified in Schwann cells (Aghamaleky 
Sarvestany et al., 2014) and hippocampus (Wishart et al., 2010) from SMA mice.  
 
A significant upregulation of ANXA2 levels was identified in the spinal cord from SMA mice 
(57%, p = 0.0119) and in fibroblast cells from SMA patients (30%, p = 0.0212) (Figure 3.7). 
Muscle and liver from SMA mice, on the other hand, showed a significant reduction of ANXA2 
levels, 77% (p = 0.0057) and 59% (p = 0.0025) respectively. The expression of ANXA2 in the 
brain and heart from SMA mice was not significantly changed when compared to healthy 
controls (Figure 3.7). A biochemical study of spinal cord tissue showed the same trend as 
proteomic studies of SMA where upregulation of ANXA2 levels was identified in mouse 
Schwann cells (Aghamaleky Sarvestany et al., 2014) and patient iPS-derived motor neurons 
(Fuller et al., 2016). Downregulation of ANXA2 levels in muscles from SMA mice in this study 
is, however, in contrast with a proteomic study that showed increased ANXA2 expression in 
muscles from P5 SMA mice (Mutsaers et al., 2013).   
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Figure 3. 6. GAPDH protein levels in tissues from late-symptomatic SMA mice (P8) and in patient fibroblast 
cells. A) Representative western blots showing GAPDH levels in the heart, spinal cord, brain, liver and muscle 
tissue extracts from SMA mice (n=5) and age-matched healthy controls (n=5), and in SMA patient fibroblast 
cells (n=3) and age-matched healthy controls (n=3). Coomassie stained gel was used as internal, total protein 
loading control. Fibroblast cells are listed in this order from left to the right: GM00498, GM05659, GM00302, 
GM03813, GM09677, GM00232. (#Spinal cord blot was also used in Figure 5.8). (B) Densitometry measurements 
of GAPDH reactive bands were first normalised to densitometry measurements of Coomassie stained gel, after 
which all samples were normalised to the average of control. The graph is presented as average protein levels 
(expressed relative to control), with error bars showing standard deviation from the mean. ns- not significant; 
**p<0.01 
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Figure 3. 7. ANXA2 protein levels in tissues from late-symptomatic SMA mice (P8) and in patient fibroblast 
cells. (A) Representative western blots showing ANXA2 levels in the heart, spinal cord, brain, liver and muscle 
tissue extracts from SMA mice (n=5) and age-matched healthy controls (n=5), and in SMA patient fibroblast 
cells (n=3) and age-matched healthy controls (n=3). Coomassie stained gel was used as internal, total protein 
loading control. Fibroblast cells are listed in this order from left to the right: GM00498, GM05659, GM00302, 
GM03813, GM09677, GM00232. (B) Densitometry measurements of ANXA2 reactive bands were first 
normalised to densitometry measurements of Coomassie stained gel, after which all samples were normalised 
to the average of control. The graph is presented as average protein levels (expressed relative to control), with 
error bars showing standard deviation from the mean. ns- not significant; *p<0.05; **p<0.01 
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GAP438 and NCAM9 are almost exclusively found in neuronal tissues and so their expression 
levels were determined biochemically only in spinal cord and brain from a mouse model of 
SMA (Figure 3.8). GAP43 and NCAM expression were not significantly changed in either spinal 
cord or brain tissue from SMA mice compared to controls. These results are in contrast with 
proteomic studies of SMA, where decreased expression of both GAP43 and NCAM was 
identified in mouse hippocampus and patient iPSC-derived motor neurons, and decreased 
expression of GAPD43 was also identified in hippocampus synaptosomes from SMA mice 
(Fuller, Gillingwater and Wishart, 2016). 
 
8 https://www.proteinatlas.org/ENSG00000172020-GAP43/tissue 
9 https://www.proteinatlas.org/ENSG00000149294-NCAM1/tissue 
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Figure 3. 8. GAP43 and NCAM protein levels in spinal cord and brain from late-symptomatic SMA mice (P8). 
Representative western blots showing GAP43 and NCAM levels in (A) spinal cord and (B) brain tissue extracts 
from SMA mice (n=5) and age-matched healthy controls (n=5). Coomassie stained gel was used as internal, 
total protein loading control. Densitometry measurements of GAP43 and NCAM reactive bands were first 
normalised to densitometry measurements of Coomassie stained gel, after which all samples were normalised 
to the average of control. Graphs are presented as average protein levels (expressed relative to control), with 
error bars showing standard deviation from the mean. ns- not significant 
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In summary, quantitative western blot analyses of SMA mouse tissues and SMA patient 
fibroblasts identified widespread dysregulation of SMN, UBA1, lamin A/C, GAPDH and ANXA2 
expression levels, where the direction of expression change varied depending on the tissue 
examined (Table 3.4). As expected, SMN levels were decreased in all cells/tissues examined, 
while a reduction of UBA1 levels was identified in the heart and liver tissue from SMA mice. 
Lamin A and/or C expression was increased in all tissues from a mouse model of SMA, except 
in skeletal muscles, while patient fibroblasts showed decreased expression of lamin A isoform 
only. SMA mouse heart and liver tissue showed reduction of GAPDH levels, while ANXA2 
expression was significantly reduced in the liver and muscle tissue from SMA mice. SMA 
mouse spinal cord and patient fibroblast cells, on the other hand, showed upregulation of 
ANXA2 levels. No obvious link between the pattern of UBA1, lamin A/C, GAPDH or ANXA2 
expression change and the level of SMN reduction was observed in SMA tissues.  
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Table 3. 4. Overview of protein levels in tissues from a mouse model of SMA and in SMA 
patient fibroblasts 
Protein Mouse Patient 
fibroblasts 
Proteomic 
studies Heart Spinal cord Brain Liver Muscle 
SMN -92% -88% -91% -94% -94% -71% NA 
UBA1 -76% -11% -5% -66% -59% -3% ↓ 
LAMIN A +69% -3% +25% +52% -45% -84% ↑ 
LAMIN C +92% +43% +43% +43% -1% +2% ↑ 
GAPDH -41% +10% +5% -49% -21% -11% ↓ 
ANXA2 -7% +57% +3% -59% -77% +31% ↑ 
GAP43 / +20% +30% / / / ↓ 
NCAM / -3% +15% / / / ↓ 
SMN, UBA1, LAMIN A/C, GAPDH, ANXA2, GAP43 and NCAM levels in the heart, spinal cord, brain, liver and muscle 
tissue from SMA mice, and in SMA patient fibroblast cells, as identified by western blotting. The results are 
expressed as average percent reduction (-) or increase (+) of protein expression in SMA samples relative to the 
control. The last column indicates direction of differential expression that was identified in proteomic studies of 
SMA. The direction of differential expression is indicated by an arrow, ↓ (downregulated) and ↑ (upregulated). 
/- protein expression was not studied biochemically in this sample; NA- not applicable 
 
3.2.3. In vitro drug screening studies in control and SMA patient fibroblast cells  
The widespread dysregulation of UBA1, lamin A/C, GAPDH and ANXA2 levels across a range of 
SMA tissues and cells indicated that these proteins might have a role in SMA disease pathways. 
Alongside SMN, restoration of UBA1, lamin A/C, GAPDH or ANXA2 expression to the levels 
observed in control healthy tissues might represent an attractive therapeutic approach in 
SMA, and so it was of interest to next identify drugs that have the potential to manipulate the 
expression of these proteins. Of specific interest were drugs that have the potential to target 
several of these proteins simultaneously as they might achieve greater therapeutic benefit 
compared to drugs that target individual proteins. Indeed, this was already demonstrated in 
a mouse model of SMA where a combination of two therapeutic strategies, aimed at 
increasing the levels of SMN protein and decreasing the levels of modifying factor neurocalcin 
137 
 
delta (NCALD), showed better results in improving neuromuscular pathology compared to 
SMN-targeted therapy alone (Torres-Benito et al., 2019). 
 
3.2.3.1. Selection of an appropriate experimental technique for protein expression 
measurements 
In vitro drug screening studies were performed in fibroblast cells from SMA patients and 
healthy controls, where the main outcome was the ability of the drug to restore the expression 
of proteins of interest to the levels observed in control cells. First, however, an appropriate 
experimental technique, that would enable quick, accurate and sensitive protein expression 
measurements, had to be determined to ensure the maximum efficiency of drug screening 
studies. Several approaches are available for protein expression measurements including, for 
example, western blotting, dot blot and ELISA (Salazar-Anton, Tellez and Lindh, 2012). 
Western blotting was used throughout this study to measure differences in protein expression 
between control and SMA samples, and so it was used here as a reference to establish 
accuracy and sensitivity of the other two methods. 
SMA and control cell extracts were first normalised to total protein, to ensure that an equal 
amount of starting material was loaded in each experiment. Cell extracts were prepared in 
triplicates in serial dilutions to establish the accuracy and sensitivity of protein expression 
measurements (the workflow is presented in Figure 3.9). Accuracy was determined by 
measuring protein levels across serial dilutions in one sample and calculating the R-squared 
(R2) value. R2 describes the linear relationship between two variables, where the value of 1 
represents perfect linear relationship, and 0 describes no linear relationship between 
variables (Schneider, Hommel and Blettner, 2010). Sensitivity was measured by quantifying 
protein levels in SMA cells relative to control in all consecutive dilutions, and comparing them 
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to western blot analysis. This was done to determine the concentration range within which 
the difference in protein expression between control and SMA samples can be accurately 
measured. 
 
 
3.2.3.1.1. Dot blot analysis showed good accuracy and sensitivity for measurements of SMN 
expression in patient fibroblasts, but failed to detect a change in lamin A levels 
Dot blotting is an immuno-associated technique were protein extracts are loaded directly on 
the nitrocellulose membrane, and the membrane is developed in the same way that a regular 
western blotting would be (Salazar-Anton, Tellez and Lindh, 2012). Protein levels are visualised 
as dots and densitometry measurements are performed using Image J software (as described 
in chapter 2, section 2.3.4). The dot blot approach was first tested on SMN as one of the 
primary targets in therapy design. Three SMN antibodies, MANSMA12 2E6, MANSMA2 8F7 
and MANSMA3 8E1, raised against different SMN epitopes (Young et al., 2000), were used for 
Figure 3. 9. Workflow of dot blot and ELISA. Linear correlation between protein levels and serial dilutions 
determines the accuracy of the method. Sensitivity is determined by comparing the relative SMN levels in SMA 
tissues (across different dilutions) to the results of western blot analysis. 
139 
 
dot blot analyses on control (GM05659) and patient (GM00232)  fibroblasts (Figure 3.10). This 
was done to determine whether this method is reliable and reproducible when different 
antibodies are used. Nitrocellulose membranes developed with MANSMA12 and MANSMA2 
antibodies showed a clear SMN signal (Figure 3.10A and 3.10B). MANSMA3, on the other 
hand, produced a weak SMN signal and strong background (Figure 3.10C), indicating that the 
antibody is perhaps not suitable for dot blot analysis. This would make quantification 
unreliable, and so SMN levels were not measured on dot blot developed with MANSMA3 
antibody. 
 
 
 
Figure 3. 10. SMN protein levels in control (GM5659) and patient (GM00232) fibroblast cells, following dot 
blot analyses. Membranes were developed with three SMN antibodies (A) MANSMA12 2E6, (B) MANSMA2 8F7 
and (C) MANSMA3 8E1. Control and SMA cell extracts were analysed in triplicates in six serial dilutions 
(expressed as μg of total protein). 
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Membranes developed with MANSMA12 and MANSMA2 were then analysed as described in 
Figure 3.9, taking into account seven exposure times, including three below and three above 
the automatic exposure. (The length of automatic exposure is determined by the number of 
saturated pixels within the imaging software, and represents the optimal exposure time). 
Different exposure times were analysed to account for variability introduced during image 
acquisition. Analyses identified R2 values between 0.99 and 0.94 for all exposure times in both 
control (Figure 3.11A) and SMA (Figure 3.11B) samples, and for both antibodies, indicating a 
good linear relationship between the data. In control samples, however, a decrease in R2 value 
was identified in longer exposure times with both antibodies (Figure 3.11A), indicating that 
overexpression of pixels can decrease the accuracy of measurements. This trend was not 
observed in SMA samples (Figure 3.11B), likely because SMN signal is weaker compared to 
control, and pixels are less likely to be overexpressed with longer exposure time.  
Quantification of SMN levels in SMA cells compared to controls, with both antibodies, showed 
variable results for different dilutions (Figure 3.11C). When compared to results from western 
blot analysis, where average SMN levels across three SMA cells were at approximately 30% 
compared to controls (Figure 3.3), MANSMA12 antibody produced similar results in a range 
between 0.75-0.1875 μg of total protein, where SMN levels were at 41.3%, 39.6% and 37.8%, 
across all exposure times (Figure 3.11C). MANSMA2 on the other hand showed comparable 
results to western blotting in a range between 1.5-0.375 μg of total protein, with SMN levels 
being at 33%, 34% and 38.4% in SMA cells across all exposure times (Figure 3.11C). 
Quantification was unreliable for the highest (3 μg) and the lowest (0.093 μg) concentration 
(with both antibodies, and across all exposure times), where SMN levels in SMA cells were at 
about 50% to those observed in control cells, or higher (Figure 3.11C). These results suggest 
that the sensitivity range for dot blot analysis is between 1.5 and 0.1875 μg of total protein.  
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Figure 3. 11. Dot blot analyses of SMN protein levels in control (GM5659) and patient (GM00232) fibroblast 
extracts. Correlation between serial dilutions (expressed as μg of total protein) and average SMN levels in (A) 
control and (B) SMA fibroblast extracts using MANSMA12 and MANSMA2 antibodies. R-squared (R2) was 
calculated for each exposure time (n = 7) to determine the strength of linear correlation. (C) Average levels of 
SMN in patient fibroblasts (expressed relative to the control), in three different exposure times. Numbers above 
the bars indicate relative SMN levels in SMA cells across different dilutions. *Exposure 4 in panels A) and B), 
and exposure 2 in panel C) indicate automatic exposure. 
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The same approach was then used to determine the accuracy and sensitivity of lamin A/C 
expression measurements in control (GM05659) and patient (GM00232) fibroblasts. Lamin 
A/C protein levels were dysregulated across a range of SMA tissues and cells (Figure 3.5), 
indicating that it may be involved in SMA disease pathways. Because of this it became one of 
the primary targets of in vitro drug screening studies, and so it was important to know whether 
a dot blot approach can be used for measurements of lamin A/C levels. For this, a membrane 
was developed with anti-lamin A/C antibody (MANLAC1 4A7) (Figure 3.12A) that had been 
used previously for western blot analysis (Figure 3.5). Weaker linear correlation between 
lamin A/C expression and serial dilutions was observed in both control and SMA samples, 0.95 
and 0.889 respectively (Figure 3.12B). This is likely caused by weak lamin A/C signal in lower 
concentration range that made quantification unreliable (Figure 3.12A), and so other exposure 
times were not examined here. In contrast to western blot analysis (Figure 3.5), lamin A/C 
levels were not significantly changed in SMA samples compared to control in dot blot analysis 
(Figure 3.12C). This could be explained by the fact that only lamin A isoform showed 
differential expression in SMA patient fibroblasts using western blotting (Figure 3.5), and so 
in dot blot analysis changes in lamin A expression could have been masked by unchanged 
levels of lamin C. To test this hypothesis, an antibody that recognises only lamin A isoform was 
used for dot blot analysis in control (GM00302) and patient (GM00232) fibroblasts (Figure 
3.12D). Once again, quantification of lamin A levels in the lower concentration range was 
unreliable in control fibroblasts, which skewed linear correlation (R2 = 0.96) between lamin A 
expression and serial dilutions (Figure 3.12E). In addition, lamin A expression showed no 
significant change in SMA patient fibroblasts compared to controls (Figure 3.12F). Although 
the same amount of total protein was initially loaded based on the results from protein assay, 
differences in loading between control and SMA samples could still be plausible. Since it is not 
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possible to check the loading in dot blot analyses, it makes it the biggest limitation of this 
approach.  
 
Figure 3. 12. Dot blot analysis of lamin A/C protein levels in SMA patient and control fibroblast extracts. (A) 
Lamin A/C (MANLAC1 4A7) and (D) lamin A levels in control and patient fibroblast extracts across serial 
dilutions (expressed as μg of total protein). Control and SMA cell extracts were analysed in triplicates. (B, E) 
Correlation between serial dilutions and average lamin A/C and lamin A levels in control and SMA cells. R-
squared (R2) represents strength of linear correlation. (C, F) Average levels of lamin A/C and lamin A in control 
and patient fibroblasts (expressed relative to the control) across serial dilutions. Ns- not significant 
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3.2.3.1.2. Lamin A was not identified in control and patient fibroblasts using enzyme-linked 
immunosorbent assay (ELISA) 
Since dot blot analysis did not show good sensitivity for measurement of lamin A/C levels, a 
lamin A specific antibody was next used to test the accuracy and sensitivity of ELISA approach 
as described above (Figure 3.9). Control and SMA cell extracts were analysed in triplicates, in 
seven serial dilutions. The analysis, however, did not produce any visible signal, and so the 
absorbance of wells was not measured on the plate reader. 
 
 To summarize, the dot blot approach showed good accuracy and sensitivity for quantification 
of SMN levels in SMA patient fibroblasts, however, it was not sensitive enough to detect 
changes in expression of lamin A specific isoform. Examination of lamin A levels, using indirect 
ELISA, produced no results, which is likely the consequence of technical problems with the 
antibody. This then means that other antibodies, that can detect lamin A and lamin C specific 
isoforms, would have to be tested for dot blot and ELISA analyses. Western blotting, on the 
other hand, is an established method in this laboratory and was shown to be a reliable method 
for measurements of protein expression across different sample types (Eaton et al., 2013). 
Western blotting was therefore chosen for verification of protein expression in drug screening 
studies.  
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3.2.3.2. Network pharmacology identified 20 new drugs that have the potential to change 
the expression of at least two protein targets 
Selection of candidate therapeutics that have the potential to target multiple proteins of 
interest can be challenging and demands application of systemic approach such as the 
network pharmacology. Network pharmacology uses different resources, such as omics 
datasets and publicly available databases, and computational techniques to study interactions 
between drugs and complex biological systems (Azuaje, 2013). These analyses are used to 
generate prediction models that can facilitate understanding of drug action and its impact on 
biological system. This knowledge is clinically translational, and it can be used, for example, 
for identification of new therapeutic compounds or optimisation of existing treatments 
(Azuaje, 2013). Casas et al., for example, used network pharmacology to identify additional 
therapeutic targets in ischemic stroke, and this was confirmed experimentally (Casas et al., 
2019). Combined inhibition of NADPH oxidase (NOX), primary therapeutic target in ischemic 
stroke, and nitric oxide synthase (NOS), newly identified therapeutic target, enhanced the 
efficiency of the treatment, which was evident by reduced cell death, reduced infarct size and 
preserved neuromotor function in a mouse model of ischemic stroke (Casas et al., 2019). In 
another study, network pharmacology was applied to the develop new algorithm that can be 
used to predict adverse effects for both clinically approved drugs and new compounds 
(Gottlieb et al., 2011). By examining inflammatory bowel disease (IBD) gene expression 
datasets, Dudley et al. identified topiramate, an anticonvulsant drug used in epilepsy, as a 
potential compound that could be repurposed for the treatment of IBD (Dudley et al., 2011). 
Therapeutic benefit of topiramate was demonstrated in vivo, in rodent model of IBD, where 
topiramate treated mice exhibited improved pathology, including reduced swelling and 
ulceration, and decreased gross inflammation compared to untreated controls (Dudley et al., 
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2011). All of these examples show that network pharmacology has real clinical applications, 
and can be used to guide development of safer and more efficient therapeutic approaches. 
 
Here, network pharmacology approach was used to identify new drugs that could potentially 
be repurposed for SMA. Drug repurposing is an attractive approach in therapy design because 
drugs tested in clinical trials have established pharmacokinetic and pharmacodynamic profiles 
(Durães, Pinto and Sousa, 2018), which significantly reduces the costs and the time of a drug 
design compared to development of new compounds (Durães, Pinto and Sousa, 2018). This is 
extremely important in SMA therapy design due to high cost and differential effects of 
available drugs (Hoolachan, Sutton and Bowerman, 2019). Upstream regulators of eight 
protein targets, SMN, lamin A/C, UBA1, GAPDH, ANXA2, GAP43, NCAM and COL6A3, identified 
in a multi-study comparison of published proteomic studies and investigated biochemically 
here, were analysed using a trial version of Ingenuity Pathway Analysis (IPA) software. The 
analysis identified 78 upstream regulators that have a known mechanism of action on at least 
two proteins (data not shown), meaning they were shown to alter the expression/ activity of 
molecules at the gene and/or protein level. Of these, 20 upstream regulators were chemical 
or biological drugs (Table 3.5) that were taken into consideration for in vitro drug studies in 
fibroblast cells. The priority was given to compounds that are safe and tolerable in clinical use, 
and commercially available for a reasonable price, as this would facilitate translation of the 
treatment into clinic. After removal of drugs that show high toxicity, i.e. those that are used 
in the treatment of different cancers like cisplatin 10, the list was reduced to nine candidates, 
including trichostatin A, dexamethasone, sirolimus, valproic acid, calcitriol, agn194204, 
 
10 https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/cisplatin 
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curcumin, desmopressin and lovastatin. To further reduce the number of potential candidate 
drugs, drugs that were identified with only two downstream targets, including curcumin, 
desmopressin and lovastatin were excluded from the list. Of the six remaining drugs, 
dexamethasone induced neurodegeneration in the brain of rat pups (Feng et al., 2009) which 
makes it unsuitable for SMA infants and young children, and sirolimus treatment decreased 
the lifespan of SMA and ALS mice compared to untreated animals (Custer and Androphy, 
2014). Histone deacetylase inhibitor valproic acid (VPA) was already tested in clinical trials on 
type I, II and III SMA patients, but showed limited benefit in improving muscle strength and 
motor function in SMA patients (Swoboda et al., 2010; Darbar et al., 2011; Kissel et al., 2011, 
2014). This left three potential candidates: trichostatin A, calcitriol and agn194204, of which 
trichostatin A was associated with five protein targets, COL6A3, GAP43, LMNA, NCAM1, SMN, 
and was therefore chosen as first candidate for in vitro drug studies.  
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Table 3. 5. Upstream regulators of eight protein targets 
Upstream regulator Molecule type p-value of 
the overlap 
Activation 
Z-score 
Protein targets 
Cisplatin chemical drug 3.02E-06 1.503 ANXA2, GAP43, LMNA, 
NCAM1, SMN1/SMN2 
Decitabine chemical drug 3.36E-06 0.447 ANXA2, COL6A3, GAP43, 
NCAM1, UBA1 
Trichostatin A chemical drug 5.64E-06 -1.397 COL6A3, GAP43, LMNA, 
NCAM1, SMN1/SMN2 
Dexamethasone  chemical drug 4.35E-03 1.111 GAP43, GAPDH, NCAM1, 
SMN1/SMN2 
Sirolimus chemical drug 2.40E-05 -0.218 GAP43, LMNA, NCAM1, UBA1 
Valproic acid chemical drug 5.45E-04  GAP43, NCAM1, SMN1/SMN2 
Calcitriol chemical drug 9.00E-04  ANXA2, GAPDH, NCAM1 
Agn194204 chemical drug 2.31E-05  ANXA2, GAPDH, LMNA 
5-fluorouracil chemical drug 9.16E-05  ANXA2, GAP43, GAPDH 
Methotrexate chemical drug 0.00333  GAP43, GAPDH 
Tamoxifen chemical drug 0.00458  GAP43, GAPDH 
Tazemetostat chemical drug 0.00496  GAP43, NCAM1 
Curcumin chemical drug 0.00704  NCAM1, SMN1/SMN2 
Doxorubicin chemical drug 0.0101  ANXA2, NCAM1 
Methylprednisolone chemical drug 0.0152  ANXA2, SMN1/SMN2 
Camptothecin chemical drug 0.0195  ANXA2, GAPDH 
Vincristine chemical drug 0.000121  GAP43, NCAM1 
Oxaliplatin chemical drug 0.000199  ANXA2, GAP43 
Desmopressin biologic drug 0.000495  GAPDH, LMNA 
Lovastatin chemical drug 0.00118  GAP43, LMNA 
Upstream regulators of eight protein targets are listed in the table (only upstream regulators that are known to 
act on at least two proteins are shown). Only chemical and biological drugs are presented, together with the p-
value of the overlap and activation Z-score. Overlap p‐value is used to identify likely upstream regulators based 
on significant overlap between dataset genes/proteins and known targets regulated by upstream regulator. 
Activation Z-score gives a prediction of whether the upstream regulator is activated (positive value) or inhibited 
(negative value) based on the direction of expression change in the input dataset. Z-score of ≥2 represents the 
prediction of activation, while Z-score ≤ -2 represents the prediction of inhibition. 
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3.2.3.2.1. Trichostatin A does not significantly change SMN and lamin A/C levels 
Trichostatin A (TSA) is an antifungal antibiotic and selective histone deacetylase inhibitor that 
showed promising anti-cancer activity in different cancer subtypes (Lernoux et al., 2018), and 
the beneficial effect of TSA was already demonstrated in SMA (Avila et al., 2007; Liu et al., 
2014). For example, TSA treatment increased the levels of SMN mRNA in SMA patient 
fibroblasts, and increased SMN mRNA and protein levels in the brain, spinal cord and liver 
tissue from a severe mouse model of SMA (Smn–/–SMN2+/+SMNΔ7+/+). In addition, TSA 
treatment attenuated weight loss, improved neuromuscular pathology and increased survival 
in severe SMA mice (Avila et al., 2007). An SMN-independent beneficial effect of TSA was also 
demonstrated in intermediate mouse model of SMA (Smn2B/-) (Liu et al., 2014). Embryonic 
fibroblasts and myoblasts, and brain, spinal cord, muscle, heart and liver tissue from Smn2B/- 
mice showed no significant change in SMN protein levels following TSA treatment, however, 
improved neuromuscular pathology and survival were identified in Smn2B/- mice (Liu et al., 
2014). This would then suggest that TSA also has an SMN-independent mechanism of action, 
possibly through regulation of lamin A/C levels (Table 3.5). Indeed, increase in lamin A/C 
expression was previously observed in TSA-treated fibroblasts from Hutchinson-Gilford 
progeria syndrome (HGPS) patients and healthy controls (Columbaro et al., 2005) and in 
mouse embryonic fibroblasts (MEFs) (Galiová et al., 2008). 
 
Here, SMN and lamin A/C protein expression was first studied in control (GM00498) and SMA 
(GM09677) fibroblasts treated with 50 nM and 100 nM TSA for four hours (Figure 3.13C and 
3.13D) to determine whether TSA has the ability to regulate their expression in vitro. 
Justification for that comes from in vitro study on SMA patient fibroblasts, where a maximum 
increase in SMN mRNA levels was observed four to five hours following exposure to 50 nM 
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TSA (Avila et al., 2007), and so it was of interest to see whether this translates to protein level. 
In addition to SMN and lamin A/C, UBA1 levels were also examined in TSA treated cells (Figure 
3.13C and 3.13D). The role for UBA1 in SMA disease pathways was well characterised across 
different models of SMA (Wishart et al., 2014; Powis et al., 2016; Shorrock et al., 2018), which 
makes it one of the primary targets of non-SMN therapeutic approaches. Cell viability was 
around 90% in all treatment groups, in both control and SMA fibroblast cells (Figure 3.13A and 
3.13B), meaning the treatment was well tolerated. Quantitative analyses, using western 
blotting, did not identify a statistically significant difference in SMN, lamin A, lamin C or UBA1 
expression following trichostatin treatment in control fibroblasts (Figure 3.13E). In SMA 
fibroblasts, SMN and lamin A/C levels were not significantly changed in TSA treated group, 
while the levels of UBA1 were significantly decreased in vehicle, 50 nM and 100 nM TSA 
treated group for 30% (p = 0.0382), 37% (p = 0.0166) and 38% (p = 0.0168) respectively (Figure 
3.13F). Significant reduction of UBA1 levels in the vehicle group suggested that vehicle (DMSO) 
might be responsible for changes in UBA1 expression in all treatment groups. However, 
technical problems, such as the variable efficiency of protein transfer onto the nitrocellulose 
membrane and unreliable quantification of UBA1 levels caused by low signal intensity, are also 
possible and should be considered when interpreting the results. 
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Figure 3. 13. SMN, lamin A/C and UBA1 protein levels in control and patient fibroblasts treated with 
trichostatin A (TSA). Cell viability in (A) control and (B) patient fibroblasts treated with 50 nM and 100 nM TSA 
for four hours. Two technical replicates were used in each group: untreated (media only), vehicle (DMSO) and 
TSA (50 nM and 100 nM). Graphs are presented as average cell viability, with error bars showing standard 
deviation from the mean. Representative western blots showing SMN, lamin A/C and UBA1 levels in (C) control 
and (D) patient fibroblasts treated with 50 nM and 100 nM TSA. Three technical replicates were used in each 
group: untreated (media only), vehicle (DMSO) and TSA (50 nM and 100 nM). Coomassie stained gel was used 
as internal, total protein loading control. Quantification of SMN, lamin A/C and UBA1 levels in (E) control and 
(F) patient fibroblasts. Densitometry measurements of SMN, lamin A, lamin C and UBA1 reactive bands were 
first normalised to densitometry measurements of Coomassie stained gel, after which all samples were 
normalised to the average of untreated. Graphs are presented as average protein levels (expressed relative to 
untreated), with error bars showing standard deviation from the mean. TSA- trichostatin A; ns- not significant; 
*p ≤ 0.05. 
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It is possible that a four-hour treatment is not sufficient to induce changes in SMN or lamin 
A/C protein levels. For example, HGSP patient fibroblasts (Columbaro et al., 2005) and  MEFs 
(Galiová et al., 2008) showed increased levels of lamin A/C after a 24-hour exposure to TSA. It 
was therefore important to investigate whether longer treatment could change the 
expression of proteins of interest. SMA fibroblasts were next exposed to 25 nM, 50 nM and 
100 nM of TSA for 8-, 16- and 24 hours to examine the expression of SMN, lamin A/C and UBA1 
(Figure 3.14B, 3.14C and 3.14D). Cell viability was between 95% and 100% in all groups and 
across all three time points (Figure 3.14A). SMN, lamin A and lamin C did not show a significant 
change in expression after 8, 16 and 24-hour exposure to TSA in any concentration examined 
(Figure 3.14E, 3.14F and 3.14G). UBA1 expression was not significantly changed after 16- and 
24-hour exposure to TSA, however, a significant reduction of UBA1 levels (22%, p = 0.0328) 
(Figure 3.14E) was identified in cells treated with 50 nM TSA for 8 hours. It would be hard to 
speculate whether this is a true finding or a result of technical problems, such as the variable 
efficiency of protein transfer or unreliable quantification of UBA1 levels. This experiment 
would thus need to be repeated again before making any conclusions. 
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Figure 3. 14. SMN, lamin A/C and UBA1 protein levels in patient fibroblasts treated with trichostatin A (TSA). 
(A) Cell viability in patient fibroblasts treated with 25 nM, 50 nM and 100 nM TSA for 8, 16 and 24 hours. Two 
technical replicates were used in each group: vehicle (DMSO) and TSA (25 nM, 50 nM and 100 nM). Graphs are 
presented as average cell viability, with error bars showing standard deviation from the mean. Representative 
western blots showing SMN, lamin A/C and UBA1 levels in patient fibroblasts following exposure to TSA for (B) 
8, (C) 16 and (D) 24 hours. Three technical replicates were used in each group: vehicle (DMSO) and TSA (25 
nM, 50 nM and 100 nM). Coomassie stained gel was used as internal, total protein loading control. 
Quantification of SMN, lamin A/C and UBA1 levels in cells exposed to TSA for (E) 8, (F) 16 and (G) 24 hours. 
Densitometry measurements of SMN, lamin A, lamin C and UBA1 reactive bands were first normalised to 
densitometry measurements of Coomassie stained gel, after which all samples were normalised to the average 
of vehicle. Graphs are presented as average protein levels (expressed relative to vehicle), with error bars 
showing standard deviation from the mean. TSA- trichostatin A. ns- not significant; *p ≤ 0.05 
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In summary, SMN and lamin A/C levels were not significantly changed in TSA treated cells in 
any of the concentrations or exposure times used, while a significant reduction of UBA1 levels 
was identified in patient fibroblasts treated with TSA for 4 and 8 hours. However, additional 
experiments are needed to investigate whether TSA can change the expression of UBA1.  
 
3.2.3.3. Identification of possible multi-target drugs using PubMed search engine 
Since trichostatin A did not show promising results in regulating the expression of target 
proteins, a more direct approach was undertaken to identify other potential drug candidates. 
A PubMed search was conducted to identify drugs with the potential to target multiple 
proteins of interest, including SMN, lamin A/C and UBA1. This approach was chosen because 
research has shown that targeting SMA modifiers like NCALD, in combination with a SMN-
targeted approach, brings greater therapeutic benefit to SMA mice (Torres-Benito et al., 
2019). Identifying a single drug that can achieve this offers an attractive alternative to 
combinatorial approach, in terms of the safety (no drug-drug interactions) and easier 
management of the pharmacokinetics and bioavailability of the drug (Hopkins, 2008). Two 
drugs, PDGF-BB and quercetin, were identified and tested in control and patient fibroblasts to 
determine whether they can change the expression of target proteins. 
 
3.2.3.3.1. Quantification of SMN and lamin A/C protein levels was unreliable in PDGF-BB 
treated fibroblasts 
Platelet-derived growth factor BB (PDGF-BB) plays an important role in cell proliferation, 
differentiation and migration, and is being used in the clinics to improve wound-healing 
(Andrae, Gallini and Betsholtz, 2008). PDGF treatment increased lamin A/C phosphorylation 
in NIH/3T3 fibroblasts (Fields et al., 1990), which was identified as an important regulator of 
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lamin A/C turnover (Cho et al., 2019). For example, increased phosphorylation promotes lamin 
A/C turnover, whereas decreased phosphorylation promotes lamin A/C stability (Cho et al., 
2019). In addition, treatment of neuronal progenitor cells (NPCs) with PDGF-BB resulted in 
upregulation of microRNA-9 (miR-9) levels (Yang et al., 2013), a negative regulator of lamin A 
expression in neuronal tissues (Jung et al., 2012), and miR-9 expression was dysregulated 
across a range of SMA tissues/cells, including spinal cord and muscles from severe SMA mice 
(Catapano et al., 2016), and SMA patient fibroblasts (Wang et al., 2014). A two-fold 
upregulation of SMN protein levels was previously observed in SMA patient fibroblasts 
following 72-hour exposure to 100 ng/mL PDGF-BB, using both immunocytochemistry and 
western blotting (Makhortova et al., 2011). The same study identified no significant change in 
SMN expression after 24- and 48-hour exposure to the same concentration of PDGF-BB, 
however, they used immunocytochemistry approach for quantitative analysis (Makhortova et 
al., 2011), which might not be sensitive enough to detect small changes in SMN expression. 
Western blotting was therefore used here as a more sensitive quantitative approach to 
determine whether 100 ng/mL PDGF-BB treatment for 24 hours can change SMN expression 
in control (GM05659) and SMA (GM00232) fibroblasts (Figure 3.15A and 3.15B). The analyses 
identified no significant change in SMN levels in control or patient fibroblasts treated with 
PDGF-BB (Figure 3.15C and 3.15D). However, quantification of SMN levels was unreliable 
because of the large variability in SMN expression within the group (Figure 3.15A and 3.15B). 
Quantification of lamin A and lamin C levels was unreliable in both control and SMA fibroblasts 
because of the large variability in lamin A/C expression in all treatment groups (Figure 3.15C 
and 3.15D). The only significant difference in lamin A expression was identified in vehicle 
treated group from control fibroblasts (Figure 3.15C), which could be a result of different 
technical problems during protein extraction and/or protein detection. Although, a vehicle (4 
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mM HCl) specific effect on lamin A expression cannot be excluded at this point without further 
experiments, especially not without the cell viability assay that is missing here. 
 
 
In summary, treatment of fibroblast cells with PDGF-BB did not offer new insights into 
mechanisms of drug action in SMA. Control and patient fibroblasts treated with PDGF-BB 
showed large variability in SMN and lamin A/C expression within all groups. 
 
 
Figure 3. 15. SMN and lamin A/C protein levels in control and patient fibroblasts treated with PDGF-BB. 
Representative western blots showing SMN and lamin A/C levels in (A) control and (B) patient fibroblasts 
treated with 100 ng/mL PDGF-BB. Three technical replicates were used in each group: untreated (media only), 
vehicle (4 mM HCl) and PDGF-BB (100 ng/mL). Coomassie stained gel was used as internal, total protein loading 
control. Quantification of SMN, lamin A and lamin C levels in (C) control and (D) patient fibroblasts. 
Densitometry measurements of SMN and lamin A/C reactive bands were first normalised to densitometry 
measurements of Coomassie stained gel, after which all samples were normalised to the average of control. 
Graphs are presented as average protein levels (expressed relative to untreated), with error bars showing 
standard deviation from the mean. ns- not significant, * p ≤ 0.05 
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3.2.3.3.2. A dose-dependent reduction of SMN, lamin A/C and active β-catenin levels, and 
increase of UBA1 levels in quercetin treated patient fibroblasts 
Quercetin is natural flavonoid with anti-inflammatory, anti-oxidant and anti-cancer properties 
that is widely available as a food supplement (Wanga et al., 2011). Quercetin already 
demonstrated therapeutic benefit in vivo, in zebrafish, Drosophila and mouse models of SMA 
(Wishart et al., 2014). For example, quercetin treatment rescued axonal defects in SMA 
zebrafish, ameliorated NMJ pathology in Drosophila and mouse models of SMA, and restored 
muscle fiber dimeter and improved muscle strength in a mouse model of SMA (Wishart et al., 
2014). The study provided several pieces of evidence that quercetin has protective effect on 
neuromuscular pathology in animal models of SMA (Wishart et al., 2014), however, the 
molecular mechanism of quercetin action in SMA tissues remains unknown. In a separate 
study, increased SMN2 mRNA levels were identified in SMA patient fibroblast cells treated 
with quercetin, with no significant change observed at the protein level, however, they used 
actin as a loading control for western blot analysis (Uzunalli et al., 2015). Considering that 
changes in actin expression have already been identified in spinal cord from SMA mice (Eaton 
et al., 2013), normalization of SMN expression to actin could be unreliable. In addition, a 24-
hour exposure to quercetin reduced levels of lamin A and lamin C levels in NCOL-1 cells 
(Herzog et al., 2004).  
 
Here, the ability of quercetin to change the expression of SMN and lamin A/C was studied in 
control (GM05659) and patient fibroblast cells (GM00232), where cells were treated with 100 
μM of quercetin for 24 hours (Figure 3.16A and 3.16B). These parameters were chosen 
because patient fibroblast cells treated with 100 μM of quercetin for 24 hours showed 
increased levels of SMN2 mRNA, however, SMN protein levels were not investigated for this 
158 
 
dose (Uzunalli et al., 2015). The same study investigated SMN protein levels in patient 
fibroblasts treated with 20 μM of quercetin and found no significant change in SMN expression 
compared to untreated group. However, they used actin as a loading control which could have 
made quantification unreliable, and so it was important to determine whether quercetin has 
the ability to change SMN protein levels by using total protein as a loading control. 
Interestingly, a reduction of SMN levels was identified in control and patient fibroblasts 
following quercetin treatment, and a lower molecular weight band was observed in drug 
treated cells (Figure 3.16A and 3.16B). Measurements of the upper band showed significant 
reduction of SMN levels in both control and patient fibroblasts, for 27% (p = 0.0347) and 52% 
(p = 0.0167) respectively (Figure 3.16C and 3.16D). Both SMN bands were then measured 
together to account for the possibility that quercetin induces SMN degradation. When both 
bands were taken into account, average SMN levels in quercetin treated control cells were 
similar to those observed in vehicle and untreated group (Figure 3.16C). In SMA cells, a 30% 
reduction of SMN levels was observed in quercetin treated group when bands were measured 
together, however, the change was not statistically significant likely because of the variability 
in SMN expression between technical replicates of the treatment group (Figure 3.16D).  Lamin 
A and lamin C expression were not significantly changed in either control or SMA fibroblasts 
following quercetin treatment (Figure 3.16C and 3.16D). Inhibition of β-catenin signalling was 
proposed as possible mechanism of quercetin action in SMA, however, this was not verified 
biochemically (Wishart et al., 2014). To test this hypothesis, total β-catenin levels were 
investigated in patient fibroblasts treated with quercetin (Figure 3.16B), however, no 
significant change in β-catenin expression was identified in cells following drug treatment 
(Figure 3.16D).  
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Figure 3. 16. SMN, lamin A/C and total β-catenin protein levels in fibroblasts treated with quercetin. 
Representative western blots showing (A) SMN and lamin A/C levels in control fibroblasts, and (B) SMN, lamin 
A/C and total β-catenin levels in patient fibroblasts treated with 100 μM of quercetin. Three technical 
replicates were used in each group: untreated (media only), vehicle (DMSO) and quercetin (100 μM). 
Coomassie stained gel was used as internal, total protein loading control.  Arrows indicate possible SMN 
degradation product. Quantification of (C) SMN and lamin A/C levels in control fibroblasts, and (D) SMN, lamin 
A/C and β-catenin levels in patient fibroblasts. Densitometry measurements of SMN, lamin A, lamin C and β-
catenin reactive bands were first normalised to densitometry measurements of Coomassie stained gel, after 
which all samples were normalised to the average of untreated. Graphs are presented as average protein 
levels (expressed relative to untreated), with error bars showing standard deviation from the mean. SMN#- 
only upper SMN band was subjected to densitometry measurements. ns- not significant 
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Although Uzunalli et al. showed good cell viability in patient fibroblast cell treated with 100 
μM of quercetin for 24 hours (Uzunalli et al., 2015), a 72-hour exposure to 100 μM quercetin, 
for example, reduced cell proliferation in NCOL-1 cell line (Herzog et al., 2004). In addition, 
incubation with 150 μM quercetin activated apoptosis in NCOL-1 cells, which was evident by 
increased caspase-3 activity and DNA fragmentation (Herzog et al., 2004). An additional SMN 
band in the quercetin treated group suggested increased SMN degradation which could be 
indicative of apoptotic process, however it is impossible to conclude anything without the cell 
viability test. To test this, patient fibroblasts (GM00232) were treated with incremental 
concentrations of quercetin, including 6.25 μM, 12.5 μM, 25 μM, 50 μM and 100 μM, to 
determine whether the same effect on SMN expression can be observed across different 
doses of quercetin (Figure 3.17B). Cell viability was assessed for all doses of quercetin using a 
trypan blue exclusion test. All treated groups showed good cell viability, with values between 
96% and 100% (Figure 3.17A).  
 
A dose dependent reduction of SMN levels was identified in quercetin treated cells starting 
with 8% in 12.5 μM treatment, 12% in 25 μM treatment, 50% in 50 μM treatment and 66% in 
100 μM treatment (Figure 3.17C). Statistical significance of these results could not be 
determined due to the low group size (i.e. n=2). The lower molecular band in SMN blot, 
observed previously in Figure 3.16 in quercetin treated cells, was not as distinct here (Figure 
3.17B). In contrast to results from a 100 μM quercetin treatment, where no change in lamin 
A/C levels was observed in fibroblasts cells (Figure 3.16), a dose dependent reduction of lamin 
A and lamin C levels was identified in quercetin treated cells (Figure 3.17C). A 64% reduction 
of lamin A levels was observed in cell treated with 12.5 μM quercetin, 85% in cells treated 
with 25 μM quercetin, 93% in cells treated with 50 μM quercetin and 92% in cells treated with 
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100 μM quercetin. Lamin C levels where reduced by 39% in cells treated with 12.5 μM 
quercetin, 80% in cells treated with 25 μM quercetin, and 94% and 93% in cell treated with 50 
μM and 100 μM quercetin respectively (Figure 3.17C). A dose dependent decrease in nuclear 
(active) β-catenin expression was identified previously in SW480 and HEK293 cells incubated 
with quercetin (Park et al., 2005). This means that changes in active β-catenin levels could 
have been masked in quercetin treated cells when total β-catenin levels where examined 
(Figure 3.16). Indeed, investigation of active β-catenin (ABC) levels in quercetin treated cells 
revealed a dose dependent reduction of ABC levels, where treatment with 25 μM quercetin 
showed 40% reduction, treatment with 50 μM quercetin showed 75% reduction and 
treatment with 100 μM quercetin showed 81% reduction in ABC levels compared to vehicle 
treated group (Figure 3.17C). A dose-dependent reduction of active β-catenin, SMN and lamin 
A/C levels suggested activation of proteasome pathway in SMA patient fibroblasts. 
Proteasome activation was identified previously in HFL-1 cells treated with 2 μg/mL quercetin 
(Chondrogianni et al., 2010), which is comparable to the lowest concentration of quercetin 
used in this study, i.e. 6.25 μM. UBA1 levels were therefore investigated in quercetin treated 
cells to determine whether activation of ubiquitin-proteasome system could be responsible 
for reduction of SMN, lamin A/C and active β-catenin levels (Figure 3.17A). Indeed, increased 
levels of UBA1 were observed in quercetin treated cells, with 29%, 31%, and 33% increase 
identified in 25 μM, 50 μM and 100 μM concentrations respectively (Figure 3.17C). 
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Figure 3. 17. SMN, lamin A/C, UBA1 and active β-catenin (ABC) protein levels in patient fibroblasts treated 
with quercetin. (A) Cell viability in patient fibroblasts treated with 0 μM (DMSO), 6.25 μM, 12.5 μM, 25 μM, 50 
μM and 100 μM quercetin. Three technical replicates were used in each group. Graph is presented as average 
cell viability, with error bars showing standard deviation from the mean. (B) Representative western blots 
showing SMN, lamin A/C, ABC and UBA1 levels in patient fibroblasts treated with 0 μM (DMSO), 6.25 μM, 12.5 
μM, 25 μM, 50 μM and 100 μM quercetin. Two technical replicates were used in each group. Coomassie stained 
gel was used as internal, total protein loading control. (C) Quantification of SMN, lamin A/C, ABC and UBA1 
levels in patient fibroblasts. Densitometry measurements of SMN, lamin A, lamin C, ABC and UBA1 reactive 
bands were first normalised to densitometry measurements of Coomassie stained gel, after which all samples 
were normalised to the average of control. Graph is presented as average protein levels (expressed relative to 
vehicle), with error bars showing standard deviation from the mean. ABC- active β-catenin. *p ≤ 0.05; ***p ≤ 
0.001 
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In summary, quercetin treatment did not affect cell viability, however, a dose-dependent 
downregulation of SMN, lamin A/C and active β-catenin level, and a small upregulation of 
UBA1 levels was observed in quercetin treated cells. 
 
To explore the potential mechanism of quercetin action in SMA fibroblast cells, SMN, lamin 
A/C, ABC and UBA1 expression were next investigate in SMA fibroblast cells (GM00232) 
treated with 6.25 μM and 100 μM quercetin using immunocytochemistry approach (Figure 
3.18, 3.19 and 3.20). These concentrations were chosen because 6.25 μM quercetin did not 
affect SMN, lamin A/C, UBA1 and ABC protein levels in previous experiment, while 100 μM 
quercetin induced the biggest change in expression of all four proteins (Figure 3.17). No 
obvious difference in SMN and lamin A/C expression or localization was observed between 
quercetin and vehicle treated group (Figure 3.18A and 3.19A). ABC and UBA1 levels, on the 
other hand, did seem increased in cells treated with 100 μM quercetin (Figure 3.20A and 
3.20B). To quantify these results, lamin A/C, ABC and UBA1 levels were measured in the 
nucleus of quercetin and vehicle treated cells as described in methods section 2.8.4.2. Nuclear 
SMN is located in structures called Gemini of the coiled bodies (GEMs) (Coovert et al., 1997), 
and reduction in the number of GEMs was previously shown to corelate with disease severity 
in SMA (Coovert et al., 1997). In addition, increased number of GEMs was identified in 
phenylbutyrate treated patient fibroblasts (Andreassi et al., 2004). This suggested that GEM 
number can be used to assess the effect of a drug treatment on SMN, and so GEMs were 
counted in quercetin treated fibroblasts. When compared to vehicle where 0.9% of cells 
showed GEMs, GEMs were identified in 2.9% cells treated with 6.25 μM quercetin and in 1.3% 
cells treated 100 μM quercetin (Figure 3.18B). Lamin A/C levels were not significantly changed 
in cells treated with 100 μM quercetin, however, although visually not obvious, a statistically 
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significant reduction of lamin A/C levels (30%, p=0.0419) was identified in cells treated with 
6.25 μM quercetin (Figure 3.19B). A statistically significant increase in ABC levels was 
identified in cells treated with 6.25 μM quercetin (38%, p=0.0349) and 100 μM quercetin (78%, 
p<0.001) (Figure 3.20C). Nuclear UBA1 levels were significantly upregulated in cells treated 
with 100 μM quercetin (111%, p<0.001), while no change in UBA1 expression was observed in 
6.25 μM quercetin (Figure 3.20D). 
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Figure 3. 18. SMN in SMA patient fibroblasts. Representative immunocytochemistry images showing (A) SMN 
(green) staining in SMA patient fibroblasts (GM00232) treated with quercetin, with DAPI shown in blue. Three 
technical replicates were used in each group: vehicle (DMSO), quercetin (6.25 μM and 100 μM). Lower 
magnification images (scale bar = 75 μm), higher magnification images (scale bar = 7.5 μm). (B) Quantification 
of GEM number in SMA patient fibroblasts following quercetin treatment. Total number of cells counted, and 
the number and percentage of cells that contained GEMs are presented in vehicle and quercetin treated 
groups.   
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Figure 3. 19. Lamin A/C staining in SMA patient fibroblasts. (A) Representative immunocytochemistry images 
showing lamin A/C (green) staining in SMA patient fibroblasts (GM00232) treated with quercetin, with DAPI 
shown in blue. Three technical replicates were used in each group: vehicle (DMSO), quercetin (6.25 μM and 
100 μM). Scale bar = 75 μm.  (B) The graph is presented as average optical density, with error bars showing 
standard deviation from the mean. ns-not significant; *p<0.05 
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Figure 3. 20. ABC and UBA1 staining in SMA patient fibroblasts. Representative immunocytochemistry images 
showing (A) ABC (green) and (B) UBA1 (green) staining in SMA patient fibroblasts (GM00232) treated with 
quercetin, with DAPI shown in blue. Three technical replicates were used in each group: vehicle (DMSO), 
quercetin (6.25 μM and 100 μM). Scale bar = 75 μm. (C) Graphs are presented as average optical density, with 
error bars showing standard deviation from the mean. ns-not significant; *p<0.05, ***p<0.001 
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Of the four proteins examined, only UBA1 showed upregulation in cells treated with 100 μM 
quercetin, both by western blotting and immunocytochemistry. Others, including SMN, lamin 
A/C and ABC showed contradictory results using two different techniques. 
 
In summary: 
a) Multi-study comparison of published transcriptomic studies of SMA identified 
widespread dysregulation of gene expression in different animal and cell models of 
SMA. However, very few commonalities were observed between the list of 
differentially expressed genes and proteins, identified in multi-study comparisons of 
published omics studies, suggesting that changes to the SMA proteome are not driven 
by aberrant transcriptional regulation. 
b) Western blot analyses identified widespread dysregulation of SMN, UBA1, lamin A/C, 
GAPDH and ANXA2 protein levels in spinal cord, brain, liver, heart and muscle tissue 
from a severe mouse model of SMA, and in fibroblasts from SMA patients. Of the 
tissues/cells examined, liver showed the greatest number of differentially expressed 
proteins, where SMN, UBA1, ANXA2 and GAPDH levels were significantly reduced, and 
lamin A/C levels were significantly upregulated. Skeletal muscles, on the other hand, 
showed very few significant changes in protein expression, likely because of the big 
variability in protein expression within the group. NCAM and GAP43 expression was 
not significantly changed in spinal cord and brain tissue from a severe mouse model of 
SMA. 
c) Identification of pharmaceutical compounds that have the potential to restore the 
expression of several proteins to the levels observed in control fibroblasts proved to 
be very challenging. A change in expression of SMN, lamin A/C and UBA1 was not 
169 
 
observed in control and SMA patient fibroblasts treated with trichostatin A and PDGF-
BB. In addition, large variability in SMN, lamin A/C and UBA1 expression within the 
group was identified in both drug treatments which made quantification unreliable. 
Quercetin, on the other hand, decreased the expression of SMN, lamin A/C and active 
β-catenin in a dose dependent manner, and a small upregulation of UBA1 levels was 
also identified in quercetin treated cells. However, SMN reduction is not a desirable 
effect in SMA therapy design, and so therapeutic benefit of quercetin remains to be 
investigated in more detail. 
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3.3. Discussion 
3.3.1. Multi-study comparison of published transcriptomic studies of SMA identified 
28 genes with a consistent direction of differential expression across at least three 
studies  
Eleven published transcriptomics studies were compared to identify core gene expression 
changes in SMA, that may have been overlooked when datasets were considered in isolation 
(Section 3.2.1.1). Studies ustilised a range of neuromuscular tissues/cells, including SMA 
mouse spinal cord at diffrent stages of disease development (Zhang et al., 2008; Bäumer et 
al., 2009; Murray et al., 2010; Huo et al., 2014), mouse motor neurons (Zhang et al., 2013; 
Maeda et al., 2014; Saal et al., 2014; Murray et al., 2015), rat motor neurons (Wertz et al., 
2016), SMA patient myoblasts (Anderson et al., 2004) and muscles, and SMA mouse kidney 
(Zhang et al., 2008). Only 28 genes showed a consistent direction of diferential expression 
across three or more studies of SMA. Considering that transcriptomic studies utilised mostly 
neuromuscular tissues, and that 608 genes were initially identified as being differentially 
expressed in at least two transcriptomic studies of SMA, the number of core gene changes in 
SMA is surprisingly low. This could be attributed to genetic differences between SMA models, 
and/or the the different response of tissues/cells to SMN reduction at diffrerent stages of the 
disease development (Groen et al., 2018). The 28 genes that showed consistent direction of 
diferential expression across at least three transcriptomic studies of SMA were connected to 
functions like regulation of gene expression and RNA metabolism. This may not be surprising 
considering that SMN controls different aspects of RNA metabolism, including transcription, 
pre-mRNA splicing, mRNA trafficking and translation (described in more detail in chapter 1, 
section 1.2.2). 
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 Nevertheless, the 28 genes may represent a core response in SMA tissues/cells, and some of 
these have already been linked to SMA disease pathogenesis, including chondrolectin 
(CHODL). Decreased expression of CHODL mRNA was identified in four transcriptomic studies 
of SMA (Zhang et al., 2008, 2013; Bäumer et al., 2009; Wertz et al., 2016), and this result was 
confirmed biochemically in SMN-knockdown motor neurons (Wertz et al., 2016). In addition, 
CHODL knockdown arrested axonal growth in zebrafish, while overexpression of CHODL 
prevented motor neurons from growing axons out of the spinal cord (Zhong et al., 2012), thus 
indicating that correct expression is important for normal motor neuron development. 
 
3.3.2. Seven molecules were dysreglated at the gene and protein level in at least two 
omics studies of SMA 
Proteins identified in a multi-study comparison of published proteomic studies (Fuller, 
Gillingwater and Wishart, 2016), were compared to the list of differentially expressed genes 
identified in this study (Section 3.2.1.1), to determine whether changes in protein expression 
can be tracked back to the aberrant transcription. This was done to gain insights into whether 
it might be necessary to target molecules at the protein and/or gene level to maximise the 
effect of the therapeutic approach. The analysis identified seven molecules that were 
differentially expressed at both the gene and protein levels. This may not be surprising since 
different experimental models and samples have been used across different omics studies, 
and at different stages of disease development, and could reflect the tissue/model specific 
differences in protein/gene expression. However, a recent study in an in vitro model of ALS 
did show little overlap between differentially expressed genes and proteins in the same 
experimental model (Kim et al., 2017). The lack of overlap between proteomic and 
transcriptomic studies of SMA could therefore be a real finding, suggesting that changes in 
protein expression in SMA are caused by aberrant post-transcriptional regulation. Indeed, 
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perturbed post-transcriptional gene regulation in SMA has been associated with several 
defective RNA processing pathways, including those that regulate RNA splicing (Gabanella et 
al., 2007), RNA stability and translation (Saal et al., 2014). 
 
3.3.3. An overview of protein expression in SMA mouse tissues and patient 
fibroblasts 
Having shown that changes in SMA proteome are not regulated by aberrant transcriptional 
regulation, the research was next focused on differentially expressed proteins. Of the seven 
proteins investigated here, including SMN, UBA1, lamin A/C, GAPDH, ANXA2, GAP43 and 
NCAM, five showed dysregulated expression across different tissues from a mouse model of 
SMA, and in patient fibroblast cells. Liver and heart from SMA mice showed the greatest 
number of dysregulated proteins, while SMA mouse skeletal muscles and brain showed 
dysregulated expression of one more protein alongside SMN, ANXA2 and lamin A/C 
respectively. This could possibly be explained by the fact that only specific brain regions 
showed vulnerability to reduced levels of SMN (Wishart et al., 2010). For example, 
morphological changes in hippocampus were observed from pre-symptomatic stage of the 
disease in severe mouse model of SMA mice, while primary somatosensory cortex remained 
unaffected throughout disease progression (Wishart et al., 2010). The contribution of 
unaffected or less vulnerable regions of the brain to the overall protein expression trends in 
whole brain extracts, could possibly mask changes that are restricted to vulnerable regions 
like the hippocampus. The same logic could then be applied to the spinal cord tissue, where 
protein expression in unaffected cell populations or spinal cord regions could mask changes 
that are specific to vulnerable alpha motor neurons. For example, Boyd et al. identified a five-
fold difference in expression of phosphoglycerate kinase 1 (PGK1) between vulnerable and 
resistant motor neuron populations in a mouse model of SMA (Boyd et al., 2017). Investigation 
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of protein expression in vulnerable regions of the brain and spinal cord would therefore be 
necessary to establish the precise pattern of protein expression in SMA tissues. 
Muscle tissue, on the other hand, showed large variability in protein expression within the 
group, with non-significant changes in protein expression. For example, 60% reduction in 
UBA1 levels in skeletal muscles from SMA mice was not statistically significant in this study, 
while a separate study showed significant reduction of UBA1 levels in skeletal muscles from 
two severe mouse models of SMA at symptomatic stage of the disease (Wishart et al., 2014), 
thus indicating that reliable quantification of UBA1 levels in skeletal muscles from SMA mice 
was hampered here for technical reasons. Differences in protein extraction efficiency of specific 
proteins are possible and could explain variability between the samples. In addition, Murgia et 
al. analysed protein profiles of four fiber-types in mouse soleus and extensor digitorum longus 
muscles, using a proteomics approach, and identified widespread differences in protein 
expression between different muscle fibers (Murgia et al., 2015). These results were verified 
biochemically in mouse skeletal muscle sections, by analysing isocitrate dehydrogenase (IDH) 
expression across four fiber-types (Murgia et al., 2015; Schiaffino, Reggiani and Murgia, 2019). 
Since only a small piece of M. gastrocnemius from each animal was analysed in this study, it is 
possible that different samples contained different fiber ratios. This suggests that different 
samples would have different absolute protein levels, and could explain why large sample 
variability is observed despite the equal loading. 
 
When taken together, western blot analyses confirmed that several proteins, identified in the 
multi-study comparison of published SMA proteomic studies (Fuller, Gillingwater and Wishart, 
2016), show dysregulation in SMA tissues/cells. However, this study also showed that 
quantification of protein expression can be challenging, and different technical aspects such 
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as the differential response of vulnerable regions of the tissue or the origin of the sample, 
have to be taken into account in future analyses.  
 
3.3.3.1 Survival of motor neuron protein (SMN) was reduced in all tissues from a severe 
mouse model of SMA and in SMA patient fibroblasts 
As expected, SMN expression was decreased in all tissues examined, with muscle and liver 
showing the greatest reduction of SMN levels, followed by the heart, brain and spinal cord 
from SMA mice, and patient fibroblast cells. SMN expression was analysed previously in 
tissues from a mouse model of SMA in a study by Groen et al. (Groen et al., 2018), where the 
lowest SMN levels were identified in the muscle and heart tissue from SMA mice, followed by 
the liver, brain and spinal cord (Groen et al., 2018). The results of SMN analyses across SMA 
mouse tissues were largely comparable between the two studies, where the difference in SMN 
expression in comparable tissues did not exceed 5% across both studies.  
 
3.3.3.2. Ubiquitin-like modifier activating enzyme 1 (UBA1) expression was reduced in the 
heart and liver tissue from a mouse model of SMA 
Ubiquitin-like modifier activating enzyme 1 (UBA1) is a well characterised modifier of SMA 
disease pathways (Wishart et al., 2014; Powis et al., 2016), and its expression levels were 
investigated previously across tissues from severe mouse model of SMA (Powis et al., 2016). 
The greatest reduction of UBA1 levels was identified in the heart, followed by the liver, muscle, 
kidney, lung and spinal cord from SMA mice, while brain showed small increase in UBA1 levels 
(Powis et al., 2016). UBA1 followed a similar expression trend in SMA mouse tissues in this 
study, where a statistically significant reduction of UBA1 levels was identified in the heart and 
liver, while non-significant reduction was identified in the muscle, spinal cord and brain tissue 
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from SMA mice (Figure 3.4). In addition, UBA1 expression was not significantly changed in 
SMA patient fibroblast cells. 
 
Although tissues followed the same expression trend, with the exception of brain, differences 
in UBA1 expression of approximately 5-40% were established between the studies, depending 
on the tissue examined. Powis et al. showed that UBA1 levels decrease with disease 
progression in tissues from a mouse model of SMA (Powis et al., 2016), and greater reduction 
of UBA1 levels in tissues from P8 SMA mice (used in this study) compared to P7 mice (Powis 
et al., 2016) could therefore reflect the disease progression. The choice of the detection 
system is another factor to consider, since fluorescent western blotting shows higher linear 
range and sensitivity compared to the enhanced chemiluminescence (ECL) western blotting 
(Eaton et al., 2014). In this study ECL western blotting was used to quantify UBA1 levels, while 
Powis et al. used fluorescent western blotting (Powis et al., 2016).  
 
Reduction of UBA1 levels was already shown to be conserved pathology in SMA, in mouse and 
zebrafish models of SMA and in SMA patient motor neurons, leading to widespread 
dysregulation of ubiquitin-proteasome pathway in SMA (Wishart et al., 2014; Powis et al., 
2016). Systemic restoration of UBA1 levels, for example, corrected defects in ubiquitin 
pathway, improved neuromuscular pathology and increased survival in severe SMA mice 
(Powis et al., 2016). In addition, heart and liver, two tissues that showed the most dramatic 
decrease in UBA1 levels in this study (Figure 3.4), had improved pathology following 
restoration of UBA1 levels in SMA mice (Powis et al., 2016). The number of megakaryocytes 
and nucleated erythrocytes was reduced in SMA mouse liver, indicating partial rescue of liver 
pathology following AAV9-UBA1 treatment, while SMA mouse hearts showed increased size 
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and weight (Powis et al., 2016). Perturbations in ubiquitin-proteasome system have already 
been associated with different heart pathologies (Li, Johnson and Su, 2018), and so 
dysregulation of ubiquitin-proteasome system could have important function in cardiac 
pathology in SMA. 
 
3.3.3.3. Lamin A/C expression was increased in the brain, spinal cord, liver and heart tissue 
from a mouse model of SMA 
Lamin A/C was increased across three proteomic studies of SMA, including mouse Schwann 
cells (Aghamaleky Sarvestany et al., 2014), mouse muscles (Mutsaers et al., 2013) and type I 
patient motor neurons (Fuller et al., 2016). In line with this, upregulation of lamin A/C levels 
was identified here across a range of tissues from a mouse model of SMA. Lamin A expression 
was upregulated in the heart, brain and liver tissue from SMA mice, while lamin C showed 
increased levels in the heart, spinal cord, liver and brain tissue from a mouse model of SMA. 
In addition, increased levels of lamin A/C were identified in the heart from SMA mice using 
immunohistochemistry approach (Šoltić et al., 2019).  
 
Interestingly, an additional band, presumed to be pre-lamin A, was observed in the liver tissue 
from SMA mice but was not observed in the liver from healthy littermate controls (Figure 3.5). 
Accumulation of pre-lamin A, as a result of zinc metallopeptidase STE24 (ZMPSTE24) 
knockdown, was previously shown to increase the levels of reactive oxygen species (ROS) and 
activate senescence pathways in skin fibroblasts (Sieprath et al., 2015), and in different liver 
diseases increased hepatocyte senescence significantly impaired liver functions and 
regeneration (Huda et al., 2019). Accumulation of pre-lamin A might thus lead to hepatocyte 
senescence in the liver of SMA mice and compromise normal functioning of the liver. 
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Patient fibroblasts were the only sample that showed statistically significant reduction of 
lamin A levels compared to controls. Control fibroblasts showed variability in lamin A 
expression, where GM05659 cells showed lower lamin A levels compared to two other control 
cells, GM00498 and GM00302 respectively. This expression pattern could be a result of 
biological variability between cells, since a previous study already showed variable levels of 
lamin A/C mRNA in primary human ovarian surface epithelial cells (Capo-chichi et al., 2011). 
In addition, expression of lamin A/C was shown to correlate with the cell density in 2D cell 
culture (Zonderland et al., 2019), and so differences in lamin A/C expression in this study could 
have been introduced by the seeding density (cell confluency). 
 
3.3.3.4. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression was reduced in 
the liver and heart tissue from a mouse model of SMA 
Reduced GAPDH levels were identified using a proteomics approach in type I, II and III patient 
plasma (Kobayashi et al., 2013), and in Schwann cells (Aghamaleky Sarvestany et al., 2014) 
and hippocampus (Wishart et al., 2010) from SMA mice, however, to date GAPDH has not 
been investigated biochemically in SMA tissues and cells. Here, GAPDH levels were decreased 
in the liver and heart tissue from SMA mice, while spinal cord, brain and muscles from SMA 
mice, and SMA patient fibroblasts showed no significant change in GAPDH expression 
compared to controls.  
High energy demanding tissues, such as muscles and neuronal tissues rely on glycolysis to 
meet their energy demands (Jang et al., 2016), and so defective  glycolytic machinery is likely 
to disturb their proper functioning. Indeed, defects in energy production, including glycolysis, 
have already been identified in mouse and zebrafish models of SMA. For example, glycolytic 
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enzyme phosphoglycerate kinase 1 (PGK1) showed reduced expression in spinal cord and 
heart tissue from a mouse model of SMA, and PGK1 knockdown in zebrafish embryos induced 
SMA-like axonal outgrowth defects (Boyd et al., 2017). Dysregulation of GAPDH levels in SMA 
mouse heart, for example, could have detrimental consequences on the heart health during 
remodelling and dedifferentiation (Szibor et al., 2014). Remodelling and dedifferentiation of 
adult cardiomyocytes are adaptive processes intended to protect the cardiomyocytes in times 
of mechanical and/or molecular stress. In this process, high-energy demanding contractile 
apparatus is degraded to reduce the oxygen-dependent generation of ATP, and the heart 
relies on glycolysis to maintain energy demands (Szibor et al., 2014). Altered expression 
and/or activity of glycolytic machinery would therefore impair glycolysis, promoting instability 
and cell death of cardiomyocytes.  
 
In addition, GAPDH is housekeeping protein often used as a loading control for western blot 
analyses. Identification of reduced levels of GAPDH in SMA tissues therefore implies that some 
results from SMA studies, that used GAPDH as a loading control, may need to be re-examined 
(Fuller, Gillingwater and Wishart, 2016). In addition, perturbations in other common 
housekeepers, such as actin and tubulin, have also been identified in SMA tissues (Eaton et 
al., 2013), emphasising the need to use total protein as a reliable loading control for 
quantitative analyses in SMA tissues. 
 
3.3.3.5. Annexin A2 (ANXA2) expression was increased in the spinal cord from SMA mice 
and in SMA patient fibroblasts, but decreased in SMA mouse muscles 
Several pieces of evidence implicate annexin A2 (ANXA2) in SMA disease pathways. First, an 
interaction between ANXA2 and SMN was identified in C2C12 muscle and PC12 neuronal cells 
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expressing SMN fusion protein using a mass spectrometry approach, and this interaction was 
verified biochemically in C2C12 and PC12 cell cultures (Shafey et al., 2010). Increased ANXA2 
levels were identified previously in proteomic studies of SMA, in mouse Schwann cells 
(Aghamaleky Sarvestany et al., 2014) and in patient iPSC-derived motor neurons (Fuller et al., 
2016), and in line with this, upregulation of ANXA2 levels was identified here in the spinal cord 
from SMA mice and in SMA patient fibroblasts. The role for ANXA2 in neuronal cell 
differentiation and development was established previously in PC12 neuronal cells, where 
increased levels of ANXA2 corelated with cell differentiation, while knockdown of ANXA2 
protein and mRNA levels inhibited neuronal differentiation (Jacovina et al., 2001). In addition, 
colocalization between ANXA2 mRNA and SMN protein was identified previously in axons of 
NSC-34 cells, and this colocalization was dramatically reduced in SMN-depleted cells despite 
the general increase in ANXA2 mRNA levels (Rage et al., 2013). The increased expression of 
ANXA2 in SMA mouse spinal cord could, therefore, be a compensatory mechanism to reduced 
SMN levels. 
 
A significant reduction of ANXA2 levels in the liver from SMA mice was identified here at the 
protein level, and at the mRNA level in the study by Szunyogova et al. (Szunyogova et al., 
2016). Brain and heart tissue from SMA mice showed no significant change in ANXA2 
expression compared to controls. In contrast to the proteomic study of SMA that identified 
increased ANXA2 levels in muscles from P5 SMA mice (Mutsaers et al., 2013), ANXA2 levels 
were decreased in muscles from P8 SMA mice in this study. Different animal models, at 
different stages of the development, and different muscle used in each study could offer some 
explanation for the discrepancy between the studies. Nevertheless, both increased and 
decreased ANXA2 levels were shown to have effect on muscle pathology. For example, ANXA2 
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deficient mice showed progressive muscle weakness with aging, and ANXA2 deficient muscles 
showed poor myofiber repair (Defour et al., 2017). However, ANXA2 also has a role in the 
inflammatory response (Swisher, Khatri and Feldman, 2007), and knockout of ANXA2 inhibited 
chronic muscle inflammation and adipogenic replacement of muscle cells, and improved 
muscle function in dysferlin deficient mice (Defour et al., 2017). ANXA2 homeostasis seems to 
be important for muscle health, and so both increased and decreased ANXA2 levels could have 
a role in muscle pathology in SMA.  
 
3.3.3.6. Neural cell adhesion molecule 1 (NCAM) and neuromodulin (GAP43) levels were not 
changed in spinal cord and brain extracts from a mouse model of SMA  
NCAM is a cell surface protein important for cell adhesion, and it has been implicated in 
different functions including neurite outgrowth, myelination, organization of synapses and 
myogenesis (Gnanapavan and Giovannoni, 2013). Structural and functional defects in NMJs 
were observed in NCAM-deficient mice, including smaller NMJs and problems with signal 
transduction (Rafuse, Polo-Parada and Landmesser, 2000). Decreased expression of NCAM 
was identified across three proteomic studies of SMA, including patient motor neurons (Fuller 
et al., 2016), patient plasma (Kobayashi et al., 2013) and mouse hippocampus (Wishart et al., 
2010). Here, the expression of NCAM was not significantly changed in spinal cord and brain 
tissues from a mouse model of SMA mice, which may not be surprising since proteomic studies 
of SMA examined vulnerable regions of the spinal cord and brain (section 3.3.3). 
GAP43 is neuronal protein involved in a range of functions, including axonal growth, neuronal 
regeneration and plasticity (Hao Le et al., 2017). Proteomic studies of SMA identified 
decreased expression of GAP43 in patient motor neurons (Fuller et al., 2016), mouse 
hippocampus (Wishart et al., 2010) and mouse hippocampus synaptosomes (Wishart et al., 
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2014). Decreased GAP43 mRNA and protein levels were previously reported in cultured motor 
neurons from a mouse model of SMA (Fallini et al., 2016), and decreased GAP43 mRNA levels 
were identified in motor neurons from a zebrafish model of SMA (Hao Le et al., 2017). In 
addition, reduced GAP43 mRNA and protein levels were observed in neuron growth cones 
from SMA mice, indicating that SMN is important for correct localization and translation of 
GAP43 mRNA (Fallini et al., 2016). The same study showed no significant change in GAP43 
levels in whole spinal cord and brain extracts from SMA mice (Fallini et al., 2016). In line with 
this, no change in GAP43 expression was identified in SMA mouse spinal cord and brain tissues 
in this study, suggesting that changes restricted to vulnerable regions are masked in whole 
tissue extracts (section 3.3.3). 
 
Analyses of vulnerable regions like hippocampus and lumbar spinal cord would help to 
determine the expression pattern of NCAM and GAP43 in SMA. Since both proteins are 
implicated in axonal outgrowth and maintenance of neuronal function, perturbed expression 
or localization of NCAM and GAP43 are likely to have important role in motor neuron 
vulnerability in SMA. Alongside SMN, NCAM and GAP43 therefore represent attractive targets 
for neuronal-specific therapy design in SMA.  
 
3.3.4. Western blotting is a sensitive and accurate method for measurement of 
protein expression in fibroblast cells 
Dot blotting and ELISA techniques were compared to the western blotting to identify the 
appropriate technique for measurement of protein expression in drug screening studies, 
where both the accuracy and sensitivity of measurements were assessed on SMN and lamin 
A/C levels. 
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The dot blot approach showed good accuracy and sensitivity for quantification of SMN levels 
in SMA patient fibroblasts, using two different antibodies, MANSMA12 and MANSMA2, while 
MANSMA3 antibody produced weak SMN signal (Section 3.2.3.1.1). Detection of changes in 
lamin A expression in patient fibroblast extracts, using an antibody raised against lamin A/C 
(MANLAC1 4A7), might have been masked by unchanged levels of lamin C. It is possible too 
that different amounts of total protein from control and patient fibroblasts were loaded on 
the nitrocellulose membrane, and could explain why changes in lamin A expression, using 
lamin A specific antibody, were not detected in patient fibroblasts. The inability to use loading 
control is thus the biggest limitation of dot blotting. 
 
Indirect ELISA, on the other hand, failed to detect lamin A in control and patient fibroblasts 
(Section 3.2.3.1.2). Although a positive control was not used in ELISA, western blotting 
previously showed that lamin A is present in fibroblasts extracts (Figure 3.5), indicating the 
low sensitivity of the method used (i.e. indirect ELISA). This problem could be resolved by using 
sandwich ELISA that can increase the sensitivity range of the detection (Aydin, 2015). Indeed, 
sandwich ELISA has been successfully used for detection of SMN levels in a range of SMA 
cells/tissues, including peripheral blood mononuclear cells (PBMC) (Kobayashi et al., 2011) 
and fibroblast cells (Nguyen et al., 2008) from SMA patients, and brain, spinal cord and 
muscles from a severe mouse model of SMA (Kobayashi et al., 2011). In addition, sandwich 
ELISA showed good sensitivity for detecting small changes in SMN expression (20-30%) 
following exposure to valproate or phenylbutyrate, indicating it can be reliably used in drug 
screening studies (Nguyen et al., 2008). 
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To summarize, the dot blot approach showed good accuracy and sensitivity for quantification 
of SMN levels in SMA patient fibroblasts, however, it was not sensitive enough to detect 
changes in expression of lamin A specific isoform. Examination of lamin A levels, using indirect 
ELISA, produced no results. This then means that other antibodies, that can detect lamin A 
and lamin C specific isoforms, would have to be tested for dot blot and ELISA analyses. When 
doing so, it would be of interest do compare indirect and sandwich ELISA, taking into account 
the sensitivity and the cost of each approach. In addition, both techniques would have to be 
optimized for a range of other protein targets, including for example, UBA1, which would 
consume more time and resources. 
 
Western blotting, on the other hand, is an established technique for measurement of protein 
expression in this lab. It can detect isoform specific changes in expression using one antibody, 
where variability in protein expression between samples can be corrected using loading 
control (Figure 3.2). In addition, western blotting can assess the expression levels of two 
proteins on the same blot, if they are not of similar molecular weight, and can be used to 
detect changes in posttranslational profile of proteins (Wilson, Garton and Fuller, 2016). In 
contrast to ELISA, however, western blotting is not a high-throughput method (Nguyen et al., 
2008), i.e. only small number of samples can be screened at a time, which can lead to logistic 
problems as demonstrated in Figure 3.17. When all is taken into account, western blotting 
seems to offer the best sensitivity, however, it would not be a good platform for high-
throughput drug screening.  
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 3.3.5. Selection of appropriate therapeutic targets for in vitro drug studies in control 
and patient fibroblasts 
Since very few molecules showed differential expression at both the gene and protein level 
(Table 3.3), chemical compounds were selected based on their potential to manipulate the 
expression of seven protein targets that were investigated biochemically in this study (Section 
3.2.2). Identification of compounds that have the ability to change the expression of several 
of these proteins at the same time would likely induce better therapeutic response in SMA 
patients, since multiple pathogenic pathways would be targeted at the same time (Torres-
Benito et al., 2019). Network pharmacology approach was first applied to do this, and 
identified 20 drugs which were then filtered to three potential candidates. Of these, 
trichostatin A was selected for in vitro studies because it showed association to 5 proteins of 
interest, among which were SMN and lamin A/C. 
 
Trichostatin A (TSA) did not significantly change the expression of SMN, lamin A/C and UBA1 
SMN protein expression was not changed in patient fibroblast cells in this study, even after a 
24-hour exposure to TSA (Figure 3.14). This is perhaps not surprising since the maximum 
increase in SMN mRNA levels was previously identified in SMA patient fibroblast cells 4 hours 
after the treatment, after which the levels dropped drastically and went below the basal levels 
(Avila et al., 2007). This would suggest that SMN mRNA levels are rapidly degraded and/or 
that mRNA is not efficiently translated. The latter explanation is supported by the finding that 
SMN reduction causes widespread defects in translation machinery in SMA tissues (Bernabò 
et al., 2017). A similar trend was observed in the severe mouse model of SMA (Smn–/–
SMN2+/+SMNΔ7+/+), where a single dose of TSA produced small increase in SMN mRNA levels, 
without an obvious change in protein levels (Avila et al., 2007). In contrast, however, repeated 
TSA injections induced an upregulation of both SMN mRNA and protein levels in SMA mouse 
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tissues (Avila et al., 2007), indicating that constant upregulation of SMN gene expression is 
necessary to induce efficient translation. 
Another study showed SMN-independent improvement of neuromuscular pathology and 
survival in SMA mice (Liu et al., 2014), suggesting that TSA acts on other pathogenic pathways 
in SMA. One of these could be lamin A/C, since TSA treatment was shown to upregulate 
expression of lamin A/C in vitro, in fibroblast cells from HGPS patients (Columbaro et al., 2005) 
and in MEFs (Galiová et al., 2008). In contrast, lamin A/C expression was not significantly 
changed in this study (Figure 3.13 and 3.14). Changes in lamin A/C expression in HGPS 
fibroblasts could be explained by the drug concentration (Columbaro et al., 2005), where 15x 
higher concentration  was used compared to concentration used in this study (i.e. 100 nM). 
However, it is not clear why the same drug treatment (100 nM for 24 hours), used here and in 
MEFs (Galiová et al., 2008), produced different results. 
A small reduction of UBA1 levels was identified in all concentrations and time points in patient 
fibroblasts, one of which, 50 nM exposure for 8 hours, showed a significant difference 
compared to vehicle. However, considering that other drug concentrations and exposure 
times did not show statistically significant difference, the result may be a false positive. In 
addition, quantification of UBA1 levels is likely unreliable because of the low signal intensity.  
 
 
PDGF-BB treatment did not change SMN and lamin A/C expression in control or SMA patient 
fibroblasts 
The results from PDGF-BB treatment indicate technical problems, such as the variable 
efficiency of the protein extraction and/or protein transfer onto the nitrocellulose membrane. 
Differences in lamin A/C expression could have also been introduced by the seeding density 
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(cell confluency) (Zonderland et al., 2019). Although seeding density has been controlled in 
drug experiments, uneven distribution of cells in the well could have caused differences in 
confluency within the well, which could affect lamin A/C expression. 
Since both SMN and lamin A/C showed large sample variability within the group in control and 
patient fibroblasts, it is not possible to conclude at this stage whether lamin A/C and SMN 
expression change after 24-hour treatment with 100 ng/mL PDGF-BB. The biggest limitation 
of this experiment is the lack of a positive control, i.e. drug treatment that was previously 
shown to increase SMN expression in fibroblast cells (100 ng/mL PDGF-BB for 72 hours). The 
dose and time response would have to be established for PDGF-BB treatment to determine 
its effect on SMN and lamin A/C levels. 
 
Quercetin induces a dose-dependent decrease in SMN, lamin A/C and active beta-catenin 
levels, and an increase in UBA1 levels in patient fibroblast cells 
Consistent with previous reports of beta-catenin signalling inhibition (Park et al., 2005) and 
lamin A/C reduction (Herzog et al., 2004), quercetin treatment decreased active β-catenin and 
lamin A/C levels in a dose dependent manner in patient fibroblast cells (Figure 3.17). 
Surprisingly, however, a dose-dependent reduction of SMN was also identified in patient 
fibroblasts using western blotting (Figure 3.17), suggesting a possible negative effect of 
quercetin treatment. Indeed, induction of apoptosis following quercetin treatment was 
identified previously in two separate studies (Herzog et al., 2004; Gelebart et al., 2008). For 
example, a dose dependent decrease in cell proliferation was observed after a 72-hour 
exposure to quercetin in NCOL-1 cell line, with EC50-values for half-maximal growth-inhibition 
of 53.4 μM (Herzog et al., 2004). A significant reduction of cell viability was also identified in 
three cancer cell lines treated with 10 μM and 50 μM quercetin for 48 hours (Gelebart et al., 
187 
 
2008). However, cell viability of patient fibroblasts was not affected here after exposure to 
6.25-100 μM quercetin for 24 hours (Figure 3.17). It is possible, however, that cancer cells and 
fibroblasts would react differently to quercetin treatment, since another study showed a 
beneficial effect of quercetin on proliferation of HFL-1 cells (human foetal lung fibroblasts) 
(Chondrogianni et al., 2010). Inhibition of proteasome activity was reported in cancer cells 
treated with quercetin, and is thought to be the major cause of quercetin-induced cancer cell 
death (Klappan et al., 2012). In contrast, however, proteasome activation was identified in 
HFL-1 cells treated with 2 μg/mL quercetin (Chondrogianni et al., 2010), which is comparable 
to the lowest concentration of quercetin used in this study, i.e. 6.25 μM. In addition, increased 
activity of proteasomal system was observed in Neuro 2a cell line expressing mutated 
huntingtin after the exposure to 20 μM of quercetin (Chakraborty et al., 2015). Here, a small 
increase in UBA1 levels was identified in quercetin treated cells, starting with the 25 μM 
concentration (Figure 3.17). Since UBA1 is the first essential protein in proteasomal 
degradation, increased levels of UBA1 following quercetin treatment indicate that activation 
of ubiquitin-proteasome system might be responsible, at least in part, for the reduction of 
SMN, lamin A/C and active β-catenin levels in SMA. This hypothesis is further supported by 
immunocytochemistry analysis showing increased UBA1 levels in the nucleus of patient 
fibroblasts treated with 100 μM quercetin (Figure 3.20). This analysis also suggested that 
quercetin treatment selectively induces expression and/or translocation of the nuclear UBA1 
isoform, UBA1a. Further experiments are clearly needed to elucidate the precise mechanism 
of quercetin action on UBA1 expression. This could be done, for example, by studying the 
expression of UBA1, after the drug treatment, using isoform specific antibodies. Nevertheless, 
induction of UBA1 expression and proteasomal degradation is proposed here as one of the 
potential molecular mechanisms of quercetin action in SMA tissues.  
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However, some differences have been identified between the two experiments (Figures 3.16 
and 3.17), and so these results should be taken with caution. For example, a lower SMN 
molecular band, identified in control and patient fibroblasts treated with one dose of 
quercetin (100 μM) (Figure 3.16), was not as distinct in the dose response experiment (Figure 
3.17). Similarly, reduction of lamin A/C levels that was detected in a dose response (Figure 
3.17) was not apparent in the first experiment (Figure 3.16). This raises a question of whether 
quercetin had a different effect in two drug treatments, and why is that so. In addition, 
immunocytochemistry analysis of SMN, lamin A/C and ABC (Figures 3.18, 3.19 and 3.20) 
expression did not agree with the results from western blotting (figure 3.17). ABC showed the 
most dramatic differences, where increased ABC levels were identified in quercetin treated 
cells using immunocytochemistry approach (Figure 3.20), compared to reduction of ABC levels 
identified by western blotting (Figure 3.17), thus indicating possible technical problems with 
protein detection. Indeed, technical problems using the same ABC antibody where already 
demonstrated in a previous study, where a strong cross-reaction of ABC antibody with an 
unknown nuclear antigen was detected in β-catenin knockout F9 cells (Maher et al., 2009). 
Similarly, the lamin A/C (MANLAC1 4A7) antibody, that was used here in 
immunocytochemistry experiment, also showed positive staining in LMNA KO MEFs, thus 
suggesting that the antibody cross-reacts with a nuclear antigen (Appendix 1). Quantification 
of lamin A/C and ABC levels in quercetin treated cells, using immunocytochemistry, is 
therefore unreliable. Another limitation of this study is the small group size that limited 
statistical analysis in quercetin treated cells (Figure 3.17). 
 
The results do, however, raise the question of quercetin action in SMA tissues: Can quercetin 
treatment induce the same changes in the expression of SMN, lamin A/C, ABC and UBA1 in 
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vivo? Quercetin treatment rescued axonal defects in SMA zebrafish, ameliorated NMJ 
pathology in Drosophila and mouse models of SMA, restored muscle fiber dimeter and 
improved muscle strength in a mouse model of SMA, however, survival of SMA mice was not 
improved with quercetin treatment (Wishart et al., 2014). On the other hand, activation of 
the proteasomal system, by systemic restoration of UBA1 levels in a mouse model of SMA, 
rescued neuromuscular and peripheral organ pathology, and improved survival of SMA mice 
without affecting SMN expression (Powis et al., 2016). This would then suggest that initial 
benefit of quercetin treatment, possibly through induction of proteasomal degradation, 
would be counteracted by excessive degradation of proteins like SMN and lamin A/C that are 
important for cell stability. It could help to explain why quercetin treatment restored 
neuromuscular pathology in SMA mice but had no benefit on their survival (Wishart et al., 
2014). It is possible too that quercetin would have a different effect on protein expression in 
vivo, since metabolic degradation of quercetin would likely produce metabolites that have 
different biological activity compared to quercetin alone (Almeida et al., 2018). Further studies 
are clearly warranted to assess the molecular mechanism of quercetin action in SMA, in vitro 
and in vivo, if quercetin or its derivatives are to be used in SMA therapy design.  
 
3.4. Conclusion 
The aim of this study was to determine whether proteins identified in a multi-study 
comparison of published proteomic studies of SMA, including UBA1, lamin A/C, GAPDH, 
ANXA2, NCAM and GAP43, are differentially expressed in SMA tissues and cells. This 
knowledge would then be used to facilitate selection of pharmaceutical compounds that have 
the potential to regulate the expression of several of these proteins. However, selection of 
pharmaceutical compounds proved to be very challenging. Although drugs with the potential 
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to change the expression of target proteins were identified, using both network pharmacology 
approach and PubMed search, when tested in fibroblasts showed no effect on expression of 
target proteins or produced unwanted effects, like reduction of SMN expression in the case of 
quercetin treatment. In addition, technical problems, i.e. variability in protein expression 
within the treatment groups made quantification of protein expression unreliable. Further 
work is clearly warranted to determine whether multi-target drugs might be viable strategy in 
SMA therapy design. 
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CHAPTER 4: Results 
Lamin A/C is mechanistically linked to UBA1, a known 
regulator of SMA disease pathways, and contributes to 
cardiac pathology in SMA  
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4.1. Introduction 
4.1.1. Diversity of proximal spinal muscular atrophy (SMA) 
Spinal muscular atrophies (SMAs) are a heterogeneous group of neuromuscular disorders, 
clinically characterised by motor neuron loss in the spinal cord and lower brainstem, muscle 
weakness and atrophy. They are roughly divided into proximal SMAs and distal SMAs (DSMAs), 
based on the limb region primarily affected by muscle weakness, where proximal SMA is 
traditionally referred to as SMA (Farrar and Kiernan, 2015). In 95% of the cases, autosomal 
recessive loss of SMN1 gene is the cause of the proximal SMA, while the minority of cases link 
to mutations in other genes (Wirth et al., 1999) (summarised in Table 4.1.). They are all 
characterized mostly, not exclusively, by proximal limb weakness, but show heterogeneity in 
mode of inheritance, age of the onset, severity of the motor function impairments and 
differential involvement of other organ systems (Table 4.1). For clarity, proximal SMA is 
referred from here on as SMA. 
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Table 4. 1. Genetics and clinical features of proximal spinal muscular atrophy 
Type of SMA Gene Inheritance Clinical manifestation Common clinical features References 
SMN-related 
SMA 
SMN Autosomal 
recessive 
Onset: SMA type I: before 6 months 
             SMA type II: between 6-18 months 
             SMA type III: after 18 months 
             SMA type IV: adulthood 
Proximal weakness of lower and upper limbs 
associated with muscle atrophy 
Diaphragm and facial muscles relatively spared                                                   
Death by the age of 2 years (SMA type I) or 
adolescence/early adulthood (SMA type II) caused by 
respiratory failure 
Problems with swallowing and 
breathing (SMA type I and II) 
Scoliosis (SMA type I-III) 
(Dubowitz, 1995) 
 
SMA with 
respiratory 
distress and 
stridor 
 
SCO2 Autosomal 
recessive 
Onset: infantile  
Generalised muscle weakness and hypotonia 
associated with muscle atrophy (similar to SMA type I) 
Respiratory insufficiency and stridor 
Lactic acidosis 
Death usually in infancy/early childhood caused by 
heart failure 
Hypertrophic cardiomyopathy 
Spasticity 
Ptosis and strabismus 
 
(Salviati et al., 2002) 
(Tarnopolsky et al., 2004) 
(Pronicki et al., 2010) 
Lower limb SMA 
with respiratory 
distress 
PLEKHG5 Autosomal 
recessive 
Onset: early childhood 
Proximal weakness of lower limbs associated with 
muscle atrophy (early evolvement of hand and foot 
muscles) 
Progressive weakening of all muscle leading to 
respiratory insufficiency 
Dorso-lumbar scoliosis and 
hyperlordosis 
Foot deformities (bilateral equinus 
varus) 
(Maystadt et al., 2006) 
(Maystadt et al., 2007) 
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SMA-PCH EXOSC8 
EXOSC3 
EXOSC9 
TSEN54 
RARS2 
VRK1 
SLC25A46 
Autosomal 
recessive 
Onset: congenital-infantile 
Loss of spinal cord anterior horn motor neurons 
Cerebellum and brainstem atrophy (pontocerebellar 
hypoplasia) 
Diffuse muscle weakness 
Death: infancy-adulthood (often caused by respiratory 
failure/complications) 
Microcephaly 
Impared vision and hearing 
Hypomyelination 
(Boczonadi et al., 2014) 
(Wan et al., 2012) 
(Burns et al., 2018) 
(Simonati et al., 2011) 
(Namavar et al., 2011) 
(Renbaum et al., 2009) 
(Van Dijk et al., 2017) 
Prenatal SMA 
with congenital 
bone fractures 
TRIP4 
ASCC1 
 
Autosomal 
recessive 
Onset: prenatal 
Decreased or absent fetal movement 
Generalised hypotonia and muscle atrophy 
Long bone fractures (femur and humerus) 
Distal and proximal joint contractures 
Dysphagia 
Respiratory distress 
Death in infancy due to respiratory failure 
Premature birth 
Microretrognathia 
Hypertelorism 
High-arched palate 
Pulmonary hypoplasia 
Patent ductus arteriosus 
(Knierim et al., 2016) 
SMA-MDS TK2 Autosomal 
recessive 
Onset: infancy 
Severe proximal limb weakness and associated with 
muscle atrophy 
Areflexia 
Scoliosis 
 (Mancuso et al., 2002) 
SMA associated 
with GMG 
HEXA Autosomal 
recessive 
Onset: childhood-adolescent 
Proximal weakness of lower and upper limbs 
associated with muscle atrophy 
 
 
Weakness and atrophy of 
paravertebral muscles and interossei 
Dysarthria 
Tendon reflexes good in upper limbs 
but unobtainable in the lower limb 
(Navon et al., 1995) 
(Navon et al., 1997) 
SMALED1 DYNC1H1 Autosomal 
dominant 
Onset: mostly early childhood (congenital- adulthood) 
Proximal lower limb weakness associated with muscle 
atrophy 
Foot deformities (equinovarus or 
valgus feet and pes cavus or planus) 
(Harms et al., 2012) 
(Tsurusaki et al., 2012) 
(Scoto et al., 2015) 
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Disease progression is slow or static 
Upper limbs mostly spared 
No sensory involvement 
Joint contractures (hips, knees and 
ankles) 
Mild to moderate cognitive 
impairments and behavioural 
comorbidities (ADHD, autism, dyslexia)  
(Niu et al., 2015) 
(Beecroft et al., 2017) 
(Das et al., 2018) 
(Chan et al., 2018) 
SMALED2 BICD2 Autosomal 
dominant 
Onset: mostly early childhood (congenital- adulthood) 
Proximal and distal lower limb weakness associated 
with muscle atrophy 
Disease progression is slow or static 
Mild or no upper limb weakness 
Ankle and knee contractures 
Foot deformities (equinovarus feet 
and pes cavus or planus) 
Skeletal deformities (lumbal 
hyperlordosis, scoliosis and scapular 
winging) 
Congenital dislocation of the hips 
(Peeters et al., 2013) 
(Neveling et al., 2013) 
(Oates et al., 2013) 
(Rossor et al., 2015) 
(Bansagi et al., 2015) 
(Fiorillo et al., 2016) 
(Rudnik-Schöneborn et al., 2016) 
SMA-PME ASAH1 Autosomal 
recessive 
Onset: childhood-adolescence (rarely adulthood) 
Proximal muscle weakness of lower and upper limbs 
associated with muscle atrophy 
Generalized epilepsy with absences and myoclonic 
seizures 
Death usually in juvenile age/ early adulthood (often 
caused by respiratory complications) 
Adult cases show slower disease progression without 
myoclonic epilepsy# 
Loss of consciousness 
Tongue fasciculations 
Difficulties swallowing (dysphagia) 
Scoliosis 
(Zhou et al., 2012) 
(Rubboli et al., 2015) 
(Giráldez et al., 2015) 
(Oguz Akarsu et al., 2016) 
(Yildiz et al., 2018) 
(Filosto et al., 2016)# 
(Ame van der Beek et al., 2019)# 
Early onset SMA 
with respiratory 
failure 
RBM7 Autosomal 
recessive 
Onset: infancy 
Proximal and distal upper and lower limb weakness 
associated with muscle atrophy 
Respiratory dificulties 
Death in early childhood caused by respiratory failure 
 (Giunta et al., 2016) 
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Adult SMA VAPB Autosomal 
dominant 
Onset: adulthood 
Proximal muscle weakness of lower and upper limbs 
associated with muscle atrophy 
Fasciculations and cramps 
 
Autonomic dysfunction (choking, 
chronic intestinal constipation, sexual 
dysfunction) 
Abdominal muscle weakness 
Lordosis 
(Nishimura et al., 2004) 
(Marques et al., 2006) 
SMA with cardiac 
involvement 
LMNA Autosomal 
dominant 
Onset: mostly adulthood (childhood-adulthood) 
Proximal muscle weakness of lower limbs associated 
with muscle atrophy 
Cardiac abnormalities (dilated cardiomyopathy, 
conduction disease, heart rhythm problems) 
Death associated with heart problems 
 (Rudnik-Schöneborn et al., 2007) 
(Iwahara et al., 2015) 
Adult SMA with 
respiratory 
failure 
MAPT Autosomal 
dominant 
Onset: adulthood  
Proximal upper limb weakness (proximal lower limb 
weakness usually presents with disease progression) 
Dyspnea and respiratory difficulties 
Death caused by respiratory failure 
Lumbar backache 
 
(Di Fonzo et al., 2014) 
ADSMA SETX Autosomal 
dominant 
Onset: adolescent-adulthood 
Proximal and distal muscle weakness of lower and 
upper limbs associated with muscle atrophy 
Slow disease progression 
 (Rudnik-Schöneborn et al., 2012) 
SBMA AR X-linked Onset: adulthood (the age of onset inversely 
correlates with the size of the CAG-repeat expansion 
within the AR gene) 
Proximal and distal limb and bulbar muscle weakness 
associated with muscle atrophy 
Dysarthria and dysphagia 
Slow disease progression 
Tremors and cramps 
Androgen insensitivity (gynaecomastia 
and sexual dysfunction) 
 
(La Spada et al., 1991) 
(Atsuta et al., 2006) 
(Rhodes et al., 2009) 
(Grunseich et al., 2014) 
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SMAX2 
 
 
UBE1 X-linked Onset: congenital-infantile 
Proximal muscle weakness and generalized hypotonia 
associated with muscle atrophy (similar to SMA type I) 
Decreased foetal movement 
Contractures (elbows, fingers, hips, knees, wrists and 
ankles) 
Areflexia 
Death usually in infancy 
Fractures of femur and humerus 
Cryptorchidism 
Tongue fasciculations 
(Greenberg et al., 1988) 
(Dlamini et al., 2013) 
(Jedrzejowska, Jakubowska-
Pietkiewicz and Kostera-
Pruszczyk, 2015) 
Genetics and clinical features of proximal spinal muscular atrophies are listed in the table, followed by corresponding references. Adjusted according to (Farrar and Kiernan, 2015). SMA- 
spinal muscular atrophy; SMA type I (also known as Werdnig-Hoffmann disease); SMA type III (also known as Kugelberg-Welander disease); SMA-PCH- spinal muscular atrophy with 
pontocerebellar hypoplasia; SMA-MDS- spinal muscular atrophy with mitochondrial DNA (mtDNA) depletion syndrome; GMG- GM2 gangliosidosis; SMA-LED1- spinal muscular atrophy, 
lower extremity predominant; SMA-LED2- spinal muscular atrophy, lower extremity predominant 2; SMA-PME- spinal muscular atrophy with progressive myoclonic epilepsy; ADSMA- 
autosomal dominant proximal SMA; SBMA- spinal and bulbar muscular atrophy (also known as Kennedy disease); SMAX2- X-linked spinal muscular atrophy; #Adult onset SMA caused by 
mutations in ASAHA1 without myoclonic epilepsy 
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4.1.2. Some SMA-causing genes are implicated in SMN-dependent disease pathways 
Some SMA-causing genes are implicated in SMN-dependent disease pathways, including for 
example, senataxin (SETX) and ubiquitin-like modifier activating enzyme 1 (UBA1).  The 
autosomal dominant proximal spinal muscular atrophy (ADSMA)- causing gene SETX (Rudnik-
Schöneborn et al., 2012) acts as a transcription regulator and regulator of genome stability 
(Groh et al., 2017). SETX is involved in the repair of DNA double-strand breaks (DSBs) and R-
loops (DNA-RNA hybrids) (Groh et al., 2017). SETX dysregulation was also observed in SMN-
dependent SMA (Kannan et al., 2018). For example, decreased SETX protein levels were 
identified in SMN-deficient HeLa cells, SMA patient fibroblasts and cultured spinal cord 
neurons from SMA mice, which coincided with the increased accumulation of R-loops and 
DSBs (Kannan et al., 2018). Decreased SETX levels were also observed in vivo, in spinal cords 
from type I SMA patients and in mouse model of SMA, and overexpression of SMN in patient 
fibroblasts and cultured mouse spinal cord neurons restored SETX levels and decreased R-loop 
accumulation. In addition, overexpression of SETX alone was sufficient to decrease R-loop 
accumulation in SMA patient fibroblasts and cultured mouse spinal cord neurons, indicating 
that low levels of SETX are directly responsible for genomic instability in SMA cells/tissues 
(Kannan et al., 2018).  
 
Mutations in the UBA1 gene, which encodes the ubiquitin-like modifier activating enzyme 1 
(UBA1) protein, cause a form of X-linked infantile SMA (SMAX2) (Ramser et al., 2008), and a 
role for UBA1 in SMN-dependent pathways has also been well characterised across several 
models of SMA. At the protein level, UBA1 was reduced in zebrafish and mouse models of 
SMA, and in iPSC-derived motor neurons from patients with type I SMA (Wishart et al., 2014; 
Fuller et al., 2016; Powis et al., 2016). Pharmacological or genetic suppression of UBA1 was 
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sufficient to induce an SMA-like phenotype in zebrafish, thus demonstrating that UBA1 
directly contributes to SMA disease pathways (Wishart et al., 2014). Restoration of UBA1 
levels increased motor performance in zebrafish and mouse models of SMA, as well as 
increased survival and improved systemic pathology in SMA mice (Powis et al., 2016).  
 
Investigation of two downstream targets of UBA1 pathways, β-catenin and glycine-tRNA ligase 
(GARS), provided further insights into fundamental molecular mechanism that drive pathology 
in different tissues (Wishart et al., 2014; Shorrock et al., 2018). β-catenin signaling pathways 
play important role in motor neuron differentiation and stability, and increased β-catenin 
levels were restricted to neuromuscular system in a mouse model of SMA (Wishart et al., 
2014). In line with this, pharmacological inhibition of β-catenin levels decreased motor neuron 
loss and restored muscle fiber diameters in SMA mice, and ameliorated NMJ pathology in 
zebrafish, Drosophila and mouse models of SMA, but did not prevent systemic pathology in 
SMA mice (Wishart et al., 2014). Similarly, increased expression of GARS in spinal cords from 
SMA mice was restricted to sensory neurons (Shorrock et al., 2018). Mutations in GARS are 
known to cause Charcot-Marie-Tooth disease Type 2D (CMT2D), typically characterised by 
sensory impairment, but also a type of SMA, called distal spinal muscular atrophy type V 
(Antonellis et al., 2003). Dysregulation of UBA1/GARS pathways disrupted sensory neuron fate 
and altered sensory-motor connectivity in SMA mice, both of which were corrected following 
restoration of UBA1 levels (Shorrock et al., 2018). 
 
Mutations in LMNA, the lamin A/C encoding gene, cause an adult form of SMA (Rudnik-
Schöneborn et al., 2007; Iwahara et al., 2015). Rudnik-Schöneborn et al., for example, 
described two cases of proximal SMA caused by mutations in LMNA gene (Rudnik-Schöneborn 
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et al., 2007). Both SMA patients developed proximal muscle weakness in adulthood, 
experienced cardiac problems with disease progression and were provided with a pacemaker. 
Examination of family history revealed high frequency of cardiac abnormalities and sudden 
unexplained cardiac deaths (Rudnik-Schöneborn et al., 2007). The third patient, initially 
diagnosed with type III SMA, experienced muscle weakness in their lower limbs since early 
childhood and had cardiac involvement that required a pacemaker to be fitted at the age of 
45 (Iwahara et al., 2015). As in the previous two cases of SMA, examination of family history 
revealed increased incidence of cardiac problems and sudden deaths (Iwahara et al., 2015). 
The evidence to implicate lamin A/C in SMN-dependent disease pathways first came from a 
multi-study proteomic comparison (Fuller, Gillingwater and Wishart, 2016), where increased 
expression of lamin A/C was identified across three separate proteomic studies of SMA, 
including in iPSC-derived motor neurons from type I SMA patients (Fuller et al., 2016), 
Schwann cells (Aghamaleky Sarvestany et al., 2014) and muscles (Mutsaers et al., 2013) from 
a mouse model of SMA. In addition, identification of widespread dysregulation of lamin A/C 
levels in fibroblast cells from SMA patients and in different tissues from a mouse model of 
SMA (chapter 3, Figure 3.5), provided further support that lamin A/C might be an important 
regulator of SMA disease pathways. Of specific interest was the heart, where a two-fold 
increase in lamin A/C expression was identified at the protein level, suggesting that lamin A/C 
might play an important role in heart pathology. Indeed, mutations in the LMNA gene have 
already been implicated in a wide range of neuromuscular conditions that present with some 
form of cardiac pathology, including Emery-Dreifuss muscular dystrophy (Bonne et al., 1999), 
limb-girdle muscular dystrophy 1B (Ki et al., 2002), dilated cardiomyopathy (Fatkin et al., 1999) 
and an adult form of SMA (Rudnik-Schöneborn et al., 2007; Iwahara et al., 2015). 
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Evidence of the heart’s involvement in SMN-dependent SMA are not lacking either. For 
example, a systematic review of the literature in 2017 found 58 studies that reported on a 
total of 264 SMA patients with cardiac abnormalities (Wijngaarde et al., 2017). A common 
finding among the 77 patients with the most severe type of SMA (type I) was structural 
pathology, observed mainly in the septum and/or cardiac outflow tract. All of the 63 type II 
SMA patients identified in the literature search had ECG abnormalities, while the 124 patients 
with type III SMA had cardiac rhythm disorders and/or structural abnormalities. In addition to 
the numerous reports of cardiac defects among SMA patients, the systematic review 
identified 14 studies that have documented cardiac pathology in mouse models of SMA 
(Wijngaarde et al., 2017). Common macroscopic findings include decreased heart size and 
decreased thickness of the left ventricular wall and interventricular septum, while a frequent 
microscopic observation was cardiac fibrosis, which was detected at a pre-symptomatic stage 
of the disease in both severe and intermediate mouse models of SMA (Shababi et al., 2010; 
Cobb et al., 2013; Wijngaarde et al., 2017). A more recent study of a severe mouse model of 
SMA at pre- and early symptomatic time points confirmed many of these previous findings, 
but also noted significant molecular defects, such as the reduced microvasculature, increased 
oxidative stress and apoptosis in the heart from early symptomatic SMA mice (Maxwell et al., 
2018). Despite this knowledge, molecular defects that drive pathology in SMA heart are not 
well investigated.  
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The aim of this chapter was to investigate the molecular mechanism of lamin A/C 
dysregulation in SMA tissues, and gain insight into its role in SMA disease pathways. 
The specific objectives were as follows: 
a) To investigate the molecular mechanism(s) of lamin A/C dysregulation in SMA 
tissues/cells 
b) To determine the functional consequences of lamin A/C dysregulation in SMA patient 
fibroblasts 
c) Mutations in the LMNA gene cause heart defects, and lamin A/C was dysregulated in 
the heart from Taiwanese SMA mice. To investigate whether other heart defects can 
be seen in SMN-dependent SMA, an unbiased view of the proteome was taken in the 
heart from a mouse model of SMA. 
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4.2. Results 
4.2.1. Investigation of the molecular mechanism of lamin A/C dysregulation in SMA  
In chapter 3, widespread dysregulation of lamin A/C protein levels was identified in the heart, 
brain, spinal cord and liver from a mouse model of SMA, and in SMA patient fibroblasts, with 
differing directions of expression change depending on the tissue/cell type examined (Chapter 
3, Figure 3.5). Here, lamin A/C was further investigated at the mRNA and protein levels to 
determine the molecular mechanism of its dysregulation in SMA. Lamin A transcript levels 
were first investigated in SMA tissues/ cells to determine whether perturbed gene expression 
can explain the direction of differential protein expression, after which, lamin A/C was 
investigated in connection to SMN and UBA1 disease pathways to try to elucidate the 
mechanism of its dysregulation in SMA. Understanding the molecular mechanism of lamin A/C 
dysregulation in SMA may have important implications in SMA therapy design. It may aid 
selection of appropriate therapeutic strategies that could target lamin A/C dysregulation in 
SMA. i.e. targeting lamin A/C at the gene and/or protein level. 
 
4.2.1.1. Lamin A transcript levels were not changed in SMA patient fibroblasts or in the heart 
from a mouse model of severe SMA 
It was of interest to first determine whether dysregulation of lamin A/C levels can be tracked 
back to the aberrant transcriptional regulation. Lamin A transcript levels were therefore 
investigated in SMA patient fibroblasts and SMA mouse heart (where lamin A protein levels 
were lowest, and highest, compared to controls, respectively) (Chapter 3, Figure 3.5). Since 
only the lamin A isoform showed dysregulation at the protein level in SMA patient fibroblasts, 
primers for qPCR were designed to specifically recognise lamin A isoform (as described in 
2.5.3.1). RT-qPCR analyses showed no significant change in lamin A transcript levels in the 
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heart from SMA mice and patient fibroblasts (Figure 4.1), indicating that dysregulation of 
lamin A/C expression occurred post-transcriptionally. 
 
 
4.2.1.2. Interaction between lamin A/C and SMN was undetectable in healthy fibroblast cells 
and in heart tissue extracts from control and SMA mice 
Lamin A/C was previously identified as a potential SMN interactor using a mass spectrometry 
approach in PC12 neuronal and C2C12 muscle cell lines expressing fusion SMN proteins 
(Shafey et al., 2010), however, this has not been verified biochemically. An SMN-lamin A/C 
interaction might be important for lamin A/C stability in healthy cells, and could possible 
explain lamin A/C dysregulation in the environment of low levels of SMN. To test this 
hypothesis, a physical interaction between lamin A/C and SMN was investigated in three 
healthy fibroblast cell lines using an immunoprecipitation technique (as described in methods 
section 2.4). Lamin A/C was successfully pulled down using a lamin A/C antibody attached to 
Figure 4. 1. Lamin A transcript levels are not dysregulated in SMA patient fibroblasts and heart tissue from a 
mouse model of SMA. Lamin A transcript levels in the (A) heart from SMA mice (n = 4) and healthy controls (n 
= 4) and in (B) fibroblasts from SMA patients (n = 3) and healthy controls (n = 3). Expression levels of lamin A 
were normalized to the geometric mean of POLR2J and TBP. Individual values for each sample and average of 
the group are presented, with error bars showing standard deviation from the mean. CTR- control; ns—not 
significant 
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magnetic beads, however, SMN was not detected in the eluate from three control fibroblasts 
(Figure 4.2A). The same was observed in the SMN pulldown, where both SMN and lamin A/C 
were easily detected in fibroblast cells by western blot analyses, however, lamin A/C was 
undetectable in the eluates from SMN pulldown in all three control fibroblast lines (Figure 
4.2B). Two additional bands in the SMN blot, in eluates from both lamin A/C and SMN 
pulldown, represent the small and large subunits of the immunoglobulin (Figure 4.2A. and 
4.2B). This result may not be surprising since an interaction between lamin A/C and SMN was 
identified previously in neuronal and muscle cells (Shafey et al., 2010), and may be restricted 
to specific tissues/cells.  
 
The possible interaction between SMN and lamin A/C was next investigated in the heart from 
control and SMA mice (Figure 4.2C). Heart was of particular interest because it showed the 
greatest upregulation of lamin A/C levels in SMA mice (chapter 3, Figure 3.5), and it already 
has an established role in the maintenance of heart health (Rudnik-Schöneborn et al., 2007; 
Iwahara et al., 2015), meaning that perturbed SMN-lamin A/C interaction might be 
responsible for heart defects in SMA. Lamin A/C was successfully pulled down in both control 
and SMA heart extracts, and a weak SMN band was also observed in the eluate from both 
samples, suggesting that a small amount of SMN could be interacting with lamin A/C in the 
heart tissue. However, the weak SMN band was also observed in the eluate from the negative 
control (Figure 4.2C), indicating that observed interaction between lamin A/C and SMN in 
heart extracts could be false positive. (The negative control refers to fibroblast extracts 
incubated with magnetic beads without the antibody). In addition, extra bands were observed 
across all samples (indicated by + sign), but the reason for this is unclear. 
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Figure 4. 2. Interaction between Lamin A/C and SMN was not identified in human fibroblasts and mouse 
heart tissues. Western blots showing lamin A/C and SMN expression in three healthy fibroblasts after 
immunoprecipitation with (A) anti-lamin A/C and (B) anti-SMN antibodies. (C) Western blots showing lamin 
A/C and SMN expression in heart tissue extracts from control and SMA mice after immunoprecipitation with 
anti-lamin A/C antibody. (Lamin A/C blot was also used in Figure 4.7C). Negative control lanes refer to 
fibroblast/ heart extracts incubated with magnetic beads without the antibody. SMN’-longer exposure time; 
*SMN band was observed in the eluate from lamin A/C pulldown and negative control; +Additional bands were 
detected in SMN blot, in the input and eluate from both lamin A/C pulldown and negative control. 
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In summary, the unchanged lamin A transcript levels in SMA patient fibroblasts and heart from 
SMA mice suggest that dysregulation of lamin A/C protein levels can be attributed to the 
aberrant posttranscriptional regulation. In addition, a direct physical interaction between 
lamin A/C and SMN was not established in human fibroblasts or mouse heart tissues, 
suggesting that dysregulation of lamin A/C levels is driven by other mechanism in SMA tissues. 
 
4.2.1.3 Lamin A/C and UBA1 are mechanistically linked  
Interestingly, heart, followed by the liver showed the greatest increase of lamin A levels and 
the greatest reduction of UBA1 levels in SMA mice compared to controls (Chapter, 3, Figures 
3.4 and 3.3), suggesting a possible link between lamin A/C and UBA1 pathways in SMA. 
Mutations in the genes that encode for lamin A/C and UBA1 are associated with an SMA 
phenotype (Ramser et al., 2008) (Rudnik-Schöneborn et al., 2007; Ramser et al., 2008; Iwahara 
et al., 2015), and UBA1 has already been implicated in SMN-dependent SMA disease pathways 
(Wishart et al., 2014; Shorrock et al., 2018). For example, perturbations in ubiquitin-
proteasome pathway (UBA1 being one of the essential components of this pathway) were 
directly responsible for increased levels of β-catenin (Wishart et al., 2014) and GARS (Shorrock 
et al., 2018) that drive motor and sensory neuron pathology in SMA. Lamin A/C was therefore 
investigated in relation to UBA1 pathways to determine whether deceased UBA1 expression 
might be responsible for lamin A/C expression defects in SMA tissues.  
 
4.2.1.3.1. Lamin A/C and UBA1 follow an inverse pattern of expression in healthy 
tissues/cells 
A western blot study of lamin A/C, UBA1 and SMN relative protein expression levels was first 
conducted using equal amounts of total protein from heart, muscle, liver, brain and spinal 
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cord tissue extracts from healthy control mice and from healthy human fibroblasts (Figure 
4.3). The analyses revealed a strong inverse pattern of lamin A/C and UBA1 expression where 
fibroblast cells, heart and muscle tissue had high relative levels of lamin A/C and low relative 
levels of UBA1. Liver, brain and spinal cord, on the other hand showed the opposite pattern, 
with low relative levels of lamin A/C and high relative levels of UBA1. SMN followed the same 
expression trend as UBA1 across the tissues examined. 
 
 
 
 
 
 
Figure 4. 3. UBA1 and lamin A/C showed the opposite expression trend across healthy mouse tissues and 
human cells. Western blots showing lamin A/C, UBA1 and SMN protein levels in the heart, muscle, liver, brain 
and spinal cord tissue from healthy mice (n=2) and in fibroblasts from healthy individuals (n=2). Fibroblasts 
are listed in this order: GM00498, GM00302. H-heart; M-muscle; L-liver; B-brain; SP-spinal cord; FC-fibroblast 
cells 
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4.2.1.3.2. Lamin A/C and UBA1 are able to regulate each other’s expression 
The inverse pattern of UBA1 and lamin A/C expression across tissues suggested a mechanistic 
link between the two proteins, which could rely on the ubiquitin-proteasome pathway. To 
determine whether UBA1 regulates lamin A/C turnover, lamin A/C expression was 
investigated in UBA1 knockdown human embryonic kidney (HEK) cells (provided by Dr Hannah 
K. Shorrock and Prof. Thomas H. Gillingwater). A 95% reduction of UBA1 levels in HEK cells 
was confirmed by western blotting and immunostaining (Figure 4.4A and 4.4B). A 43% 
upregulation of lamin A expression (p = 0.0398) was identified in UBA1 KD HEK cells using 
western blotting, independent of changes to lamin C and SMN expression (Figure 4.4A). Lamin 
A localization, on the other hand, was unaffected in UBA1 KD HEK cells compared to controls 
(Figure 4.4C). 
 
The unchanged levels of lamin C in UBA1 knockdown HEK cells suggest that UBA1-mediated 
protein degradation cannot completely explain the inverse pattern of lamin A/C and UBA1 
expression in healthy tissues. It was of interest therefore to determine whether lamin A/C 
regulates UBA1 stability. To investigate this, UBA1 expression and localization were 
investigated in mouse embryonic fibroblast cells lacking the LMNA gene (LMNA KO MEFs) 
(Sullivan et al., 1999). As expected, lamin A/C was undetectable In LMNA KO MEFs by western 
blotting and immunocytochemistry (Figure 4.5A and 4.5B). Western blot analyses identified a 
55% downregulation of UBA1 levels (p = 0.0053) and a 21% downregulation of SMN (21%, p = 
0.0016) compared to healthy controls (Figure 4.5A). The cytoplasm was more spread in LMNA 
KO MEFs compared to wild type MEFs, however, SMN and UBA1 localization seemed 
unchanged when compared to wild type MEFs (Figure 4.5C and 4.5D).  
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Figure 4. 4. Lamin A expression was increased in UBA1 KD HEK cells. (A) Western blots showing lamin A/C, 
UBA1 and SMN protein levels in UBA1 KD and control HEK cells (n=3), where n=3 represents technical 
replicates. Coomassie stained gel was used as internal, total protein loading control. Densitometry 
measurements of UBA1, lamin A, lamin C and SMN reactive bands were first normalised to densitometry 
measurements of Coomassie stained gel, after which all samples were normalised to the average of control. 
The graph is presented as average protein levels (expressed relative to the control), with error bars showing 
standard deviation from the mean. Representative immunocytochemistry images showing (B) UBA1 (red) and 
(C) lamin A (green) staining in UBA1 KD and control HEK cells, with DAPI shown in blue. Scale bar = 50 μm. ns- 
not significant; *p<0.05; ***p<0.001 
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Figure 4. 5. SMN and UBA1 expression were decreased in LMNA KO MEFs. (A) Western blots showing lamin 
A/C, UBA1 and SMN protein levels in LMNA KO and wild type MEFs (n=3), where n=3 represents technical 
replicates. Coomassie stained gel was used as internal, total protein loading control. Densitometry 
measurements of UBA1, lamin A, lamin C and SMN reactive bands were first normalised to densitometry 
measurements of Coomassie stained gel, after which all samples were normalised to the average of control. 
The graph is presented as average protein levels (expressed relative to the control), with error bars showing 
standard deviation from the mean. Representative immunocytochemistry images showing (B) lamin A (green), 
(C) UBA1 (green) and (D) SMN (red) staining in LMNA KO and wild type MEFs, with DAPI shown in blue. Scale 
bar = 25 μm, except in wild type MEFs stained with UBA1 where scale bar = 10 μm. **p<0.01 
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Having demonstrated that UBA1 and SMN are decreased in MEFs from a LMNA deficient 
mouse, it was next of interest to determine whether restoration of lamin A/C levels can 
reverse defects in SMN and UBA1 expression. For this, LMNA KO MEFs were transfected with 
a recombinant LMNA plasmid expressing FLAG tag (pSVK3), as described in section 2.7. 
Western blot analysis showed no significant difference in lamin A/C expression in LMNA KO 
MEFs following transfection (Figure 4.6A), suggesting that transfection did not work. In 
addition, binding of the antibody to the epitope is conformation-dependent (Nguyen et al., 
2008), and addition of a tag to the protein can affect its conformation. To account for the 
possibility that lamin A/C was not detected in transfected cells due to the inability of lamin 
A/C antibody (MANLAC1 4A7) to bind the epitope, MEFs transfected with lamin A-FLAG were 
stained with anti-FLAG antibody (Figure 4.6B). Immunocytochemistry analysis showed very 
few FLAG positive cells (5%±1.7), thus confirming the low transfection efficiency in LMNA KO 
MEFs. As expected, western blot analyses showed unchanged levels of both UBA1 and SMN 
in cells transfected with recombinant lamin A-FLAG (Figure 4.6A). 
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Figure 4. 6. Low transfection efficiency in LMNA KO MEFs. (A) Western blots showing lamin A/C, SMN and 
UBA1 levels in LMNA KO MEFs and in LMNA KO MEFs transfected with recombinant lamin A-FLAG plasmid 
(pSVK3) (n=3), where n=3 represents technical replicates. Coomassie stained gel was used as internal, total 
protein loading control. Densitometry measurements of UBA1 and SMN reactive bands were first normalised 
to densitometry measurements of Coomassie stained gel, after which all samples were normalised to the 
average of LMNA KO. The graph is presented as average protein levels (expressed relative to the LMNA KO), 
with error bars showing standard deviation from the mean. (B) Representative immunocytochemistry images 
showing FLAG (red) staining in LMNA KO MEFs transfected with lamin A-FLAG plasmid (pSVK3), with DAPI 
shown in blue. Cells that were successfully transfected are indicated by an arrow, with non-transfected cells 
indicated by chevron arrow. Scale bar = 75 μm in the first row and scale bar = 25 μm in the second row. The 
graph is showing percentage of transfected cells, with error bars showing standard deviation from the mean. 
ns- not significant 
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The inverse pattern of lamin A/C and UBA1 expression across healthy tissues implicated that 
lamin A/C and UBA1 might be mechanistically linked, and indeed experiments on UBA1 
knockdown HEK cells and LMNA KO MEFs showed that lamin A/C and UBA1 are able to 
regulate each other’s expression. 
 
4.2.1.3.3. Lamin A/C colocalizes with UBA1 in fibroblast cells, and interacts with beta-
catenin in mouse heart tissue 
UBA1 already has an established role in SMA (Wishart et al., 2014; Powis et al., 2016; Shorrock 
et al., 2018), and lamin A/C is emerging as a potential modulator of disease pathways in SMA, 
especially in the context of heart pathology. Establishing the link between UBA1 and lamin 
A/C may offer the opportunity to therapeutically target two SMA disease pathways at the 
same time which may offer better therapeutic benefit to SMA patients. To further explore the 
relationship between them, lamin A and UBA1 staining was examined in three control and 
three SMA patient fibroblast cell lines (Figure 4.7A). On average, 57% of control fibroblasts 
and 47% of patient fibroblasts showed co-localisation between UBA1 and lamin A at the 
nuclear periphery (Figure 4.7B), suggesting they might be physically interacting. To investigate 
this possibility, control and SMA mouse heart extracts were subjected to immunoprecipitation 
using a lamin A/C monoclonal antibody attached to magnetic beads. Although both lamin A/C 
and UBA1 were easily detected in SMA and control heart extracts by western blot analyses, 
UBA1 was undetectable in the eluates following lamin A/C pull-down (Figure 4.7C). 
 
Both lamin A/C and UBA1 are implicated in the regulation of  β-catenin (Wishart et al., 2014; 
Bermeo et al., 2015; Le Dour, Macquart, et al., 2017). UBA1, for example, controls the stability 
of β-catenin through the canonical ubiquitin-proteasome pathway, and deficiency in UBA1 
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protein levels leads to β-catenin accumulation and neuromuscular pathology in SMA (Wishart 
et al., 2014). Lamin A/C was shown to control the dynamics of the Wnt/β-catenin signalling 
pathway, where lamin A/C overexpression increased nuclear levels of β-catenin and activated 
the Wnt signalling pathway to promote osteoblast differentiation (Bermeo et al., 2015). The 
same study also provided evidence of an interaction between lamin A/C and β-catenin by 
immunoprecipitation of nuclear proteins from mesenchymal stem cells (MSCs) forcibly 
overexpressing lamin A/C (Bermeo et al., 2015). There is a possibility, therefore, that lamin 
A/C and UBA1 converge on the β-catenin signalling pathway. β-catenin levels were next 
examined in control and SMA heart tissue extracts to determine whether interaction between 
lamin A/C and β-catenin occurs under normal physiological conditions (Figure 4.7C). Indeed, a 
small proportion of the total β-catenin co-immunoprecipitated with lamin A/C from both SMA 
and control heart extracts (Figure 4.7C). 
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Figure 4. 7. Lamin A/C interacts with β-catenin in the heart of control and SMA mice. (A) Representative 
immunocytochemistry images showing lamin A and UBA1 staining in control and SMA patient fibroblast cells. 
Arrows in the lower magnification images indicate cells with the most obvious UBA1 staining at the nuclear 
periphery. Scale bar = 25 μm. Scale bar = 10 μm (control) and 7.5 μm (SMA) in higher magnification images. 
(B) The graph is presented as percentage of fibroblasts cells that showed lamin A and UBA1 co-localization. 
Individual values for each cell and average of the group are presented, with error bars showing standard 
deviation from the mean. (C) Western blots showing lamin A/C, UBA1 and β-catenin expression in the heart 
tissue from control and SMA mice after immunoprecipitation with anti-lamin A/C antibody (Lamin A/C blot 
was also used in Figure 4.2C). Beads alone control lanes refer to heart extracts incubated with magnetic beads 
without the antibody, and represent negative control. #β-catenin band was detected in the eluate from lamin 
A/C pulldown in both control and SMA samples, but was not observed in the eluate from the beads alone 
control. 
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When taken together, these experiments demonstrate a mechanistic link between lamin A/C 
and UBA1. Lamin A/C and UBA1 regulate each other’s expression, they are both observed at 
the nuclear rim in human fibroblasts, and immunoprecipitation experiments highlighted β-
catenin signalling as a potential pathway upon which they both converge.  
 
4.2.2. Functional consequences of lamin A/C dysregulation in SMA patient fibroblasts  
It was of interest to next determine the functional consequences of lamin A/C dysregulation 
in SMA tissues/cells as this would help to determine the role of lamin A/C in SMA disease 
pathways.  
 
4.2.2.1. Lamin localization is not changed in SMA patient fibroblasts 
Lamin A localization was first investigated in control (GM00302, GM05659, GM00498) and 
patient (GM00232, GM03813, GM09677) fibroblasts (Figure 4.8). This was done because 
dysregulation of lamin A/C localization was previously shown to induce molecular defects in 
HEK293 cells and mouse cardiomyocyte cell line (Carmosino et al., 2016; Gerbino et al., 2017). 
For example, in HEK cells expressing R321X lamin A/C mutant, lamin A/C was mis-localised to 
the endoplasmic reticulum (ER) which induced ER stress response and altered calcium (Ca2+) 
dynamics. In addition, mouse cardiomyocytes carrying a different lamin A/C mutation 
(D243Gfs∗4) showed mis-localization of lamin A/C to the ER, altered Ca2+ dynamics and 
defective electrical coupling (Gerbino et al., 2017). It was important, therefore, to investigate 
whether altered lamin A/C localization might be implicated in SMA disease pathways. 
Immunocytochemistry analysis were conducted on control and SMA patient fibroblasts to 
investigate the subcellular distribution of lamin A levels, however, no difference in lamin A 
localization was observed in SMA patient fibroblasts when compared to controls (Figure 4.8). 
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4.2.2.2. SMA patient fibroblasts showed increased number of nuclear defects 
Nuclear abnormalities were occasionally observed in SMA patient fibroblasts during the 
analysis of lamin A localization. Interestingly, one recent study characterised nuclear 
morphology defects in fibroblast cells carrying different lamin A/C mutations (van Tienen et 
al., 2019). The cells were derived from patients with a range of conditions including Emery-
Dreifuss muscular dystrophy, dilated cardiomyopathy, HGPS and lipodystrophy. The study 
demonstrated 77% sensitivity, where 10 out 13 cells carrying likely pathogenic mutation 
where identified as laminopathies, based on the increased number of cells showing nuclear 
morphology defects (van Tienen et al., 2019). More importantly, this study showed that 
nuclear morphology defects are conserved across a range of conditions associated with 
defects in nuclear lamins. Similar defects in SMA patient fibroblasts would suggest that 
changes in lamin A expression are likely to have functional consequences for the cell. Here, 
fibroblast cells stained with lamin A were examined retrospectively to determine the extent 
of nuclear defects in SMA patient fibroblasts compared to control. Based on the results from 
the previous study (van Tienen et al., 2019), cells were examined for morphology defects such 
as the donut and honeycomb-like structures, blebs, micronuclei and nuclear shape 
Figure 4. 8. Lamin A localization is not changed in SMA patient fibroblasts. Representative 
immunocytochemistry images showing lamin A staining in fibroblasts from SMA patients (n = 3) and healthy 
controls (n = 3). Scale bar = 10 μm, except in CTR0498 (scale bar = 25 μm) and SMA0232 (scale bar = 7.5 μm). 
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abnormalities (examples are shown in Figure 4.9). On average, 4.3% of healthy control cells 
showed nuclear abnormalities (Table 4.2) which is comparable to the previous study where 
nuclear abnormalities were identified in 4.8% of control cells (van Tienen et al., 2019). 
Interestingly, GM00232 cell line showed very few abnormal nuclei (2.9%), while 20.3% and 
14.9% of nuclei showed morphological defects in GM03813 and GM09677 cells lines 
respectively (Table 4.2). The most common type of nuclear malformation was bleb, followed 
by the donut-like structure. Nuclear morphology defects suggest that lamin A dysregulation 
could have pathological consequences in SMA patient fibroblasts. The analysis would, 
however, have to be repeated on a larger number of patient fibroblasts, to determine whether 
nuclear morphology defects are a conserved phenotype in SMA.  
 
 
 
 
 
 
 
 
Figure 4. 9. SMA patient fibroblasts show nuclear morphology defects. Examples of nuclear morphology 
defects in SMA patient fibroblasts. N- normal fibroblast; BL-bleb; D-donut-like structure; HC-honeycomb-like 
structure; NSA-nuclear shape abnormalit 
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Table 4. 2. Nuclear morphology defects in control and SMA patient fibroblasts 
Cell line % abnormal 
nuclei 
# abnormal 
nuclei 
# normal 
nuclei 
# total 
nuclei 
BL MI D HC NSA D+BL 
CTR5659 5.9 6 95 101 1 1 4 0 0 0 
CTR0498 
 
4.3 5 111 116 2 0 2 0 1 0 
CTR0302 
 
2.7 3 109 112 2 0 1 0 0 0 
SMA9677 
 
14.9 15 86 101 13 0 0 2 0 0 
SMA0232 
 
2.9 3 99 102 1 0 2 0 0 0 
SMA3813 
 
20.3 26 102 128 22 0 0 0 3 1 
Nuclear morphology defects in three control and three SMA fibroblasts. Number of abnormal and normal nuclei, 
as well as total number of nuclei is listed in the table. Type of malformation found in each cell is listed in the 
table: BL-blebs; MI-micronuclei; D-donut-like structures; HC-honeycomb-like structures; NSA-nuclear shape 
abnormalities 
 
4.2.2.3. Proliferation and migration are not altered in SMA patient fibroblasts  
Previous work has shown that increased and decreased lamin A/C expression affected cell 
proliferation and migration, with differing results observed depending on the in vitro model 
used (Kong et al., 2012; Harada et al., 2014). In the prostate cancer cell lines, LNCaP, DU145, 
and PC3, for example, downregulation of lamin A/C levels decreased cell migration, while 
lamin A/C overexpression increased migration of all three cell lines in a 2D and 3D 
environment (Kong et al., 2012). In addition, proliferation was decreased in LNCaP, DU145, 
and PC3 cell lines following lamin A/C knockdown, and increased in all three cell lines 
overexpressing lamin A/C (Kong et al., 2012). Harada et al., on the other hand, found that 
lamin A/C knockdown increases migration of lung carcinoma-derived A549 cells, glioblastoma-
derived U251 cells and MSCs in 2D and 3D environment, and A549 cell proliferation was not 
affected following lamin A/C knockdown (Harada et al., 2014). This would then mean that 
proliferation and migration of different cells in SMA tissues could have been affected by lamin 
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A/C dysregulation, which could result in aberrant development of tissues that is often 
observed in SMA (discussed in chapter 1, section 1.3). To investigate this hypothesis, SMA 
patient fibroblasts were used for functional studies, as this in vitro model of SMA was readily 
available in the laboratory. 
 
Cell proliferation was first determined by measuring cell doubling time in three control 
(GM00302, GM05659, GM00498) and three patient (GM00232, GM03813, GM09677) 
fibroblasts (as described in section 2, section 2.6.1). On average, SMA fibroblasts showed a 
longer doubling time (67.3± 18.9 hours) compared to control cells (48.3±7.57 hours), meaning 
their proliferation rate was decreased compared to control cells, however, this difference was 
not statistically significant (Figure 4.10A). Interestingly, of the three fibroblasts cells examined, 
GM09677, showed the highest proliferation rate, which was comparable to all three healthy 
fibroblasts. GM09677 was also the only cell derived from the eye lens, while others, that have 
a known biopsy source, originate from the skin (Table 2.1). 
 
Cell migration was next assessed by a 3D migration assay (as described in chapter 2, section 
2.6.2). The speed of cell migration in confined space, such as the extracellular matrix (ECM), 
depends on the physical properties of the nucleus, i.e. size, shape, and rigidity. Deformation 
of the nucleus to the 1/10 of its original size, for example, was shown to be the lower limit for 
cell migration in a range of cells, including tumour cell lines, T-cells and neutrophils (Wolf et 
al., 2013). Deformation of the nucleus for factor 2-5, on the other hand, was shown 
sustainable for cell migration, but at the same time affected the rate of migration (Wolf et al., 
2013). Since the average diameter of fibroblast cells is 20-30 μm (Figure 4.8), the 5 μm pore 
well inserts were chosen for the experiment. This pore size provides sufficient challenge to 
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cell migration, where the effect of lamin A/C expression (i.e. cell rigidity) could be assessed on 
fibroblast cell migration. First, one control (GM00498) and one patient (GM003813) fibroblast 
cell line were plated on the apical side of the 5 μm well insert, and cell migration was assessed 
after 6, 24, 48 and 72 hours to determine the optimal time for the large-scale experiment 
(Figure 4.10B). In control and patient fibroblasts equally, no migration was observed after 6 
hours, with very few cells observed on the dorsal side of the membrane after 24 hours. 
However, the number of migrating cells increased after 48 and 72 hours in cell culture. This 
data was then used to set up a migration assay, with three control (GM00302, GM05659, 
GM00498) and three patient (GM00232, GM03813, GM09677) fibroblasts, where the cells 
were allowed to migrate for 70 hours (Figure 4.10C). No significant difference in migration 
rate between control and patient fibroblasts was observed following 70 hours in cell culture. 
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In summary, functional studies did not show significant changes in cell proliferation or 
migration in SMA patient fibroblasts. In addition, lamin A localization was not changed in SMA 
patient fibroblasts. The increased number of patient fibroblast cells that showed nuclear 
morphology defects does, however, indicate that dysregulation of lamin A/C levels is likely to 
induce pathological changes in cells which are to be explored in the future.  
 
Figure 4. 10. Cell proliferation and migration are not affected in SMA patient fibroblasts. (A) Cell proliferation 
expressed as doubling time in fibroblast cells from SMA patients (n = 3) and healthy controls (n = 3). Individual 
values for each cell and average of the group are presented, with error bars showing standard deviation from 
the mean. (B) Orthogonal view of the 3D projection showing migration of control (GM00498) and patient 
(GM003813) fibroblasts through a 5 μm pore size membrane after 6, 24, 48 and 72 hours in cell culture. The 
membrane is stained blue with DAPI, and fibroblast cells are shown in red (lamin A). Up-down arrows indicate 
membrane thickness, where A stands for apical, and D for dorsal side of the membrane. (C) The percentage of 
cells that migrated through a 5 μm pore size membrane was assessed in control (n = 3) and patient (n = 3) 
fibroblasts after 70 hours in cell culture. Individual values for each cell and average of the group are presented, 
with error bars showing standard deviation from the mean. CTR- control; ns—not significant 
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4.2.3. Lamin A/C levels decrease with aging 
Mutations in the lamin A/C gene, LMNA, have been implicated in Hutchinson-Gilford progeria 
syndrome (HGPS), a premature aging syndrome, and a role for lamin A/C in normal 
physiological aging has been demonstrated in human fibroblast cells (Scaffidi and Misteli, 
2006), and in mouse cardiomyocytes (Afilalo et al., 2007) and osteoblasts (Duque and Rivas, 
2006). Reduction of lamin A/C levels, for example, was identified in fibroblasts from older 
healthy individuals (81-96 years) compared to the younger healthy individuals (7-11 years) 
(Scaffidi and Misteli, 2006). In addition, nuclear defects, similar to the ones observed in HGPS 
patient fibroblasts, where observed in older cells, including an increased number of foci 
containing phosphorylated H2A.X Variant Histone (H2AX), thus directly implicating lamin A/C 
in aging process (Scaffidi and Misteli, 2006). Development of new therapies and better clinical 
care has created an aging population of SMA patients, with new phenotypes that differ from 
the natural history of the disease (Tizzano and Finkel, 2017; Schorling, Pechmann and 
Kirschner, 2020). In the case of nusinersen, for example, where neuronal tissue is the only 
target of the treatment, peripheral pathologies are still a concern (Tizzano and Finkel, 2017), 
and a major question  is whether natural aging could affect/exacerbate these pathologies in 
SMA patients. In the case of fibroblast cells, for example, further reduction of lamin A/C levels 
could bring lamin A/C levels below the crucial point where different cell functions, like 
proliferation and migration, could be affected. 
 
Lamin A/C expression was first examined by western blotting in a range of fibroblast cells from 
healthy individuals (10 month, 1, 3, 27, 34, 39, 45 and 66 years) to verify previous results, and 
to expand the knowledge of age-dependent lamin A/C changes by using a wider age-range of 
fibroblast cells (Figure 4.11A). When compared to the average lamin A/C levels across three 
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young cells, an average reduction of 65% in lamin A levels and 70% in lamin C levels (p = 
0.0213) was observed across five older cells. Interestingly, cells from a 27-year old female and 
a 39-years old male showed a 25% reduction of lamin A/C levels, while the levels of both lamin 
A and C were almost undetectable in fibroblasts from other three female subjects, i.e. 34, 45 
and 66 years. Though it is not possible to conclude from a single sample, this result suggests a 
possibility that changes in lamin A/C expression with aging could also be gender-dependent, 
however, a large scale study would have to be conducted to investigate this in detail. Another 
important observation is that lamin A levels were lower in fibroblasts from a 1-year old 
(GM05659) compared to two other young subjects (10-month old corresponding to GM00302, 
and a 3-year old corresponding to GM00498), and two adult subjects (27 and 39 years).  
 
Having confirmed that both lamin A and lamin C levels decrease with aging, it was next of 
interest to investigate whether this reduction would affect cell proliferation and migration. 
Proliferation and migration rate were, therefore, investigated in three older cell lines that 
showed the greatest reduction of lamin A/C levels (34, 45 and 66 years), and three younger 
cell lines (10 m, 1 and 3 years) as described in chapter 2, section  2.6. The analyses showed no 
significant change in proliferation or migration rate between young and old fibroblast cells 
(Figure 4.11B and 4.11C).  
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Figure 4. 11. Lamin A/C expression decreases with aging. (A) Representative western blots showing lamin A/C 
levels in healthy fibroblasts of different ages. Coomassie stained gel was used as internal, total protein loading 
control. Fibroblast cells are listed in chronological order from the youngest to the oldest one (left to right): 
GM00302, GM05659, GM00498, F152, F154, F008, F011, F067. Densitometry measurements of lamin A and 
lamin C reactive bands were first normalised to densitometry measurements of Coomassie stained gel, after 
which all samples were normalised to the average of young group (first three cells). (B) Cell proliferation and 
(C) migration were assessed in healthy fibroblast cells from younger (n = 3) and older (n = 3) individuals. 
Fibroblast cells are listed in chronological order from the youngest to the oldest one (left to right): GM00302, 
GM05659, GM00498, F154, F011, F067. Cell proliferation is expressed as doubling time, and cell migration as 
percentage of cells that migrated through a 5 μm pore size membrane after 70 hours in cell culture. Individual 
values for each cell line and average of the group are presented, with error bars showing standard deviation 
from the mean. m- month; y- year; ns—not significant; *p<0.05 
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In summary, western blot analyses identified decreased lamin A/C levels in healthy fibroblasts 
from older individual, confirming previous results of age-dependent changes in lamin A/C 
expression. Functional studies did not, however, identify significant changes in cell 
proliferation or migration in older healthy fibroblasts cells. 
 
4.2.4. Heart pathology in SMA 
Structural and functional cardiac defects were reported in numerous studies in SMA patients 
and  mouse models of SMA (Wijngaarde et al., 2017), however, only one study to date 
undertook a systematic approach to examine molecular defects in the heart from Taiwanese 
mouse model of severe SMA (Sheng et al., 2018). Transcriptomic study identified numerous 
changes in the heart from early symptomatic Taiwanese mice, of which 205 genes were 
downregulated and 269 genes were upregulated (Sheng et al., 2018). Several of these changes 
were tracked back to a pre-symptomatic time-point, suggesting that cardiac defects might be 
attributable, at least in part, to cell autonomous mechanisms (Sheng et al., 2018). And whilst 
it has generated novel insights about changes to the transcriptome, proteomic insights into 
the SMA heart are lacking. 
 
4.2.4.1. Quantitative proteomics analysis identified widespread molecular defects in the 
heart tissue from severe SMA mice 
Here, a quantitative comparison of the SMA and age-matched control heart proteome was 
undertaken using iTRAQTM mass spectrometry approach (as described in methods section 
2.11), to determine whether depletion of SMN protein levels leads to alterations to the heart 
proteome. This approach identified 3105 proteins in total (data not shown), of which 2479 
were identified with a 5% local false-discovery rate. After filtering the data (as described in 
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section 2.11.4), 383 proteins were identified as differentially expressed in SMA mouse heart 
compared to controls. Of these, 177 proteins were increased and 206 were decreased in 
expression in SMA mouse heart compared to controls (Appendix 2). Among these was lamin 
A/C that showed a statistically significant 4-fold increase in the heart from Taiwanese SMA 
mice when compared to controls. 
 
Gene ontology (GO) analysis using the DAVID platform (Huang, Sherman and Lempicki, 2009b, 
2009a) highlighted enriched biological processes and cellular components relating to the up- 
and down-regulated proteins, respectively (Appendix 3). A relatively high proportion of up-
regulated proteins were found to be blood-specific (n=16), and although this compliments a 
previous report of blood pooling in the hearts of the Taiwanese SMA mouse model (Maxwell 
et al., 2018), these proteins were excluded from further analysis to retain focus on changes 
specific to the heart tissue. After also removing keratin-associated proteins (n=4), the 
remaining proteins were then subject to analysis using STRING 10 (Szklarczyk et al., 2015) to 
identify statistically significant associations between them. Comparison of the resulting 
networks with the GO analysis output (Appendix 3) identified protein clusters associated with 
highly enriched molecular and/or biological processes (Figure 4.12). For the up-regulated 
proteins, enriched processes included organization and/or regulation of the cytoskeleton, cell 
junction, and extracellular matrix (Figure 4.12A), while clusters of down-regulated proteins 
were associated with translation and metabolic processes (Figure 4.12B). 
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Figure 4. 12. Bioinformatics analysis of the proteins dysregulated in heart tissue from SMA mice. A) Upregulated proteins and (B) downregulated proteins were subjected to STRING 10 
analysis. Protein associations were identified with high confidence (0.700) interaction score for (A) upregulated and with the highest confidence (0.900) interaction score for (B) 
downregulated proteins. The thickness and colour of the lines indicate confidence of the interaction (see legend inset in figure). Protein networks were compared to the GO analysis output 
(Appendix 3). The analysis identified protein clusters that associate with enriched GO terms in the cellular component (black) and biological process (red) domain. Proteins annotated to 
each term are shown in corresponding circles.  
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In summary, it was shown here that: 
a) The molecular mechanism of lamin A/C dysregulation in SMA tissues/cells does not 
rely on aberrant transcriptional regulation, nor is it likely to be dependent on the 
physical interaction between SMN and lamin A/C, and remains to be further 
investigated. However, a mechanistic link between lamin A/C and UBA1, a known 
regulator of disease pathways, was identified in UBA1 knockdown HEK cells and LMNA 
KO MEFs where lamin A/C and UBA1 were shown to regulate each other’s expression. 
In addition, it was shown here that lamin A/C interacts with β-catenin under normal 
physiological conditions in the heart from control and SMA mice. Considering that 
UBA1 is a known β-catenin interacting partner, it is possible that lamin A/C and UBA1 
converge on β-catenin signalling pathway, which could have important implications for 
SMA therapy design.   
b) Decreased levels of lamin A in SMA patient fibroblasts did not significantly affect cell 
proliferation and migration. An increased number of dysmorphic nuclei, identified in 
SMA patient fibroblasts, indicates that decreased levels of lamin A could cause defects 
in nuclear stability.  
c) The highest upregulation of lamin A/C levels in the heart tissue from SMA mice 
suggested that lamin A/C might be implicated in the heart pathology in SMA. This is 
supported by numerous finding of severe heart defect caused by mutations in LMNA 
gene. In addition, widespread dysregulation of proteome was identified in SMA mouse 
heart. Dysregulated proteins were associated with metabolic processes and 
cytoskeletal and extracellular matrix organisation, indicating de-differentiation 
process in cardiomyocytes. 
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4.3. Discussion 
4.3.1. Dysregulation of lamin A/C protein levels in SMA tissues and cells is not caused 
by aberrant transcription 
Lamins A and C, A-type lamins, are filament proteins of the nuclear lamina that provide 
structural support to the nucleus (Naetar, Ferraioli and Foisner, 2017). They are encoded by 
the LMNA gene, whose alternative splicing gives rise to two isoforms, pre-lamin A and lamin 
C, where mature lamin A is produced by post-translational modifications of pre-lamin A (Lin 
and Worman, 1993). In addition to maintaining nuclear integrity, lamin A and C are involved 
in several other functions including mechanosignaling, chromatin organization and regulation 
of gene expression (Naetar, Ferraioli and Foisner, 2017). 
 
Interestingly, mutations in lamin A/C gene are associated with an adult form of SMA (Rudnik-
Schöneborn et al., 2007; Iwahara et al., 2015), and increased expression of lamin A/C was 
previously identified in three proteomic studies of SMA, including mouse Schwann cells 
(Aghamaleky Sarvestany et al., 2014), mouse muscles (Mutsaers et al., 2013) and type I patient 
motor neurons (Fuller et al., 2016). The widespread dysregulation of lamin A and C levels, 
identified in SMA tissues and cells by western blotting (chapter 3, Figure 3.5), provided further 
evidence that lamin A/C might be implicated in SMA disease pathways. For example, a 
statistically significant upregulation of both lamin A and C levels was identified in the heart, 
liver and brain from a mouse model of SMA, while spinal cord tissue from SMA mice showed 
significant upregulation of lamin C levels only. In line with this, immunohistochemistry analysis 
showed increased levels of lamin A/C in the heart from 8 days old SMA mice (Šoltić et al., 
2019). In addition, dysregulation of lamin A/C levels seems to occur post-transcriptionally 
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since both SMA patient fibroblasts and SMA mouse heart tissue showed unchanged lamin A 
transcript levels (Figure 4.1). 
 
4.3.2. Lamin A/C does not interact with SMN in human fibroblast and mouse heart 
tissue 
Immunoprecipitation experiments using both SMN and lamin A/C antibodies showed no 
evidence that SMN and lamin A/C physically interact in healthy fibroblast cells. This may not 
be surprising since lamin A/C was previously identified as SMN interactor in PC12 neuronal 
and C2C12 muscle cell lines (Shafey et al., 2010), meaning that SMN-lamin A/C interaction 
might be cell type specific. Indeed, the same study identified a range of SMN interactors that 
were specific to either PC12 or C2C12 cells, and some of these interactions were found only 
in specific stages of cell differentiation, thus emphasizing the dynamic nature of the protein 
interactions (Shafey et al., 2010). A pulldown of lamin A/C from the heart tissue of control and 
SMA mice, on the other hand, showed inconclusive results. Although a small amount of SMN 
was identified in the eluate from the pulldown, bands were also detected in the negative 
control lanes which indicates the non-specific binding of proteins to the beads (Louche, 
Salcedo and Bigot, 2017). It is important to note though that an interaction between lamin 
A/C and SMN cannot be ruled out on this basis since physiological interactions may occur 
between a minor proportion of the total protein present and/or may be vulnerable to 
disruption by protein extraction methods (Kubben et al., 2010). This could be tested in future 
using different buffers (with /without detergents, low /high salt, sonication vs no sonication 
etc). The biggest limitation of both pulldowns is the absence of the positive control, i.e. 
verified lamin A/C and SMN interactors that could identify potential problems with the 
extraction method.  
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4.3.3. Lamin A/C and UBA1 are mechanistically linked  
A role for lamin A/C in SMA is strengthened by experiments showing a mechanistic link 
between lamin A/C and UBA1, a key contributor to SMN-dependent disease pathways 
(Wishart et al., 2014; Powis et al., 2016; Shorrock et al., 2018). For example, a strong inverse 
pattern of lamin A/C and UBA1 expression was identified in healthy mouse tissues and 
fibroblasts from healthy individuals (Figure 4.3). Heart, muscles, and fibroblasts showed high 
relative levels of lamin A/C and low relative levels of UBA1, whereas, spinal cord, brain and 
liver showed low relative levels of lamin A/C and high relative levels of UBA1. This pattern of 
lamin A/C expression is not surprising, since a previous study already showed that lamin A/C 
expression correlates with tissue stiffness (Swift et al., 2013). Stiffer tissues like heart and 
muscles induce high levels of mechanical stress, and so high levels of lamin A/C are necessary 
for the maintenance of nuclear stability (Swift et al., 2013). The inverse pattern of UBA1 
expression, on the other hand, was a new finding, and suggested that UBA1 might be 
implicated in the regulation of lamin A/C homeostasis through a canonical ubiquitin-
proteasome pathway. Upregulation of lamin A levels in UBA1 knockdown HEK cells supported 
this idea (Figure 4.4). However, the unchanged levels of lamin C, following UBA1 knockdown, 
indicate that lamin A/C homeostasis is also regulated by other mechanisms like 
phosphorylation (Cho et al., 2019). In addition, downregulation of UBA1 and SMN expression 
was identified in LMNA KO MEFs (Figure 4.5), suggesting that lamin A/C might also play a role 
in SMN and UBA1 homeostasis. Indeed, several studies showed that lamin A/C directly binds 
to DNA to regulate gene expression (summarised in (Naetar, Ferraioli and Foisner, 2017)), and 
decreased expression of both SMN and UBA1, following lamin A/C knockout, gives additional 
evidence for the role of lamin A/C in transcription regulation.  
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To further investigate the role for lamin A/C in the regulation of UBA1 and SMN expression, 
LMNA KO MEFs were transfected with wild type lamin A (Figure 4.6). This was done to assess 
whether restoration of lamin A/C levels can correct UBA1 and SMN expression defects in 
LMNA KO MEFs, however, this was not possible due to the low transfection efficiency (5% of 
cells). This indicated possible technical problems, since a 38% transfection efficiency was 
identified previously in LMNA KO MEFs, using the same method and the same lamin A plasmid 
(Holt et al., 2003). One possibility is that long-term storage compromised plasmid integrity, 
i.e. 15 years at -20°C. In addition, some cells, especially primary cells, electroporate poorly and 
are easily killed by high voltage (Potter and Heller, 2003). Indeed, approximately 40% of cells 
were lost during electroporation which could explain low transfection efficiency in LMNA KO 
MEFs. Before further experiments are undertaken, both plasmid integrity and optimal 
electroporation conditions would have to be determined to reduce cell death and increase 
the efficiency of the transfection rate.  
 
4.3.3.1 Lamin A/C and UBA1 converge on β-catenin signalling 
Further evidence for the mechanistic link between lamin A/C and UBA1 was provided in 
control and patient fibroblasts, where UBA1 co-localized with lamin A at the nuclear lamina 
(Figure 4.7A). A physical interaction between lamin A/C and UBA1 was not identified in the 
heart from control and SMA mice, however, a small amount of total β-catenin was successfully 
pulled down using a lamin A/C antibody (Figure 4.7C). Lamin A/C and UBA1 might thus 
converge on the β-catenin signalling pathway, since both proteins were implicated in its 
regulation (Wishart et al., 2014; Bermeo et al., 2015; Le Dour, Macquart, et al., 2017). UBA1, 
for example, controls the stability of β-catenin through the canonical ubiquitin-proteasome 
pathway, and deficiency in UBA1 protein levels leads to β-catenin accumulation and 
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neuromuscular pathology in SMA (Wishart et al., 2014). Pharmacological inhibition of β-
catenin signalling, using quercetin, ameliorated neuromuscular pathology in Drosophila, 
zebrafish and mouse models of SMA (Wishart et al., 2014). Results from this study suggest 
that the mechanism of quercetin action might be due, at least in part, to the upregulation of 
UBA1 levels (chapter 3, Figure 3.17). At the same time quercetin induced a dose-dependent 
reduction of lamin A/C, beta catenin and SMN levels in patient fibroblasts, indicating a 
mechanistic link between lamin A/C, UBA1, β-catenin and SMN pathways that could together 
contribute to SMA pathogenesis. In addition, defective Wnt/β-catenin signalling was also 
found to contribute to the pathology of dilated cardiomyopathy caused by mutation in LMNA 
gene (Le Dour, Macquart, et al., 2017). Decreased expression of several components of Wnt/β-
catenin pathway, including β-catenin, was identified in the heart from a mouse model of 
LMNA cardiomyopathy (Le Dour, Macquart, et al., 2017). Interestingly, pharmacological 
activation of WNT/β-catenin signalling improved cardiac pathology in a mouse model of LMNA 
cardiomyopathy, directly implicating it in disease pathways in cardiomyopathy associated with 
LMNA mutation (Le Dour, Macquart, et al., 2017). In a separate study, lamin A/C was shown 
to regulate the differentiation fate of mesenchymal stem cells (MSCs) by controlling dynamics 
of the Wnt/β-catenin signalling pathway (Bermeo et al., 2015). Lamin A/C overexpression, for 
example, increased nuclear levels of β-catenin and activated the Wnt signalling pathway to 
promote osteoblast differentiation (Bermeo et al., 2015). The same study also provided 
evidence of an interaction between lamin A/C and β-catenin by immunoprecipitation of 
nuclear proteins from MSCs forcibly overexpressing lamin A/C (Bermeo et al., 2015). Here, this 
knowledge was further expanded, by demonstrating that lamin A/C and β-catenin interact in 
heart extracts under normal physiological conditions. In a recent study, β-catenin was 
implicated in regulation of mechanosignaling by connecting adherens junctions to actin 
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cytoskeleton (Towbin et al., 2019). This is enabled by direct interaction of β-catenin with 
transmembrane protein N-cadherin on one end, and through interactions with α-catenin and 
vinculin on the other side that bind to actin cytoskeleton (Towbin et al., 2019). 
 
It seems likely that UBA1 and lamin A/C converge on β-catenin signalling pathway, since they 
both have important functions in the regulation of its stability. It is possible, for example, that 
increased levels of lamin A/C are responsible, at least in part, for increased levels of β-catenin 
in neuromuscular tissues from SMA mice that was directly implicated in motor neuron 
degeneration (Wishart et al., 2014). There is evidence too, that lamin A/C might be directly 
implicated in regulation of UBA1 levels, perhaps through regulation of its transcriptional 
activity. The exact link between lamin A/C and UBA1 pathways, however, remains to be 
determined, as it might have important implications in SMA therapy design. Carefully 
designed therapies that could restore the expression of all these targets may need to be 
designed to increase the therapeutic benefit in SMA patients.  
 
4.3.4. Functional consequences of lamin A/C dysregulation in SMA cel ls and tissues  
4.3.4.1. Cell proliferation and migration were not significantly changed in SMA fibroblast 
cells 
Reduced cell proliferation and migration rates were identified in SMA patient fibroblasts 
compared to control cells, however, this change was not statistically significant (Figure 4.10). 
This could be explained by the fact that only lamin A levels were reduced in patient cells 
compared to controls, while the levels of lamin C stayed unchanged. This change in lamin A 
levels may not be sufficient to recapitulate changes in proliferation and migration that were 
previously identified in cells with lamin A/C knockdown (Kong et al., 2012; Harada et al., 2014). 
237 
 
However, different technical considerations have to be taken into account when interpreting 
the results, especially since SMA cells showed variable proliferation rates. Of the three SMA 
fibroblast cell lines examined, GM09677 showed the highest proliferation rate (comparable to 
all three healthy fibroblasts). GM09677 was also the only cell derived from the eye lens, while 
others, that have a known biopsy source, originate from the skin (Table 2.1). Indeed, biopsy 
location might offer an explanation for differences in proliferation ad migration rate between 
SMA cells. For example, it was shown previously that skin fibroblasts from the abdominal scar 
tissue have higher proliferation rate compared to skin fibroblasts from the back of the ear and 
the eyelid (Fernandes et al., 2016), and in a separate study, fetal lung and skin fibroblasts 
derived from the same individual showed different migration rates (Kondo and Yonezawa, 
1992). In line with this, widespread differences in gene expression profiles were identified 
between fibroblast cells derived from different anatomical locations (Chang et al., 2002). 
Genes implicated in cell proliferation and migration were among those identified, thus 
supporting the idea that biopsy location has important implications for cell dynamics (Chang 
et al., 2002). Another important consideration is passage number. For example, migration rate 
of fetal skin fibroblasts decreased with higher passage number, while fetal lung fibroblasts 
showed consistent migration throughout passages (Kondo and Yonezawa, 1992). In addition, 
reduction in proliferation rate was observed in skin fibroblasts with higher passage number 
(Ng et al., 2009). Unfortunately, not all information (i.e. passage number and biopsy source) 
were available for fibroblast cells (Table 2.1) and so complete control of experimental 
conditions was not possible.  
 
In conclusion, proliferation and migration were not significantly changed in SMA patient 
fibroblasts, although interpretation of results was hampered here for technical reasons. It 
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would be of interest in the future to assess how lamin A/C dysregulation affects SMA patient 
cell proliferation and migration, as this may have important implications for cell/tissue health 
and integrity. When doing so, both biopsy source and passage number should be taken into 
account to facilitate interpretation of results. 
 
4.3.4.2. Nuclear morphology defects are present in SMA patient fibroblasts 
SMA patient fibroblasts showed increased number of dysmorphic nuclei compared to healthy 
age-matched healthy controls (Table 4.2). The same nuclear morphology defects were 
previously observed in fibroblast cells from Emery-Dreifuss, dilated cardiomyopathy, HGPS 
and lipodystrophy patients caused by lamin A/C mutations (van Tienen et al., 2019), and 
downregulation of lamin A/C levels in ovarian surface epithelial cells was sufficient to induce 
nuclear morphology defects (Capo-chichi et al., 2011). Aberrant nuclei could thus be more 
susceptible to apoptosis compared to control cells, either because of the altered response to 
mechanical stress or altered gene expression (Mallampalli et al., 2005).  
 
4.3.4.3. Proliferation and migration rate were not significantly changed in fibroblast cells 
from older healthy individuals 
There are several lines of evidence that implicate lamin A/C in aging. For example, 
accumulation of truncated pre-lamin A protein progerin (Δ50 lamin A) is a pathological feature 
of premature aging syndrome, Hutchinson-Gilford progeria syndrome (HGPS) (Verstraeten et 
al., 2008), and a small amount of progerin was detected previously in healthy fibroblast cells 
of different ages (Scaffidi and Misteli, 2006). In addition, increased number of TP53-binding 
protein 1 (53BP1) foci and increased levels of histone γ-H2AX, markers of DNA damage, were 
identified in HGPS patient fibroblasts, indicating altered DNA damage response that promotes 
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genomic instability and cell apoptosis in HGPS cells (Liu et al., 2005). Similarly, the  percentage 
of nuclei with phospho- H2AX foci was significantly higher in fibroblasts from older individuals 
compared to younger individuals (Scaffidi and Misteli, 2006), suggesting that the same 
mechanism is responsible for aging in healthy and HGSP fibroblasts. Reduction of lamin A/C 
levels is another feature of aging cells, and was previously reported by immunocytochemistry 
in dermal fibroblasts from older healthy individuals (81-96 years) compared to younger heathy 
individuals (7-11 years) (Scaffidi and Misteli, 2006). Here, a drastic reduction of lamin A/C 
levels was identified by western blotting in fibroblasts from healthy individuals starting from 
the age of 27 (Figure 4.11A), which expands the knowledge of age-dependent changes in lamin 
A/C levels in healthy fibroblasts. Increased number of γ-H2AX foci was observed in LMNA 
depleted 293 cells treated with interstrand cross-link agents, indicating compromised DNA 
damage response (Singh et al., 2013), and in human skin fibroblasts, lamin A/C knockdown 
induced production of ROS (Sieprath et al., 2015). In a separate study a link between DNA 
damage, ROS production and cell apoptosis was established (Kang et al., 2012). For example, 
overexpression of histone H2AX and/or its accumulation as a result of DNA damage, was 
shown to be sufficient to increase production of ROS in human osteosarcoma (U2OS) and 
human mammary epithelia (HBL100) cell lines (Kang et al., 2012). When taken together, these 
findings indicate that reduction of lamin A/C levels might be directly responsible for 
compromised DNA damage response in aging cells that results in genomic instability and cell 
death.  
 
A key question here is: can age-related changes in lamin A/C levels affect the pathology in 
aging population of SMA patients? For example, decreased cell proliferation was identified 
previously in lamin A/C depleted human fibroblasts (Sieprath et al., 2015). It is possible 
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therefore that further reduction of lamin A/C levels in SMA fibroblast cells, as a consequence 
of aging, would exacerbate defects in cell dynamics. Since fibroblasts from adult SMA patients 
were not available for these experiments, cell proliferation and migration were assessed in 
older healthy fibroblasts that showed the greatest reduction of lamin A/C levels (Figure 4.11). 
No significant difference in proliferation or migration rate was identified between older and 
younger cells, which is in line with previous studies showing similar doubling times between 
fibroblasts of different ages (Ng et al., 2009; Moulin et al., 2011). However, it is possible too, 
that different passage numbers and/or biopsy locations masked changes between two 
fibroblast populations. Indeed, one previous study showed that older fibroblasts (77 years) 
migrate slower compared to the younger fibroblasts (36-years), and in both cases cell 
migration decreased with increasing passage number (Kondo and Yonezawa, 1992). The most 
obvious consequence of reduced fibroblast migration is impaired skin wound healing (Li et al., 
2004) which could significantly decrease the quality of life of SMA patients. Though the 
question remains: how would an age-dependent reduction of lamin A/C levels affect other 
SMA tissues/cells that showed increased levels of lamin A/C? In the heart tissue, for example, 
increased levels of lamin A/C are likely implicated in the heart pathology. Can reduction of 
lamin A/C levels improve heart pathology, or will reduction of lamin A/C levels induce 
mechanical stress in cardiomyocytes and lead to cell apoptosis? Liver tissue from SMA mice, 
on the other hand, showed increased levels of pre-lamin A, which could result in cell 
senescence as shown previously in skin fibroblasts (Sieprath et al., 2015). It was already shown 
that liver function declines with aging in healthy individuals (Cieslak et al., 2016), and this can 
be linked, at least in part, to the decreased DNA repair activity, identified in hepatocytes from 
old SMA mice (Intano et al., 2003). This would then mean that aging process could exacerbate 
liver dysfunction in SMA, where decreased levels of lamin A/C are likely to impair DNA damage 
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response and induce cell apoptosis. All of these questions warrant further experimental 
attention to determine the best strategy in development of therapies for aging population of 
SMA patients.  
 
4.3.5. Lamin A/C is likely implicated in the regulation of SMA heart pathology  
Mutations in LMNA gene cause a spectrum of disorders known as laminopathies, the majority 
of which prominently feature cardiac pathology, including autosomal dominant Emery-
Dreifuss muscular dystrophy (EDMD) (Bonne et al., 1999), limb-girdle muscular dystrophy 1B 
(LGMD1B) (Ki et al., 2002), dilated cardiomyopathy (DCM) (Fatkin et al., 1999) and an adult 
from of SMA (Rudnik-Schöneborn et al., 2007; Iwahara et al., 2015). Remarkably, some 
mutations in the LMNA gene can result in different pathologies (Kang, Yoon and Park, 2018). 
For example, a missense mutation (c.1130G > T) in exon 6 of LMNA gene, found in a case of 
adult onset SMA (Rudnik-Schöneborn et al., 2007), has also been attributed to LGMD1B (Ki et 
al., 2002); both of which share heart conduction problems and dilated cardiomyopathy. This 
indisputable link between lamin A/C mutations and cardiac pathology in a wide range of 
conditions, including a rare form of SMA, leaves very little doubt that correct functioning of 
lamin A/C is a key requirement for the maintenance of cardiac health. The finding here that 
lamin A/C is robustly increased in heart tissue from a mouse model of SMA therefore strongly 
suggests that lamin A/C is responsible, at least in part, for previously reported cardiac defects 
in SMA. 
 
Lamin A/C expression levels correlate with tissue stiffness, where rigid tissues have the highest 
levels and softer tissues the least (Swift et al., 2013), and this expression trend has functional 
implications for cell stability and cell dynamics (Harada et al., 2014). In stiff tissues like heart 
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and bone, where cells sustain higher levels of mechanical stress, higher lamin A/C levels 
protect the integrity of the genome by stiffening the nucleus (Swift et al., 2013). However, if 
overexpressed, lamin A/C was shown to alter cell dynamics (Kong et al., 2012; Harada et al., 
2014). Kong et al., for example, showed increased migration rate of three prostate cancer cell 
lines, following overexpression of lamin A/C levels (Kong et al., 2012), while Harada et al., 
found that lamin A/C overexpression decreases migration of lung carcinoma-derived A549 
cells (Harada et al., 2014). This therefore suggests that changes in lamin A/C expression may 
be most pathologically relevant in SMA in highly mechanically active tissues such as the heart, 
where increased expression of lamin A/C is likely to impair its proper functioning. Indeed, 
increased rigidity of human and rat cardiomyocytes increased the extent to which cells/tissues 
resist deformation (i.e. passive tension) in vitro (Borbély et al., 2005; Røe et al., 2017), and in 
vivo rat experiments showed that higher passive tension slows the dynamics of myocardium 
contractions and induces functional heart defects (Røe et al., 2017). Increased cardiomyocyte 
rigidity was also identified in a cell model carrying D192G mutation in LMNA gene, where 
mutant lamin A and lamin C accumulate as distinct foci in the nucleus (Lanzicher et al., 2015). 
This mutation causes severe dilated cardiomyopathy in humans (Lanzicher et al., 2015), which 
strongly mirrors the phenotype previously observed in severe and mild mouse models of SMA, 
including thinning of ventricle walls and interventricular septum (Shababi et al., 2010; Maxwell 
et al., 2018), and dilation of ventricles (Heier et al., 2010; Bogdanik et al., 2015; Maxwell et 
al., 2018). The pathological end-point of dilated cardiomyopathy is systolic heart failure where 
the heart cannot pump blood properly. This would be evidenced by decreased ejection 
fraction and blood pooling in ventricles; both of which were identified in SMA mice (Heier et 
al., 2010; Shababi et al., 2012; Bogdanik et al., 2015; Maxwell et al., 2018) and SMA patients 
(Yasuma, Kuru and Konagaya, 2004; Roos et al., 2009; Iwahara et al., 2015). In the context of 
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SMN-dependent SMA, it seems highly likely, therefore, that increased levels of lamin A/C 
would lead to stiffening of the cardiomyocytes, impeding their ability to contract properly and 
inducing the cardiac defects previously reported in SMA. In addition, cardiac fibrosis has been 
described in patients harbouring a LMNA mutation (van Tintelen et al., 2007; Le Dour, Wu, et 
al., 2017), and was frequently reported in SMA patients and mouse models of SMA 
(Wijngaarde et al., 2017), even at a pre-symptomatic stage of the disease in both severe and 
intermediate mouse models of SMA (Shababi et al., 2010; Cobb et al., 2013). Cardiac fibrosis 
is a key contributor to myocardial rigidity (Røe et al., 2017), and supports the idea that 
increased rigidity of cardiac muscle could be responsible for pathological defects in SMA 
hearts. 
 
The fact that fibrosis is observed at a pre-symptomatic stage of the disease gives confidence 
that lamin A/C dysregulation might also be an early phenotype in SMA heart. This is supported 
by studies showing direct relationship between tissues stiffness and lamin A/C expression 
(Buxboim et al., 2014). Phosphorylation, for example, was identified as an important regulator 
of lamin A/C turnover, where hypo-phosphorylation promotes lamin A/C stability and 
decreases its degradation (Cho et al., 2019), and this process seems to depend on the rigidity 
of ECM (Buxboim et al., 2014). For example, in-vitro investigation of MSCs showed that stiffer 
matrix promotes lamin A/C dephosphorylation in favour of the genome stability (Buxboim et 
al., 2014). Indeed, western blot analysis did indicate a small difference in electrophoretic 
mobility of lamin A and C between control and SMA heart tissue samples, indicating possible 
differences in the post-translational status of lamin A/C (Appendix 4). The lower position of 
lamin A/C bands in SMA heart samples compared to control samples suggest that lamin A/C 
hypo-phosphorylation could indeed be responsible for increased lamin A/C levels in SMA heart 
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tissue, and possible other tissues from a mouse model of SMA. This may also help to explain 
why changes in lamin A/C protein levels in the heart form SMA mice and patient fibroblasts 
could not be tracked back to the aberrant transcription. Additional experiments are clearly 
warranted to determine whether changes in phosphorylation state of lamin A/C exist between 
control and SMA samples in all tissues examined, as this would help to explain the mechanism 
of lamin A/C dysregulation in SMA tissues. Antibodies that are raised against phosphorylated 
lamin A/C, and are available commercially, could thus help to answer this question. This may 
have important implications in SMA therapy design to determine the best approach to target 
lamin A/C dysregulation. 
 
4.3.5.1. Widespread molecular defects in the heart from a severe mouse model of SMA 
The arguments above (section 4.3.5) support the hypothesis that lamin A/C dysregulation is 
likely to be responsible, at least in part, for previously reported cardiac defects in SMA, but 
other proteins identified in proteomics screen also offer insight into the molecular defects 
underlying cardiac abnormalities in SMA. For example, two such proteins, SUN domain-
containing protein 2 (SUN2) (Taranum et al., 2012) and cell division cycle 5-like protein (Cdc5l) 
(Zahr and Jaalouk, 2018), are known lamin A/C interactors and may provide further insights 
into lamin A/C-associated pathways in SMA. Like LMNA, mutations in SUN2, the gene encoding 
the SUN2 protein, have been associated with Emery-Dreifuss muscular dystrophy, a 
neuromuscular disorder often associated with cardiac defects (Meinke et al., 2014). Cdc5l, on 
the other hand, is a known splicing complex component that appears to require lamin A/C in 
order to regulate its assembly and targeting to the spliceosomal complex (Zahr and Jaalouk, 
2018). Alterations to this interaction may therefore affect splicing, further exacerbating the 
downstream molecular consequences of reduced SMN expression. It is interesting to note that 
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a large proportion of the downregulated proteins in the SMA mouse heart were associated 
with translation, and re-enforces previous work showing that the SMN protein plays 
fundamental roles in protein translation (Sanchez et al., 2013; Bernabò et al., 2017). It is also 
highly relevant that a large proportion of the downregulated proteins in the SMA heart to be 
associated with metabolic processes, while the upregulated proteins were strongly associated 
with cytoskeletal and extracellular matrix organisation (Figure 4.12). Imbalances in contractile 
performance or energy supply are known to promote remodelling and dedifferentiation of 
adult cardiomyocytes; the consequences of which include cytoskeletal rearrangement, 
restructuring of contractile apparatus, and reduced oxidative metabolism (Szibor et al., 2014). 
Ironically, it seems that these adaptive processes - presumably intended to protect the 
cardiomyocytes in times of mechanical and/or molecular stress – can lead to adverse 
consequences for the heart (Szibor et al., 2014). Disruption of the actin cytoskeleton, for 
example, can impair contractile properties of cardiomyocytes and was implicated in initiation 
of cardiomyocyte apoptosis (Communal et al., 2002). Here, a model is proposed of how lamin 
A/C dysregulation, together with other molecular changes, may contribute to cardiac 
pathology in SMA (Figure 4.13).  
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Figure 4. 13. Model of how lamin A/C dysregulation, in combination with other molecular changes, may 
contribute to cardiac pathology in SMA. A model is proposed in which lamin A/C up-regulation, in 
combination with other molecular changes that occur in SMA, may lead to cardiac fibrosis and impaired 
cardiac function. Thinner ventricle walls and dilated ventricles in SMA heart are clinical features of dilated 
cardiomyopathy. 
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4.4. Conclusion 
The widespread dysregulation of lamin A/C levels, coupled with the nuclear morphology 
defects that were identified in SMA patient fibroblasts indicate that lamin A/C might have an 
important role in SMA disease pathways. This is supported by experiments showing 
mechanistic link between lamin A/C and UBA1, a known regulator of SMA disease pathways. 
It would be of interest in the future to explore lamin A/C expression in cells and tissues 
throughout the natural history of disease progression in SMA to determine whether lamin A/C 
is an early pathology in SMA, and to investigate the functional consequences of lamin A/C 
dysregulation in SMA cells and tissues. This might be especially relevant for tissues like the 
heart, where early dysregulation of lamin A/C expression could contribute to the heart 
pathology in SMA. Moreover, identification of upstream regulators of lamin A/C may help to 
unravel the tissue-specific regulatory mechanisms that act on lamin A/C in response to SMN 
depletion. Regulation of lamin A/C levels through phosphorylation is one possibility that 
should be explored in SMA, as it may have important implications for SMA therapy design. For 
example, increasing lamin A/C phosphorylation and turnover (Buxboim et al., 2014) could be 
sufficient to restore normal levels of lamin A/C in SMA tissues. This could be achieved, for 
example, by using dephosphorylation inhibitors, such as the okadaic acid that was previously 
shown to phosphorylate nuclear proteins like p80 coilin (Lyon et al., 1997). However, caution 
should be taken, since downregulation of lamin A/C might also have negative effect on SMA 
cells. i.e. induce cell death (Harada et al., 2014). Indeed, in cells that are already stressed by 
SMN depletion, decreasing the levels of lamin A/C might have unwanted effect on cell 
stability. For example, reduction of lamin A/C levels could lead to reduction of UBA1 levels (as 
observed in Figure 4.5), which could in turn hamper protein turnover. Establishing the precise 
link between lamin A/C and UBA1 pathways in SMA disease pathogenesis should therefore be 
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the aim of future studies, to ensure the best efficiency of SMA therapy design. It would be 
important too, to monitor SMA patient health longitudinally to determine whether new 
phenotypes emerge with increasing age. Therapies primarily designed to target neuronal 
tissues, such as Nusinersen, are especially relevant in this context since they are unlikely to 
rescue peripheral pathologies. This knowledge, together with a broader understanding of the 
interplay between lamin A/C and other regulators of SMA disease pathways, would help to 
isolate the most appropriate targets for therapy design that could, in combination with SMN-
targeted therapy, offer maximum therapeutic benefit to all SMA patients. 
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CHAPTER 5: Results 
Multi-Study proteomic and bioinformatic identification 
of molecular overlap between Amyotrophic lateral 
sclerosis (ALS) and Spinal muscular atrophy (SMA) 
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5.1. Introduction 
Deletions and mutations within the SMN1 gene account for more than 95% of SMA cases, 
resulting in insufficient levels of the ubiquitously-expressed survival of motor neuron (SMN) 
protein  (Bowerman et al., 2018). On the pathological level, SMA is characterised by the loss 
of motor neurons in the anterior horn of the spinal cord (“lower motor neurons”) and muscle 
atrophy. Interestingly, the loss of lower motor neurons is also a primary pathology in 
amyotrophic lateral sclerosis (ALS), an adult form of motor neuron disease (Bowerman et al., 
2018). In contrast to SMA, however, only 10% of ALS cases have known etiology, while 90% of 
ALS patients present with sporadic ALS (Bowerman et al., 2018). 
Despite variation in the genetic basis of fALS and sALS, there is little difference recognized in 
their clinical presentation (aside from younger age at presentation in fALS) or any phenotypic 
pattern related to different genes (Naganska and Matyja, 2011; Ravits et al., 2013). This would 
suggest that the disease mechanisms of ALS likely converge on common molecular pathways, 
that ultimately result in similar phenotypes. This then raises the question of whether there 
are general regulatory pathways that drive disease pathology in both ALS and SMA, that may 
prove useful for guiding research into therapeutic development.  
 
5.1.1. Amyotrophic lateral sclerosis (ALS) 
Amyotrophic lateral sclerosis (ALS), also known as Charcot’s disease or Lou Gehrig’s disease, 
is the most common adult form of motor neuron disease, characterised by progressive muscle 
wasting due to loss of motor neurons in the anterior horn of the spinal cord (“lower motor 
neurons”) and spasticity due to loss of cortical neurons (“upper motor neurons”) (Naganska 
and Matyja, 2011). In ALS, 90% of cases occur sporadically (sALS), while only 10% of cases are 
attributable to a familial form of ALS (fALS) that typically follow an autosomal dominant 
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inheritance pattern (Mathis et al., 2019). Mutations in more than 30 genes have been linked  
to cases of familial ALS, the most common of which include superoxide dismutase 1 (SOD1) 
gene, TAR DNA Binding protein-43 (TDP-43) gene, fused-in-sarcoma (FUS) gene, and a 
hexonucleotide repeat within the C9orf72 gene (Mathis et al., 2019). The frequency of 
mutations depends on the geographical region where, for example, mutations in the C9orf72 
gene have the highest frequency in European fALS patients (33.7%), followed by SOD1 (14.8%), 
TDP-43 (4.2%) and FUS (2.8%) (Mathis et al., 2019). In comparison, Asian fALS patients most 
commonly present with mutations in SOD1 (30%), whereas, C9orf72 accounts for only 2.3% of 
all fALS cases (Mathis et al., 2019). 
 
5.1.1.1 ALS disease pathways 
Glutamate excitotoxicity 
Research into ALS disease pathways identified several molecular mechanisms that contribute 
to motor neuron degeneration in both sALS and fALS (summarised in Figure 5.1). Glutamate 
excitotoxicity is one of the first described mechanisms, and has been identified in fALS and 
sALS patients, and in animal models of ALS (Ilieva, Polymenidou and Cleveland, 2009). The 
neurotransmitter glutamate is synthesized in presynaptic neuron terminals and is realised into 
the synaptic cleft during signal transduction for activation of postsynaptic receptors. 
Glutamate recycling is mediated by several transporter proteins, including the glial protein, 
excitatory amino acid transporter 2 (EAAT2) (Zarei et al., 2015). In ALS, the loss of EAAT2 
protein results in the build-up of glutamate in synaptic cleft that has a toxic effect on motor 
neurons. Reduced EAAT2 expression was demonstrated in spinal cord and motor cortex from 
sALS patients (Glenn Lin et al., 1998), and in ventral horn spinal cord sections from pre-
symptomatic SOD1G93A mice (Howland et al., 2002). The reduction of EAAT2 protein levels is 
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thought to be driven by aberrant mRNA processing (Glenn Lin et al., 1998) and/or transcription 
deficiency (Yang et al., 2009). For example, increased levels of aberrant EAAT2 transcripts 
were identified in spinal cord and motor cortex from sALS patients, and in vitro expression 
studies in COS7 cell line suggested that unstable truncated proteins, translated from this 
transcripts, get rapidly degraded (Glenn Lin et al., 1998). Decreased efficiency of EAAT2 
transcription, identified  in lumbar spinal cord from SOD1G93A mice, offers additional 
explanation for decreased EAAT2 protein levels in ALS tissues (Yang et al., 2009). Glutamate 
accumulation leads to overactivation of glutamate receptors, N-methyl-d-aspartic acid 
(NMDA) and alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA), and 
consequent Ca2+ influx that overwhelms mitochondrial and ER storage capacities (Ilieva, 
Polymenidou and Cleveland, 2009). Dysregulation of Ca2+ homeostasis can directly activate 
apoptotic pathways, but Ca2+ is also known to contribute to apoptosis indirectly (Foran and 
Trotti, 2009). For example, Ca2+ can activate catabolic enzymes, i.e. nucleases and proteases, 
resulting in irreversible damage that promotes cell death, and induces production of ROS 
(Foran and Trotti, 2009). 
 
Protein aggregation and ER stress 
Misfolded protein aggregation and induction of endoplasmic reticulum (ER) stress is another 
mechanism known to contribute to ALS pathology. Insoluble protein aggregates have been 
identified in a range of neuronal tissues in ALS, including spinal cord from sALS and fALS 
patients (Neumann et al., 2006; Atkin et al., 2008; Forsberg et al., 2010), hippocampus and 
neocortex from sALS patients (Neumann et al., 2006) and spinal cord from symptomatic 
SOD1L126Z and SOD1G93A mice (Deng et al., 2006; Furukawa et al., 2006). Accumulation of 
misfolded proteins triggers the unfolded protein response (UPR), an adaptive process that 
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promotes protein homeostasis by improving the folding capacity of the cell and clearing of the 
misfolded proteins (Rozas et al., 2017). Indeed, increased expression of folding machinery was 
demonstrated in the spinal cord from sALS patients (Ilieva et al., 2007; Atkin et al., 2008; Hetz 
et al., 2009) and fALS patients (Hetz et al., 2009; Farg et al., 2012), and in spinal cord from 
mutant SOD1 (Atkin et al., 2006; Kikuchi et al., 2006) and TDP-43 mice (Walker et al., 2013). 
In addition, upregulation of protein folding machinery was observed in early symptomatic 
(Kikuchi et al., 2006) and pre-symptomatic stages of the disease (Atkin et al., 2008) in SOD1G93A 
mice, thus indicating that ER stress is early pathology in ALS. Chronic ER stress triggers the 
UPR-mediated cell death pathway (Rozas et al., 2017), and in ALS, chronic ER stress is 
maintained by impaired expression and/or function of the UPR machinery (Nishitoh et al., 
2008). For example, impaired function of the ER-associated degradation (ERAD) pathway 
could explain the toxic accumulation of mutant SOD1 in ALS (Nishitoh et al., 2008). An 
interaction between SOD1 mutants and derlin-1, a crucial component of the ERAD pathway, 
was demonstrated in the spinal cord and brain from SOD1G93A mice, and in SOD1 mutant 
HEK293 and NSC34 cell cultures, with no specific interaction detected between WT SOD1 and 
derlin-1. Binding of mutant SOD1 to derlin-1 was sufficient to inhibit ERAD pathway in HEK293 
cell line and was proposed as a mechanism that drives accumulation of mutant SOD1 in ALS 
(Nishitoh et al., 2008). In addition, overexpression of derlin-1 reduced mutant SOD1 aggregate 
formation, supressed ER stress and improved the viability of Neuro2a cell line (Mori et al., 
2010).  
 
Structural and functional mitochondria abnormalities  
Structural and functional abnormalities in mitochondria were also shown to play an important 
role in ALS pathogenesis. For example, structural abnormalities in mitochondria, such as 
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fragmentation, swelling and abnormal cristae have been identified in muscles and spinal cord 
from sALS patients (Chung and Suh, 2002; Sasaki and Iwata, 2007), and in spinal cord from 
SOD1G93A mice (Kong and Xu, 1998). On a functional level, ALS mitochondria showed abnormal 
oxidative respiration and ATP production, increased production of ROS and altered Ca2+ 
homeostasis (Zarei et al., 2015). For example, decreased activity of mitochondrial respiratory 
chain complexes was detected in the spinal cord from sALS and fALS patients (Wiedemann et 
al., 2002), in muscles from sALS patients (Wiedemann et al., 1998; Vielhaber et al., 2000), and 
in the spinal cord from SOD1G93A mouse model of ALS (Jung, Higgins and Xu, 2002; Mattiazzi 
et al., 2002). In addition, ATP synthesis was significantly diminished in the spinal cord from 
SOD1G93A mice, and taken together with impaired function of respiratory chain complexes, 
suggests perturbations in energy production that are likely to contribute to motor neuron 
degeneration in ALS (Mattiazzi et al., 2002).  
 
Abnormalities in respiratory chain complexes could offer an explanation for increased 
oxidative stress in ALS, since defects in complex I are known to increase the production of ROS 
(Tan, Pasinelli and Trotti, 2014). Indeed, increased oxidative stress was detected in spinal cord 
and muscles from sALS and  fALS patients (Pedersen et al., 1998; Vielhaber et al., 2000; 
Wiedemann et al., 2002), and in spinal cord from SOD1G93A mouse model of ALS (Andrus et al., 
1998). If left unresolved, oxidative stress can cause severe damage to biological molecules 
that triggers cell death, and was thus proposed as important pathological mechanism in ALS 
neuron death (Tan, Pasinelli and Trotti, 2014).  
 
Higher intracellular Ca2+ levels, caused by overactivation of glutamate receptors (described 
above), were shown critical in ALS pathogenesis, however, intrinsic defect in mitochondria 
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Ca2+ handling have also been implicated in motor neuron vulnerability (Tan, Pasinelli and 
Trotti, 2014). For example, Ca2+ buffering capacity was significantly decreased in spinal cord 
and brain mitochondria from SOD1G93A mice before the symptom onset (Damiano et al., 2006), 
and it was attributed, at least in part, to decreased activity of mitochondrial calcium uniporter, 
a channel that mediates Ca2+ uptake into mitochondria (Fuchs et al., 2013). Altered buffering 
capacity of mitochondria is thought to contributes to accumulation of calcium in cytosol, 
therefore enhancing glutamate excitotoxic effect, and promoting production of ROS 
(Manfredi and Xu, 2005)
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Figure 5. 1. Disease pathways in ALS. Excitotoxicity, ER stress and mitochondrial dysfunction are well characterised disease mechanisms in ALS. ROS-reactive oxygen species; EAAT2- 
excitatory amino acid transporter 2; NMDA- N-methyl-d-aspartic acid; AMPA- alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate. Image created with BioRender.com. 
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5.1.2. Therapeutic strategies in ALS and SMA 
There is no cure for either disease, though some progress has been made in recent years 
towards the development of therapies that may extend survival or alleviate symptoms 
(reviewed most recently for SMA (Waldrop and Kolb, 2019), and for ALS (Nowicka et al., 
2019)). 
First, treatment available to ALS patients was Riluzol (commercially known as Rilutek), 
approved for clinical use in 1995, which may prolong survival by 2–3 months (Nowicka et al., 
2019). The precise mechanism of riluzol action is not well established, although it has been 
shown to decrease glutamate toxicity by targeting several of its pathways; riluzol inhibits 
glutamate release from neuronal terminals, it inactivates voltage‐dependent sodium 
channels, and has antagonist action on glutamate receptor NMDA (Zarei et al., 2015). 
Edaravone, also known as Radicava, was recently approved by the FDA to slow disease 
progression in ALS patients in the USA (Nowicka et al., 2019). Indeed, inhibition of motor 
neuron function deterioration was demonstrated in 137 ALS patients following treatment with 
edaravone, however, only patients at an early stage of the disease (i.e. within 2 years of onset), 
and with forced vital capacity of 80% or more where included in the study (Abe et al., 2017). 
The therapeutic benefit of edaravone has not been demonstrated in the wider population of 
ALS patients (Nowicka et al., 2019), and was therefore rejected for clinical use by the European 
Medicines Agency11. The mechanism of action is not well defined, but it seems that edaravone 
exhibits antioxidant activity that helps to eliminate reactive oxygen species and reduces 
oxidative injury in neurons and neighbouring glia cells (Nowicka et al., 2019). 
 
11 https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/radicava 
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Research into SMA therapy resulted in development of two approaches, the antisense 
oligonucleotide drug Nusinersen (SpinrazaTM), and adeno-associated virus-based gene 
replacement therapy ZolgensmaTM, both of which have been approved for clinical use in the 
last three years (reviewed in chapter 1, section 1.5.1). Though undoubtedly an enormous 
step forward, none of the strategies that have been developed so far show complete 
efficiency (Finkel et al., 2017; Mendell et al., 2017; Mercuri et al., 2018; Sumner and Crawford, 
2018). Coupled with uncertainties around long-term effectiveness and extremely high price 
of both strategies, there is keen interest to find alternative therapeutic strategies that could, 
in combination with SMN-targeted therapy, offer maximum therapeutic benefit to all SMA 
patients (Bowerman, 2019). 
 
5.1.3. Pathogenic commonalities between ALS and SMA 
Targeting the same pathogenic mechanism in SMA and ALS, for example, represents an 
attractive approach in therapy design, as it would allow more rapid and cost-effective 
identification of new treatments for both diseases. It is not surprising, therefore, that the 
potential molecular similarities between ALS and SMA are receiving significant attention 
(Gama-Carvalho et al., 2017; Bowerman et al., 2018; Hensel and Claus, 2018).  
 
5.1.3.1. Altered RNA metabolism 
Physical interactions between SMA and ALS- associated proteins offer the first line of evidence 
that the two disease converge on common mechanisms. For example, FUS and SMN 
interacted in NSC34 cells and mouse brain tissue extracts (Groen et al., 2013), while an 
interaction between SOD1 and SMN was detected in spinal cords from wild type and SOD1G93A 
mice (Groen et al., 2013). In mouse primary neurons expressing ALS-associated FUS mutant 
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protein, SMN was redistributed to cytoplasmic FUS aggregates causing a reduction in axonal 
SMN levels (Groen et al., 2013). Considering the role for SMN in regulation of axonal mRNA 
trafficking and translation (described in detail in chapter 1, section 1.2.2.2), reduction of 
axonal SMN levels could be responsible, at least in part, for axonal defect in FUS model of ALS 
(Groen et al., 2013). In addition, reduction of SMN levels was observed in spinal cords from 
SOD1G93A mice, and further depletion of SMN protein levels aggravated disease progression in 
ALS mice (Turner et al., 2009). Overexpression of SMN rescued axonal defects in primary 
neuron cultures expressing transgenic FUS (Groen et al., 2013), and rescued motor neuron 
loss and improved motor function in SOD1G93A mouse model of ALS (Turner et al., 2014), 
suggesting that SMN has the potential to modify ALS disease pathways. 
Interestingly, loss of GEMs, nuclear complexes that have essential role in biogenesis of snRNP 
(revised in chapter 1, section 1.2.2.1), was identified in ALS patient fibroblasts that carry 
mutations in FUS and TDP43 (Yamazaki et al., 2012) and in spinal cord motor neurons from a 
transgenic SOD1G86R mouse model of ALS (Kariya et al., 2012; Turner et al., 2014). In SMA, loss 
of GEMs was first reported in SMA patient fibroblast cells, where the degree of loss correlated 
with disease severity (Coovert et al., 1997). The loss of GEMs seems to be a conserved 
pathology in ALS and SMA, and suggests perturbations in RNA metabolism, specifically the 
pre-mRNA splicing, as a common pathological mechanism in both diseases. Indeed, splicing 
defects have been identified in different tissues from intermediate and severe  mouse models 
of SMA, including spinal cord, brain and kidney (Zhang et al., 2008; Bäumer et al., 2009), and 
in motor neurons from severe SMA mice (Huo et al., 2014). In ALS, widespread splicing defects 
have been identified in the brain from TDP43 and FUS transgenic mice (Lagier-Tourenne et al., 
2012). 
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5.1.3.2. Intrinsic muscle defects 
Muscle atrophy is usually associated with the functional loss of motor neurons in both SMA 
and ALS, however, intrinsic muscle defects including for example, dysregulation of myogenic 
program and defective satellite cell function, have been recognised in the pathogenesis of 
both diseases (Bowerman et al., 2018). By specifically depleting SMN in murine skeletal 
muscles, Cifuentes-Diaz et al. demonstrated severe muscular dystrophy phenotype, providing 
one of the earliest evidence that intrinsic muscle defects contribute to disease pathogenesis 
in SMA (Cifuentes-Diaz et al., 2001). In addition, muscle-specific restoration of SMN levels was 
sufficient to increase muscle fiber size, and improve survival and motor functions in SMA mice 
(Martinez et al., 2012). The same effect was confirmed in SOD1 transgenic mice, where 
muscle-specific expression of SOD1 mutants (G93A and G37R) induced progressive muscle 
atrophy and abnormalities in NMJs, including smaller motor endplates and loss of innervation 
(Dobrowolny et al., 2008; Wong and Martin, 2010).  
Early pre-symptomatic reduction in the expression of myogenic regulatory factors, including 
paired box protein Pax7 (Pax7),  myoblast determination protein (MyoD) and myogenin, has 
been detected in muscles from severe (Smn-/-;SMN2) and intermediate (Smn2B/-) mouse 
models of SMA (Boyer et al., 2014). Decreased expression of all three factors was confirmed 
at symptomatic stage of the disease in severe mouse models of SMA (Smn-/-;SMN2, Smn-/-
;SMN2;Δ7), while Smn2B/- mice demonstrated increased expression levels of all three factors 
with the onset of disease symptoms (Boyer et al., 2014). In the SOD1G93A mouse model of ALS, 
the expression of myogenic factors including Pax7, MyoD, myogenic factor 5 (Myf5), and 
myogenin, was altered at the mRNA and protein levels at pre and early- symptomatic stages 
of the disease (Manzano et al., 2011). Disruption of the myogenic program indicates possible 
defects in the muscle development in both disease, but this has only been confirmed in SMA 
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by histological analysis of muscle sections in Smn2B/- and Smn-/-;SMN2 mouse models (Boyer 
et al., 2014).  The analysis identified reduction in myofiber size and increased number of 
myofibers with centrally located nuclei (Boyer et al., 2014), the later one being an indication 
of maturation defects (Bowerman et al., 2018). Indeed, myoblasts from Smn2B/- mice showed 
defective fusion in vitro by generating less myotubes compared to controls (Boyer et al., 2014), 
and the same defect was observed in SMN deficient C2C12 myoblast cell line (Shafey, Côté 
and Kothary, 2005). 
In addition, satellite cells from skeletal muscles of pre-symptomatic SOD1G93A mice 
demonstrated lower proliferation rate in vitro when compared to controls (Manzano et al., 
2013). Satellite cells from skeletal muscles from early symptomatic SMA mice did not show 
altered proliferation, however, defects in the differentiation potential of SMA satellite cells 
have been demonstrated in vitro (Hayhurst et al., 2012). The cells undergo earlier 
differentiation compared to control cells, but fail to efficiently finish differentiation, as 
evidenced by decreased myotube formation in cell cultures (Hayhurst et al., 2012).  
 
5.1.3.3. Neuroinflammation 
Astrocytes and microglia have an important role in maintaining motor neuron health and 
function, and naturally they received significant attention in SMA and ALS pathogenesis as 
non-cell autonomous mechanisms of motor neuron injury. For example, murine SOD1G93A glial 
cells significantly reduced viability of SOD1G93A and wild type motor neurons in co-culture, 
providing evidence that healthy and disease motor neurons an both affected by defective 
microglia (Di Giorgio et al., 2007). Murine microglia and human astrocytes expressing mutant 
SOD1 proteins, G93A and G37R respectively, demonstrated the same toxic effect on human 
ESC-derived motor neurons (Di Giorgio et al., 2008; Marchetto et al., 2008). This effect was 
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also demonstrated in vivo in mouse models of ALS, where selective deletion of mutant SOD1 
in astrocytes delayed disease onset (Wang, Gutmann and Roos, 2011), prolonged survival and 
reduced microgliosis in ALS mice (Wang, Gutmann and Roos, 2011; Yamanaka et al., 2011). 
 
Changes typical of reactive astrocytes have been described in type I SMA patient iPSC-derived 
astrocytes and spinal cord sections from SMA patients (McGivern et al., 2013; Rindt et al., 
2015), and in ventral horn spinal cord sections from severe SMA mice (McGivern et al., 2013; 
Tarabal et al., 2014; Rindt et al., 2015). These include upregulation of glial fibrillary acidic 
protein (GFAP) and nestin (McGivern et al., 2013; Tarabal et al., 2014; Rindt et al., 2015), and 
changes in cell morphology, including enlarged cell bodies and short thick processes 
(McGivern et al., 2013). Increased expression of proinflammatory cytokines, including 
interleukin 1β (IL-1β) and interleukin 8 (IL-8), has been reported in spinal cords from SMA 
patients and SMA mice, both of which are markets of glial activation (Rindt et al., 2015). 
Restoration of SMN levels specifically in astrocytes improved motor function and survival of 
SMA mice, improved NMJ pathology and supressed production of pro-inflammatory cytokines 
in lumbar spinal cord (Rindt et al., 2015). Increased levels of proinflammatory factors such as 
interferon gamma 1 (IFNγ) and prostaglandin D were also detected in glia cells from SOD1G93A 
mouse model of ALS (Di Giorgio et al., 2008; Aebischer et al., 2011). The collection of evidence 
indicates an active role of glial cells in ALS and SMA pathology, where activation of 
proinflammatory response in astrocytes and microglia aggravates motor neuron injury and 
contributes to motor neuron death in both diseases. 
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5.1.3.4. Actin cytoskeleton alterations 
Actin cytoskeleton was first implicated in SMA by the finding that SMN and profilins, important 
regulators of actin cytoskeleton dynamics, interact in Hela cell extracts (Giesemann et al., 
1999). Profilin-2, a neuronal specific profilin isoform, demonstrated stronger binding to SMN 
compared to profilin-1 (Giesemann et al., 1999), and this interaction was validated in NSC34 
cell line (Nölle et al., 2011). In addition, mutations in profilin-1 have been implicated in cases 
of fALS (Wu et al., 2012). Profilins bind globular (G)-actin and regulate its polymerization to 
filamentous (F)-actin by dual action; profilin binds G-actin that dissociates from the filament 
and facilitates ADP- to ATP-G-actin recycling; profilin assists in filament elongation by adding 
ATP-G-actin to the capped end of the filament, a process known as transient capping (Hensel 
and Claus, 2018). 
Knockdown of both profilin isoforms inhibited neurite outgrowth in PC12 cells and induced 
accumulation of SMN in cytoplasmic aggregates (Sharma et al., 2005). Increased levels of 
profilin-2a isoform were identified in SMN depleted PC12 cells (Bowerman, Shafey and 
Kothary, 2007). In addition, in vitro polymerisation experiments showed that SMN in 
combination with profilin-2a increases actin polymerization compared to profilin-2a alone 
(Sharma et al., 2005), indicating a functional link between the two proteins in the regulation 
of actin dynamics. Although the precise mechanism of SMN action on actin polymerization has 
yet to be determined, it was proposed that SMN accelerates the release of profilin from 
filament-bound actin after capping, a process that is necessary for further filament elongation 
(Hensel and Claus, 2018). Another theory proposes a role for SMN in preventing profilin 
inhibition; with SMN loss, profilin binding domain could become more accessible for 
phosphorylation, which is known to have inhibitory effect on profilin binding to actin. Indeed, 
profilin hyperphosphorylation has been identified in SMN deficient PC12 cells and in spinal 
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cord from symptomatic SMA mice, and activation of ROCK pathway was proposed as a 
mechanism that induces profilin phosphorylation (Nölle et al., 2011). This was confirmed in a 
separate study in PC12 cells where SMN depletion increased formation of profilin-2-ROCK 
complexes (Bowerman, Shafey and Kothary, 2007). 
 
A range of mutations in profilin-1 have been identified in fALS cases, most of which showed 
typical ALS pathology characterised by cytoplasmic protein aggregations (Hensel and Claus, 
2018). Protein aggregates have also been identified in HEK293 and Neuro2a cell cultures 
carrying ALS-associated profilin-1 mutants, some of which contained TDP-43 protein (Wu et 
al., 2012; Smith et al., 2015). Transgenic mice carrying profilin mutations recapitulated 
pathologies observed in ALS patients, including the loss of motor neurons and progressive 
muscle wasting, accumulation of insoluble protein aggregates in motor neurons and increased 
ubiquitin levels (Yang et al., 2016; Fil et al., 2017). Protein aggregation and impaired 
proteasomal degradation indicate toxic gain of function of mutant profilin-1, however, in a 
study by Yung et al., motor neuron degeneration preceded protein aggregation in a transgenic 
mouse model carrying profilin-1 mutation (Yang et al., 2016). This result indicates that other 
mechanisms, like impaired ability of profilin to regulate actin dynamics may be crucial in early 
stages of the disease, although the contribution of protein aggregates to motor neuron 
pathology cannot be ruled out (Hensel and Claus, 2018). Indeed, mutations identified in the 
actin-binding domain of profilin-1 directly affected the affinity of profilin to bind actin (Hensel 
and Claus, 2018). The precise mechanisms of action of profilin mutants on the dynamics of 
actin cytoskeleton remains to be investigated, so does the role for profilin in the pathogenesis 
of sALS and non-profilin-associated fALS.   
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5.1.3.5. Altered architecture of the spleen and thymus 
Compromised spleen development was identified in severe (Taiwanese and SMN-/-; SMN2) 
and intermediate (Smn2B- ) mouse models of SMA, as evidenced by the failure of the spleen to 
grow and develop mature morphology (Deguise et al., 2017; Khairallah et al., 2017; Thomson 
et al., 2017). During normal postnatal development, homogenous spleen tissue differentiates 
into distinct red and white pulp, and the spleen develops defined capsule and trabeculae 
(Thomson et al., 2017). In contrast, spleens from SMA mice maintained homogenous 
morphology throughout development, with no segregation between red and white pulp 
(Deguise et al., 2017; Khairallah et al., 2017; Thomson et al., 2017), and failed to develop 
defined capsule and trabeculae (Thomson et al., 2017). Pathological changes in the spleen 
were also confirmed in approximately 50% of type I SMA patients (Thomson et al., 2017). 
Similarly, spleen from symptomatic SOD1G93A mice had reduced size and weight and altered 
morphology as demonstrated by immunohistochemistry analysis (Banerjee et al., 2008). 
 
Morphological abnormalities in thymus have been observed in symptomatic stage of the 
disease in severe (SMN-/-; SMN2) and intermediate (Smn2B- ) mouse models of SMA, including 
decreased size, thinner cortex, reduced cell content, and increased number of apoptotic 
bodies and tangible body macrophages (Deguise et al., 2017). Decreased size, reduced cell 
content and loss of typical structures (e.g. cortex and medulla) have also been identified in 
SOD1G93A mouse model of ALS at symptomatic stage of the disease (Seksenyan et al., 2010).  
In both diseases, the expression and distribution of immune cells was altered. For example, B- 
lymphocytes in the spleen from both SMA and ALS mice showed reduced numbers and altered 
localization when compared to healthy controls (Banerjee et al., 2008; Deguise et al., 2017; 
Thomson et al., 2017), and a general reduction in the number of circulating lymphocytes was 
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identified in the blood from severe SMA mice (Thomson et al., 2017). Diffuse distribution and 
expression pattern of T cells was also evident in the spleen from SMA and ALS mice (Banerjee 
et al., 2008; Deguise et al., 2017). For example, increased levels of killer (CD8+) and helper 
(CD4+) T cells were detected in the spleen from SMA mice (Deguise et al., 2017; Khairallah et 
al., 2017), while ALS mice demonstrated increased levels of natural killer T (NKT) cell, CD4+ 
naïve T cells, but decreased levels of CD4+ memory T cells. (Finkelstein et al., 2011). 
 
 
Despite the wealth of knowledge showing shared pathological features between SMA and ALS, 
the precise molecular overlap between SMA and ALS is still unknown. The aim of this chapter 
was to identify the molecular overlap between SMA and ALS, and gain insights into shared 
disease pathways between the two diseases that would help in the development of therapies 
for both SMA and ALS patients. 
The specific objectives were as follows: 
a) To identify core protein changes in ALS tissues/cells by comparison of published 
proteomic studies of ALS, and investigate their likely function by using bioinformatics.   
b) To identify core molecular overlap between SMA and ALS, by comparing the results 
from an ALS multi-study comparison to the previously published dataset of conserved 
molecular alterations in SMA, and gain insights into the likely function of these proteins 
by using bioinformatics tools. 
c) To investigate the expression of five protein targets, identified as differentially 
expressed in both SMA and ALS, in spinal cord from comparable mouse models of ALS 
and SMA. 
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5.2. Results 
5.2.1. Overview of ALS proteomic studies 
A total of 33 proteomic studies of ALS were eligible for comparison (as described in the 
methods section 2.9.4) (Table 5.1), and as expected, the number of differentially expressed 
proteins identified in studies correlated with the sensitivity of the method used, with label-
free technologies having identified by far the greatest number of protein changes compared 
to 2D-gel approaches. Samples from animal models and ALS patients were equally 
represented across studies (Table 5.1), and were derived from a range of sources, including 
ALS patient cerebrospinal fluid (CSF) (Ranganathan et al., 2005, 2007; Pasinetti et al., 2006; 
Brettschneider et al., 2008; Ryberg et al., 2010; Von Neuhoff et al., 2012; Mendonça et al., 
2012; Varghese et al., 2013; Collins et al., 2015; Chen et al., 2016; Thompson et al., 2018), ALS 
patient serum (De Benedetti et al., 2017), ALS patient muscles (Conti et al., 2014; Elf et al., 
2014), ALS patient blood mononuclear cells (PBMC) (Nardo et al., 2011), ALS patient spinal 
cord (Engelen-Lee et al., 2017), ALS patient prefrontal cortex (Umoh et al., 2018), a range of 
cell models (Allen et al., 2003; Fukada et al., 2004; Stalekar et al., 2015; Schwenk et al., 2016), 
and tissues/cells from various mouse and rat models of ALS including astrocytes (Basso et al., 
2013), skeletal muscles (Staunton, Jockusch and Ohlendieck, 2011), ventral roots (Zhou et al., 
2010), embryonic motor neurons (Duplan et al., 2010), spinal cord (Strey et al., 2004; 
Massignan et al., 2007; Basso et al., 2009; Bastone et al., 2009; Bergemalm et al., 2009; Li et 
al., 2010; Sharma et al., 2016), and hippocampus (Shin et al., 2005).
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Table 5. 1. ALS proteomic studies used in the comparison 
Reference Sample Type/ ALS model Differentially 
exp. proteins 
Analysis platform Protein Database 
(Chen et al., 2016) Patient CSF 35/35 iTRAQ; API QSTAR XL (Applied Biosystems) UniProt/ Swiss-Prot 
(Collins et al., 2015) Patient CSF 123/110 Label-Free; linear ion trap (ThermoFisher Scientific) UniProt/Swiss-Prot 
(Varghese et al., 2013) Patient CSF 48/47 iTRAQ; LTQ-Orbitrap Velos (Thermo Electron) Human Protein Database 
(NCBI) 
(Mendonça et al., 2012) Patient CSF 17*/17 2D electrophoresis; Voyager-DE Pro MALDI-TOF  
(Applied Biosystems) 
NCBI and UniProt/ Swiss-Prot 
(Von Neuhoff et al., 2012) Patient CSF 153/11 Peak recognition (statistical analysis; linear Microflex 
MALDI-TOF (Bruker) 
Entrez Protein Database 
(Ryberg et al., 2010) Patient CSF 33/7 SELDI-TOF-MS Empirical Proteomics Ontology 
Knowledge Base 
(Brettschneider et al., 2008) Patient CSF 6/5 2D-DIGE; Voyager DE-STR (Applied Biosystems) NCBI database 
(Ranganathan et al., 2005) Patient CSF 52+/3 SELDI-TOF-MS/MS; Ciphergen ProteinChip Reader  
(Ciphergen Biosystems) 
UniProt/Swiss-Prot 
(Ranganathan et al., 2007) Patient CSF 10/2 (PM-ALS) + 
9/2 (L-ALS) + 
SELDI-TOF-MS; Ciphergen ProteinChip Reader 
(Ciphergen Biosystems) 
UniProt/Swiss-Prot 
(Pasinetti et al., 2006) Patient CSF 3/2 SELDI-TOF-MS Unknown 
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(Thompson et al., 2018) Patient CSF 3/3 UHPLC LC-MS/MS; Q Exactive HF tandem mass 
spectrometer (Thermo Fisher Scientific) 
UniProt 
(De Benedetti et al., 2017) Patient serum 7/7 2D-GE; SYNAPT-MS G1 (Waters Corporation) UniProt 
(Schwenk et al., 2016) Rat neurons/ 
TDP-43 Knockdown 
63/63 Label-free; Orbitrap Q Exactive (Thermo Fisher 
Scientific) 
UniProt/Swiss-Prot 
(Sharma et al., 2016) Patient CSF injected into rat 
spinal cord/MF 
49/48 iTRAQ; LTQ-Orbitrap Velos (Thermo Electron) RefSeq 
(Stalekar et al., 2015) SH-SY5Y cells/ TDP-43 Loss 273/270 Label-free; LTQ Orbitrap XL (Thermo Fisher 
Scientific) 
UniProt/Swiss-Prot 
(Conti et al., 2014) Patient muscle 5/5 2D-GE; API QStar PULSAR (AB-Sciex) UniProt/Swiss-Prot 
(Elf et al., 2014) Patient muscle 11/11 Stable-isotope dimethyl labels; 7 T hybrid LTQ FT 
Ultra mass spectrometer (ThermoFisher Scientific) 
UniProt/Swiss-Prot 
(Basso et al., 2013) Mouse astrocytes/ SOD1 
G93A 
31/31 2D-GE; Reflex III MALDI-TOF (Bruker Daltonics) UniProt/Swiss-Prot 
(Nardo et al., 2011) Patient blood mononuclear 
cells 
44/44 2D DIGE; 4800 MALDI TOF/TOF (Applied Biosystems) UniProt/Swiss-Prot 
(Bastone et al., 2009) Mouse spinal cord/ Wobbler 
Mouse 
13/13 2D DIGE; Model 6430 Ion Trap (Agilent Technologies) NCBI 
(Zhou et al., 2010) Mouse ventral roots/ SOD1 
G93A 
14#/14 Label Free; LTQ (Thermo Finnigan) UniProt/Swiss-Prot 
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(Duplan et al., 2010) Mouse embryonic motor 
neurons/ SOD1 G85R 
6/4 2D-GE; UltraFlex MALDI TOF/TOF 
(Bruker-Franzen Analytik) 
UniProt/Swiss-Prot 
(Bergemalm et al., 2009) Mouse spinal cord/ SOD1 
G127X 
53/47 2D-DIGE; Voyager DE-STR MALDI-TOF 
(Applied Biosystems) 
UniProt/Swiss-Prot 
(Staunton, Jockusch and 
Ohlendieck, 2011) 
Mouse muscle/ Wobbler 
Mouse 
31/26 2D-GE; Reflex III MALDI-TOF 
(Bruker Daltonics) 
UniProt/Swiss-Prot 
(Basso et al., 2009) Mouse spinal cord (IF)/ SOD1 
G93A 
32/32 2DE; Reflex III MALDI-TOF ( 
Bruker Daltonics) 
UniProt/Swiss-Prot 
(Massignan et al., 2007) Mouse spinal cord (pre-
symptomatic)/ SOD1 G93A 
15/15 2D-GE; ReflexIII MALDI mass spectrometer 
(Bruker Daltonics) 
UniProt/Swiss-Prot 
(Strey et al., 2004) Mouse spinal cord / SOD1 
G93A 
7/7 2D-GE; VG 2E Tofspec laser desorption time of flight 
mass spectrometer (Waters) 
NCBI 
(Fukada et al., 2004) NSC34 cells (MF)/ SOD1 G93A 40/38 2D-GE; Qstar XL Q-TO 
(Applied Biosystems) 
NCBI and UniProt/ 
Swiss-Prot 
(Li et al., 2010) Rat spinal cord (MF)/ SOD1 
G93A 
40/40 2D-GE; MudPIT RCADiA platform Saccharomyces Genome 
Database/ Ensembl 
(Allen et al., 2003) NSC34 cells/ SOD1 
G93A/G37R 
7/7 2D-GE; Voyager-DE STR  
(Perspective Biosystems) 
UniProt/Swiss-Prot 
(Shin et al., 2005) Mouse hippocampus/ Tg152 
line overexpressing hSOD1 
41/41 2D-GE; Ultraflex MALDI TOF/TOF 
(Bruker Daltonics) 
NCBI and UniProt/ 
Swiss-Prot 
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(Engelen-Lee et al., 2017) Patient anterior and posterior 
horn 
32/18 (AH) 
3/3 (PH) 
2D-GE; LTQ linear ion trap mass spectrometer 
(ThermoFisher Scientific) 
UniProt 
(Umoh et al., 2018) Patient prefrontal cortex 103/101 Label-free; Fusion mass spectrometer (ThermoFisher 
Scientific) 
UniProt 
ALS studies included in the proteomic comparison are listed in table, together with ALS model, sample type, analysis platform and database used in each study. Number of differentially 
expressed proteins identified in each study/ number of those proteins that were included in the comparison are listed in column three. * Proteins were considered significantly changed if 
they were identified in ALS samples, but not in CTR samples. † Significantly changed proteins in ALS were identified by applying second-pass peak selection with a signal to noise ratio of 
1.5 and p < 0.01. # By dynamically adjusting the p-value cut-off, p-value of 0.05 was chosen for the identification of significantly changed proteins in ALS. PM-ALS- samples from ALS patients 
taken post-mortem; L-ALS- samples from living patients; CSF- cerebrospinal fluid; IF- insoluble fraction; MF- mitochondrial fraction; AH-anterior horn; PH-posterior horn. 
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5.2.2. Identification of protein changes in biofluids from ALS patients 
Protein expression changes in biofluids may not necessarily correlate with protein changes at 
the cellular level and may in fact be contradictory. It is possible that secretion or leakage of 
proteins into the CSF or serum may, for example, be accompanied by a concomitant decrease 
of expression levels in tissues (Anderson and Anderson, 2002). Thus, studies that utilised 
cells/tissues were compared separately to those that examined biofluids. 
Comparison across the 12 proteomic studies that examined biofluids from ALS patients 
(Ranganathan et al., 2005, 2007; Pasinetti et al., 2006; Brettschneider et al., 2008; Ryberg et 
al., 2010; Von Neuhoff et al., 2012; Mendonça et al., 2012; Varghese et al., 2013; Collins et al., 
2015; Chen et al., 2016; De Benedetti et al., 2017; Thompson et al., 2018) identified 11 
proteins that were consistently changed in the same direction across at least two studies 
(Table 5.2). Of these, one protein – cystatin C - was decreased in expression across four 
separate studies (Ranganathan et al., 2005, 2007; Pasinetti et al., 2006; Ryberg et al., 2010) 
and one protein – chitinase 3-like protein 1 - was increased in expression across three separate 
studies (Von Neuhoff et al., 2012; Varghese et al., 2013; De Benedetti et al., 2017). The 
remaining eight proteins showed opposing directions of differential expression (Table 5.3). 
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Table 5. 2. Proteins differentially expressed in the same direction in biofluids from ALS 
patients 
Proteins with a consistent change in expression in biofluids from ALS patients across two or more proteomic 
studies are shown. Proteins are listed according to direction of differential expression (proteins with increased 
expression are listed first, followed by proteins with decreased expression). Protein name is given, followed by 
official gene symbol in brackets. Studies and ALS patient sample type are listed in columns two and three. CSF- 
cerebrospinal fluid 
Protein name  
(official gene symbol) 
References Sample Type 
Decreased expression 
Cystatin C (CST3) (Ranganathan et al., 2005) 
(Ranganathan et al., 2007) 
(Pasinetti et al., 2006) 
(Ryberg et al., 2010) 
Patient CSF 
Patient CSF 
Patient CSF 
Patient CSF 
Alpha-1-Acid Glycoprotein 1 (ORM1) (Varghese et al., 2013) 
(Chen et al., 2016) 
Patient CSF 
Patient CSF 
Apolipoprotein A-IV (APOA4) (Von Neuhoff et al., 2012) 
(De Benedetti et al., 2017) 
Patient CSF 
Patient serum 
Haptoglobin (HP) (Varghese et al., 2013) 
(Chen et al., 2016) 
Patient CSF 
Patient CSF 
Neurosecretory Protein VGF (VGF) (Pasinetti et al., 2006) 
(Von Neuhoff et al., 2012) 
Patient CSF 
Patient CSF 
Ribonuclease Pancreatic (RNASE1) (Ryberg et al., 2010) 
(Chen et al., 2016) 
Patient CSF 
Patient CSF 
Transferrin (TF) (Brettschneider et al., 2008) 
(Varghese et al., 2013) 
Patient CSF 
Patient CSF 
Increased expression 
Chitinase 3-Like Protein 1 (CHI3L1) (Von Neuhoff et al., 2012) 
(Varghese et al., 2013) 
(De Benedetti et al., 2017) 
Patient CSF 
Patient CSF 
Patient serum 
Chitinase 3-Like Protein 2 (CHI3L2) (Varghese et al., 2013) 
(Collins et al., 2015) 
Patient CSF 
Patient CSF 
Chitotriosidase-1 (CHIT1) (Varghese et al., 2013) 
(De Benedetti et al., 2017) 
Patient CSF 
Patient serum 
Hemoglobin Subunit Alpha 1 (HBA1) (Ryberg et al., 2010) 
(Chen et al., 2016) 
Patient CSF 
Patient CSF 
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Table 5. 3. Proteins that showed contradictory direction of differential expression in 
biofluids from ALS patients across at least two proteomic studies 
Proteins that showed contradictory change in expression in biofluids from ALS patients in two or more proteomic 
studies. Protein name is given, followed by official gene symbol in brackets. Studies that identified increased or 
decreased protein expression are listed in column two and three. *CysGly-transthyretin-modified form of 
transthyretin generated by oxidative damage.  
 
Gene ontology analysis was performed using the DAVID software as described in methods 
section 2.9.4.1 (Huang, Sherman and Lempicki, 2009b, 2009a) to investigate the likely function 
of the 11 proteins that showed a consistent change in expression. “Establishment of 
localization” was the most enriched biological process term, with seven of the eleven proteins 
mapping to it (Figure 5.2A), and complementary to this, 9 of the 11 proteins were associated 
with the term “vesicles”; eight of which were connected to the term “extracellular vesicles” 
(Figure 5.2B). STRING 10 (Szklarczyk et al., 2015) analysis identified association network 
between four proteins: HBA1, HP, TF and ORM1 (Figure 5.2C), all of which appear to be 
plasma-derived proteins. 
Protein name 
(official gene symbol) 
Increased expression Decreased expression 
Transthyretin (TTR) (Ryberg et al., 2010)* (Ranganathan et al., 2005) 
(Ranganathan et al., 2007) 
(De Benedetti et al., 2017) 
Hemoglobin Subunit Beta (HBB) (Ryberg et al., 2010) 
(Chen et al., 2016)  
(Varghese et al., 2013) 
Protein AMBP (AMBP) (De Benedetti et al., 2017) (Von Neuhoff et al., 2012) 
(Chen et al., 2016)  
Apolipoprotein A-II (APOA2) (Chen et al., 2016) (De Benedetti et al., 2017) 
Apolipoprotein B-100 (APOB) (Varghese et al., 2013) (Collins et al., 2015) 
Prothrombin (F2) (Varghese et al., 2013) (Von Neuhoff et al., 2012) 
Testican-2 (SPOCK2) (Chen et al., 2016) (Collins et al., 2015) 
Zinc-Alpha-2-Glycoprotein (AZGP1) (Brettschneider et al., 2008) (Chen et al., 2016) 
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Figure 5. 2. Bioinformatics analysis of eleven proteins that showed consistent change in expression across 
biofluids from ALS patients. Gene ontology analysis revealed enriched terms connected to (A) biological 
process, (B) cellular component. Enriched terms are shown in the chord diagram, together with the proteins 
annotated to each term. (C) STRING 10 analysis identified association network between four proteins: HBA1- 
haemoglobin subunit alpha 1, HP- haptoglobin, ORM1- alpha-1-acid glycoprotein 1 and TF- transferrin. The 
type of association is indicated by the colour (pink: experimentally determined interactors; light blue: 
interactors form curated database; black: co-expression; yellow: text-mining). 
 
Figure 5. 4. Gene ontology analysis of the proteins consistently changed in the same direction in ALS tissues 
and cells. Adapted from (Šoltić et al., 2018). Gene ontology analysis revealed enriched terms connected to (A) 
biological processes and (B) cellular component. Top eight enriched terms from biological process domain, and 
top six enriched terms from cellular component domain are shown in the chord diagram, together with the 
proteins annotated to each term.Figure 5. 5. Bioinformatics analysis of eleven proteins that showed 
consistent change in expression across biofluids from ALS patients. Adapted from (Šoltić et al., 2018). Gene 
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5.2.3 Multi-study proteomic identification of conserved molecular response in 
cells/tissues from ALS patients and animal models of ALS 
Comparison of the 21 studies that investigated proteome changes in tissues and cells from 
ALS patients and animal models identified 80 proteins that were differentially expressed 
across two or more studies. Of these, 42 proteins showed a consistent direction of differential 
expression (Table 5.4), eleven of which were upregulated across three or more studies: 
aldolase A, superoxide dismutase 1 and 2, 14-3-3 protein gamma, calreticulin, glyceraldehyde-
3-phosphate dehydrogenase, heat shock protein 1, heat shock protein family A member 8, 
peroxiredoxin 2  and 6  and glial fibrillary acidic protein. The remaining 38 proteins showed a 
contradictory direction of expression in different studies (Table 5.5).  
 
Table 5. 4. Proteins that showed consistent direction of differential expression in ALS cells 
and tissues across two or more proteomic studies 
Protein 
(Official Gene Symbol) 
References Sample Type/ ALS Model 
Increased expression 
Aldolase A (ALDOA) (Fukada et al., 2004) 
(Staunton, Jockusch and 
Ohlendieck, 2011) 
(Bastone et al., 2009) 
(Nardo et al., 2011) 
(Basso et al., 2013) 
NSC34 cells (MF)/ SOD1 G93A 
Mouse muscle/ Wobbler Mouse 
 
Mouse spinal cord/ Wobbler Mouse 
Patient blood mononuclear cells 
Mouse astrocytes/ SOD1 G93A 
Superoxide Dismutase 2 (SOD2) (Bergemalm et al., 2009) 
(Li et al., 2010) 
(Nardo et al., 2011) 
(Stalekar et al., 2015) 
Mouse spinal cord/ SOD1 G127X 
Rat spinal cord (MF)/ SOD1 G93A 
Patient blood mononuclear cells 
SH-SY5Y cells/ TDP-43 Loss 
Superoxide Dismutase 1 (SOD1) (Strey et al., 2004) 
(Basso et al., 2009) 
(Staunton, Jockusch and 
Ohlendieck, 2011) 
Mouse spinal cord / SOD1 G93A 
Mouse spinal cord (IF)/ SOD1 G93A 
Mouse muscle/ Wobbler Mouse 
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Peroxiredoxin 2 (PRDX2) (Duplan et al., 2010) 
 
(Nardo et al., 2011) 
(Stalekar et al., 2015) 
Mouse embryonic motor neurons/ 
SOD1 G85R 
Patient blood mononuclear cells 
SH-SY5Y cells/ TDP-43 Loss 
14-3-3 Protein Gamma (YWHAG) (Basso et al., 2009) 
(Bergemalm et al., 2009) 
(Stalekar et al., 2015) 
Mouse spinal cord (IF)/ SOD1 G93A 
Mouse spinal cord/ SOD1 G127X 
SH-SY5Y cells/ TDP-43 Loss 
Heat Shock Protein 1 (HSPB1) (Strey et al., 2004) 
(Basso et al., 2009) 
(Stalekar et al., 2015) 
Mouse spinal cord / SOD1 G93A 
Mouse spinal cord (IF)/ SOD1 G93A 
SH-SY5Y cells/ TDP-43 Loss 
Calreticulin (CALR) (Zhou et al., 2010) 
(Nardo et al., 2011) 
(Stalekar et al., 2015) 
Mouse ventral roots/ SOD1 G93A 
Patient blood mononuclear cells 
SH-SY5Y cells/ TDP-43 Loss 
Heat Shock Protein Family A, 
Member 8 (HSPA8) 
(Basso et al., 2009) 
(Nardo et al., 2011) 
(Stalekar et al., 2015) 
Mouse spinal cord (IF)/ SOD1 G93A 
Patient blood mononuclear cells 
SH-SY5Y cells/ TDP-43 Loss 
Peroxiredoxin 6 (PRDX6) (Strey et al., 2004) 
(Nardo et al., 2011) 
(Bastone et al., 2009) 
Mouse spinal cord / SOD1 G93A 
Patient blood mononuclear cells 
Mouse spinal cord/ Wobbler Mouse 
Glial Fibrillary Acidic Protein 
(GFAP) 
(Basso et al., 2009) 
(Basso et al., 2013) 
(Umoh et al., 2018) 
Mouse spinal cord (IF)/ SOD1 G93A 
Mouse astrocytes/ SOD1 G93A 
Patient prefrontal cortex 
Glyceraldehyde-3-Phosphate 
Dehydrogenase (GAPDH) 
(Basso et al., 2009) 
(Staunton, Jockusch and 
Ohlendieck, 2011) 
(Bastone et al., 2009) 
Mouse spinal cord (IF)/ SOD1 G93A 
Mouse muscle/ Wobbler Mouse 
 
Mouse spinal cord/ Wobbler Mouse 
Valosin Containing Protein (VCP) (Basso et al., 2009) 
(Elf et al., 2014) 
Mouse spinal cord (IF)/ SOD1 G93A 
Patient muscle 
Septin 9 (SEPT9) (Zhou et al., 2010) 
(Stalekar et al., 2015) 
Mouse ventral roots/ SOD1 G93A 
SH-SY5Y cells/ TDP-43 Loss 
Malate Dehydrogenase 1 
(MDH1) 
(Basso et al., 2009) 
(Bergemalm et al., 2009) 
Mouse spinal cord (IF)/ SOD1 G93A 
Mouse spinal cord/ SOD1 G127X 
Actin, Alpha Cardiac Muscle 1 
(ACTC1) 
(Staunton, Jockusch and 
Ohlendieck, 2011) 
(Stalekar et al., 2015) 
Mouse muscle/ Wobbler Mouse 
 
SH-SY5Y cells/ TDP-43 Loss 
NADH Dehydrogenase 
[Ubiquinone] Iron-Sulfur Protein 
8, Mitochondrial (NDUFS8) 
(Fukada et al., 2004) 
(Engelen-Lee et al., 2017) 
NSC34 cells (MF)/ SOD1 G93A 
Patient anterior and posterior horn 
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Calumenin (CALU) (Zhou et al., 2010) 
(Stalekar et al., 2015) 
Mouse ventral roots/ SOD1 G93A 
SH-SY5Y cells/ TDP-43 Loss 
Creatine Kinase, Mitochondrial 1 
(CKMT1B) 
(Basso et al., 2009) 
(Bastone et al., 2009) 
Mouse spinal cord (IF)/ SOD1 G93A 
Mouse spinal cord/ Wobbler Mouse 
Glutamate Dehydrogenase 
(GLUD1) 
(Basso et al., 2009) 
(Bastone et al., 2009) 
Mouse spinal cord (IF)/ SOD1 G93A 
Mouse spinal cord/ Wobbler Mouse 
Apolipoprotein E (APOE) (Strey et al., 2004) 
(Zhou et al., 2010) 
Mouse spinal cord / SOD1 G93A 
Mouse ventral roots/ SOD1 G93A 
Enoyl Coenzyme A Hydratase, 
Short Chain 1 (ECHS1) 
(Massignan et al., 2007) 
 
(Basso et al., 2013) 
Mouse spinal cord (pre-symptomatic)/ 
SOD1 G93A 
Mouse astrocytes/ SOD1 G93A 
Single Stranded DNA Binding 
Protein 1 (SSBP1) 
(Li et al., 2010) 
(Stalekar et al., 2015) 
Rat spinal cord (MF)/ SOD1 G93A 
SH-SY5Y cells/ TDP-43 Loss 
Glycerol Phosphate 
Dehydrogenase 2 (GPD2) 
(Basso et al., 2009) 
(Bastone et al., 2009) 
Mouse spinal cord (IF)/ SOD1 G93A 
Mouse spinal cord/ Wobbler Mouse 
Aldolase C (ALDOC) (Basso et al., 2009) 
(Basso et al., 2013) 
Mouse spinal cord (IF)/ SOD1 G93A 
Mouse astrocytes/ SOD1 G93A 
Glutamine Ammonia Ligase 
(GLUL) 
(Basso et al., 2009) 
(Bastone et al., 2009) 
Mouse spinal cord (IF)/ SOD1 G93A 
Mouse spinal cord/ Wobbler Mouse 
Endoplasmic Reticulum Protein 
29 (ERP29) 
(Bergemalm et al., 2009) 
(Nardo et al., 2011) 
Mouse spinal cord/ SOD1 G127X 
Patient blood mononuclear cells 
Isocitrate Dehydrogenase 2 
(IDH2) 
(Basso et al., 2009) 
(Li et al., 2010) 
Mouse spinal cord (IF)/ SOD1 G93A 
Rat spinal cord (MF)/ SOD1 G93A 
Lactate Dehydrogenase B (LDHB) (Basso et al., 2009) 
(Nardo et al., 2011) 
Mouse spinal cord (IF)/ SOD1 G93A 
Patient blood mononuclear cells 
Decreased expression 
Neurosecretory protein VGF 
(VGF) 
(Stalekar et al., 2015) 
(Umoh et al., 2018) 
SH-SY5Y cells/ TDP-43 Loss 
Patient prefrontal cortex 
Myosin Light Chain, 
Phosphorylatable, Fast Skeletal 
Muscle (MYLPF) 
(Zhou et al., 2010) 
(Conti et al., 2014) 
Mouse ventral roots/ SOD1 G93A 
Patient muscle 
Nudix Motif 2 (NUDT2) (Bergemalm et al., 2009) 
(Sharma et al., 2016) 
Mouse spinal cord/ SOD1 G127X 
Patient CSF injected into rat spinal 
cord/MF 
Adenylate Kinase 2 (AK2) (Fukada et al., 2004) 
(Li et al., 2010) 
NSC34 cells (MF)/ SOD1 G93A 
Rat spinal cord (MF)/ SOD1 G93A 
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Far Upstream Element-Binding 
Protein 1 (FUBP1) 
(Nardo et al., 2011) 
(Stalekar et al., 2015) 
Patient blood mononuclear cells 
SH-SY5Y cells/ TDP-43 Loss 
Filamin A (FLNA) (Nardo et al., 2011) 
(Basso et al., 2013) 
Patient blood mononuclear cells 
Mouse astrocytes/ SOD1 G93A 
Golgin B1 (GOLGB1) (Nardo et al., 2011) 
(Stalekar et al., 2015) 
Patient blood mononuclear cells 
SH-SY5Y cells/ TDP-43 Loss 
Heat Shock Protein Family D, 
Member 1 (HSPD1) 
(Li et al., 2010) 
(Stalekar et al., 2015) 
Rat spinal cord (MF)/ SOD1 G93A 
SH-SY5Y cells/ TDP-43 Loss 
Acyl- Coenzyme A 
Dehydrogenase, Medium Chain 
(ACADM) 
(Fukada et al., 2004) 
(Elf et al., 2014) 
NSC34 cells (MF)/ SOD1 G93A 
Patient muscle 
Nadh Dehydrogenase 1 Beta 
Subcomplex Subunit 10 
(NDUFB10) 
(Fukada et al., 2004) 
(Stalekar et al., 2015) 
NSC34 cells (MF)/ SOD1 G93A 
SH-SY5Y cells/ TDP-43 Loss 
Solute Carrier Family 25, 
Member 4 (SLC25A4) 
(Li et al., 2010) 
(Stalekar et al., 2015) 
Rat spinal cord (MF)/ SOD1 G93A 
SH-SY5Y cells/ TDP-43 Loss 
Ubiquinol-Cytochrome C 
Reductase Core Protein I 
(UQCRC1) 
(Basso et al., 2013) 
(Stalekar et al., 2015) 
Mouse astrocytes/ SOD1 G93A 
SH-SY5Y cells/ TDP-43 Loss 
Chaperonin Containing Tcp1 
Subunit 6a (CCT6A) 
(Fukada et al., 2004) 
(Stalekar et al., 2015) 
NSC34 cells (MF)/ SOD1 G93A 
SH-SY5Y cells/ TDP-43 Loss 
2',3'-Cyclic Nucleotide 3' 
Phosphodiesterase (CNP) 
(Bergemalm et al., 2009) 
(Stalekar et al., 2015) 
Mouse spinal cord/ SOD1 G127X 
SH-SY5Y cells/ TDP-43 Loss 
Proteins that showed consistent direction of differential expression in cells and tissues in at least two proteomic 
studies of ALS. Proteins are listed according to direction of differential expression (proteins with increased 
expression are listed first, followed by proteins with decreased expression). Protein name is given, followed by 
official gene symbol in brackets. ALS model and sample type used in each study are listed (studies are listed in 
the reference column). IF- insoluble fraction; MF- mitochondrial fraction 
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Table 5. 5. Proteins that showed contradictory direction of differential expression in cells 
and tissues across two or more proteomic studies of ALS 
Protein (Official Gene Symbol) Increased expression Decreased expression 
Prolyl 4-Hydroxylase Subunit Beta (P4HB) 
(Massignan et al., 2007) 
(Basso et al., 2009) 
(Zhou et al., 2010) 
(Nardo et al., 2011) 
(Basso et al., 2013) 
Phosphoglycerate Mutase 1 (PGAM1) 
(Bastone et al., 2009) 
(Bergemalm et al., 2009) 
(Nardo et al., 2011) 
(Shin et al., 2005) 
(Massignan et al., 2007) 
(Stalekar et al., 2015) 
Peptidylprolyl Isomerase A (PPIA) 
(Massignan et al., 2007) 
(Basso et al., 2009) 
(Nardo et al., 2011) 
(Basso et al., 2013) 
Dihydropyrimidinase-Like 2 (DPYSL2) 
(Basso et al., 2009) 
(Bastone et al., 2009) 
(Shin et al., 2005) 
(Bergemalm et al., 2009) 
(Basso et al., 2013) 
Pyruvate Kinase, Muscle (PKM) 
(Basso et al., 2009) 
(Bastone et al., 2009) 
(Shin et al., 2005) 
(Basso et al., 2013) 
NADH Dehydrogenase Fe-S Protein 1 (NDUFS1) 
(Basso et al., 2009) (Shin et al., 2005) 
(Li et al., 2010) 
Enolase 1 (ENO1) 
(Massignan et al., 2007) 
(Basso et al., 2009) 
(Nardo et al., 2011) 
(Basso et al., 2013) 
ATP Synthase, H+ Transporting, Mitochondrial F1 
Complex, Alpha Subunit 1 (ATP5A1) 
(Basso et al., 2009) (Fukada et al., 2004) 
(Shin et al., 2005) 
(Basso et al., 2013) 
Tubulin Alpha 1b (TUBA1B) (Shin et al., 2005) (Fukada et al., 2004) 
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(Stalekar et al., 2015) 
Voltage-Dependent Anion Channel 1 (VDAC1) 
(Basso et al., 2013) (Fukada et al., 2004) 
(Bergemalm et al., 2009) 
Transketolase (TKT) 
(Bastone et al., 2009) 
(Stalekar et al., 2015) 
(Basso et al., 2013) 
Pyruvate Dehydrogenase E1 Alpha 1 (PDHA1) 
(Massignan et al., 2007) 
(Basso et al., 2009) 
(Fukada et al., 2004) 
4-Aminobutyrate Aminotransferase (ABAT) 
(Bastone et al., 2009) 
(Li et al., 2010) 
(Bergemalm et al., 2009) 
Atp Synthase, H+ Transporting, Mitochondrial F1 
Complex, Beta Polypeptide (ATP5B) 
(Shin et al., 2005) 
(Nardo et al., 2011) 
(Nardo et al., 2011) 
(Stalekar et al., 2015) 
Aconitase 2 (ACO2) 
(Fukada et al., 2004) 
(Basso et al., 2009) 
(Bastone et al., 2009) 
(Fukada et al., 2004) 
Vimentin (VIM) 
(Basso et al., 2009) 
(Basso et al., 2013) 
(Stalekar et al., 2015) 
(Basso et al., 2013) 
Heat Shock Protein Family A, Member 5 (HSPA5) 
(Engelen-Lee et al., 2017) (Fukada et al., 2004) 
(Nardo et al., 2011) 
(Basso et al., 2013) 
Actin Beta (ACTB) 
(Nardo et al., 2011) 
(Basso et al., 2013) 
(Umoh et al., 2018) 
Phosphoglycerate kinase 1 (PGK1) 
(Shin et al., 2005) 
(Bastone et al., 2009) 
(Nardo et al., 2011) 
(Bastone et al., 2009) 
(Nardo et al., 2011) 
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Tubulin Beta-2B Chain (TUBB2B) 
(Shin et al., 2005) 
(Stalekar et al., 2015) 
(Umoh et al., 2018) 
Glutathione S-Transferase Mu 1 (GSTM1) (Umoh et al., 2018) (Allen et al., 2003) 
Dipeptidyl Peptidase 3 (DPP3) (Engelen-Lee et al., 2017) (Umoh et al., 2018) 
Prohibitin (PHB) (Basso et al., 2013) (Li et al., 2010) 
Tubulin, Beta 4b (TUBB4B) (Basso et al., 2013) (Stalekar et al., 2015) 
Electron Transferring Flavoprotein, Alpha (ETFA) (Massignan et al., 2007) (Bergemalm et al., 2009) 
Actin, Gamma, Cytoplasmic 1 (ACTG1) (Bergemalm et al., 2009) (Fukada et al., 2004) 
Annexin A5 (ANXA5) (Basso et al., 2009) (Bergemalm et al., 2009) 
Creatine Kinase, Muscle (CKM) 
(Staunton, Jockusch and 
Ohlendieck, 2011) 
(Zhou et al., 2010) 
(Staunton, Jockusch and 
Ohlendieck, 2011) 
Crystallin, Alpha B (CRYAB) (Basso et al., 2009) (Basso et al., 2013) 
Growth Factor Receptor-Bound Protein 2 (GRB2) (Stalekar et al., 2015) (Bergemalm et al., 2009) 
Hexosaminidase Subunit Alpha (HEXA) (Zhou et al., 2010) (Sharma et al., 2016) 
Heat Shock Protein 90 Alpha Family Class A 
Member 1 (HSP90AA1) 
(Basso et al., 2009) (Stalekar et al., 2015) 
Isocitrate Dehydrogenase 3 (NAD+) Beta (IDH3B) (Li et al., 2010) (Fukada et al., 2004) 
Heat Shock Protein 90, Beta (Grp94), Member 1 
(HSP90B1) 
(Basso et al., 2009) (Basso et al., 2013) 
Mitogen-Activated Protein Kinase 1 (MAPK1) (Basso et al., 2009) (Basso et al., 2013) 
Lon Peptidase 1 (LONP1) (Stalekar et al., 2015) (Fukada et al., 2004) 
Dynamin 1 (DNM1) 
(Bergemalm et al., 2009) 
(Umoh et al., 2018) 
(Shin et al., 2005) 
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2,4-Dienoyl Coa Reductase 1 (DECR1) (Li et al., 2010) (Stalekar et al., 2015) 
Proteins that showed contradictory direction of differential expression in cells and tissues in at least two 
proteomic studies of ALS. Protein name is given, followed by official gene symbol in brackets. Studies that 
identified increased or decreased protein expression are listed in column two and three. 
 
GO analysis of the 42 proteins using the DAVID platform (Huang, Sherman and Lempicki, 
2009b, 2009a) highlighted enriched biological process terms, including programmed cell 
death, protein transport and localization, response to oxidative stress and metabolism (Figure 
5.3A). Cellular component GO analysis returned a range of terms, but similar to the 
bioinformatics finding from the CSF studies, the greatest number (i.e. 64%) of annotated 
proteins were associated with the term “extracellular vesicles” (Figure 5.3B). Proteins were 
then subjected to analysis using STRING 10 (Szklarczyk et al., 2015) to identify statistically 
significant associations between them (Figure 5.4). Comparison of the resulting networks with 
the GO analysis output (Figure 5.3) identified strong association between mitochondrial and 
endoplasmic reticulum proteins that are involved in the control of energy homeostasis, 
oxidative stress response and protein homeostasis (Figure 5.4). Within the networks, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was found to have the greatest number 
of known associations, linking with proteins involved in each of the three main domains.  
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Figure 5. 3. Gene ontology analysis of the proteins consistently changed in the same direction in ALS tissues 
and cells. Gene ontology analysis revealed enriched terms connected to (A) biological processes and (B) cellular 
component. Top eight enriched terms from biological process domain, and top six enriched terms from cellular 
component domain are shown in the chord diagram, together with the proteins annotated to each term. 
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5.2.4. Multi-study proteomic identification of conserved molecular changes in both 
SMA and ALS 
To identify conserved protein changes common to SMA and ALS, differentially expressed 
proteins identified in the ALS multi-study comparison (Table 5.2 – 5.5) were compared with 
the differentially expressed proteins identified in a previous multi-study comparison of SMA 
proteomic datasets (Fuller, Gillingwater and Wishart, 2016). Fifteen proteins, summarised in 
Figure 5.5, were found to be differentially expressed in both diseases. 
 
 
Figure 5.4. STRING 10 analysis of the proteins consistently changed in the same direction in ALS tissues and 
cells. Protein associations were identified with high confidence (0.700) interaction score, and only proteins 
that demonstrated significant associations are shown in the figure. The type of association between proteins 
is indicated by the colour (pink: experimentally determined interactors; light blue: interactors form curated 
database; grey: protein homology; black: co-expression; yellow: text-mining; dark blue: gene co-occurrence; 
green: gene neighbourhood). Three functional groups of proteins associated with regulation of oxidative 
stress, energy homeostasis and protein homeostasis were identified in the network from Figure 5.3. 
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Figure 5.5. Proteins differentially expressed in both SMA and ALS proteomic studies. Heat map of proteins 
that were differentially expressed in both SMA and ALS proteomic studies. Protein names are presented as 
official gene symbols. The reference for each study is given in the corresponding squares of the heat map and 
in the Figure legend. Experimental model and sample type used in each study are indicated above the table. 
ALDOA- aldolase, fructose-bisphosphate A; ANXA5- annexin A5; ATP5A1- ATP synthase subunit alpha 
mitochondrial; CALR- calreticulin; CNP- 2,3-cyclic nucleotide 3-phosphodiesterase; GAPDH- glyceraldehyde-3-
phosphate dehydrogenase; HSP90AA1- heat shock protein HSP 90 alpha; HSP90B1- heat shock protein 90 beta 
family member 1; HSPD1- heat shock protein family D, member 1; PGK1- phosphoglycerate kinase 1; PRDX2- 
peroxiredoxin 2; SOD1- superoxide dismutase 1; VDAC1- voltage dependent anion channel 1; VIM- vimentin; 
YWHAG- 14-3-3 protein gamma. 
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String 10 analysis revealed a strong association network between 14 of the 15 proteins (Figure 
5.6). Programmed cell death was one of the most enriched biological process GO terms (Figure 
5.7A) and is likely describing the downstream consequences of disease pathogenesis. Other 
highly enriched terms included regulation of immune system, regulation of protein 
metabolism, cytoskeleton organization, and mitochondrial transport and organization. 
Strikingly, all fifteen proteins identified in the comparison were associated with the cellular 
component term “extracellular vesicles” (Figure 5.7B).  
 
Figure 5. 6. String 10 association network of proteins that were differentially expressed in SMA and ALS. The 
analysis revealed strong association network between 14 of the 15 proteins. The type of the association between 
proteins is indicated by the colour (pink: experimentally determined interactors; light blue: interactors form 
curated databases; grey: protein homology; black: co-expression; yellow: text-mining; dark blue: gene co-
occurrence; green: gene neighbourhood). 
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Figure 5. 7. Gene ontology analysis of the fifteen proteins differentially expressed in both SMA and ALS 
proteomic studies. Gene ontology analysis revealed enriched terms connected to (A) biological process and 
(B) cellular component. Top ten enriched terms from each domain are shown in the chord diagram, together 
with the proteins annotated to each term. 
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In summary, multi-study comparison of published proteomic studies of ALS and SMA 
identified fifteen proteins that were found to be differentially expressed in both diseases. 
Enriched terms associated with regulation of protein metabolism, regulation of immune 
system and mitochondrial transport were identified in the bioinformatics analysis, and all 15 
proteins were linked to the GO cellular component term “extracellular vesicles”. 
 
5.2.5. Verification of differential protein expression in spinal cords from SMA and ALS 
mice 
Having established the core molecular overlap between SMA and ALS, it was next important 
to verify these changes biochemically in SMA and ALS tissues to establish how translatable 
these findings are to different biological systems. Spinal cord extracts from a mouse model of 
ALS (SOD1G93A) and a mouse model of SMA (severe ‘Taiwanese’ model; Smn−/−;SMN2tg/+) at 
late symptomatic time-points (20 weeks and 8 days respectively), and from age-matched 
healthy controls were subjected to western blot analyses to determine the expression levels 
of five protein targets, including SOD1, CALR, ALDOA, GAPDH and HSP90B1 (Figure 5.8A and 
5.8B). Only one of these proteins, calreticulin (CALR), was dysregulated in ALS and SMA spinal 
cords, and increased calreticulin expression in spinal cord extracts from ALS mice (73%, p = 
0.0028) was in line with proteomic studies of ALS (Figure 5.5). Decreased calreticulin 
expression, identified in spinal cord extracts from SMA mice (22%, p = 0.0079), was in contrast 
with proteomic studies of SMA that showed increased calreticulin expression in iPSC-derived 
motor neurons from type I SMA patients and in SMA mouse muscles (Figure 5.5). As expected, 
SOD1 was significantly increased in ALS spinal cords (p < 0.0001), with no significant change 
observed in the spinal cord from SMA mice. ALDOA and GAPDH did not show a statistically 
significant change in expression in ALS and SMA spinal cords compared to healthy controls. It 
was not possible to reliably quantify the expression of HSP90B1 in spinal cords from ALS and 
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SMA mice due to low signal intensity, and/ or the presence of non-specific bands in samples 
(Figure 5.8A), both of which indicate technical problems with the antibody. 
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Figure 5.8. Verification of protein targets in spinal cord extracts from late-symptomatic ALS mice (20 week) 
and late-symptomatic SMA mice (P8). Representative western blots showing SOD1, CALR, ALDOA, GAPDH and 
HSP90B1 protein levels in (A) spinal cords from ALS mice (n=4) and age-matched healthy controls (n=5) and in 
(B) spinal cords from SMA mice (n=5) and age-matched healthy controls (n=5). (#GAPDH graph was also used 
in Figure 3.6). Graphs are presented as average integrated density (normalised to Coomassie stained gel), with 
error bars showing standard deviation from the mean. ALDOA- aldolase, fructose-bisphosphate A; CALR- 
calreticulin; GAPDH- glyceraldehyde-3-phosphate dehydrogenase; HSP90B1- heat shock protein 90 beta family 
member 1; SOD1- superoxide dismutase 1; ns-not significant; ** p<0.01; ***p<0.001 
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5.2.6. Calreticulin expression is dysregulated in spinal cord tissue from ALS and SMA  
mice 
Calreticulin was the only protein that showed dysregulated expression in both ALS and SMA 
spinal cord extracts (Figure 5.8). However, the direction of expression change in SMA mouse 
spinal cord was in contrast with proteomic studies, where iPSC-derived motor neurons from 
type I SMA patients (Fuller et al., 2016) and SMA mouse muscle (Mutsaers et al., 2013) showed 
increased CALR levels. Differences in calreticulin expression in different cell populations could, 
according to a theory proposed by Bernard-Marissal et al. (Bernard-Marissal et al., 2012), have 
contributed to the overall calreticulin expression levels in spinal cord, masking changes that 
were previously reported to be specific to vulnerable lower motor neurons. They show that 
reduction of calreticulin levels is restricted to lumbar motor neurons form SOD1G93A mice, 
since no obvious change in calreticulin expression was detected in thoracic motor neurons 
(Bernard-Marissal et al., 2012). In addition, differences in calreticulin expression have been 
identified between different motor neuron populations within the lumbar spinal cord, where 
vulnerable motor neurons showed decreased calreticulin levels, and resistant motor neurons 
showed unchanged calreticulin levels when compared to control (Bernard-Marissal et al., 
2012). To determine the contribution of vulnerable motor neuron population to the overall 
calreticulin expression trends in ALS and SMA spinal cords, lumbar spinal cord sections from 
late-symptomatic ALS (20 weeks) and SMA mice (P8), and age-matched healthy controls were 
stained with an antibody against calreticulin (Figure 5.9). The analysis of the ventral horn of 
lumbar spinal cord sections from control and SMA mice closely aligned with the quantitative 
western blotting, showing reduction of calreticulin levels by an average of 25% in SMA 
compared to controls (p<0.001) (Figure 5.9B). A significant difference in calreticulin expression 
was not detected by immunohistochemistry analysis of ALS and control lumbar spinal cord 
sections (Figure 5.9A).  
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Figure 5.9. Reduced levels of calreticulin in lumbar spinal cords from late-symptomatic SMA mice. 
Representative immunohistochemistry images showing calreticulin expression in the ventral horn of lumbar 
spinal cord sections in (A) 20-week old control and ALS mice, and in (B) control and SMA mice (P8). Scale bar = 
50 μm. Densitometry measurements of calreticulin levels in alpha motor neurons are presented as mean optical 
density, with error bars showing standard deviation from the mean. CALR- calreticulin; ns-not significant; *** 
p<0.001 
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In vitro studies of cultured mouse motor neurons demonstrated that activation of Fas/NO 
pathway specifically induces cell death in SOD1G93A and SOD1G85R vulnerable motor neurons, 
without affecting the survival of healthy cells (Raoul et al., 2006; Bernard-Marissal et al., 
2012). Several proteins of this pathway including Fas ligand (FasL), whose binding to the Fas 
receptor initiates the pathway, demonstrated increased expression in lumbar spinal cord 
sections from SOD1G93A and SOD1G85R mice at the pre-symptomatic stage of the disease (Raoul 
et al., 2006), and ALS mice deficient for FasL function (SOD1G93A; FasL-/-) demonstrated 
increased survival and decreased motor neuron loss in lumbar spinal cord (Petri et al., 2006). 
In SMA, activation of Fas death pathway was identified in iPSC-derived motor neurons from 
type I SMA patients (Sareen et al., 2012), while no significant change in FasL expression was 
demonstrated in whole spinal cord extracts from SMA mice (P8) (Tsai et al., 2006). By studying 
SOD1G93A motor neurons in vitro, Bernard-Marissal et al. demonstrated that activation of 
Fas/NO pathway triggers reduction of calreticulin levels, which in turn promotes ER stress and 
further activation of Fas/NO pathway leading to the vicious cycle of changes that result in 
motor neuron death (Bernard-Marissal et al., 2012). To investigate whether the same 
mechanism might be responsible for calreticulin downregulation in vulnerable motor neurons 
in SMA, lumbar spinal cord sections from SMA mouse and healthy control were stained for 
FasL and calreticulin (Figure 5.10A). Calreticulin showed clear staining in ventral horn motor 
neurons from SMA and control mice, however, no specific FasL staining was detected in either 
SMA or control sections. To determine whether FasL detection was hampered for technical 
reasons, including the tissue processing method and/or immunohistochemistry protocol used 
in the study, the FasL antibody was next tested in quantitative western blotting on whole 
spinal cord extracts from SMA and control mice (Figure 5.10B). Surprisingly, the analysis 
showed strong cross-reaction of anti-FasL antibody with protein standards (indicated by arrow 
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in Figure 5.10B). To facilitate detection of specific bands, the blot had to be re-imaged with 
protein ladder outside of the field of view. Following this, three bands, in the range of 55-130 
kDa, were detected in spinal cord extracts from SMA mice and healthy controls (indicated by 
chevron arrows in Figure 5.10B), however none of these correspond to monomeric FasL (~30 
kDa). Western blot analysis of spinal cord extracts from ALS and control mice demonstrated 
the same cross-reaction of anti-FasL antibody with protein standards (Figure 5.10C). The 
greatest limitation of this study is the lack of positive control, i.e. purified FasL or extract of 
cells exposed to nitric oxide (NO) as in Bernard-Marissal et al. (Bernard-Marissal et al., 2012). 
Positive control can confirm possible technical problems with the antibody, and since one was 
not used in this study, it is not possible to determine with certainty whether the Fas pathway 
is activated or not in spinal cord tissue from SMA and ALS mice. 
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Figure 5.10. FasL antibody cross-reacts with proteins of the ladder in spinal cord extracts from late-
symptomatic ALS (20 week) and SMA mice (P8). (A) Representative immunohistochemistry images showing 
calreticulin and FasL expression in the ventral horn of lumbar spinal cord sections from SMA mouse and age-
matched healthy control. Scale bar = 10 μm. Representative western blots showing FasL protein levels in (B) 
spinal cords from SMA mice (n=5) and age-matched healthy controls (n=5), and in (C) spinal cords from ALS 
mice (n=4) and age-matched healthy controls (n=5). Arrows indicate cross-reaction of FasL antibody with 
protein standards. Chevron arrows indicate non-specific bands, detected when protein ladder was moved 
outside of the field of view. CALR- calreticulin; FasL- Fas ligand 
297 
 
In summary, calreticulin showed the opposite direction of differential expression in whole 
spinal cord extracts from ALS and SMA mice, and decreased expression of calreticulin, 
identified in spinal cords from SMA mice, was in contrast with proteomic studies of SMA. The 
link between calreticulin dysregulation and Fas death pathway was not observed in ventral 
horn motor neurons from SMA mice. 
 
5.2.7. ALDOA and GAPDH activity in spinal cord extracts from ALS and SMA mice  
Glycolysis is the main source of ATP in high energy demanding tissues like muscles and 
neuronal tissues (Jang et al., 2016), and defects in energy homeostasis, caused by abnormal 
glycolysis, were shown to contribute to selective death of vulnerable motor neurons and 
muscle atrophy in mouse models of SMA (Boyd et al., 2017) and ALS (Palamiuc et al., 2015). 
Two glycolytic enzymes identified in this study, aldolase fructose-bisphosphate A (ALDOA) and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Kanungo et al., 2018), showed no 
significant change in expression in spinal cord extracts from late-symptomatic ALS mice (20 
weeks) and late-symptomatic SMA mice (P8) (Figure 5.8). In a separate study, GAPDH protein 
levels were unchanged in muscles from symptomatic SOD1G93A mice (130 days) and late-
symptomatic SOD1H46R/H48Q mice (230 days), however, a significant reduction of GAPDH 
activity was identified in muscles from both mouse models of ALS (Pierce et al., 2008). There 
is a possibility therefore that ALDOA and GAPDH activity might be dysregulated in spinal cord 
extracts from late-symptomatic ALS and SMA mice despite showing unchanged protein levels. 
In addition, oxidative stress was identified as a shared link between ALS and SMA (Figure 5.7A), 
and exposure to oxidative stress was previously shown to decrease the activity of both GAPDH 
(Pierce et al., 2008) and ALDOA (Koeck et al., 2004) in vitro. To test this hypothesis, ALDOA 
and GAPDH activity levels were investigated in whole spinal cord extracts from late-
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symptomatic ALS mice (20 weeks) and late-symptomatic SMA mice (P8), and in age-matched 
healthy controls as described in chapter 2, section 2.10 (Figure 5.11A and 5.11B). Neither 
ALDOA or GAPDH showed a change in activity levels in spinal cord extracts from late-
symptomatic SMA mice, however, a statistically significant reduction of ALDOA (64%, p < 
0.0001) and GAPDH (42%, p = 0.0452) activity was identified in spinal cord extracts from late-
symptomatic ALS mice when compared to controls (Figure 5.11C and 5.11D). It was of interest 
to next determine whether changes in ALDOA and GAPDH activity can be detected at an earlier 
stage of the disease, as this would suggest that metabolic changes drive motor neuron 
pathology in ALS. ALDOA and GAPDH activity levels were not significantly changed in spinal 
cord extracts from early-symptomatic ALS mice (12 week) compared to age-matched healthy 
controls (Figure 5.12A). As expected, western blot analysis showed no significant change in 
ALDOA and GAPDH protein levels in spinal cord extracts from 12-week old ALS mice (Figure 
5.12B) (western blot analysis of ALDOA expression in 12-week old ALS mice were conducted 
by Dr Heidi Fuller (Keele) and are presented here for the purpose of comparison).  
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Figure 5.11. ALDOA and GAPDH activity levels are deceased in spinal cord extracts from late-symptomatic 
ALS mice (20 week). (A) ALDOA activity, measured as optical density (OD) over time, in spinal cord extracts 
from 20-week old ALS mice (n = 3) and age-matched healthy controls (n = 5), and in spinal cord extracts from 
8-days old SMA mice (n = 3) and age-matched healthy controls (n = 3). (B) GAPDH activity, measured as optical 
density (OD) over time, in spinal cord extracts from 20-week old ALS mice and 8-days old SMA mice (n = 3) and 
their respective age-matched healthy controls (n = 3). #Lower GAPDH activity of this sample is caused by higher 
dilution factor, which was taken into account during quantitative analysis. Graphs are presented as average (C) 
ALDOA and (D) GAPDH activity levels, with error bars showing standard deviation from the mean. ALDOA- 
aldolase, fructose-bisphosphate A; GAPDH- glyceraldehyde-3-phosphate dehydrogenase; ns- not significant; 
*p<0.05; *** p<0.001 
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Figure 5. 12. ALDOA and GAPDH expression and activity are not changed in spinal cord extracts from early-
symptomatic ALS mice (12 week). (A) ALDOA and GAPDH activity, measured as optical density (OD) over time, 
in spinal cord extracts from 12-week old ALS mice (n = 4 for ALDOA, and n = 3 for GAPDH) and age-matched 
healthy controls (n = 3). Graph is presented as average ALDOA and GAPDH activity levels, with error bars 
showing standard deviation from the mean. (B) Representative western blots showing ALDOA and GAPDH 
protein levels in spinal cords from 12-week old ALS mice (n = 4) and age-matched healthy controls (n = 3). The 
graph is presented as average protein levels (expressed relative to the control), with error bars showing 
standard deviation from the mean. ALDOA- aldolase, fructose-bisphosphate A; GAPDH- glyceraldehyde-3-
phosphate dehydrogenase; ns- not significant 
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In summary, a statistically significant reduction of ALDOA and GAPDH activity was identified 
in spinal cord extracts from late-symptomatic ALS mice. In addition, defects in ALDOA and 
GAPDH activity seem to be an ALS specific pathology, since SMA mouse spinal cords showed 
no significant change in ALDOA and GAPDH activity levels compared to controls. 
 
Protein tyrosine nitration increases in vitro as a result of oxidative stress (Koeck et al., 2004), 
and it was shown to be responsible for decreased GAPDH and ALDOA activity in vitro (Koeck 
et al., 2004; Palamalai and Miyagi, 2010). Oxidative stress is an important pathological feature 
in ALS (Tan, Pasinelli and Trotti, 2014), and increased nitrotyrosine levels were identified 
previously in spinal cords from pre- and early symptomatic ALS mice (Bruijn et al., 1997; 
Ferrante et al., 1997; Casoni et al., 2005). To date, however, protein tyrosine nitration has not 
been investigated as a direct mechanism of dysregulated ALDOA and GAPDH activity in ALS. 
To test this hypothesis, equal amounts of total protein from spinal cord extracts of 20-week 
old ALS and control mice were immunoprecipitated with mouse antibody raised against 3-
nitrotyrosine and subjected to western blot analysis to detect nitrotyrosine and ALDOA (Figure 
5.13A). ALDOA was easily detected in the input and unbound part of the pulldown but was 
absent from the eluate in both control and ALS samples. When the blot was developed with 
anti-nitrotyrosine antibody, two bands, most likely corresponding to large and small subunits 
of the mouse IgG, were identified in the eluate from control and ALS samples, however, no 
specific nitrotyrosine bands were observed in either of the sample. This would suggest 
technical problems with the antibody (e.g. it is not suitable for immunoprecipitation) since 
nitrotyrosine did not pull itself down, and so GAPDH protein levels were not investigated in 
this experiment. It is possible too that proteins are not nitrated in spinal cords from 20-week 
old ALS mice, and/or that protein nitration is below the levels of detection in whole spinal cord 
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extracts. This is supported by the finding that nitrotyrosine bands were not detected in the 
input from either control or ALS spinal cord extracts in the pulldown experiment (Figure 
5.13A). To test this hypothesis, 20 μg of total protein was used for western blot analysis of ALS 
and control spinal cord extract to increase the sensitivity of signal detection, however, the 
same result was demonstrated in this experiment showing no specific nitrotyrosine bands in 
control and ALS samples (Figure 5.13B). The only band detected had a molecular weight of 
around 55 kDa and likely represents the large subunit of mouse IgG. It is still not possible to 
reliably interpret these results, since a positive control, that could validate the sensitivity of 
the antibody, was not used in this experiment. 
 
Aldolase A is glycolytic enzyme that catalyses the reversible conversion of fructose-1,6-
bisphosphate to glyceraldehyde 3-phosphate and dihydroxyacetone phosphate (Kanungo et 
al., 2018). There is also evidence to support the role for ALDOA in regulating neurofilament 
light (NF-L) mRNA stability (Canete-Soler et al., 2005). For example, ALDOA and NF-L mRNA 
demonstrated interaction in Neuro-2a cell line and in mouse brain extracts, and constitutive 
ectopic expression of ALDOA induced NF-L mRNA degradation in Neuro-2a cell line (Canete-
Soler et al., 2005). As a subunit of neurofilament proteins, NF-L regulates cell shape, and is 
involved in control of different neuronal functions including signal conduction, synaptic vesicle 
trafficking and neurite growth (Didonna and Opal, 2019). NF-L subunit is required for initiation 
of neurofilament assembly, and defects in NF-L expression or function are therefore likely to 
impair different neuronal functions (Didonna and Opal, 2019). Nuclease activity was proposed 
as a mechanism by which ALDOA controls the stability of NF-L mRNA (Canete-Soler et al., 
2005), and since ALDOA already demonstrated perturbed glycolytic activity in spinal cord 
extracts from 20-week old ALS mice (Figure 5.10C), it was of interest to next determine 
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whether ALDOA nuclease activity is also affected in ALS. Decreased NF-L mRNA levels were 
previously identified in cervical motor neurons from sporadic ALS patients (Wong, He and 
Strong, 2000), and so the aim here was to determine whether NF-L dysregulation translates 
functionally on the protein level. NF-L expression was analysed in spinal cord extracts from 
late-symptomatic ALS mice and age-matched healthy controls using quantitative western 
blotting (Figure 5.13C). The analysis identified decreased NF-L protein levels in spinal cord 
extracts from 20-week old ALS mice, however the change was not statistically significant, likely 
caused by big sample variability in control group. 
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Protein tyrosine nitration was not identified in spinal cord extracts from 20-week old ALS mice. 
It is not possible, however, to determine at this point whether this is a true finding or a result 
of technical problems with the antibody. Finding of decreased NF-L protein levels in spinal 
Figure 5.13. Protein nitration was not detected in spinal cord extracts from late-symptomatic ALS mice (20 
week). (A) Western blots showing nitrotyrosine and ALDOA protein levels in spinal cord extracts from control 
(n = 2) and ALS (n = 2) mice after immunoprecipitation with anti-nitrotyrosine antibody. Specific nitrotyrosine 
bands were not detected in control or ALS spinal cords. Bands in the eluate represent large and small subunits 
of mouse IgG. Western blots showing (B) nitrotyrosine and (C) NF-L levels in spinal cord extracts from ALS mice 
(n = 4) and age-matched healthy controls (n = 5). The graph is presented as average protein levels (expressed 
relative to the control), with error bars showing standard deviation from the mean. CTR- control; ALDOA- 
aldolase, fructose-bisphosphate A; NF-L- light-neurofilament; ns- not significant 
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cord extracts from ALS mice suggested that ALDOA nuclease activity might also be altered in 
ALS. The result was, however, statistically insignificant, and to be confirmed, this hypothesis 
requires further experimental attention. 
 
In summary: 
a) The multi-study comparison identified 42 proteins that showed consistent direction of 
differential expression across at least two proteomic studies of ALS. These proteins 
were associated with mitochondrial and endoplasmic reticulum functions such as the 
control of energy homeostasis, oxidative stress response and protein homeostasis. 
b) Fifteen proteins identified in the comparison of ALS and SMA proteomic datasets 
represent core molecular overlap between SMA and ALS, and are associated with 
functions like regulation of protein metabolism, regulation of immune system and 
mitochondrial transport. All fifteen proteins were also associated with extracellular 
vesicles, indicating alterations in exosome transport as a shared link between SMA and 
ALS. 
c) Biochemical analyses of the five proteins, SOD1, CALR, ALDOA, GAPDH and HSP90B1, 
showed very few similarities between SMA and ALS. Calreticulin was the only protein 
that showed dysregulated expression in the spinal cord from symptomatic SMA and 
ALS mice, where increased expression was identified in the spinal cord from ALS mice 
and decreased expression was identified in the spinal cord from SMA mice. Although 
no significant change was detected in ALDOA and GAPDH protein levels, the activity of 
both proteins was decreased in the spinal cord extracts from late-symptomatic ALS 
mice. 
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5.3. Discussion 
5.3.1. Differentially expressed proteins in biofluids from ALS patients  
Eleven proteins were consistently changed in the same direction in ALS patient biofluids across 
at least two proteomic studies (Table 5.2), some of which like putative auxiliary biomarker, 
cystatin C (Zhu et al., 2018), have already gained significant attention in the context of ALS. 
The neurosecretory protein VGF emerged in recent years as a potential biomarker of disease 
progression, having demonstrated decreased levels in post-mortem spinal cord samples from 
sporadic ALS patients (Shimazawa et al., 2010), in plasma and fibroblast cells from sporadic 
and familial ALS patients in an advanced stage of the disease (Brancia et al., 2016), and in CSF 
from ALS patients, the levels of VGF decreased with disease progression (Zhao et al., 2008). In 
addition, decreased levels of VGF were identified at a pre-symptomatic stage of the disease in 
CSF, serum and in lumbar and cervical spinal cord sections from transgenic SOD1G93A mice 
(Zhao et al., 2008; Brancia et al., 2016), suggesting VGF as a potential modifier of disease 
pathogenesis in ALS. For example, overexpression of VGF prevented ER-stress induced cell 
death in SH-SY5Y cell cultures (Shimazawa et al., 2010), and in-vitro restoration of VGF levels 
in motor neurons derived from SOD1G93A mice demonstrated neuroprotective action, 
highlighting VGF as a potential therapeutic target in ALS (Zhao et al., 2008). 
 
A relatively high number of blood-derived proteins was detected in the comparison, including 
for example, Hemoglobin subunit alpha 1 (HBA1) and Hemoglobin subunit beta (HBB), both of 
which are indicators of blood contamination in CSF, most likely caused by poor quality control 
during sample processing (Barschke et al., 2017). Another source of blood-derived proteins is 
CSF itself, as it is mainly the product of plasma filtration. Abundant proteins originating from 
blood can hamper detection of CNS-specific proteins and are usually removed from the 
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sample prior to proteomics analysis (Hu, Loo and Wong, 2006), however, the efficiency of the 
protein depletion varies depending on the method used (Polaskova et al., 2010). This and 
other technical variabilities between different proteomics approaches can significantly alter 
sensitivity of the protein detection (Barschke et al., 2017). It is perhaps not surprising that 
comparison identified very few similarities, emphasising the need to standardize proteomics 
protocols that would enable reliable and reproducible comparison between the studies.  
 
5.3.2. Differentially expressed proteins in ALS patient samples and animal models of 
ALS associate with mitochondria and endoplasmic reticulum (ER)  
Comparison of published proteomic studies that utilised tissues and cells from patients and 
animal models of ALS identified 42 proteins with a consistent direction of differential 
expression across at least two studies, some of which appear to have been overlooked when 
these datasets were considered in isolation. One such protein, aldolase A, for example, was 
increased in expression in five separate studies (Fukada et al., 2004; Bastone et al., 2009; 
Nardo et al., 2011; Staunton, Jockusch and Ohlendieck, 2011; Basso et al., 2013). Given its 
importance in glycolysis (Magistretti and Allaman, 2015), overexpression of this protein is 
highly likely to reflect perturbed metabolic activity. Indeed, mitochondrial dysfunction (Tan, 
Pasinelli and Trotti, 2014) and ER stress (Rozas et al., 2017) are known early pathological 
features and a major contributing factor of motor neuron death in ALS. Not surprisingly, most 
of the dysregulated proteins identified in tissues and cells from ALS patients and models were 
associated with energy homeostasis, oxidative stress response and control of protein stability, 
confirming the importance of ER and mitochondria in ALS disease pathways.  
 
Another important finding is that most proteins with a consistent direction of differential 
expression across ALS proteomic studies were associated with extracellular vesicles. 
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Significant attention has been given to extracellular vesicles in the context of 
neurodegenerative disorders, including ALS, as a potential source of biomarkers and as a 
possible mechanism of misfolded protein spreading in CNS (Quek and Hill, 2017). Mutant 
SOD1 and TDP-43 proteins are among molecules whose prion-like properties, facilitated by 
exosome transport, are thought to contribute to spreading of protein misfolding in ALS (Quek 
and Hill, 2017). 
 
5.3.3. Impaired protein metabolism and mitochondrial dysfunction are shared 
pathologies in ALS and SMA 
Interestingly, all fifteen proteins identified in the comparison between ALS and SMA 
proteomics studies were also associated with extracellular vesicles. Increased levels of 
exosomes were recently reported in culture media from SMN-depleted cells, SMA patient 
fibroblasts, and in serum from SMA patients and mouse model of SMA (Nash et al., 2017), 
indicating alterations in exosome transport as a shared link between SMA and ALS. 
 
Other enriched terms, identified in the bioinformatics analysis of the 15 proteins that were 
differentially expressed in ALS and SMA, included cell death, protein metabolism and 
mitochondria-associated functions. Considering the role for protein aggregation and ER stress 
in ALS pathology (Section 5.1.1), it is not surprising that four out of fifteen proteins identified, 
including CALR, HSPD1, HSP90B1 and HSP90AA1, are chaperones that promote correct folding 
of proteins. In spinal cord tissue from SOD1G93A mice upregulation of proteins in the UPR 
pathway was identified at a pre-symptomatic stage of the disease (Atkin et al., 2008) directly 
implicating it in ALS pathogenesis. Using transcriptomics approach, Ng et al. also 
demonstrated activation of the UPR pathway in induced pluripotent derived-motor neurons 
from type I SMA patients, the results of which were verified by qPCR analyses in motor 
309 
 
neurons from type I and type II SMA patients (Ng et al., 2015). An inverse correlation between 
the levels of SMN protein and the degree of ER stress was identified in human motor neuron 
cultures in vitro, and pharmacological inhibition of the UPR pathway increased the survival of 
motor neurons from type I SMA patients (Ng et al., 2015).  
 
In recent years, ER-Golgi protein trafficking has also been identified as a shared link between 
SMA and ALS. Impaired ER-Golgi transport mechanisms can trigger ER stress and Golgi 
alterations, ultimately leading to induction of the cell death-related pathways (Preston et al., 
2009; Atkin et al., 2014). Indeed, dysregulated ER-Golgi trafficking was observed as an early 
event in embryonic cortical and motor neurons in a mouse model of ALS (Soo et al., 2015), 
and in NSC34 cells expressing mutant SOD1, dysregulation of ER-Golgi trafficking preceded 
protein aggregation, ER stress, Golgi fragmentation and axon degeneration (Atkin et al., 2014). 
Overexpression of Ras-related protein Rab 1A (Rab1), a master regulator of ER-Golgi transport, 
restored ER-Golgi trafficking and prevented induction of ER stress, formation of intracellular 
aggregations and apoptosis in in vitro model of ALS (Soo et al., 2015). Several studies also 
indicate a role for defective ER-Golgi transport in SMA. SMN interacts with coatomer subunit 
alpha (α-COP), a member of coat protein complex I (COPI) vesicles that mediate ER-Golgi 
transport (Peter et al., 2011; Ting et al., 2012; Custer et al., 2013; Li et al., 2015), and 
knockdown of α-COP caused SMN accumulation in Golgi apparatus of neuron-like NSC34 cells 
(Ting et al., 2012) and produced developmental defects in motor neuron-like NSC34 cells and 
primary cortical murine neurons (Li et al., 2015). Overexpression of human α-COP reversed 
motor neuron defects in SMN-depleted NSC34 cells (Custer et al., 2013; Li et al., 2015) and in 
motor neurons from a zebrafish model of SMA (Li et al., 2015). In a most recent study, 
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transgenic expression of α-COP increased survival and improved muscle pathology in a severe 
mouse model of SMA (Custer et al., 2019). 
 
Dysregulation of protein metabolism has been demonstrated on multiple levels in SMA and 
ALS, however, investigation of specific protein targets, in comparable models of ALS and SMA, 
is needed to elucidate precise molecular mechanisms of protein metabolism dysregulation. 
Identification of similarities and differences in specific disease pathways in ALS and SMA would 
aid the selection of protein targets for therapy design that could bring benefit to both patient 
populations. With this in mind, the expression of several protein targets, identified in this 
study, was investigated in SMA and ALS spinal cords, starting with the calreticulin. 
 
5.3.4. Calreticulin is dysregulated in spinal cord from symptomatic ALS and SMA mice  
Calreticulin is a multifunctional protein involved in a range of processes, including the 
regulation of Ca2+ homeostasis in the ER, chaperone activity in secretory pathways, folding of 
nascent proteins, regulation of immune system, and modulation of cell adhesion (Gelebart, 
Opas and Michalak, 2005). Calreticulin was previously identified from proteomic studies as 
having increased levels in iPSC-derived motor neurons from type I SMA patients (Fuller et al., 
2016) and in SMA mouse muscle (Mutsaers et al., 2013), and this was verified biochemically 
in muscles from SMA mice and SMA patients (Mutsaers et al., 2013). In contrast, a statistically 
significant decrease of calreticulin levels was observed in spinal cord extracts and in motor 
neurons of lumbar spinal cord sections from late symptomatic SMA mice. In proteomic studies 
of ALS, calreticulin was found to be increased in the ventral roots from the spinal cord of ALS 
SOD1G93A mice (Zhou et al., 2010), blood mononuclear cells from ALS patients (Nardo et al., 
2011), and in TDP-43 knockdown SH-SY5Y cells (Stalekar et al., 2015), and in agreement with 
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this, increased levels of calreticulin were also found in spinal cord extracts from late-
symptomatic ALS SOD1G93A mice. This is, however, in contrast with a biochemical study of 
lower motor neurons isolated from ALS SOD1G93A mice that reported decreased expression of 
calreticulin (Bernard-Marissal et al., 2012). Differences in calreticulin expression in different 
cell populations could have contributed to the overall calreticulin expression levels in spinal 
cord, masking changes that were previously reported to be specific to vulnerable lower motor 
neurons (Bernard-Marissal et al., 2012). In addition, it has been shown that calreticulin levels 
increase under stress conditions prior to being secreted to the cell surface; a process that is 
associated with the functional role of calreticulin in apoptosis (Tarr et al., 2010). It is thus 
possible that opposing directions of perturbed calreticulin expression reflect ongoing cycles 
of apoptosis in vulnerable motor neurons. The time-course of disease is another potential 
variable to consider, since Bernard-Marissal et al. (Bernard-Marissal et al., 2012) studied ALS 
mice up to 110 days of age, compared to the later time-point of 140 days in the present study.  
 
5.3.4.1. Activation of Fas death pathway was not observed in spinal cord from SMA and ALS 
mice 
Activation of Fas/NO pathway was previously demonstrated in vitro in motor neurons carrying 
mutant SOD1G93A and SOD1G85R (Raoul et al., 2006; Bernard-Marissal et al., 2012), and in iPSC-
derived motor neurons from type I SMA patients (Sareen et al., 2012), and in SOD1G93A motor 
neurons, activation of Fas pathway was responsible for reduction of calreticulin levels 
(Bernard-Marissal et al., 2012). It appears that only one study to date investigated FasL 
expression in vivo in SMA mouse model, and identified no significant change in FasL expression 
in whole spinal cords from SMA mice (P8) compared to healthy controls (Tsai et al., 2006). 
However, as shown before, changes in protein expression may be restricted to vulnerable 
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motor neurons (Bernard-Marissal et al., 2012) and may not be easily detectable in whole 
spinal cord extracts. To investigate whether the same mechanism might be responsible for 
calreticulin downregulation in vulnerable motor neurons in SMA, the expression of FasL was 
investigated in lumbar spinal cord sections from SMA mouse and healthy control. 
Immunohistochemistry analysis of ventral horn motor neurons did not identify specific FasL 
staining in either SMA or control spinal cord sections. The cross-reaction between anti-FasL 
antibody and protein ladder, following western blot analysis of SMA and control spinal cord 
extracts, indicated technical problems with the antibody. After removing the protein ladder 
outside of the field of view, three bands were identified, none of which corresponded to 
monomeric FasL. Some of these bands may correspond to FasL dimer and trimer, as they were 
previously identified in COS cell line, after chemical crosslinking of FasL and under non-
reducing conditions (Tanaka et al., 1995). None of these conditions are applicable to 
experimental design in this study, and so it is likely that these are non-specific bands caused 
by antibody cross-reaction. However, without a positive control it is not possible to determine 
with certainty whether Fas pathway is activated in spinal cord from SMA or ALS mice.  
 
5.3.5. Unchanged SOD1 expression in the spinal cord of symptomatic SMA mice 
Transgenic SOD1 mice, carrying high copy number of mutant SOD1 gene, have been developed 
to investigate SOD1 disease pathways (Turner and Talbot, 2008), and can explain the 
increased expression of SOD1 identified in spinal cord extracts from late-symptomatic ALS 
mice. There are several lines of evidence that support the role for SMN in ALS disease 
pathways, including the reduction of SMN levels in spinal cords from SOD1G93A mice (Turner 
et al., 2009), and the beneficial effect of SMN overexpression on neuromuscular pathology in 
SOD1G86R model of ALS (Kariya et al., 2012). However, very few studies support the link 
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between SOD1 and SMA disease pathways. For example, one study investigated SOD1 mRNA 
levels in SMA patient iPSC-derived motor neurons and astrocytes, but found no significant 
change in SMA cells compared to controls (Patitucci and Ebert, 2016), and in a mouse model 
of SMA, overexpression of SOD1 showed no benefit on survival of SMA mice (Turner et al., 
2009). In this study, no significant change in SOD1 protein expression was identified in spinal 
cords from SMA mice compared to healthy controls, although it is possible that changes in 
SOD1 expression in vulnerable cell populations would be masked in whole spinal cord extracts 
(Bernard-Marissal et al., 2012). Indeed, in proteomic studies of SMA upregulation of SOD1 
levels was identified in Schwann cells (Aghamaleky Sarvestany et al., 2014) and hippocampus 
(Wishart et al., 2010) from severe mouse models of SMA. Increased production of reactive 
oxygen species, identified in motor neuron cultures from SMA mice and human ESC-derived 
motor neurons (Wang, Zhang and Li, 2013; Miller et al., 2016) supports this theory, as it is 
likely to increase the expression of proteins involved in oxidative stress response, including 
the SOD1. It would be of interest, therefore, to investigate the expression of SOD1 and other 
markers of oxidative stress in pathologically affected lumbar spinal cord sections, to 
determine the extent of oxidative stress in SMA motor neurons in vivo. This is important since 
oxidative stress indicates impaired mitochondrial health and function that can be detrimental 
for the survival of motor neurons (Miller et al., 2016), and could be contributing to SMA 
pathology. 
 
5.3.6. Unchanged levels of ALDOA and GAPDH in spinal cord extracts from 
symptomatic ALS and SMA mice 
In this study, western blot analyses showed unchanged protein levels of ALDOA and GAPDH 
in whole spinal cord extracts from ALS and SMA mice. This is perhaps not surprising since none 
of the SMA proteomic studies, that identified decreased GAPDH expression, investigated 
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protein profile in spinal cord tissue (Fuller, Gillingwater and Wishart, 2016), and to date, 
GAPDH has not been investigated biochemically in spinal cord tissue from SMA mice. In 
addition, there are no published studies that investigated ALDOA protein levels in ALS or SMA 
tissues. 
 
Upregulation of ALDOA and GAPDH levels was identified in a proteomic study that 
investigated protein changes in spinal cord from a Wobbler mouse model (Bastone et al., 
2009). Wobbler mice represent general model of neurodegeneration where motor neuron 
loss is restricted to cervical region of the spinal cord (Bastone et al., 2009). The purpose of this 
study was to identify proteins involved in mechanisms of motor neuron degeneration in 
general, that would facilitate investigation of disease pathways in ALS models with 
heterogeneous genetic background (Bastone et al., 2009). However, increased ALDOA and 
GAPDH levels, identified in cervical but not lumbar spinal cord from Wobbler mice, possibly 
reflect the primary pathology in this mouse model (Bastone et al., 2009), and may not 
necessarily recapitulate changes that are specific to ALS or SMA disease pathways. For 
example, increased levels of GAPDH, identified in proteomic study in skeletal muscles from a 
Wobbler mouse model, and verified biochemically by quantitative western blotting (Staunton, 
Jockusch and Ohlendieck, 2011), contradict the results from SOD1G93A mouse model of ALS, 
where GAPDH levels were decreased in muscles from ALS mice compared to healthy controls 
(Desseille et al., 2017). 
 
Here, GAPDH levels were also decreased in the heart and liver tissue from a severe mouse 
model of SMA using western blotting, and in addition to the spinal cord, unchanged levels of 
GAPDH were demonstrated in the brain and muscle tissues from SMA mice, and in SMA 
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patient fibroblast cells (Figure 3.6). Proteomic studies of SMA identified  downregulation of 
GAPDH levels in hippocampus (Wishart et al., 2010) and Schwann cells (Aghamaleky 
Sarvestany et al., 2014) from SMA mice, and in SMA patient plasma (Kobayashi et al., 2013), 
and so it is possible that differential expression of GAPDH in vulnerable regions of the tissue 
examined (i.e. spinal cord and brain) would get masked in whole tissue extracts.  
  
5.3.7. Impaired ALDOA and GAPDH activity are pathological features of symptomatic 
ALS mice 
Decreased GAPDH activity was previously demonstrated in skeletal muscles from 
symptomatic ALS mice (Pierce et al., 2008), and in line with this, reduction of ALDOA and 
GAPDH activity levels was identified in spinal cord extracts from late-symptomatic ALS mice in 
this study. In contrast, spinal cord extracts from late-symptomatic SMA mice showed no 
significant change in ALDOA and GAPDH activity when compared to age-matched controls. 
Oxidative stress can inform about the possible activity defects, since it was shown to hamper 
the activity of both GAPDH and ALDOA (Koeck et al., 2004; Palamalai and Miyagi, 2010). 
Investigation of oxidative stress in in vitro and in vivo models of SMA, however, showed 
contradicting results (Wang, Zhang and Li, 2013; Miller et al., 2016; Patitucci and Ebert, 2016), 
where motor neuron cultures from SMA mice and human ESC-derived motor neurons showed 
increased production of reactive oxygen species (Wang, Zhang and Li, 2013; Miller et al., 
2016). SMA patient iPSC-derived motor neurons and astrocytes, on the other hand, showed 
decreased levels of reactive oxygen species, and lumbar spinal cord sections from severe SMA 
mice showed unchanged levels of oxidative stress marker 8-hydroxydeoxyguanosine (Patitucci 
and Ebert, 2016). It would be difficult to speculate, therefore, whether unchanged GAPDH and 
ALDOA activity are a real finding in SMA spinal cords, or whether examination of vulnerable 
regions of the spinal cord could produce different results. In addition, increased ALDOA 
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activity levels in CSF from ALS patients (Diószeghy, Mechler and Csenkér, 1981) and in serum 
from type III SMA patients (Mastaglia and Walton, 1971), indicate that different mechanisms 
might be responsible for defects in enzyme activity in different ALS and SMA tissues. 
 
5.3.7.1. Protein nitration was not detected in spinal cord extracts from symptomatic ALS 
mice 
Increased nitrotyrosine levels were shown to impair activity of both ALDOA and GAPDH in 
vitro (Koeck et al., 2004; Palamalai and Miyagi, 2010), but to date, nitration of ALDOA and 
GAPDH has not been investigated specifically in ALS models as a mechanism of dysregulated 
enzyme activity. Here, anti-nitrotyrosine antibody was used to pulldown nitrated proteins 
from spinal cords of control and ALS mice, however, subsequent western blot analysis did not 
identify specific nitrotyrosine bands in either control or ALS mice samples. In addition, western 
blot analysis of whole spinal cord extracts (20μL) from symptomatic ALS mice confirmed the 
results from the pulldown, indicating that protein nitration is not present in ALS mouse spinal 
cords. However, without a positive control (i.e. nitrated purified aldolase A (Koeck et al., 
2004)) this result cannot be interpreted, since technical problems with the antibody are also 
possible. Increased nitrotyrosine levels were previously identified in lumbar and thoracic 
spinal cord from sALS and fALS patients (Beal et al., 1997), in the anterior horn neurons (Sasaki 
et al., 2001) and in whole spinal cords and cerebral cortex from transgenic SOD1 mice (Bruijn 
et al., 1997; Ferrante et al., 1997; Casoni et al., 2005). In addition, Casoni et al. identified 
several protein targets that showed nitration in spinal cord from pre-symptomatic ALS mice, 
GAPDH being one of them (Sasaki et al., 2001). Several studies strongly implicate nitrative 
stress in ALS pathogenesis, and so further research is needed to determine the role for protein 
nitration in GAPDH and ALDOA activity. Elucidating the mechanism of ALDOA and GAPDH 
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activity perturbations in vivo would help to develop targeted therapies, aiming to restore 
metabolic defects and slow disease progression in ALS.  
 
5.3.8. Neurofilament-L levels are not changed in spinal cord from ALS mice 
As a subunit of neurofilament proteins, NF-L regulates different neuronal functions including 
signal conduction, synaptic vesicle trafficking and neurite growth (Didonna and Opal, 2019). 
Neurofilament light (NF-L) is well characterised diagnostic and prognostic marker in ALS, 
(Poesen and Van Damme, 2019), and neurofilament abnormalities have also been directly 
implicated in ALS disease pathogenesis (Williamson et al., 1998; Wong, He and Strong, 2000). 
Decreased NF-L mRNA levels were previously identified in cervical motor neurons from 
sporadic ALS patients (Wong, He and Strong, 2000), and ALDOA was shown to control the 
stability of NF-L mRNA through its nuclease activity (Canete-Soler et al., 2005). It was of 
interest, therefore, to determine whether NF-L is dysregulated on the protein level in this 
study, as this would indicate changes in ALDOA nuclease activity. Western blot analysis did 
identify reduction of NF-L protein levels in spinal cord extracts from late-symptomatic ALS 
mice. This difference, however, was not statistically significant, likely because of the large 
variability in protein expression within the group. It would be of interest in the future to 
determine NF-L expression at both the mRNA and protein level in ALS mouse spinal cords, 
since perturbations in NF-L expression are likely to affect neuronal function on multiple levels. 
If the results showed statistically significant difference, further experiments would need to be 
conducted to demonstrate that ALDOA is driving these defects, including the comparison of 
ALDOA activity from ALS and control samples in vitro.  
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5.4. Conclusion and future work 
5.4.1. ALS-specific disease pathways and therapies 
The main purpose of this work was to determine whether analysis of big data, in combination 
with bioinformatics analysis can help unravel complex disease mechanisms and facilitate 
selection of drug targets. Multi-study comparison identified 42 proteins that showed 
consistent direction of differential expression in ALS tissues and cells across at least two 
proteomic studies, and bioinformatics analysis implicated them in functions including protein 
metabolism, oxidative stress response and energy production. Within these functions, 
different pathways have already been implicated in ALS disease pathogenesis, including for 
example, UPR pathway (Nishitoh et al., 2008) and glycolysis (Palamiuc et al., 2015), confirming 
the validity of this approach. 
 
Identification of several proteins that have not been previously implicated in ALS, offers the 
opportunity to expand knowledge of existing disease pathways or to provide explanation for 
novel mechanisms that drive pathology in ALS. The glycolytic enzymes GAPDH (Basso et al., 
2009; Bastone et al., 2009; Staunton, Jockusch and Ohlendieck, 2011) and ALDOA (Fukada et 
al., 2004; Bastone et al., 2009; Nardo et al., 2011; Staunton, Jockusch and Ohlendieck, 2011; 
Basso et al., 2013) are a good example, as their expression levels were increased across at 
least three proteomic studies of ALS, however, in depth studies of ALDOA and GAPDH 
expression and function in ALS are missing. Glycolysis is the main source of ATP in high energy 
demanding tissues like muscles and neuronal tissues (Jang et al., 2016). Alterations in the 
expression or function of glycolytic enzymes, such as ALDOA and GAPDH, are likely to induce 
defects in energy production that is crucial for the maintenance of neuromuscular health 
(Kanungo et al., 2018). Unchanged ALDOA and GAPDH protein levels, identified biochemically 
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in spinal cord from ALS mice, were not in accordance with proteomic studies of ALS, however, 
differences between experimental models used in each study could explain these 
discrepancies (revised in section 5.3.6). Importantly the activity of both proteins was altered 
at a symptomatic stage of the disease in ALS mouse spinal cords, potentially implicating them 
in disease mechanisms in ALS. 
 
Determining the mechanism of perturbed ALDOA and GAPDH activity is crucial for the 
development of appropriate therapies. Protein nitration is one possible mechanism (Koeck et 
al., 2004; Palamalai and Miyagi, 2010), and although it was not demonstrated in this study, 
protein nitration has been implicated in ALS pathogenesis (Beal et al., 1997; Ferrante et al., 
1997; Sasaki et al., 2001; Casoni et al., 2005). Further studies to examine protein nitration in 
spinal cord tissue, and its implication in GAPDH and ALDOA activity defects, are needed. When 
doing so it would be important to expand the research by including other pathologically 
relevant tissues like muscles, since increased nitrotyrosine levels (Wong and Martin, 2010) 
and decreased GAPDH activity (Pierce et al., 2008) have previously been demonstrated in 
skeletal muscles from ALS mice. 
 
Antioxidant compounds or inhibitors of inducible nitric oxide synthase (iNOS) represent 
potential therapeutic strategies for reducing protein nitration (Sasaki et al., 2001). iNOS is one 
of the enzymes that produces high quantities of NO, and has been implicated in protein 
nitration in ALS (Sasaki et al., 2001). Aminoguanidine, selective iNOS inhibitor, has shown 
success in reducing the levels of nitrotyrosine in A549 cell cultures stimulated with 
inflammatory cytokines (Aulak et al., 2001), and in a rat model of radiculopathy (Lee et al., 
2013), and attenuated muscle weakness in radiculopathy rats (Lee et al., 2013). Edaravone, 
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antioxidant compound, has shown therapeutic benefit in ALS patients, where reduced 
nitrotyrosine levels were detected in CSF of treated patients (Sawada, 2017). However, as 
demonstrated previously in clinical trials with edaravone (Nowicka et al., 2019), targeting 
oxidative stress and protein nitration is likely to have beneficial effect at earlier stages of the 
disease, and can only slow disease progression in ALS patients. 
 
A combinatorial approach, with therapies that would, for example, aim to restore intrinsic 
muscle defects or decrease protein aggregation, could bring greater benefit to ALS patients. 
Indeed, several compounds have been effective in decreasing protein aggregates in animal 
and in vitro models of ALS (Nowicka et al., 2019). These include migration inhibitory factor and 
[4,5-bis{(N-carboxy methyl imidazolium)methyl}acridine] dibromide, that successfully 
decreased SOD1 and TDP-43 aggregates (Nowicka et al., 2019), and could potentially be used 
in combination with antioxidant compounds to alleviate disease symptoms in a wider 
population of ALS patients.   
 
5.4.2. SMA and ALS commonalities 
The molecular overlap between ALS and SMA consists of fifteen proteins, most of which were 
implicated in the regulation of protein metabolism and mitochondria-associated functions. 
Specific pathways, like activation of the unfolded protein repose (UPR) (Atkin et al., 2008; Ng 
et al., 2015) and defects in glycolysis (Palamiuc et al., 2015; Boyd et al., 2017), have already 
been implicated in the pathogenesis of both diseases. The fifteen proteins identified here 
represent the opportunity to study the same pathogenic mechanism in comparable models of 
ALS and SMA. However, as demonstrated in this study, different factors (technical and 
biological) can make this very challenging. 
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Of the five proteins investigated in this study using western blotting, only calreticulin showed 
changed expression in spinal cords from ALS and SMA mice. Detection of HSP90B1 was 
unreliable, likely because of the poor antibody specificity. SOD1 showed increased expression 
only in the spinal cord from ALS mice, while expression of both GAPDH and ALDOA was 
unchanged in ALS and SMA tissues. There are several possible explanations for discrepancies 
between ALS and SMA studies: 
a) First, protein levels in different cell populations or unaffected regions of the spinal cord 
could have masked protein changes that are restricted to vulnerable motor neurons 
(Bernard-Marissal et al., 2012), thus hampering detection of differential expression in 
whole spinal cord extracts. 
b) The experimental model/sample type used in proteomic studies in comparison to 
biochemical study could also help to explain some differences. For example, none of 
the SMA proteomic studies used spinal cord tissue (Fuller, Gillingwater and Wishart, 
2016), suggesting that changes in protein expression might be tissue specific. On the 
other hand, proteomic studies of ALS studied protein profiles in spinal cord from 
Wobbler mouse model (Bastone et al., 2009), making it challenging to correlate this 
results to the whole spinal cord extracts from SOD1G93A mice used in this study. 
c) Some protein changes might be induced or exacerbated with aging (Krisko and 
Radman, 2019), and so eight days old SMA mice and 20-week old ALS mice, although 
pathologically comparable, might not necessarily have the same molecular response 
at given time-points. 
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When taken together, biochemical studies of spinal cord tissue identified very few similarities 
between ALS and SMA, and one of these was calreticulin. Calreticulin showed increased 
expression in the spinal cord from ALS mice, but decreased expression in the spinal cord from 
SMA mice. Designing therapeutic strategies that would simultaneously target calreticulin 
expression in ALS and SMA would therefore be very challenging, and individual strategies 
would have to be applied in each disease.  
 
Genetic approaches for restoring calreticulin levels in spinal cord from ALS and SMA mice 
could be used to assess the effect on NMJ pathology, muscle strength and survival in 
transgenic mouse models. This could be achieved by a knockdown of calreticulin levels in ALS, 
and by calreticulin overexpression in SMA. There is a possibility, however, that decreasing the 
levels of calreticulin in spinal cord from ALS mice would not be beneficial, since overexpression 
of calreticulin in murine SOD1G93A motor neurons showed a positive effect on cell survival 
(Bernard-Marissal et al., 2012). In addition, examination of calreticulin expression in other 
tissues from SMA and ALS mice would help to determine whether systemic or neuronal-
specific restoration of calreticulin levels is necessary.  This is important since both increased 
and decreased levels of calreticulin were shown to impair proper functioning of the heart 
(Gelebart, Opas and Michalak, 2005). 
The second approach to therapy design involves identification of upstream regulators of 
calreticulin expression, and several of these have been identified using IPA software (Stock, 
unpublished Master’s dissertation, 2017). Some of these are already in clinical use, including 
Formoterol, beta-2 receptor agonist used in asthma and chronic obstructive pulmonary 
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disease12, and Azathioprine, anti-inflammatory drug used in rheumatoid arthritis and Crohn’s 
disease13 (Stock, unpublished Master’s dissertation, 2017). Because they already have 
established pharmacokinetic and pharmacodynamic profiles, these compounds are especially 
interesting for drug repurposing (Durães, Pinto and Sousa, 2018). Formoterol, for example, 
could be an interesting choice for SMA, since it was shown to increase calreticulin expression 
in human bronchial smooth muscle cells (Miglino et al., 2012). In addition, treatment with 
Formoterol significantly improved cognitive functions and restored synaptic density in 
hippocampus of Ts65Dn mouse model of Down syndrome (Phillips et al., 2016), showing its 
beneficial effect on neuronal tissue.   
 
Although the same biological functions are impaired in ALS and SMA, biochemical studies of 
spinal cord from SMA and ALS mice produced very little evidence that these changes converge 
on the same molecular mechanism. Comparison of proteomic studies has shown useful for 
identifying core molecular changes in individual diseases, however, a clear molecular link 
between SMA and ALS disease pathways remains to be established. Standardising methods 
for proteomics dataset deposition and presentation would perhaps give better results in the 
future analysis (Martens and Vizcaíno, 2017). Not all proteomic studies publicly present 
complete lists of differentially expressed proteins, while even smaller number of studies 
present raw (unfiltered) data. This can undoubtedly lead to the loss of important information 
that can compromise the integrity of data reanalysis. Comparison of raw datasets would thus 
allow for stringent data processing, increasing the sensitivity and reliability of detected 
information, and allow for better correlation between proteomics and biochemical studies. 
 
12 https://bnf.nice.org.uk/drug/formoterol-fumarate.html 
13 https://bnf.nice.org.uk/drug/azathioprine.html 
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Chapter 6: General discussion and conclusion 
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It is becoming evident that SMN-targeted therapies are not sufficient to completely 
ameliorate pathology in SMA patients (Finkel et al., 2017; Mendell et al., 2017; Mercuri et al., 
2018; Sumner and Crawford, 2018), and other non-SMN targeted approaches, like 
neuroprotection and muscle enhancers (Shorrock, Gillingwater and Groen, 2018), are already 
under development to try to tackle this problem. However, most non-SMN strategies are still 
focused on preserving motor neuron and/or muscle health (chapter 1, section 1.5.2), and so 
peripheral pathologies remain largely overlooked in SMA therapy design. Understanding the 
molecular mechanisms that drive disease pathology in individual tissues is crucial for the 
development of therapies that can target both neuromuscular and systemic pathology. Here, 
core protein changes in SMA, identified by comparison of published proteomic studies of SMA 
(Fuller, Gillingwater and Wishart, 2016), were investigated biochemically across tissues from 
severe Taiwanese mouse model of SMA and in SMA patient fibroblasts, and four of these 
proteins, lamin A/C, UBA1, GAPDH and ANXA2, showed widespread dysregulation in SMA 
tissues and cells. These proteins might have important role in SMA disease pathways across a 
range of tissues, and are therefore worthy of further experimental attention.  
 
Increased levels of lamin A/C, for example, might offer an explanation for previously reported 
cardiac defects in SMA patients and mouse models of SMA, including thinning of the ventricle 
walls and interventricular septum (Shababi et al., 2010; Maxwell et al., 2018), dilation of 
ventricles (Heier et al., 2010; Bogdanik et al., 2015; Maxwell et al., 2018), and decreased 
ejection fraction and blood pooling in ventricles (Yasuma, Kuru and Konagaya, 2004; Roos et 
al., 2009; Heier et al., 2010; Shababi et al., 2012; Bogdanik et al., 2015; Iwahara et al., 2015; 
Maxwell et al., 2018). Further work is clearly warranted to investigate lamin A/C expression 
throughout natural history of disease progression in SMA heart, and to determine the 
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molecular mechanism of lamin A/C dysregulation in SMA tissues/cells. Knowledge of the 
molecular mechanism of lamin A/C dysregulation would aid selection of appropriate 
therapeutic approaches that can restore lamin A/C expression to the levels observed in control 
tissues/cells. These could then be tested in vivo to determine whether systemic restoration of 
lamin A/C levels can rescue peripheral pathology in SMA, with the specific interest in the heart. 
 
It is worth noting too that most of these proteins, including lamin A/C, GAPDH and ANXA2, 
showed both increased and decreased expression in SMA, depending on the tissue/cell type 
examined. These findings highlighted the differential response of different SMA tissues/cells 
to low levels of SMN, however, they also opened a range of new questions that need to be 
addressed. For example, does differential protein expression have pathological significance in 
all cells and tissues examined, and if so, how can these proteins be therapeutically targeted? 
Systemic targeting could result in unwanted protein expression changes, meaning that tissue-
specific approach in therapy design would have to be applied to restore protein levels to the 
ones observed in healthy tissues. Selection of drugs that have the potential to target several 
of these proteins at the same time would therefore be even more challenging. Indeed, drugs 
that have the potential to change the expression of target proteins were already identified in 
this thesis using two different approaches, network pharmacology approach and PubMed 
search. However, when tested in fibroblast cells, the drugs showed no effect on expression of 
target proteins or produced unwanted effects. In addition, technical problems, including large 
variability in protein expression within the treatment group, have also been encountered 
during drug studies which made interpretation of results extremely difficult. The mixed 
pattern of protein expression across different tissues represents yet another challenge for the 
design of therapies that can effectively target several disease pathways at the same time.   
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A multi-study comparison approach was also used here to identify conserved protein changes 
in ALS cells and tissues, with the aim to compare these to the list of conserved protein changes 
from a multi-study comparison of published proteomic studies of SMA (Fuller, Gillingwater 
and Wishart, 2016). This was done to identify pathogenic commonalities between SMA and 
ALS that could potentially be used in a therapy design for both diseases. Fifteen molecules 
were identified as differentially expressed in proteomic studies of SMA and ALS, however, 
when investigated biochemically proteins showed little overlap. Calreticulin was the only 
protein that showed differential expression in the spinal cord from both SMA and ALS mice, 
with the opposite direction of expression change identified in each model. This means that 
individual strategies would likely have to be applied in each disease to normalise calreticulin 
levels, which would prevent development of drug repurposing strategies in SMA and ALS. 
However, the lack of overlap between SMA and ALS could also be a result of different 
biological and technical variations, and so further research in needed to establish a clear 
molecular link between SMA and ALS disease pathways. 
 
The multi-study comparison did, however, successfully identify conserved protein changes in 
ALS tissues and cells, some of which were investigated biochemically in the spinal cord from 
SOD1G93A mouse model of ALS. For example, two essential enzymes of glycolysis, GAPDH and 
ALDOA, showed decreased activity in the spinal cord from symptomatic ALS mice. Glycolysis 
is the main source of ATP in high energy demanding tissues like muscles and neuronal tissues 
(Jang et al., 2016), and so altered function of ALDOA and GAPDH is likely to have pathological 
implications for neuromuscular tissues in ALS. Therapeutic targeting of glycolytic pathways 
could be used as a strategy to preserve motor neuron and muscle health in ALS, although, 
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further studies are also warranted to determine the exact mechanism of ALDOA and GAPDH 
dysregulation in ALS tissues. 
 
In conclusion, the work presented here demonstrated that published proteomic studies 
contain valuable information that are often deposited in supplementary files and disregarded 
in the future work. These proteomic datasets were exploited here to investigate conserved 
protein changes across a range of SMA and ALS tissues and cells. Information, extracted using 
this approach, can be used to expand the understanding of known disease mechanisms or 
inform about the new potential disease pathways, which could then be used to develop new 
therapies for all patients. Development of therapies that can tackle systemic pathology in SMA 
remains one of the main goals of research and clinical community, and data presented here 
might be useful in achieving this goal.  
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Appendix 
 
 Appendix 1. MANLAC 4A7 cross-reaction in LMNA KO MEFs. Representative immunocytochemistry images 
showing lamin A/C staining in wild type and LMNA KO cells, with DAPI shown in blue. 
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Appendix 2. Proteins that were differentially expressed when SMA and control mouse heart tissue extracts were quantitatively compared using iTRAQ 
mass spectrometry 
Accession Name Peptides (95%) Fold change 
(SMA:CTR) 
p-value 
(SMA:CTR) 
EF 
(SMA:CTR) 
INCREASED EXPRESSION      
sp|Q6ZQH8|NU188_MOUSE Nucleoporin NUP188 homolog OS=Mus musculus GN=Nup188 PE=1 SV=2 3 99.083 0.036 1.000 
sp|Q62219|TGFI1_MOUSE Transforming growth factor beta-1-induced transcript 1 protein OS=Mus 
musculus GN=Tgfb1i1 PE=1 SV=2 
2 99.083 0.032 1.000 
sp|Q9Z0P4|PALM_MOUSE Paralemmin-1 OS=Mus musculus GN=Palm PE=1 SV=1 3 99.083 0.020 1.000 
sp|O54946|DNJB6_MOUSE DnaJ homolog subfamily B member 6 OS=Mus musculus GN=Dnajb6 PE=1 
SV=4 
3 99.083 0.020 1.000 
sp|P39655|LOX12_MOUSE Arachidonate 12-lipoxygenase, 12S-type OS=Mus musculus GN=Alox12 PE=1 
SV=4 
3 99.083 0.019 1.000 
sp|P11798|KCC2A_MOUSE Calcium/calmodulin-dependent protein kinase type II subunit alpha OS=Mus 
musculus GN=Camk2a PE=1 SV=2 
9 99.083 0.019 1.000 
sp|Q8BFS6|CPPED_MOUSE Calcineurin-like phosphoesterase domain-containing protein 1 OS=Mus 
musculus GN=Cpped1 PE=2 SV=1 
5 99.083 0.018 1.000 
sp|P62627|DLRB1_MOUSE Dynein light chain roadblock-type 1 OS=Mus musculus GN=Dynlrb1 PE=1 SV=3 2 87.902 0.021 2.291 
sp|Q9D6V8|PAIP2_MOUSE Polyadenylate-binding protein-interacting protein 2 OS=Mus musculus 
GN=Paip2 PE=2 SV=1 
3 87.902 0.021 2.291 
sp|O08734|BAK_MOUSE Bcl-2 homologous antagonist/killer OS=Mus musculus GN=Bak1 PE=1 SV=2 2 87.902 0.020 2.291 
sp|Q7TSQ8|PDPR_MOUSE Pyruvate dehydrogenase phosphatase regulatory subunit, mitochondrial 
OS=Mus musculus GN=Pdpr PE=2 SV=1 
3 87.902 0.020 2.291 
sp|Q91WV0|NC2B_MOUSE Protein Dr1 OS=Mus musculus GN=Dr1 PE=2 SV=1 2 87.902 0.020 2.291 
sp|P61967|AP1S1_MOUSE AP-1 complex subunit sigma-1A OS=Mus musculus GN=Ap1s1 PE=1 SV=1 3 87.902 0.020 2.291 
sp|Q9Z1K6|ARI2_MOUSE E3 ubiquitin-protein ligase ARIH2 OS=Mus musculus GN=Arih2 PE=2 SV=1 2 87.902 0.020 2.291 
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sp|Q924C1|XPO5_MOUSE Exportin-5 OS=Mus musculus GN=Xpo5 PE=2 SV=1 4 87.902 0.020 2.291 
sp|Q8C7R4|UBA6_MOUSE Ubiquitin-like modifier-activating enzyme 6 OS=Mus musculus GN=Uba6 PE=1 
SV=1 
3 87.902 0.019 2.291 
sp|Q61210|ARHG1_MOUSE Rho guanine nucleotide exchange factor 1 OS=Mus musculus GN=Arhgef1 
PE=1 SV=2 
3 87.902 0.019 2.291 
sp|Q62193|RFA2_MOUSE Replication protein A 32 kDa subunit OS=Mus musculus GN=Rpa2 PE=1 SV=1 2 87.902 0.019 2.291 
sp|Q9DCG9|TR112_MOUSE tRNA methyltransferase 112 homolog OS=Mus musculus GN=Trmt112 PE=2 
SV=1 
2 87.902 0.019 2.291 
sp|P70333|HNRH2_MOUSE Heterogeneous nuclear ribonucleoprotein H2 OS=Mus musculus GN=Hnrnph2 
PE=1 SV=1 
18 87.902 0.019 2.291 
sp|P12265|BGLR_MOUSE Beta-glucuronidase OS=Mus musculus GN=Gusb PE=2 SV=2 3 87.902 0.019 2.291 
sp|Q60649|CLPB_MOUSE Caseinolytic peptidase B protein homolog OS=Mus musculus GN=Clpb PE=1 
SV=1 
2 87.902 0.019 2.291 
sp|P84096|RHOG_MOUSE Rho-related GTP-binding protein RhoG OS=Mus musculus GN=Rhog PE=2 SV=1 2 87.902 0.018 2.291 
sp|Q61646|HPT_MOUSE Haptoglobin OS=Mus musculus GN=Hp PE=1 SV=1 2 87.902 0.018 2.291 
sp|Q9JLN9|MTOR_MOUSE Serine/threonine-protein kinase mTOR OS=Mus musculus GN=Mtor PE=1 
SV=2 
8 87.902 0.018 2.291 
sp|P61458|PHS_MOUSE Pterin-4-alpha-carbinolamine dehydratase OS=Mus musculus GN=Pcbd1 PE=1 
SV=2 
3 87.096 0.021 2.270 
sp|Q91WG2|RABE2_MOUSE Rab GTPase-binding effector protein 2 OS=Mus musculus GN=Rabep2 PE=2 
SV=3 
2 87.096 0.018 2.270 
sp|Q3SXD3|HDDC2_MOUSE HD domain-containing protein 2 OS=Mus musculus GN=Hddc2 PE=2 SV=1 3 87.096 0.017 2.270 
sp|O88531|PPT1_MOUSE Palmitoyl-protein thioesterase 1 OS=Mus musculus GN=Ppt1 PE=2 SV=2 5 86.298 0.018 2.249 
sp|Q8VEH3|ARL8A_MOUSE ADP-ribosylation factor-like protein 8A OS=Mus musculus GN=Arl8a PE=2 
SV=1 
5 83.946 0.018 2.270 
sp|Q91VC4|PLVAP_MOUSE Plasmalemma vesicle-associated protein OS=Mus musculus GN=Plvap PE=2 
SV=1 
2 82.414 0.021 2.291 
sp|O35344|IMA3_MOUSE Importin subunit alpha-3 OS=Mus musculus GN=Kpna3 PE=1 SV=1 4 79.433 0.020 2.312 
sp|Q6DVA0|LEMD2_MOUSE LEM domain-containing protein 2 OS=Mus musculus GN=Lemd2 PE=1 SV=1 2 73.790 0.018 2.421 
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sp|P59242|CING_MOUSE Cingulin OS=Mus musculus GN=Cgn PE=1 SV=1 2 67.298 0.020 2.466 
sp|Q80UY2|KCMF1_MOUSE E3 ubiquitin-protein ligase KCMF1 OS=Mus musculus GN=Kcmf1 PE=2 SV=1 2 67.298 0.019 2.489 
sp|Q62141|SIN3B_MOUSE Paired amphipathic helix protein Sin3b OS=Mus musculus GN=Sin3b PE=1 
SV=2 
2 62.517 0.020 2.559 
sp|Q3UHU5|SOGA2_MOUSE Protein SOGA2 OS=Mus musculus GN=Soga2 PE=1 SV=1 4 61.944 0.016 4.055 
sp|P97311|MCM6_MOUSE DNA replication licensing factor MCM6 OS=Mus musculus GN=Mcm6 PE=1 
SV=1 
6 61.376 0.021 2.655 
sp|P17095|HMGA1_MOUSE High mobility group protein HMG-I/HMG-Y OS=Mus musculus GN=Hmga1 
PE=1 SV=4 
2 32.211 0.002 5.105 
sp|P84228|H32_MOUSE Histone H3.2 OS=Mus musculus GN=Hist1h3b PE=1 SV=2 29 27.797 0.000 2.270 
sp|Q61102|ABCB7_MOUSE ATP-binding cassette sub-family B member 7, mitochondrial OS=Mus 
musculus GN=Abcb7 PE=1 SV=3 
6 25.351 0.000 2.965 
sp|P46467|VPS4B_MOUSE Vacuolar protein sorting-associated protein 4B OS=Mus musculus GN=Vps4b 
PE=1 SV=2 
3 23.550 0.001 1.959 
sp|P82349|SGCB_MOUSE Beta-sarcoglycan OS=Mus musculus GN=Sgcb PE=1 SV=1 5 20.701 0.001 4.446 
sp|Q3UV70|PDP1_MOUSE [Pyruvate dehydrogenase [acetyl-transferring]]-phosphatase 1, mitochondrial 
OS=Mus musculus GN=Pdp1 PE=2 SV=1 
4 20.324 0.020 32.509 
sp|P05784|K1C18_MOUSE Keratin, type I cytoskeletal 18 OS=Mus musculus GN=Krt18 PE=1 SV=5 23 19.409 0.002 1.380 
sp|P43276|H15_MOUSE Histone H1.5 OS=Mus musculus GN=Hist1h1b PE=1 SV=2 13 19.231 0.002 1.786 
sp|P43275|H11_MOUSE Histone H1.1 OS=Mus musculus GN=Hist1h1a PE=1 SV=2 4 18.535 0.001 4.018 
sp|P15864|H12_MOUSE Histone H1.2 OS=Mus musculus GN=Hist1h1c PE=1 SV=2 12 17.539 0.015 1.837 
sp|Q8CGB3|UACA_MOUSE Uveal autoantigen with coiled-coil domains and ankyrin repeats OS=Mus 
musculus GN=Uaca PE=1 SV=2 
9 16.904 0.020 19.231 
sp|Q8K0E8|FIBB_MOUSE Fibrinogen beta chain OS=Mus musculus GN=Fgb PE=2 SV=1 36 15.849 0.005 1.445 
sp|Q8CG76|ARK72_MOUSE Aflatoxin B1 aldehyde reductase member 2 OS=Mus musculus GN=Akr7a2 
PE=1 SV=3 
4 15.704 0.028 1.706 
sp|Q9Z2D8|MBD3_MOUSE Methyl-CpG-binding domain protein 3 OS=Mus musculus GN=Mbd3 PE=1 
SV=1 
2 15.560 0.036 32.211 
sp|P11679|K2C8_MOUSE Keratin, type II cytoskeletal 8 OS=Mus musculus GN=Krt8 PE=1 SV=4 33 13.932 0.001 1.343 
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sp|Q8BVQ5|PPME1_MOUSE Protein phosphatase methylesterase 1 OS=Mus musculus GN=Ppme1 PE=1 
SV=5 
4 13.305 0.041 32.211 
sp|Q61687|ATRX_MOUSE Transcriptional regulator ATRX OS=Mus musculus GN=Atrx PE=1 SV=3 5 13.062 0.025 3.837 
sp|Q6PAR5|GAPD1_MOUSE GTPase-activating protein and VPS9 domain-containing protein 1 OS=Mus 
musculus GN=Gapvd1 PE=1 SV=2 
3 12.823 0.036 32.211 
sp|Q8K3H5|MYO3A_MOUSE Myosin-IIIa OS=Mus musculus GN=Myo3a PE=2 SV=1 4 12.589 0.035 4.699 
sp|Q6PDL0|DC1L2_MOUSE Cytoplasmic dynein 1 light intermediate chain 2 OS=Mus musculus 
GN=Dync1li2 PE=1 SV=2 
4 10.965 0.002 4.446 
sp|P43025|TETN_MOUSE Tetranectin OS=Mus musculus GN=Clec3b PE=1 SV=2 2 10.568 0.034 2.831 
sp|Q80WJ7|LYRIC_MOUSE Protein LYRIC OS=Mus musculus GN=Mtdh PE=1 SV=1 3 10.280 0.037 5.200 
sp|Q99JI6|RAP1B_MOUSE Ras-related protein Rap-1b OS=Mus musculus GN=Rap1b PE=2 SV=2 14 10.000 0.041 31.623 
sp|G5E8K5|ANK3_MOUSE Ankyrin-3 OS=Mus musculus GN=Ank3 PE=1 SV=1 10 9.638 0.001 3.311 
sp|Q80W54|FACE1_MOUSE CAAX prenyl protease 1 homolog OS=Mus musculus GN=Zmpste24 PE=1 SV=2 2 9.462 0.019 31.623 
sp|P10605|CATB_MOUSE Cathepsin B OS=Mus musculus GN=Ctsb PE=1 SV=2 8 8.790 0.046 1.995 
sp|A4Q9F4|TTL11_MOUSE Tubulin polyglutamylase TTLL11 OS=Mus musculus GN=Ttll11 PE=2 SV=1 2 8.790 0.041 33.113 
sp|Q9D8S9|BOLA1_MOUSE BolA-like protein 1 OS=Mus musculus GN=Bola1 PE=1 SV=1 2 8.790 0.002 4.487 
sp|Q8R3B1|PLCD1_MOUSE 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1 OS=Mus 
musculus GN=Plcd1 PE=2 SV=2 
5 8.472 0.043 31.623 
sp|Q8VCM7|FIBG_MOUSE Fibrinogen gamma chain OS=Mus musculus GN=Fgg PE=2 SV=1 28 8.166 0.006 1.380 
sp|P57784|RU2A_MOUSE U2 small nuclear ribonucleoprotein A' OS=Mus musculus GN=Snrpa1 PE=1 
SV=2 
3 8.091 0.038 31.333 
sp|Q8R2G4|NAR3_MOUSE Ecto-ADP-ribosyltransferase 3 OS=Mus musculus GN=Art3 PE=2 SV=2 4 8.091 0.001 4.487 
sp|Q80U72|SCRIB_MOUSE Protein scribble homolog OS=Mus musculus GN=Scrib PE=1 SV=2 2 7.516 0.039 4.487 
sp|Q8K2C6|SIR5_MOUSE NAD-dependent protein deacylase sirtuin-5, mitochondrial OS=Mus musculus 
GN=Sirt5 PE=1 SV=1 
2 7.516 0.001 6.252 
sp|B2RU80|PTPRB_MOUSE Receptor-type tyrosine-protein phosphatase beta OS=Mus musculus 
GN=Ptprb PE=1 SV=1 
2 7.447 0.001 3.597 
sp|Q9EPS3|GLCE_MOUSE D-glucuronyl C5-epimerase OS=Mus musculus GN=Glce PE=1 SV=2 2 7.244 0.003 4.446 
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sp|P07759|SPA3K_MOUSE Serine protease inhibitor A3K OS=Mus musculus GN=Serpina3k PE=1 SV=2 19 7.178 0.015 1.419 
sp|P28843|DPP4_MOUSE Dipeptidyl peptidase 4 OS=Mus musculus GN=Dpp4 PE=1 SV=3 3 7.112 0.004 4.487 
sp|Q6P1F6|2ABA_MOUSE Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha 
isoform OS=Mus musculus GN=Ppp2r2a PE=1 SV=1 
3 6.855 0.035 33.420 
sp|Q61233|PLSL_MOUSE Plastin-2 OS=Mus musculus GN=Lcp1 PE=1 SV=4 14 6.730 0.030 1.803 
sp|Q9D8E6|RL4_MOUSE 60S ribosomal protein L4 OS=Mus musculus GN=Rpl4 PE=1 SV=3 10 6.607 0.041 1.500 
sp|Q04857|CO6A1_MOUSE Collagen alpha-1(VI) chain OS=Mus musculus GN=Col6a1 PE=2 SV=1 29 6.607 0.025 1.282 
sp|P62806|H4_MOUSE Histone H4 OS=Mus musculus GN=Hist1h4a PE=1 SV=2 37 6.081 0.010 1.445 
sp|P17047|LAMP2_MOUSE Lysosome-associated membrane glycoprotein 2 OS=Mus musculus GN=Lamp2 
PE=2 SV=2 
2 5.058 0.015 2.729 
sp|Q9JLC8|SACS_MOUSE Sacsin OS=Mus musculus GN=Sacs PE=1 SV=2 6 4.742 0.004 4.446 
sp|Q9CQD1|RAB5A_MOUSE Ras-related protein Rab-5A OS=Mus musculus GN=Rab5a PE=1 SV=1 5 4.742 0.003 3.664 
sp|Q8BI84|MIA3_MOUSE Melanoma inhibitory activity protein 3 OS=Mus musculus GN=Mia3 PE=1 SV=2 2 4.656 0.043 31.333 
sp|Q9CQW2|ARL8B_MOUSE ADP-ribosylation factor-like protein 8B OS=Mus musculus GN=Arl8b PE=2 
SV=1 
5 4.613 0.019 4.446 
sp|Q9WVH9|FBLN5_MOUSE Fibulin-5 OS=Mus musculus GN=Fbln5 PE=2 SV=1 13 4.571 0.035 1.406 
sp|Q9CPY7|AMPL_MOUSE Cytosol aminopeptidase OS=Mus musculus GN=Lap3 PE=1 SV=3 20 4.487 0.012 1.854 
sp|Q9CSU0|RPR1B_MOUSE Regulation of nuclear pre-mRNA domain-containing protein 1B OS=Mus 
musculus GN=Rprd1b PE=1 SV=2 
2 4.406 0.002 4.529 
sp|P97449|AMPN_MOUSE Aminopeptidase N OS=Mus musculus GN=Anpep PE=1 SV=4 11 4.130 0.019 2.291 
sp|P48678|LMNA_MOUSE Prelamin-A/C OS=Mus musculus GN=Lmna PE=1 SV=2 47 4.130 0.004 1.225 
sp|Q9DBH5|LMAN2_MOUSE Vesicular integral-membrane protein VIP36 OS=Mus musculus GN=Lman2 
PE=2 SV=2 
5 4.093 0.003 2.188 
sp|P61358|RL27_MOUSE 60S ribosomal protein L27 OS=Mus musculus GN=Rpl27 PE=2 SV=2 8 4.018 0.004 2.032 
sp|P18242|CATD_MOUSE Cathepsin D OS=Mus musculus GN=Ctsd PE=1 SV=1 18 3.981 0.003 1.570 
sp|Q6R0H7|GNAS1_MOUSE Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas OS=Mus 
musculus GN=Gnas PE=2 SV=1 
7 3.908 0.041 2.965 
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sp|Q9D1X0|NOL3_MOUSE Nucleolar protein 3 OS=Mus musculus GN=Nol3 PE=1 SV=1 6 3.733 0.052 4.487 
sp|Q91YE8|SYNP2_MOUSE Synaptopodin-2 OS=Mus musculus GN=Synpo2 PE=1 SV=2 8 3.733 0.007 2.780 
sp|P45376|ALDR_MOUSE Aldose reductase OS=Mus musculus GN=Akr1b1 PE=1 SV=3 24 3.664 0.000 1.169 
sp|Q8BVZ1|PLIN5_MOUSE Perilipin-5 OS=Mus musculus GN=Plin5 PE=1 SV=1 4 3.532 0.047 4.699 
sp|Q3TJD7|PDLI7_MOUSE PDZ and LIM domain protein 7 OS=Mus musculus GN=Pdlim7 PE=2 SV=1 2 3.436 0.019 2.704 
sp|Q60770|STXB3_MOUSE Syntaxin-binding protein 3 OS=Mus musculus GN=Stxbp3 PE=1 SV=1 3 3.311 0.031 14.191 
sp|Q6PDQ2|CHD4_MOUSE Chromodomain-helicase-DNA-binding protein 4 OS=Mus musculus GN=Chd4 
PE=1 SV=1 
8 3.281 0.019 4.406 
sp|P17182|ENOA_MOUSE Alpha-enolase OS=Mus musculus GN=Eno1 PE=1 SV=3 70 3.251 0.004 1.419 
sp|Q8K1J6|TRNT1_MOUSE CCA tRNA nucleotidyltransferase 1, mitochondrial OS=Mus musculus 
GN=Trnt1 PE=2 SV=1 
2 3.048 0.046 4.446 
sp|P37804|TAGL_MOUSE Transgelin OS=Mus musculus GN=Tagln PE=1 SV=3 22 3.048 0.002 1.247 
sp|Q8CHT0|AL4A1_MOUSE Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial OS=Mus 
musculus GN=Aldh4a1 PE=1 SV=3 
16 3.020 0.030 1.368 
sp|O08677|KNG1_MOUSE Kininogen-1 OS=Mus musculus GN=Kng1 PE=1 SV=1 26 2.992 0.044 1.330 
sp|P10852|4F2_MOUSE 4F2 cell-surface antigen heavy chain OS=Mus musculus GN=Slc3a2 PE=1 SV=1 4 2.938 0.016 2.729 
sp|P24452|CAPG_MOUSE Macrophage-capping protein OS=Mus musculus GN=Capg PE=1 SV=2 3 2.911 0.038 28.314 
sp|Q6PGC1|DHX29_MOUSE ATP-dependent RNA helicase Dhx29 OS=Mus musculus GN=Dhx29 PE=2 SV=1 3 2.780 0.001 4.742 
sp|P09671|SODM_MOUSE Superoxide dismutase [Mn], mitochondrial OS=Mus musculus GN=Sod2 PE=1 
SV=3 
21 2.754 0.031 1.236 
sp|Q60675|LAMA2_MOUSE Laminin subunit alpha-2 OS=Mus musculus GN=Lama2 PE=1 SV=1 54 2.489 0.048 1.169 
sp|P97478|COQ7_MOUSE Ubiquinone biosynthesis protein COQ7 homolog OS=Mus musculus GN=Coq7 
PE=2 SV=3 
4 2.421 0.001 2.089 
sp|Q9CWE0|FA54B_MOUSE Protein FAM54B OS=Mus musculus GN=Fam54b PE=1 SV=1 3 2.399 0.004 2.729 
sp|Q61292|LAMB2_MOUSE Laminin subunit beta-2 OS=Mus musculus GN=Lamb2 PE=2 SV=2 30 2.377 0.005 1.888 
sp|Q61554|FBN1_MOUSE Fibrillin-1 OS=Mus musculus GN=Fbn1 PE=1 SV=1 28 2.355 0.048 1.236 
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sp|Q99KK2|NEUA_MOUSE N-acylneuraminate cytidylyltransferase OS=Mus musculus GN=Cmas PE=1 
SV=2 
4 2.312 0.033 4.446 
sp|Q9JK48|SHLB1_MOUSE Endophilin-B1 OS=Mus musculus GN=Sh3glb1 PE=1 SV=1 4 2.291 0.002 2.421 
sp|Q3TTY5|K22E_MOUSE Keratin, type II cytoskeletal 2 epidermal OS=Mus musculus GN=Krt2 PE=1 SV=1 2 2.270 0.045 5.012 
sp|Q91WK0|LRRF2_MOUSE Leucine-rich repeat flightless-interacting protein 2 OS=Mus musculus 
GN=Lrrfip2 PE=1 SV=1 
8 2.270 0.015 2.228 
sp|P30681|HMGB2_MOUSE High mobility group protein B2 OS=Mus musculus GN=Hmgb2 PE=1 SV=3 12 2.249 0.045 1.754 
sp|P40142|TKT_MOUSE Transketolase OS=Mus musculus GN=Tkt PE=1 SV=1 23 2.249 0.037 1.191 
sp|P04444|HBBZ_MOUSE Hemoglobin subunit beta-H1 OS=Mus musculus GN=Hbb-bh1 PE=2 SV=3 8 2.188 0.003 1.514 
sp|Q9ESB3|HRG_MOUSE Histidine-rich glycoprotein OS=Mus musculus GN=Hrg PE=1 SV=2 3 2.168 0.040 4.446 
sp|Q5XKE0|MYPC2_MOUSE Myosin-binding protein C, fast-type OS=Mus musculus GN=Mybpc2 PE=1 SV=1 3 2.148 0.007 3.281 
sp|P05125|ANF_MOUSE Natriuretic peptides A OS=Mus musculus GN=Nppa PE=1 SV=2 32 2.148 0.006 1.225 
sp|Q811D0|DLG1_MOUSE Disks large homolog 1 OS=Mus musculus GN=Dlg1 PE=1 SV=1 3 2.128 0.019 4.487 
sp|Q9DCV7|K2C7_MOUSE Keratin, type II cytoskeletal 7 OS=Mus musculus GN=Krt7 PE=1 SV=1 10 2.109 0.021 2.704 
sp|P04919|B3AT_MOUSE Band 3 anion transport protein OS=Mus musculus GN=Slc4a1 PE=1 SV=1 39 2.089 0.004 1.180 
sp|Q9CQX2|CYB5B_MOUSE Cytochrome b5 type B OS=Mus musculus GN=Cyb5b PE=1 SV=1 2 2.089 0.003 2.729 
sp|Q9QWY8|ASAP1_MOUSE Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 
OS=Mus musculus GN=Asap1 PE=1 SV=2 
4 2.070 0.007 5.012 
sp|Q9WVA3|BUB3_MOUSE Mitotic checkpoint protein BUB3 OS=Mus musculus GN=Bub3 PE=2 SV=2 3 2.070 0.001 2.014 
sp|P04370|MBP_MOUSE Myelin basic protein OS=Mus musculus GN=Mbp PE=1 SV=2 4 2.032 0.034 2.965 
sp|Q64152|BTF3_MOUSE Transcription factor BTF3 OS=Mus musculus GN=Btf3 PE=2 SV=3 9 2.014 0.004 2.729 
sp|P31428|DPEP1_MOUSE Dipeptidase 1 OS=Mus musculus GN=Dpep1 PE=1 SV=2 7 1.995 0.039 1.514 
sp|Q8K4G5|ABLM1_MOUSE Actin-binding LIM protein 1 OS=Mus musculus GN=Ablim1 PE=1 SV=1 20 1.995 0.016 1.225 
sp|Q9CRD2|EMC2_MOUSE ER membrane protein complex subunit 2 OS=Mus musculus GN=Emc2 PE=2 
SV=1 
2 1.977 0.045 4.487 
sp|Q99KN9|EPN4_MOUSE Clathrin interactor 1 OS=Mus musculus GN=Clint1 PE=1 SV=2 6 1.977 0.024 2.729 
sp|O70622|RTN2_MOUSE Reticulon-2 OS=Mus musculus GN=Rtn2 PE=1 SV=1 6 1.941 0.004 3.802 
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sp|Q8C7H1|MMAA_MOUSE Methylmalonic aciduria type A homolog, mitochondrial OS=Mus musculus 
GN=Mmaa PE=2 SV=1 
2 1.923 0.037 2.729 
sp|Q61234|SNTA1_MOUSE Alpha-1-syntrophin OS=Mus musculus GN=Snta1 PE=1 SV=1 5 1.905 0.008 1.722 
sp|Q9WUZ7|SH3BG_MOUSE SH3 domain-binding glutamic acid-rich protein OS=Mus musculus GN=Sh3bgr 
PE=2 SV=1 
5 1.888 0.034 1.259 
sp|P62315|SMD1_MOUSE Small nuclear ribonucleoprotein Sm D1 OS=Mus musculus GN=Snrpd1 PE=2 
SV=1 
2 1.854 0.043 4.446 
sp|P07356|ANXA2_MOUSE Annexin A2 OS=Mus musculus GN=Anxa2 PE=1 SV=2 44 1.854 0.001 1.191 
sp|Q6DFW4|NOP58_MOUSE Nucleolar protein 58 OS=Mus musculus GN=Nop58 PE=1 SV=1 6 1.820 0.043 4.571 
sp|Q3UM45|PP1R7_MOUSE Protein phosphatase 1 regulatory subunit 7 OS=Mus musculus GN=Ppp1r7 
PE=1 SV=2 
12 1.820 0.011 1.247 
sp|Q9DAW9|CNN3_MOUSE Calponin-3 OS=Mus musculus GN=Cnn3 PE=2 SV=1 6 1.820 0.001 2.399 
sp|Q8BR92|PALM2_MOUSE Paralemmin-2 OS=Mus musculus GN=Palm2 PE=1 SV=1 2 1.738 0.042 23.550 
sp|Q921J2|RHEB_MOUSE GTP-binding protein Rheb OS=Mus musculus GN=Rheb PE=1 SV=1 2 1.614 0.037 4.446 
sp|P70336|ROCK2_MOUSE Rho-associated protein kinase 2 OS=Mus musculus GN=Rock2 PE=1 SV=1 8 1.614 0.020 22.909 
sp|Q9ER72|SYCC_MOUSE Cysteine--tRNA ligase, cytoplasmic OS=Mus musculus GN=Cars PE=1 SV=2 6 1.614 0.018 1.923 
sp|Q91WU5|AS3MT_MOUSE Arsenite methyltransferase OS=Mus musculus GN=As3mt PE=2 SV=2 2 1.585 0.036 2.312 
sp|P11276|FINC_MOUSE Fibronectin OS=Mus musculus GN=Fn1 PE=1 SV=4 76 1.585 0.009 1.107 
sp|Q9D7J9|ECHD3_MOUSE Enoyl-CoA hydratase domain-containing protein 3, mitochondrial OS=Mus 
musculus GN=Echdc3 PE=2 SV=1 
2 1.570 0.039 22.699 
sp|Q99K85|SERC_MOUSE Phosphoserine aminotransferase OS=Mus musculus GN=Psat1 PE=1 SV=1 2 1.570 0.010 4.529 
sp|Q6A068|CDC5L_MOUSE Cell division cycle 5-like protein OS=Mus musculus GN=Cdc5l PE=1 SV=2 4 1.542 0.006 2.858 
sp|P08032|SPTA1_MOUSE Spectrin alpha chain, erythrocytic 1 OS=Mus musculus GN=Spta1 PE=2 SV=3 95 1.514 0.023 1.259 
sp|Q9WVA4|TAGL2_MOUSE Transgelin-2 OS=Mus musculus GN=Tagln2 PE=1 SV=4 36 1.486 0.053 1.191 
sp|Q9CPQ3|TOM22_MOUSE Mitochondrial import receptor subunit TOM22 homolog OS=Mus musculus 
GN=Tomm22 PE=2 SV=3 
6 1.472 0.002 3.105 
sp|Q03958|PFD6_MOUSE Prefoldin subunit 6 OS=Mus musculus GN=Pfdn6 PE=2 SV=1 2 1.459 0.038 4.446 
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sp|Q8BHC4|DCAKD_MOUSE Dephospho-CoA kinase domain-containing protein OS=Mus musculus 
GN=Dcakd PE=2 SV=1 
2 1.459 0.018 1.977 
sp|Q8K4L3|SVIL_MOUSE Supervillin OS=Mus musculus GN=Svil PE=1 SV=1 5 1.459 0.006 4.529 
sp|Q8VE95|CH082_MOUSE UPF0598 protein C8orf82 homolog OS=Mus musculus PE=2 SV=1 2 1.459 0.001 1.706 
sp|P15508|SPTB1_MOUSE Spectrin beta chain, erythrocytic OS=Mus musculus GN=Sptb PE=1 SV=4 87 1.445 0.012 1.213 
sp|P97447|FHL1_MOUSE Four and a half LIM domains protein 1 OS=Mus musculus GN=Fhl1 PE=2 SV=3 9 1.432 0.012 1.282 
sp|O08582|GTPB1_MOUSE GTP-binding protein 1 OS=Mus musculus GN=Gtpbp1 PE=1 SV=2 3 1.393 0.053 4.446 
sp|Q9CX80|CYGB_MOUSE Cytoglobin OS=Mus musculus GN=Cygb PE=2 SV=1 3 1.380 0.043 1.941 
sp|Q8CC88|VWA8_MOUSE von Willebrand factor A domain-containing protein 8 OS=Mus musculus 
GN=Vwa8 PE=2 SV=2 
33 1.380 0.018 1.236 
sp|P46412|GPX3_MOUSE Glutathione peroxidase 3 OS=Mus musculus GN=Gpx3 PE=2 SV=2 7 1.380 0.012 1.259 
sp|Q9QZE7|TSNAX_MOUSE Translin-associated protein X OS=Mus musculus GN=Tsnax PE=1 SV=1 3 1.368 0.034 1.380 
sp|Q9JM76|ARPC3_MOUSE Actin-related protein 2/3 complex subunit 3 OS=Mus musculus GN=Arpc3 
PE=1 SV=3 
5 1.355 0.042 1.236 
sp|Q9EPK7|XPO7_MOUSE Exportin-7 OS=Mus musculus GN=Xpo7 PE=2 SV=3 5 1.343 0.032 2.208 
sp|Q3TL44|NLRX1_MOUSE NLR family member X1 OS=Mus musculus GN=Nlrx1 PE=2 SV=1 2 1.330 0.019 1.556 
sp|P32233|DRG1_MOUSE Developmentally-regulated GTP-binding protein 1 OS=Mus musculus GN=Drg1 
PE=1 SV=1 
3 1.318 0.050 1.343 
sp|Q571C7|BDP1_MOUSE Transcription factor TFIIIB component B'' homolog OS=Mus musculus 
GN=Bdp1 PE=2 SV=2 
2 1.306 0.040 5.200 
sp|P17710|HXK1_MOUSE Hexokinase-1 OS=Mus musculus GN=Hk1 PE=1 SV=3 57 1.306 0.037 1.117 
sp|Q9ES82|POPD2_MOUSE Popeye domain-containing protein 2 OS=Mus musculus GN=Popdc2 PE=2 
SV=1 
2 1.282 0.002 1.148 
DECREASED EXPRESSION 
     
sp|Q9Z126|PLF4_MOUSE Platelet factor 4 OS=Mus musculus GN=Pf4 PE=2 SV=1 2 0.731 0.054 21.478 
sp|Q9D7G0|PRPS1_MOUSE Ribose-phosphate pyrophosphokinase 1 OS=Mus musculus GN=Prps1 PE=1 
SV=4 
4 0.711 0.054 1.738 
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sp|Q920A5|RISC_MOUSE Retinoid-inducible serine carboxypeptidase OS=Mus musculus GN=Scpep1 
PE=2 SV=2 
4 0.705 0.006 1.786 
sp|Q9WV80|SNX1_MOUSE Sorting nexin-1 OS=Mus musculus GN=Snx1 PE=1 SV=1 6 0.692 0.017 2.729 
sp|Q9D1M0|SEC13_MOUSE Protein SEC13 homolog OS=Mus musculus GN=Sec13 PE=2 SV=3 3 0.667 0.039 1.888 
sp|Q9JI46|NUDT3_MOUSE Diphosphoinositol polyphosphate phosphohydrolase 1 OS=Mus musculus 
GN=Nudt3 PE=1 SV=1 
2 0.661 0.049 2.051 
sp|P60824|CIRBP_MOUSE Cold-inducible RNA-binding protein OS=Mus musculus GN=Cirbp PE=1 SV=1 3 0.655 0.009 4.529 
sp|Q9CQF3|CPSF5_MOUSE Cleavage and polyadenylation specificity factor subunit 5 OS=Mus musculus 
GN=Nudt21 PE=2 SV=1 
2 0.643 0.010 2.729 
sp|Q9DBC7|KAP0_MOUSE cAMP-dependent protein kinase type I-alpha regulatory subunit OS=Mus 
musculus GN=Prkar1a PE=1 SV=3 
15 0.637 0.045 1.202 
sp|Q9QXS1|PLEC_MOUSE Plectin OS=Mus musculus GN=Plec PE=1 SV=2 150 0.637 0.043 1.076 
sp|Q64213|SF01_MOUSE Splicing factor 1 OS=Mus musculus GN=Sf1 PE=1 SV=6 5 0.631 0.038 1.786 
sp|Q99L04|DHRS1_MOUSE Dehydrogenase/reductase SDR family member 1 OS=Mus musculus GN=Dhrs1 
PE=2 SV=1 
2 0.625 0.031 2.729 
sp|Q8BL66|EEA1_MOUSE Early endosome antigen 1 OS=Mus musculus GN=Eea1 PE=2 SV=2 11 0.614 0.048 1.472 
sp|Q91XQ0|DYH8_MOUSE Dynein heavy chain 8, axonemal OS=Mus musculus GN=Dnahc8 PE=2 SV=2 7 0.614 0.025 1.614 
sp|Q9D9V3|ECHD1_MOUSE Ethylmalonyl-CoA decarboxylase OS=Mus musculus GN=Echdc1 PE=1 SV=2 3 0.608 0.011 1.528 
sp|Q9R062|GLYG_MOUSE Glycogenin-1 OS=Mus musculus GN=Gyg1 PE=2 SV=3 11 0.592 0.054 1.486 
sp|Q9CQS4|S2546_MOUSE Solute carrier family 25 member 46 OS=Mus musculus GN=Slc25a46 PE=1 
SV=1 
4 0.586 0.027 2.992 
sp|Q9CQC9|SAR1B_MOUSE GTP-binding protein SAR1b OS=Mus musculus GN=Sar1b PE=1 SV=1 9 0.586 0.025 1.459 
sp|Q8VDD5|MYH9_MOUSE Myosin-9 OS=Mus musculus GN=Myh9 PE=1 SV=4 145 0.581 0.019 1.096 
sp|Q91YH5|ATLA3_MOUSE Atlastin-3 OS=Mus musculus GN=Atl3 PE=2 SV=1 3 0.575 0.036 4.487 
sp|Q91W50|CSDE1_MOUSE Cold shock domain-containing protein E1 OS=Mus musculus GN=Csde1 PE=2 
SV=1 
3 0.570 0.052 1.837 
sp|Q71LX4|TLN2_MOUSE Talin-2 OS=Mus musculus GN=Tln2 PE=1 SV=3 65 0.570 0.029 1.368 
sp|P09103|PDIA1_MOUSE Protein disulfide-isomerase OS=Mus musculus GN=P4hb PE=1 SV=2 59 0.555 0.022 1.202 
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sp|Q9JI39|ABCBA_MOUSE ATP-binding cassette sub-family B member 10, mitochondrial OS=Mus 
musculus GN=Abcb10 PE=2 SV=1 
4 0.550 0.005 1.854 
sp|Q1HFZ0|NSUN2_MOUSE tRNA (cytosine(34)-C(5))-methyltransferase OS=Mus musculus GN=Nsun2 
PE=1 SV=2 
5 0.540 0.030 4.446 
sp|P62259|1433E_MOUSE 14-3-3 protein epsilon OS=Mus musculus GN=Ywhae PE=1 SV=1 38 0.535 0.030 1.213 
sp|P08113|ENPL_MOUSE Endoplasmin OS=Mus musculus GN=Hsp90b1 PE=1 SV=2 50 0.530 0.041 1.202 
sp|Q3B7Z2|OSBP1_MOUSE Oxysterol-binding protein 1 OS=Mus musculus GN=Osbp PE=1 SV=2 4 0.525 0.028 1.459 
sp|O35972|RM23_MOUSE 39S ribosomal protein L23, mitochondrial OS=Mus musculus GN=Mrpl23 PE=2 
SV=1 
2 0.525 0.011 1.600 
sp|Q8BX02|KANK2_MOUSE KN motif and ankyrin repeat domain-containing protein 2 OS=Mus musculus 
GN=Kank2 PE=1 SV=1 
3 0.520 0.051 24.210 
sp|Q61941|NNTM_MOUSE NAD(P) transhydrogenase, mitochondrial OS=Mus musculus GN=Nnt PE=1 
SV=2 
42 0.520 0.000 1.127 
sp|P63017|HSP7C_MOUSE Heat shock cognate 71 kDa protein OS=Mus musculus GN=Hspa8 PE=1 SV=1 103 0.515 0.047 1.117 
sp|P27773|PDIA3_MOUSE Protein disulfide-isomerase A3 OS=Mus musculus GN=Pdia3 PE=1 SV=2 35 0.511 0.020 1.138 
sp|P62192|PRS4_MOUSE 26S protease regulatory subunit 4 OS=Mus musculus GN=Psmc1 PE=1 SV=1 19 0.501 0.031 1.247 
sp|Q9D0F9|PGM1_MOUSE Phosphoglucomutase-1 OS=Mus musculus GN=Pgm1 PE=1 SV=4 50 0.497 0.044 1.294 
sp|Q9JI91|ACTN2_MOUSE Alpha-actinin-2 OS=Mus musculus GN=Actn2 PE=1 SV=2 191 0.497 0.003 1.086 
sp|Q6ZQ38|CAND1_MOUSE Cullin-associated NEDD8-dissociated protein 1 OS=Mus musculus GN=Cand1 
PE=2 SV=2 
29 0.492 0.015 1.191 
sp|Q3UHX2|HAP28_MOUSE 28 kDa heat- and acid-stable phosphoprotein OS=Mus musculus GN=Pdap1 
PE=1 SV=1 
4 0.488 0.013 4.093 
sp|O08807|PRDX4_MOUSE Peroxiredoxin-4 OS=Mus musculus GN=Prdx4 PE=1 SV=1 7 0.483 0.013 4.487 
sp|O35737|HNRH1_MOUSE Heterogeneous nuclear ribonucleoprotein H OS=Mus musculus GN=Hnrnph1 
PE=1 SV=3 
22 0.479 0.013 2.109 
sp|Q9DCF9|SSRG_MOUSE Translocon-associated protein subunit gamma OS=Mus musculus GN=Ssr3 
PE=1 SV=1 
4 0.474 0.039 2.754 
sp|Q921I1|TRFE_MOUSE Serotransferrin OS=Mus musculus GN=Tf PE=1 SV=1 144 0.474 0.001 1.169 
sp|P14211|CALR_MOUSE Calreticulin OS=Mus musculus GN=Calr PE=1 SV=1 33 0.466 0.010 1.406 
412 
 
sp|Q99MR8|MCCA_MOUSE Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial OS=Mus 
musculus GN=Mccc1 PE=2 SV=2 
4 0.461 0.053 4.446 
sp|Q9D8N0|EF1G_MOUSE Elongation factor 1-gamma OS=Mus musculus GN=Eef1g PE=1 SV=3 24 0.445 0.033 1.330 
sp|P80314|TCPB_MOUSE T-complex protein 1 subunit beta OS=Mus musculus GN=Cct2 PE=1 SV=4 38 0.445 0.004 1.202 
sp|O35295|PURB_MOUSE Transcriptional activator protein Pur-beta OS=Mus musculus GN=Purb PE=1 
SV=3 
7 0.441 0.019 2.831 
sp|Q8BH59|CMC1_MOUSE Calcium-binding mitochondrial carrier protein Aralar1 OS=Mus musculus 
GN=Slc25a12 PE=1 SV=1 
42 0.437 0.025 1.169 
sp|Q9DC77|SMPX_MOUSE Small muscular protein OS=Mus musculus GN=Smpx PE=2 SV=2 4 0.433 0.005 1.472 
sp|Q8BMJ3|IF1AX_MOUSE Eukaryotic translation initiation factor 1A, X-chromosomal OS=Mus musculus 
GN=Eif1ax PE=2 SV=3 
6 0.425 0.013 1.660 
sp|Q99N92|RM27_MOUSE 39S ribosomal protein L27, mitochondrial OS=Mus musculus GN=Mrpl27 PE=2 
SV=1 
3 0.413 0.017 2.188 
sp|P14824|ANXA6_MOUSE Annexin A6 OS=Mus musculus GN=Anxa6 PE=1 SV=3 62 0.413 0.002 1.138 
sp|P20029|GRP78_MOUSE 78 kDa glucose-regulated protein OS=Mus musculus GN=Hspa5 PE=1 SV=3 64 0.406 0.033 1.117 
sp|P62843|RS15_MOUSE 40S ribosomal protein S15 OS=Mus musculus GN=Rps15 PE=2 SV=2 11 0.406 0.009 1.854 
sp|Q9DB77|QCR2_MOUSE Cytochrome b-c1 complex subunit 2, mitochondrial OS=Mus musculus 
GN=Uqcrc2 PE=1 SV=1 
94 0.406 0.001 1.259 
sp|Q61768|KINH_MOUSE Kinesin-1 heavy chain OS=Mus musculus GN=Kif5b PE=1 SV=3 32 0.402 0.002 1.330 
sp|P99024|TBB5_MOUSE Tubulin beta-5 chain OS=Mus musculus GN=Tubb5 PE=1 SV=1 100 0.384 0.054 1.282 
sp|P09411|PGK1_MOUSE Phosphoglycerate kinase 1 OS=Mus musculus GN=Pgk1 PE=1 SV=4 74 0.373 0.036 1.213 
sp|Q99KI0|ACON_MOUSE Aconitate hydratase, mitochondrial OS=Mus musculus GN=Aco2 PE=1 SV=1 151 0.370 0.006 1.096 
sp|Q9CY58|PAIRB_MOUSE Plasminogen activator inhibitor 1 RNA-binding protein OS=Mus musculus 
GN=Serbp1 PE=1 SV=2 
13 0.363 0.014 1.570 
sp|P54731|FAF1_MOUSE FAS-associated factor 1 OS=Mus musculus GN=Faf1 PE=1 SV=2 6 0.360 0.019 4.285 
sp|P14152|MDHC_MOUSE Malate dehydrogenase, cytoplasmic OS=Mus musculus GN=Mdh1 PE=1 SV=3 74 0.360 0.014 1.107 
sp|P14869|RLA0_MOUSE 60S acidic ribosomal protein P0 OS=Mus musculus GN=Rplp0 PE=1 SV=3 17 0.356 0.030 1.368 
sp|P38647|GRP75_MOUSE Stress-70 protein, mitochondrial OS=Mus musculus GN=Hspa9 PE=1 SV=3 81 0.350 0.017 1.138 
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sp|Q9R0Y5|KAD1_MOUSE Adenylate kinase isoenzyme 1 OS=Mus musculus GN=Ak1 PE=1 SV=1 21 0.347 0.009 1.472 
sp|O55126|NIPS2_MOUSE Protein NipSnap homolog 2 OS=Mus musculus GN=Gbas PE=2 SV=1 21 0.340 0.038 1.406 
sp|P14131|RS16_MOUSE 40S ribosomal protein S16 OS=Mus musculus GN=Rps16 PE=2 SV=4 10 0.331 0.034 2.109 
sp|Q5SYD0|MYO1D_MOUSE Unconventional myosin-Id OS=Mus musculus GN=Myo1d PE=1 SV=1 4 0.331 0.018 2.704 
sp|P15116|CADH2_MOUSE Cadherin-2 OS=Mus musculus GN=Cdh2 PE=1 SV=2 24 0.331 0.015 1.514 
sp|Q9WTQ5|AKA12_MOUSE A-kinase anchor protein 12 OS=Mus musculus GN=Akap12 PE=1 SV=1 25 0.331 0.013 1.419 
sp|P20152|VIME_MOUSE Vimentin OS=Mus musculus GN=Vim PE=1 SV=3 103 0.328 0.003 1.318 
sp|Q921F4|HNRLL_MOUSE Heterogeneous nuclear ribonucleoprotein L-like OS=Mus musculus GN=Hnrpll 
PE=1 SV=3 
5 0.322 0.053 2.729 
sp|O35943|FRDA_MOUSE Frataxin, mitochondrial OS=Mus musculus GN=Fxn PE=1 SV=1 6 0.322 0.034 1.837 
sp|Q8BKC5|IPO5_MOUSE Importin-5 OS=Mus musculus GN=Ipo5 PE=1 SV=3 21 0.322 0.001 1.486 
sp|P02772|FETA_MOUSE Alpha-fetoprotein OS=Mus musculus GN=Afp PE=2 SV=1 51 0.322 0.000 1.107 
sp|Q91VH6|MEMO1_MOUSE Protein MEMO1 OS=Mus musculus GN=Memo1 PE=1 SV=1 3 0.319 0.015 5.012 
sp|Q8R086|SUOX_MOUSE Sulfite oxidase, mitochondrial OS=Mus musculus GN=Suox PE=1 SV=2 4 0.313 0.046 2.704 
sp|P31786|ACBP_MOUSE Acyl-CoA-binding protein OS=Mus musculus GN=Dbi PE=1 SV=2 8 0.313 0.042 1.888 
sp|P12815|PDCD6_MOUSE Programmed cell death protein 6 OS=Mus musculus GN=Pdcd6 PE=1 SV=2 4 0.313 0.001 1.905 
sp|P14142|GTR4_MOUSE Solute carrier family 2, facilitated glucose transporter member 4 OS=Mus 
musculus GN=Slc2a4 PE=1 SV=3 
4 0.310 0.005 2.355 
sp|Q9Z1E4|GYS1_MOUSE Glycogen [starch] synthase, muscle OS=Mus musculus GN=Gys1 PE=1 SV=2 11 0.310 0.000 1.722 
sp|Q69ZR2|HECD1_MOUSE E3 ubiquitin-protein ligase HECTD1 OS=Mus musculus GN=Hectd1 PE=1 SV=2 7 0.305 0.029 2.443 
sp|Q91V61|SFXN3_MOUSE Sideroflexin-3 OS=Mus musculus GN=Sfxn3 PE=1 SV=1 5 0.305 0.017 4.656 
sp|P97807|FUMH_MOUSE Fumarate hydratase, mitochondrial OS=Mus musculus GN=Fh PE=1 SV=3 82 0.296 0.022 1.542 
sp|P35486|ODPA_MOUSE Pyruvate dehydrogenase E1 component subunit alpha, somatic form, 
mitochondrial OS=Mus musculus GN=Pdha1 PE=1 SV=1 
54 0.296 0.020 1.514 
sp|Q9Z2I9|SUCB1_MOUSE Succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial OS=Mus 
musculus GN=Sucla2 PE=1 SV=2 
41 0.294 0.054 1.432 
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sp|P56480|ATPB_MOUSE ATP synthase subunit beta, mitochondrial OS=Mus musculus GN=Atp5b PE=1 
SV=2 
296 0.291 0.013 1.086 
sp|P62245|RS15A_MOUSE 40S ribosomal protein S15a OS=Mus musculus GN=Rps15a PE=2 SV=2 8 0.288 0.044 1.706 
sp|Q3UZ39|LRRF1_MOUSE Leucine-rich repeat flightless-interacting protein 1 OS=Mus musculus 
GN=Lrrfip1 PE=1 SV=2 
6 0.283 0.017 4.487 
sp|Q8JZQ2|AFG32_MOUSE AFG3-like protein 2 OS=Mus musculus GN=Afg3l2 PE=1 SV=1 22 0.281 0.012 1.259 
sp|Q8BMF4|ODP2_MOUSE Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial OS=Mus musculus GN=Dlat PE=1 SV=2 
32 0.275 0.047 1.355 
sp|P70404|IDHG1_MOUSE Isocitrate dehydrogenase [NAD] subunit gamma 1, mitochondrial OS=Mus 
musculus GN=Idh3g PE=1 SV=1 
34 0.270 0.009 1.432 
sp|Q60864|STIP1_MOUSE Stress-induced-phosphoprotein 1 OS=Mus musculus GN=Stip1 PE=1 SV=1 30 0.265 0.034 1.355 
sp|Q3TMH2|SCRN3_MOUSE Secernin-3 OS=Mus musculus GN=Scrn3 PE=1 SV=1 2 0.265 0.023 2.729 
sp|Q9D2R6|COA3_MOUSE Cytochrome C oxidase assembly factor 3 homolog, mitochondrial OS=Mus 
musculus GN=Ccdc56 PE=2 SV=1 
3 0.254 0.009 2.466 
sp|Q07417|ACADS_MOUSE Short-chain specific acyl-CoA dehydrogenase, mitochondrial OS=Mus 
musculus GN=Acads PE=2 SV=2 
36 0.251 0.035 1.500 
sp|Q9QXS6|DREB_MOUSE Drebrin OS=Mus musculus GN=Dbn1 PE=1 SV=4 2 0.247 0.023 2.208 
sp|P47857|K6PF_MOUSE 6-phosphofructokinase, muscle type OS=Mus musculus GN=Pfkm PE=1 SV=3 41 0.247 0.013 1.169 
sp|P51174|ACADL_MOUSE Long-chain specific acyl-CoA dehydrogenase, mitochondrial OS=Mus musculus 
GN=Acadl PE=2 SV=2 
77 0.244 0.053 1.432 
sp|Q9R1P0|PSA4_MOUSE Proteasome subunit alpha type-4 OS=Mus musculus GN=Psma4 PE=1 SV=1 5 0.244 0.053 1.542 
sp|P62717|RL18A_MOUSE 60S ribosomal protein L18a OS=Mus musculus GN=Rpl18a PE=1 SV=1 8 0.242 0.035 1.486 
sp|P25444|RS2_MOUSE 40S ribosomal protein S2 OS=Mus musculus GN=Rps2 PE=1 SV=3 15 0.240 0.000 1.259 
sp|Q8BVA5|CB043_MOUSE UPF0554 protein C2orf43 homolog OS=Mus musculus PE=2 SV=1 3 0.238 0.042 2.805 
sp|Q9WTP7|KAD3_MOUSE GTP:AMP phosphotransferase, mitochondrial OS=Mus musculus GN=Ak3 PE=1 
SV=3 
15 0.238 0.023 1.820 
sp|P05201|AATC_MOUSE Aspartate aminotransferase, cytoplasmic OS=Mus musculus GN=Got1 PE=1 
SV=3 
58 0.238 0.021 1.236 
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sp|P99028|QCR6_MOUSE Cytochrome b-c1 complex subunit 6, mitochondrial OS=Mus musculus 
GN=Uqcrh PE=1 SV=2 
16 0.236 0.053 3.020 
sp|P56392|CX7A1_MOUSE Cytochrome c oxidase subunit 7A1, mitochondrial OS=Mus musculus 
GN=Cox7a1 PE=2 SV=1 
5 0.236 0.034 1.556 
sp|Q2TPA8|HSDL2_MOUSE Hydroxysteroid dehydrogenase-like protein 2 OS=Mus musculus GN=Hsdl2 
PE=2 SV=1 
32 0.233 0.043 1.282 
sp|Q8CI94|PYGB_MOUSE Glycogen phosphorylase, brain form OS=Mus musculus GN=Pygb PE=1 SV=3 54 0.233 0.007 1.330 
sp|P05202|AATM_MOUSE Aspartate aminotransferase, mitochondrial OS=Mus musculus GN=Got2 PE=1 
SV=1 
76 0.229 0.004 1.247 
sp|Q3UBX0|TM109_MOUSE Transmembrane protein 109 OS=Mus musculus GN=Tmem109 PE=1 SV=2 3 0.227 0.035 1.941 
sp|Q91VR2|ATPG_MOUSE ATP synthase subunit gamma, mitochondrial OS=Mus musculus GN=Atp5c1 
PE=1 SV=1 
39 0.223 0.010 2.168 
sp|P24369|PPIB_MOUSE Peptidyl-prolyl cis-trans isomerase B OS=Mus musculus GN=Ppib PE=2 SV=2 13 0.219 0.039 1.406 
sp|P08249|MDHM_MOUSE Malate dehydrogenase, mitochondrial OS=Mus musculus GN=Mdh2 PE=1 
SV=3 
129 0.219 0.008 1.629 
sp|Q8VEA4|MIA40_MOUSE Mitochondrial intermembrane space import and assembly protein 40 OS=Mus 
musculus GN=Chchd4 PE=1 SV=1 
3 0.217 0.048 5.248 
sp|P52480|KPYM_MOUSE Pyruvate kinase isozymes M1/M2 OS=Mus musculus GN=Pkm PE=1 SV=4 83 0.215 0.000 1.318 
sp|Q0II04|NEBL_MOUSE Nebulette OS=Mus musculus GN=Nebl PE=2 SV=1 25 0.209 0.003 1.236 
sp|P23116|EIF3A_MOUSE Eukaryotic translation initiation factor 3 subunit A OS=Mus musculus GN=Eif3a 
PE=1 SV=5 
23 0.207 0.007 1.570 
sp|Q8C5Q4|GRSF1_MOUSE G-rich sequence factor 1 OS=Mus musculus GN=Grsf1 PE=1 SV=2 4 0.205 0.024 4.529 
sp|Q9DCL9|PUR6_MOUSE Multifunctional protein ADE2 OS=Mus musculus GN=Paics PE=1 SV=4 17 0.205 0.009 2.992 
sp|Q9CZX8|RS19_MOUSE 40S ribosomal protein S19 OS=Mus musculus GN=Rps19 PE=1 SV=3 11 0.205 0.000 1.660 
sp|P41216|ACSL1_MOUSE Long-chain-fatty-acid--CoA ligase 1 OS=Mus musculus GN=Acsl1 PE=1 SV=2 48 0.203 0.012 1.306 
sp|O70435|PSA3_MOUSE Proteasome subunit alpha type-3 OS=Mus musculus GN=Psma3 PE=1 SV=3 9 0.198 0.003 1.368 
sp|Q91YT0|NDUV1_MOUSE NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial OS=Mus 
musculus GN=Ndufv1 PE=1 SV=1 
34 0.196 0.028 1.770 
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sp|Q78PY7|SND1_MOUSE Staphylococcal nuclease domain-containing protein 1 OS=Mus musculus 
GN=Snd1 PE=1 SV=1 
19 0.196 0.022 1.247 
sp|P62270|RS18_MOUSE 40S ribosomal protein S18 OS=Mus musculus GN=Rps18 PE=1 SV=3 12 0.196 0.002 2.109 
sp|Q8K0D5|EFGM_MOUSE Elongation factor G, mitochondrial OS=Mus musculus GN=Gfm1 PE=2 SV=1 17 0.194 0.012 1.419 
sp|O35857|TIM44_MOUSE Mitochondrial import inner membrane translocase subunit TIM44 OS=Mus 
musculus GN=Timm44 PE=2 SV=2 
12 0.192 0.042 1.294 
sp|Q8BTG7|NDRG4_MOUSE Protein NDRG4 OS=Mus musculus GN=Ndrg4 PE=1 SV=1 2 0.192 0.011 3.436 
sp|P62821|RAB1A_MOUSE Ras-related protein Rab-1A OS=Mus musculus GN=Rab1A PE=1 SV=3 25 0.192 0.001 2.188 
sp|Q8BMS1|ECHA_MOUSE Trifunctional enzyme subunit alpha, mitochondrial OS=Mus musculus 
GN=Hadha PE=1 SV=1 
202 0.187 0.018 1.706 
sp|P54071|IDHP_MOUSE Isocitrate dehydrogenase [NADP], mitochondrial OS=Mus musculus GN=Idh2 
PE=1 SV=3 
94 0.184 0.029 1.368 
sp|P54822|PUR8_MOUSE Adenylosuccinate lyase OS=Mus musculus GN=Adsl PE=2 SV=2 11 0.184 0.027 1.528 
sp|P16125|LDHB_MOUSE L-lactate dehydrogenase B chain OS=Mus musculus GN=Ldhb PE=1 SV=2 46 0.184 0.007 1.259 
sp|Q9CZR8|EFTS_MOUSE Elongation factor Ts, mitochondrial OS=Mus musculus GN=Tsfm PE=2 SV=1 10 0.182 0.012 2.089 
sp|P18572|BASI_MOUSE Basigin OS=Mus musculus GN=Bsg PE=1 SV=2 7 0.179 0.002 2.228 
sp|Q60597|ODO1_MOUSE 2-oxoglutarate dehydrogenase, mitochondrial OS=Mus musculus GN=Ogdh 
PE=1 SV=3 
103 0.179 0.000 1.259 
sp|P46638|RB11B_MOUSE Ras-related protein Rab-11B OS=Mus musculus GN=Rab11b PE=1 SV=3 18 0.177 0.008 1.556 
sp|P63028|TCTP_MOUSE Translationally-controlled tumor protein OS=Mus musculus GN=Tpt1 PE=1 
SV=1 
13 0.177 0.007 1.419 
sp|P30416|FKBP4_MOUSE Peptidyl-prolyl cis-trans isomerase FKBP4 OS=Mus musculus GN=Fkbp4 PE=1 
SV=5 
7 0.175 0.010 3.698 
sp|Q9DC69|NDUA9_MOUSE NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, 
mitochondrial OS=Mus musculus GN=Ndufa9 PE=1 SV=2 
43 0.175 0.000 1.600 
sp|Q9QYG0|NDRG2_MOUSE Protein NDRG2 OS=Mus musculus GN=Ndrg2 PE=1 SV=1 28 0.174 0.008 1.445 
sp|P04117|FABP4_MOUSE Fatty acid-binding protein, adipocyte OS=Mus musculus GN=Fabp4 PE=1 SV=3 25 0.174 0.006 2.630 
sp|Q9CQ62|DECR_MOUSE 2,4-dienoyl-CoA reductase, mitochondrial OS=Mus musculus GN=Decr1 PE=1 
SV=1 
34 0.169 0.021 2.489 
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sp|O08759|UBE3A_MOUSE Ubiquitin-protein ligase E3A OS=Mus musculus GN=Ube3a PE=2 SV=1 5 0.167 0.029 4.529 
sp|Q91VM9|IPYR2_MOUSE Inorganic pyrophosphatase 2, mitochondrial OS=Mus musculus GN=Ppa2 PE=2 
SV=1 
12 0.167 0.001 1.803 
sp|P11499|HS90B_MOUSE Heat shock protein HSP 90-beta OS=Mus musculus GN=Hsp90ab1 PE=1 SV=3 74 0.166 0.023 1.294 
sp|P97443|SMYD1_MOUSE SET and MYND domain-containing protein 1 OS=Mus musculus GN=Smyd1 
PE=1 SV=3 
22 0.166 0.005 3.192 
sp|Q9QYJ0|DNJA2_MOUSE DnaJ homolog subfamily A member 2 OS=Mus musculus GN=Dnaja2 PE=1 
SV=1 
13 0.164 0.005 1.472 
sp|Q91ZJ5|UGPA_MOUSE UTP--glucose-1-phosphate uridylyltransferase OS=Mus musculus GN=Ugp2 
PE=2 SV=3 
27 0.164 0.000 1.500 
sp|Q60676|PPP5_MOUSE Serine/threonine-protein phosphatase 5 OS=Mus musculus GN=Ppp5c PE=2 
SV=2 
5 0.163 0.043 2.559 
sp|P01867|IGG2B_MOUSE Ig gamma-2B chain C region OS=Mus musculus GN=Igh-3 PE=1 SV=3 7 0.163 0.027 1.888 
sp|P42125|ECI1_MOUSE Enoyl-CoA delta isomerase 1, mitochondrial OS=Mus musculus GN=Eci1 PE=2 
SV=2 
29 0.161 0.000 1.318 
sp|Q6GQT9|NOMO1_MOUSE Nodal modulator 1 OS=Mus musculus GN=Nomo1 PE=1 SV=1 6 0.160 0.030 4.446 
sp|Q91YP2|NEUL_MOUSE Neurolysin, mitochondrial OS=Mus musculus GN=Nln PE=2 SV=1 4 0.158 0.035 2.858 
sp|Q924X2|CPT1B_MOUSE Carnitine O-palmitoyltransferase 1, muscle isoform OS=Mus musculus 
GN=Cpt1b PE=2 SV=1 
49 0.158 0.002 1.432 
sp|P50544|ACADV_MOUSE Very long-chain specific acyl-CoA dehydrogenase, mitochondrial OS=Mus 
musculus GN=Acadvl PE=1 SV=3 
110 0.157 0.002 1.445 
sp|P70670|NACAM_MOUSE Nascent polypeptide-associated complex subunit alpha, muscle-specific form 
OS=Mus musculus GN=Naca PE=1 SV=2 
82 0.156 0.003 1.368 
sp|O55143|AT2A2_MOUSE Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 OS=Mus musculus 
GN=Atp2a2 PE=1 SV=2 
207 0.156 0.000 1.117 
sp|P34928|APOC1_MOUSE Apolipoprotein C-I OS=Mus musculus GN=Apoc1 PE=2 SV=1 5 0.150 0.041 1.995 
sp|Q8QZT1|THIL_MOUSE Acetyl-CoA acetyltransferase, mitochondrial OS=Mus musculus GN=Acat1 
PE=1 SV=1 
72 0.149 0.011 1.675 
sp|P62852|RS25_MOUSE 40S ribosomal protein S25 OS=Mus musculus GN=Rps25 PE=2 SV=1 8 0.146 0.015 1.803 
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sp|Q8BGK2|ARHL1_MOUSE [Protein ADP-ribosylarginine] hydrolase-like protein 1 OS=Mus musculus 
GN=Adprhl1 PE=2 SV=1 
12 0.146 0.000 2.355 
sp|Q01768|NDKB_MOUSE Nucleoside diphosphate kinase B OS=Mus musculus GN=Nme2 PE=1 SV=1 32 0.145 0.014 1.614 
sp|P31001|DESM_MOUSE Desmin OS=Mus musculus GN=Des PE=1 SV=3 101 0.142 0.000 1.138 
sp|O70325|GPX41_MOUSE Phospholipid hydroperoxide glutathione peroxidase, mitochondrial OS=Mus 
musculus GN=Gpx4 PE=1 SV=4 
5 0.141 0.008 4.406 
sp|Q8CGK3|LONM_MOUSE Lon protease homolog, mitochondrial OS=Mus musculus GN=Lonp1 PE=1 SV=2 38 0.139 0.037 1.247 
sp|P34914|HYES_MOUSE Bifunctional epoxide hydrolase 2 OS=Mus musculus GN=Ephx2 PE=1 SV=2 26 0.137 0.026 1.225 
sp|Q00623|APOA1_MOUSE Apolipoprotein A-I OS=Mus musculus GN=Apoa1 PE=1 SV=2 44 0.136 0.000 1.355 
sp|P58252|EF2_MOUSE Elongation factor 2 OS=Mus musculus GN=Eef2 PE=1 SV=2 79 0.132 0.000 1.318 
sp|P61759|PFD3_MOUSE Prefoldin subunit 3 OS=Mus musculus GN=Vbp1 PE=2 SV=2 6 0.131 0.042 2.070 
sp|Q80YD1|SUV3_MOUSE ATP-dependent RNA helicase SUPV3L1, mitochondrial OS=Mus musculus 
GN=Supv3l1 PE=2 SV=1 
2 0.129 0.026 4.742 
sp|P62301|RS13_MOUSE 40S ribosomal protein S13 OS=Mus musculus GN=Rps13 PE=1 SV=2 15 0.129 0.000 1.343 
sp|P60867|RS20_MOUSE 40S ribosomal protein S20 OS=Mus musculus GN=Rps20 PE=1 SV=1 5 0.126 0.042 3.020 
sp|Q9D173|TOM7_MOUSE Mitochondrial import receptor subunit TOM7 homolog OS=Mus musculus 
GN=Tomm7 PE=2 SV=1 
3 0.122 0.008 3.698 
sp|Q9D1G3|HHATL_MOUSE Protein-cysteine N-palmitoyltransferase HHAT-like protein OS=Mus musculus 
GN=Hhatl PE=1 SV=2 
5 0.120 0.054 4.055 
sp|P28650|PURA1_MOUSE Adenylosuccinate synthetase isozyme 1 OS=Mus musculus GN=Adssl1 PE=1 
SV=2 
18 0.120 0.029 1.600 
sp|P05064|ALDOA_MOUSE Fructose-bisphosphate aldolase A OS=Mus musculus GN=Aldoa PE=1 SV=2 111 0.112 0.000 1.306 
sp|P49717|MCM4_MOUSE DNA replication licensing factor MCM4 OS=Mus musculus GN=Mcm4 PE=2 
SV=1 
2 0.101 0.026 5.649 
sp|P11404|FABPH_MOUSE Fatty acid-binding protein, heart OS=Mus musculus GN=Fabp3 PE=1 SV=5 50 0.096 0.005 1.923 
sp|P14873|MAP1B_MOUSE Microtubule-associated protein 1B OS=Mus musculus GN=Map1b PE=1 SV=2 4 0.095 0.044 3.192 
sp|Q6ZWV3|RL10_MOUSE 60S ribosomal protein L10 OS=Mus musculus GN=Rpl10 PE=2 SV=3 16 0.095 0.000 1.355 
sp|P62702|RS4X_MOUSE 40S ribosomal protein S4, X isoform OS=Mus musculus GN=Rps4x PE=2 SV=2 15 0.084 0.000 2.377 
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sp|Q9WUB3|PYGM_MOUSE Glycogen phosphorylase, muscle form OS=Mus musculus GN=Pygm PE=1 SV=3 73 0.082 0.000 1.271 
sp|P62631|EF1A2_MOUSE Elongation factor 1-alpha 2 OS=Mus musculus GN=Eef1a2 PE=1 SV=1 38 0.082 0.026 1.660 
sp|P01869|IGH1M_MOUSE Ig gamma-1 chain C region, membrane-bound form OS=Mus musculus 
GN=Ighg1 PE=1 SV=2 
8 0.082 0.001 1.472 
sp|P07310|KCRM_MOUSE Creatine kinase M-type OS=Mus musculus GN=Ckm PE=1 SV=1 112 0.077 0.002 1.247 
sp|Q99KV1|DJB11_MOUSE DnaJ homolog subfamily B member 11 OS=Mus musculus GN=Dnajb11 PE=1 
SV=1 
3 0.077 0.048 1.690 
sp|P21550|ENOB_MOUSE Beta-enolase OS=Mus musculus GN=Eno3 PE=1 SV=3 91 0.076 0.000 1.803 
sp|Q921U8|SMTN_MOUSE Smoothelin OS=Mus musculus GN=Smtn PE=2 SV=2 3 0.074 0.020 4.571 
sp|P04247|MYG_MOUSE Myoglobin OS=Mus musculus GN=Mb PE=1 SV=3 94 0.074 0.004 1.629 
sp|P45591|COF2_MOUSE Cofilin-2 OS=Mus musculus GN=Cfl2 PE=1 SV=1 14 0.073 0.022 1.690 
sp|Q8R5A0|SMYD2_MOUSE N-lysine methyltransferase SMYD2 OS=Mus musculus GN=Smyd2 PE=1 SV=1 2 0.065 0.022 2.333 
sp|P70335|ROCK1_MOUSE Rho-associated protein kinase 1 OS=Mus musculus GN=Rock1 PE=1 SV=1 5 0.065 0.006 2.938 
sp|Q99MS7|EH1L1_MOUSE EH domain-binding protein 1-like protein 1 OS=Mus musculus GN=Ehbp1l1 
PE=2 SV=1 
12 0.061 0.015 2.729 
sp|O09110|MP2K3_MOUSE Dual specificity mitogen-activated protein kinase kinase 3 OS=Mus musculus 
GN=Map2k3 PE=1 SV=2 
3 0.060 0.010 8.630 
sp|Q62446|FKBP3_MOUSE Peptidyl-prolyl cis-trans isomerase FKBP3 OS=Mus musculus GN=Fkbp3 PE=1 
SV=2 
8 0.059 0.047 2.754 
sp|Q9CU62|SMC1A_MOUSE Structural maintenance of chromosomes protein 1A OS=Mus musculus 
GN=Smc1a PE=1 SV=4 
6 0.057 0.021 8.166 
sp|Q8BJS4|SUN2_MOUSE SUN domain-containing protein 2 OS=Mus musculus GN=Sun2 PE=1 SV=3 5 0.054 0.027 4.831 
sp|P82348|SGCG_MOUSE Gamma-sarcoglycan OS=Mus musculus GN=Sgcg PE=1 SV=2 3 0.046 0.004 13.305 
sp|Q80VP1|EPN1_MOUSE Epsin-1 OS=Mus musculus GN=Epn1 PE=1 SV=3 5 0.045 0.037 2.754 
sp|Q9QZ08|NAGK_MOUSE N-acetyl-D-glucosamine kinase OS=Mus musculus GN=Nagk PE=2 SV=3 4 0.044 0.051 32.810 
sp|P62073|TIM10_MOUSE Mitochondrial import inner membrane translocase subunit Tim10 OS=Mus 
musculus GN=Timm10 PE=1 SV=1 
2 0.033 0.007 2.858 
sp|Q9Z2N8|ACL6A_MOUSE Actin-like protein 6A OS=Mus musculus GN=Actl6a PE=1 SV=2 5 0.028 0.007 4.365 
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sp|Q8BU85|MSRB3_MOUSE Methionine-R-sulfoxide reductase B3, mitochondrial OS=Mus musculus 
GN=Msrb3 PE=1 SV=2 
2 0.024 0.004 2.148 
sp|Q63810|CANB1_MOUSE Calcineurin subunit B type 1 OS=Mus musculus GN=Ppp3r1 PE=1 SV=3 5 0.021 0.004 2.884 
To be included here, proteins had to meet the following criteria: a protein threshold (Unused ProtScore (conf)) > 0.05, detected with 2 or more peptides and a statistically significant (i.e. 
p<0.05) fold change of >1.25 or <0.75. For each protein identified, the corresponding Swiss-Prot Accession number is shown, together with the protein name as it is given in the Swiss-Prot 
database, iTRAQ ratio (fold change), p value and the number of peptides used for the identification. iTRAQ ratios were bias and background corrected. p-values were generated by the 
ProteinPilot software. 
 
Appendix 3. Gene ontology (GO) analysis of the proteins differentially expressed in the heart from SMA mice 
ENRICHED TERMS COUNT P-VALUE PROTEINS 
UPREGULATED PROTEINS 
Biological process 
Protein transport 14 3.10E-03 Rab5a, Ap1s1, Btf3, Xpo5, Xpo7, Kpna3, Lman2, Mia3, Nup188, Ppt1, Rabep2, Stxbp3, 
Tomm22, Vps4b 
Cell-cell adhesion 12 1.30E-06 Dhx29, Gapvd1, Cnn3, Capg, Cgn, Clint1, Eno1, Hist2h3c1, Ppme1, Scrib, Slc3a2, Tagln2 
Nucleosome assembly 6 2.60E-03 Atrx, Hist1h1a, Hist1h1b, Hist1h1c, Hist1h4h, Hist2h3c1 
Epithelial cell differentiation 5 3.30E-03 Cnn3, Ctsb, Tgfb1i1, Tagln2, Tagln 
Extracellular matrix organization 5 2.10E-02 Dnajb6, Fn1, Fbln5, Lama2, Lamb2 
Regulation of cell shape 5 3.90E-02 Dlg1, Fn1, Palm2, Palm, Spta1 
Actin cytoskeleton organization 5 4.10E-02 Dnajb6, Pdlim7, Rock2, Rhog, Spta1 
Fibrinolysis* 4 3.10E-04 Anxa2, Fgb, Fgg, Hrg 
Negative regulation of extrinsic apoptotic 
signaling pathway via death domain receptors* 
4 1.50E-03 Fgb, Fgg, Hmgb2, Nol3 
Platelet aggregation* 4 5.00E-03 Gnas, Fgb, Fgg, Stxbp3 
Hemostasis* 4 8.50E-03 Fgb, Fgg, Hrg, Kng1 
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Response to hydrogen peroxide* 4 1.60E-02 Bak1, Hp, Slc4a1, Sod2 
Positive regulation of smooth muscle cell 
proliferation 
4 3.70E-02 Rab5a, Akr1b3, Alox12, Mtor 
Blood coagulation* 4 4.20E-02 Fgb, Fgg, Hrg, Kng1 
Chromosome segregation 4 4.80E-02 Arl8a, Arl8b, Bub3, Ppp1r7 
Establishment or maintenance of epithelial cell 
apical/basal polarity 
3 8.00E-03 Dlg1, Mtcl1, Scrib 
Plasma membrane organization* 3 9.10E-03 Ank3, Spta1, Sptb 
Actin filament capping* 3 1.20E-02 Capg, Spta1, Sptb 
Nuclear envelope organization 3 1.60E-02 Lemd2, Lmna, Zmpste24 
Tumor necrosis factor-mediated signaling 
pathway* 
3 2.20E-02 Krt18, Krt8, Plvap 
Protein targeting to plasma membrane 3 2.30E-02 Ank3, Anxa2, Palm 
Bicellular tight junction assembly 3 2.50E-02 Cgn, Dlg1, Mtdh 
Positive regulation of exocytosis* 3 2.70E-02 Rab5a, Fgg, Fgb 
Response to nutrient levels 3 4.00E-02 Mbd3, Sirt5, Sod2 
Response to ischemia 3 4.30E-02 Camk2a, Hk1, Nol3 
Neuromuscular junction development 3 4.70E-02 Ank3, Lamb2, Snta1 
Platelet activation* 3 4.90E-02 Fgb, Fgg, Hrg 
Negative regulation of muscle atrophy 2 1.80E-02 Mtor, Nlo3 
Positive regulation of membrane tubulation 2 2.70E-02 Asap1, Sh3glb1 
Age-dependent response to oxidative stress 2 2.70E-02 Coq7, Sod2 
Membrane raft organization 2 4.50E-02 Dlg1, Ppt1 
Cellular component 
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Nucleus 71 4.30E-03 Bdp1, Bub3, Dhx29, Dnajb6, Emc2, Gnas, Lemd2, Nop58, Pdlim7, Rock2, Atrx, Anxa2, Arih2, 
Btf3, Camk2a, Capg, Cdc5l, Chd4, Cmas, Coq7, Dlg1, Dr1, Eno1, Xpo5, Xpo7, Fhl1, Hnrnph2, 
Hmga1, Hmgb2, Hist1h1a, Hist1h1b, Hist1h1c, Hist1h4h, Hist2h3c1, Kpna3, Krt18, Krt2, Krt7, 
Krt8, Lmna, Lap3, Mtor, Mtdh, Mbd3, Mcm6, Mbp, Nppa, Nup188, Ppt1, Palm, Plcd1, Pfdn6, 
Ppp1r7, Pcbd1, Rprd1b, Rpa2, Rpl27, Rpl4, Sirt5, Snrpd1, Snrpa1, Slc3a2, Svil, Synpo2, Sin3b, 
Tgfb1i1, Tkt, Tsnax, Uaca, Vps4b, Zmpste24 
Exosome 69 3.30E-17 Arl8a, Arl8b, Art3, Clec3b, Gnas, Hddc2, Rab5a, Rap1b, Rheb, Sh3glb1, Arpc3, Ap1s1, Anpep, 
Akr1b3, Akr7a5, Anxa2, Alox12, Cpped1, Capg, Ctsb, Ctsd, Col6a1, Dpep1, Dpp4, Dlg1, Eno1, 
Fbn1, Fgb, Fgg, Fn1, Fbln5, Gusb, Gpx3, Hp, Hrg, Hist1h4h, Hist2h3c1, Krt18, Krt2, Krt7, Krt8, 
Kng1, Lama2, Lamb2, Lman2, Lap3, Lcp1, Lamp2, Ppt1, Plcd1, Psat1, Plvap, Ppp1r7, Pcbd1, 
Rhog, Rpl27, Rpl4, Scrib, Serpina3k, Slc3a2, Slc4a1, Sod2, Stxbp3, Trmt112, Tagln2, Tkt, Uaca, 
Vps4b, Zmpste24 
Mitochondrion 35 6.70E-06 Abcb7, Bak1, Clpb, Dhx29, Emc2, Hddc2, Nlrx1, CH082, Sh3glb1, Aldh4a1, Akr7a5, As3mt, 
Bola1, Camk2a, Ctsb, Ctsd, Cyb5b, Coq7, Dcakd, Echdc3, Hk1, Lap3, Mtor, Mmaa, Mtfr1l, Nol3, 
Plin5, Pdpr, Pdp1, Sirt5, Sod2, Trnt1, Tomm22, Uaca, Vwa8 
Extracellular space* 26 1.70E-03 Clec3b, Anpep, Akr1b3, Anxa2, Ctsb, Ctsd, Dpep1, Eno1, Fbn1, Fgb, Fgg, Fn1, Fbln5, Gusb, 
Gpx3, Hp, Hmgb2, Krt2, Kng1, Lman2, Lcp1, Lamp2, Mtcl1, Nppa, Ppt1, Serpina3k 
Cytoskeleton 21 2.00E-03 Arl8b, Pdlim7, Rock2, Arpc3, Ablim1, Ank3, Chd4, Dynlrb1, Dync1li2, Lcp1, Mtcl1, Myo3a, 
Mybpc2, Sgcb, Spta1, Sptb, Svil, Snta1, Tgfb1i1, Ttll11, Uaca 
Cell-cell adherens junction 17 2.30E-08 Asap1, Dhx29, Gapvd1, Sh3glb1, Anxa2, Cnn3, Capg, Cgn, Clint1, Dlg1, Eno1, Hist2h3c1, Krt18, 
Ppme1, Scrib, Slc3a2, Tagln2 
Perinuclear region of cytoplasm 16 1.30E-03 Dnajb6, Gnas, Rab5a, Akr1b3, Anxa2, Ctsb, Cdc5l, Clint1, Dlg1, Hmgb2, Lmna, Mtdh, Nppa, 
Plvap, Tsnax, Uaca 
Focal adhesion 14 4.70E-05 Pdlim7, Arpc3, Cnn3, Dpp4, Fhl1, Hmga1, Lap3, Lcp1, Rhog, Rpl27, Rpl4, Svil, Synpo2, Tgfb1i1 
Protein complex 13 1.00E-02 Rab5a, Sh3glb1, Anxa2, Chd4, Col6a1, Hk1, Hmgb2, Hist1h4h, Hist2h3c1, Mbd3, Sptb, Snta1, 
Trmt112 
Cell junction 13 2.60E-02 Rap1b, Ank3, Anxa2, Camk2a, Cgn, Dpp4, Dlg1, Lcp1, Mtdh, Scrib, Svil, Snta1, Tgfb1i1 
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Sarcolemma 11 9.70E-08 Gnas, Ank3, Anxa2, Alox12, Ctsb, Col6a1, Krt8, Lama2, Popdc2, Sgcb, Snta1 
Membrane raft 10 5.60E-04 Gnas, Rab5a, Anxa2, Ctsd, Dpp4, Dlg1, Hk1, Lamp2, Ppt1, Plcd1 
Extracellular matrix 10 1.30E-03 Ctsd, Col6a1, Fbn1, Fn1, Fbln5, Hist1h4h, Lmna, Lamb2, Rpl27, Tgfb1i1 
Blood microparticle* 9 2.50E-05 Fgb, Fgg, Fn1, Hp, Hbb-bh1, Hrg, Kng1, Serpina3k, Slc4a1 
Apical plasma membrane 9 9.00E-03 Ctsb, Dpep1, Dpp4, Fn1, Mtdh, Mtcl1, Scrib, Slc3a2, Stxbp3 
Lysosome 9 9.40E-03 Arl8a, Arl8b, Ank3, Ctsb, Ctsd, Gusb, Lamp2, Mtor, Ppt1 
Proteinaceous extracellular matrix 8 2.30E-02 Clec3b, Anxa2, Col6a1, Fbn1, Fn1, Fbln5, Lama2, Lamb2 
Chromosome 8 3.40E-02 Bub3, Atrx, Hmgb2, Hist1h1a, Hist1h1b, Hist1h1c, Mbd3, Ppp1r7 
Actin cytoskeleton 7 9.10E-03 Pdlim7, Rab5a, Ablim1, Cnn3, Lcp1, Svil, Synpo2 
Basolateral plasma membrane 7 9.50E-03 Ank3, Anxa2, Dlg1, Palm, Scrib, Slc4a1, Stxbp3 
Melanosome 6 2.00E-03 Rab5a, Anxa2, Capg, Ctsb, Ctsd, Slc3a2 
Midbody 6 6.00E-03 Arl8a, Arl8b, Sh3glb1, Anxa2, Mtcl1, Svil 
Late endosome membrane 5 7.80E-03 Arl8a, Arl8b, Anxa2, Lamp2, Vps4b 
Ruffle 5 1.00E-02 Gnas, Pdlim7, Rab5a, Anxa2, Lcp1 
Basement membrane 5 1.10E-02 Anxa2, Fbn1, Fn1, Lama2, Lamb2 
Nucleosome 5 1.60E-02 Hist1h1a, Hist1h1b, Hist1h1c, Hist1h4h, Hist2h3c1 
Intermediate filament* 5 2.00E-02 Krt18, Krt2, Krt7, Krt8, Lmna 
Z disc 5 2.40E-02 Dnajb6, Ank3, Krt8, Slc4a1, Synpo2 
Nuclear chromosome, telomeric region 5 2.60E-02 Atrx, Hist1h4h, Hist2h3c1, Mcm6, Rpa2 
Stress fiber 4 2.20E-02 Pdlim7, Ablim1, Anxa2, Lcp1 
Fibrinogen complex* 3 1.60E-03 Fgb, Fgg, Fn1 
Platelet alpha granule* 3 7.60E-03 Fgb, Fgg, Stxbp3 
Apicolateral plasma membrane 3 1.50E-02 Krt8, Mtcl1, Palm 
Podosome 3 3.20E-02 Asap1, Lcp1, Svil 
Spectrin* 2 4.30E-02 Spta1, Sptb 
DOWNREGULATED PROTEINS       
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Biological process       
Transport 36 8.40E-04 Atp5b, Atp5c1, Abcb10, Atp2a2, Ndufa9, Ndufv1, Rab11b, Rab1a, Sec13, Afp, Apoa1, Apoc1, 
Cpt1b, Chchd4, Dbi, Fabp3, Fabp4, Fxn, Got2, Ipo5, Mb, Naca, Osbp, Sar1b, Sfxn3, Slc2a4, 
Slc25a12, Slc25a46, Snx1, Trf, Timm10, Timm44, Tomm7, Tmem109, Uqcrc2, Uqcrh 
Oxidation-reduction process 25 4.90E-07 Decr1, Ndufa9, Ndufv1, Acadl, Acads, Acadvl, Chchd4, Dhrs1, Fxn, Gpx4, Hadha, Hsdl2, Idh2, 
Idh3g, Ldhb, Mdh1, Mdh2, Msrb3, Nnt, Ogdh, Prdx4, Pdha1, Suox, Uqcrc2, Uqcrh 
Translation 21 2.20E-08 Gfm1, Tsfm, Eef1a2, Eef1g, Eef2, Eif1ax, Eif3a, Mrpl23, Mrpl27, Rpl10, Rpl18a, Rps13, Rps15, 
Rps15a, Rps16, Rps18, Rps19, Rps2, Rps20, Rps4x, Slc25a12 
Metabolic process 21 2.30E-07 Ugp2, Acat1, Aco2, Acsl1, Acadl, Acads, Acadvl, Pygb, Dlat, Echdc1, Eci1, Ephx2, Gys1, Hadha, 
Pygm, Ogdh, Pfkm, Paics, Pdha1, Pkm, Sucla2 
Protein folding 15 1.50E-10 Dnaja2, Dnajb11, Fkbp3, Fkbp4, Calr, Cct2, Hspa8, Hspa9, Hsp90ab1, Hsp90b1, Ppib, P4hb, 
Pdia3, Tubb5, Vbp1 
Lipid metabolic process 11 3.20E-02 Decr1, Atp5b, Acsl1, Acadl, Acads, Acadvl, Apoa1, Cpt1b, Eci1, Ephx2, Hadha 
Tricarboxylic acid cycle 10 1.70E-11 Aco2, Dlat, Fh1, Idh2, Idh3g, Mdh1, Mdh2, Ogdh, Pdha1, Sucla2 
Fatty acid metabolic process 9 3.50E-04 Decr1, Acsl1, Acadl, Acads, Acadvl, Cpt1b, Eci1, Fabp4, Hadha 
Cell-cell adhesion 9 1.20E-03 Aldoa, Bsg, Eef1g, Lrrfip1, Paics, Plec, Rps2, Serbp1, Snd1 
Carbohydrate metabolic process 9 2.10E-03 Pygb, Dlat, Ldhb, Mdh1, Mdh2, Pygm, Pgm2, Pgk1, Pdha1 
Glycolytic process 6 4.50E-05 Aldoa, Eno3, Ogdh, Pfkm, Pgk1, Pkm 
Protein homotetramerization 6 1.40E-03 Decr1, Actn2, Acadl, Acads, Aldoa, Pfkm 
2-oxoglutarate metabolic process 5 3.90E-05 Got2, Got1, Idh2, Idh3g, Ogdh 
ATP metabolic process 5 9.70E-04 Atp5b, Atp5c1, Ak1, Ak3, Hspa8 
Proteolysis involved in cellular protein catabolic 
process 
5 3.60E-03 Hspa5, Lonp1, Psma3, Psma4, Scpep1 
Response to nutrient 5 8.70E-03 Acsl1, Adsl, Apoa1, Plec, Suox 
Response to endoplasmic reticulum stress 5 1.00E-02 Atp2a2, Eef2, Hspa5, P4hb, Pdia3 
NADH metabolic process 4 2.70E-04 Idh3g, Mdh1, Mdh2, Ogdh 
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Oxaloacetate metabolic process 4 4.40E-04 Got2, Got1, Mdh1, Mdh2 
Ribosomal small subunit assembly 4 1.50E-03 Rps15, Rps19, Rps2, Rps25 
Cellular response to interleukin-4 4 3.20E-03 Hspa5, Hsp90ab1, Rps2, Rplp0 
Glycogen metabolic process 4 9.10E-03 Ugp2, Pygb, Gys1, Pygm 
Aerobic respiration 4 9.10E-03 Ndufv1, Adsl, Fxn, Uqcrc2 
Microtubule-based process 4 1.00E-02 Kif5b, Map1b, Tubb5, Vbp1 
Positive regulation of phagocytosis 4 1.60E-02 Calr, Hspa8, Ighg1, Ighg2b 
Receptor-mediated endocytosis 4 2.90E-02 Atp5b, Apoa1, Calr, Hsp90b1 
Cellular response to oxidative stress 4 3.30E-02 Atp2a2, Nme2, Chchd4, Lonp1 
Cholesterol homeostasis 4 3.30E-02 Apoa1, Ephx2, Fabp3, Fabp4 
Glucose metabolic process 4 4.00E-02 Dlat, Pgm2, Pdha1, Pkm 
AMP biosynthetic process 3 1.20E-03 Adsl, Adssl1, Prps1 
Aspartate metabolic process 3 1.80E-03 Adssl1, Got2, Got1 
Isocitrate metabolic process 3 1.80E-03 Aco2, Idh2, Idh3g 
Malate metabolic process 3 3.30E-03 Fh1, Mdh1, Mdh2 
Purine nucleotide metabolic process 3 3.30E-03 Nme2, Adsl, Adssl1 
Muscle cell cellular homeostasis 3 1.70E-02 Aldoa, Cfl2, Pfkm 
Ribosomal small subunit biogenesis 3 1.80E-02 Rps15, Rps16, Rps19 
Skeletal muscle tissue regeneration 3 2.00E-02 Eno3, Naca, Pkm 
Antigen processing and presentation of 
exogenous peptide antigen via MHC class I, tap-
dependent 
3 4.30E-02 Calr, Psma3, Psma4 
Sarcomere organization 3 4.60E-02 Actn2, Cfl2, Prkar1a 
Protein import into mitochondrial 
intermembrane space 
2 3.30E-02 Afg3l2, Afg3l2 
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Regulation of postsynaptic density protein 95 
clustering 
2 4.40E-02 Cdh2, Dbn1 
ADP biosynthetic process 2 4.40E-02 Ak1, Ak3 
Cellular component       
Exosome 93 2.10E-28 Decr1, Atp5b, Atp5c1, Dnaja2, Fkbp4, Nagk, Ndrg2, Nme2, Rab11b, Rab1a, Sec13, Ugp2, 
Acat1, Actn2, Ak1, Aldoa, Anxa6, Apoa1, Apoc1, Bsg, Pygb, Cdh2, Calr, Cct2, Cfl2, Cand1, Des, 
Dbi, Eea1, Eno3, Echdc1, Eci1, Ephx2, Eef1g, Eef2, Fabp3, Fabp4, Fh1, Got2, Got1, Gpx4, Gyg, 
Hspa5, Hspa8, Hspa9, Hsp90ab1, Hsp90b1, Idh2, Ldhb, Mdh1, Mdh2, Pygm, Mb, Myo1d, 
Myh9, Naca, Nudt3, Ppib, Prdx4, Pfkm, Pgm2, Pgk1, Paics, Plec, Pdcd6, P4hb, Psma3, Psma4, 
Pdia3, Ppa2, Pkm, Rps13, Rps15a, Rps16, Rps18, Rps19, Rps2, Rps20, Rps25, Rps4x, Rplp0, 
Scpep1, Serbp1, Slc2a4, Snd1, Sucla2, Trf, Tmem109, Tubb5, Tpt1, Ywhae, Uqcrc2, Vim 
Nucleus 84 1.20E-03 Decr1, Atp5b, Dnaja2, Dnajb11, Fkbp3, Fkbp4, Faf1, Hectd1, Ndrg2, Ndufa9, Nme2, Nsun2, 
Sec13, Smyd1, Smyd2, Sun2, Tsfm, Ugp2, Aco2, Actl6a, Acads, Acadvl, Aldoa, Anxa6, Apoa1, 
Calr, Cfl2, Cirbp, Cand1, Dbi, Epn1, Eef1a2, Eef1g, Eef2, Eif3a, Fabp4, Got1, Gpx4, Hspa5, 
Hspa8, Hspa9, Hsp90b1, Hnrnph1, Hnrnpll, Ipo5, Lrrfip1, Lonp1, Mdh2, Memo1, Mcm4, Myh9, 
Naca, Nudt21, Nudt3, Osbp, Ppib, Prdx4, Pdcd6, Psmc1, Psma3, Psma4, Pdia3, Ppp5c, Purb, 
Pdha1, Pkm, Rps13, Rps18, Rps2, Rps25, Rps4x, Rplp0, Serbp1, Smpx, Sf1, Snd1, Stip1, Smc1a, 
Supv3l1, Tmem109, Tubb5, Tpt1, Ube3a, Vbp1 
Mitochondrion 76 8.90E-29 Decr1, Afg3l2, Atp5b, Atp5c1, Abcb10, Fkbp4, Gfm1, Grsf1, Kank2, Ndrg4, Ndufa9, Ndufv1, 
Nme2, Rab11b, Tsfm, Acat1, Aco2, Acsl1, Acadl, Acads, Acadvl, Ak3, Adsl, Aldoa, Anxa6, Bsg, 
Cpt1b, Chchd4, Coa3, Cox7a1, Dhrs1, Dbi, Dlat, Eci1, Fxn, Fh1, Gbas, Got2, Gpx4, Hspa5, 
Hspa9, Hsp90ab1, Hadha, Hsdl2, Idh2, Idh3g, Ldhb, Lonp1, Mdh1, Mdh2, Msrb3, Mccc1, 
Mrpl23, Mrpl27, Nln, Nnt, Ogdh, Prdx4, Pdia3, Ppa2, Pdha1, Pkm, Rps15a, Sfxn3, Slc25a12, 
Slc25a46, Snd1, Sucla2, Suox, Supv3l1, Timm10, Timm44, Tomm7, Ywhae, Uqcrc2, Uqcrh 
Focal adhesion 26 3.60E-13 Akap12, Actn2, Anxa6, Bsg, Cdh2, Calr, Hspa5, Hspa8, Hspa9, Hsp90b1, Myh9, Ppib, Plec, 
P4hb, Pdia3, Rps13, Rps15, Rps16, Rps18, Rps19, Rps2, Rps4x, Rplp0, Tln2, Ywhae, Vim 
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Endoplasmic reticulum 26 2.50E-03 Atp2a2, Dnajb11, Rab1a, Sec13, Acsl1, Apoc1, Atl3, Calr, Dhrs1, Dbi, Eef1g, Hspa5, Hsp90b1, 
Hhatl, Ldah, Msrb3, Osbp, Ppib, Prdx4, Pdcd6, P4hb, Pdia3, Rpl10, Sar1b, Ssr3, Tmem109 
Mitochondrial inner membrane 25 2.10E-12 Afg3l2, Atp5b, Atp5c1, Abcb10, Ndufa9, Ndufv1, Acat1, Acadvl, Csde1, Coa3, Cox7a1, Dhrs1, 
Eci1, Got2, Gpx4, Hadha, Idh2, Mdh2, Mccc1, Nnt, Slc25a12, Timm10, Timm44, Uqcrc2, Uqcrh 
Myelin sheath 23 5.60E-17 Atp5b, Atp5c1, Nme2, Aco2, Aldoa, Cct2, Dlat, Eef1a2, Got2, Hspa5, Hspa8, Hspa9, Ldhb, 
Mdh1, Mdh2, Myo1d, Pdia3, Pdha1, Pkm, Slc25a12, Stip1, Sucla2, Uqcrc2 
Extracellular matrix 22 3.80E-12 Atp5b, Calr, Cct2, Eef2, Hspa5, Hspa8, Hspa9, Hsp90b1, Hadha, Myh9, Plec, P4hb, Pkm, Rps13, 
Rps15a, Rps16, Rps18, Rps19, Rps20, Rps25, Tubb5, Vim 
Cell-cell adherens junction 22 1.50E-11 Rab11b, Rab1a, Aldoa, Bsg, Cdh2, Dbn1, Eef1g, Eef2, Hspa5, Hspa8, Hsp90ab1, Kif5b, Lrrfip1, 
Myh9, Paics, Plec, Pkm, Rps2, Serbp1, Snx1, Snd1, Ywhae 
Perinuclear region of cytoplasm 21 3.40E-05 Atp2a2, Fkbp4, Faf1, Ndrg2, Nme2, Ak1, Anxa6, Calr, Dbn1, Hspa8, Hsp90b1, Hhatl, Kif5b, 
Map1b, Osbp, Ppib, Plec, Serbp1, Slc2a4, Trf, Vim 
Intracellular ribonucleoprotein complex 17 2.30E-07 Eef2, Hspa8, Hnrnph1, Hnrnpll, Mrpl23, Mrpl27, Rpl18a, Rps13, Rps15, Rps16, Rps18, Rps19, 
Rps2, Rps20, Rps25, Rps4x, Rplp0 
Ribosome 15 9.90E-09 Mrpl23, Mrpl27, Rpl10, Rpl18a, Rps13, Rps15, Rps15a, Rps16, Rps18, Rps19, Rps2, Rps20, 
Rps25, Rps4x, Rplp0 
Mitochondrial matrix 15 9.90E-09 Ndufa9, Tsfm, Acat1, Acadl, Acads, Ak3, Eci1, Got2, Lonp1, Mdh2, Mccc1, Ogdh, Pdha1, 
Supv3l1, Timm44 
Melanosome 12 7.70E-09 Rab1a, Anxa6, Bsg, Hspa5, Hspa8, Hsp90ab1, Hsp90b1, Ppib, P4hb, Pdia3, Snd1, Ywhae 
Mitochondrial nucleoid 7 7.50E-06 Atp5b, Grsf1, Acadvl, Hspa9, Hadha, Lonp1, Supv3l1 
Mitochondrial membrane 7 6.30E-04 Atp5b, Ndufa9, Nme2, Acadl, Acads, Ogdh, Sfxn3 
Sarcolemma 7 1.40E-03 Anxa6, Bsg, Des, Plec, Ppp3r1, Sgcg, Slc2a4 
Z disc 6 9.30E-03 Actn2, Aldoa, Cfl2, Des, Pygm, Nebl 
Polysome 5 9.90E-04 Calr, Eef2, Rps25, Rps4x, Vbp1 
Mitochondrial intermembrane space 5 7.60E-03 Ak3, Chchd4, Nln, Pdia3, Suox 
Peroxisome 5 4.70E-02 Acsl1, Ephx2, Hsdl2, Idh2, Vim 
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Blood microparticle 5 4.90E-02 Apoa1, Hspa8, Ighg1, Ighg2b, Trf 
Contractile fiber 4 9.30E-04 Des, Dbi, Plec, Smpx 
Sarcoplasmic reticulum 4 2.20E-02 Atp2a2, Calr, Pygm, Tmem109 
Respiratory chain 4 2.20E-02 Ndufa9, Ndufv1, Uqcrc2, Uqcrh 
Proteasome complex 4 3.10E-02 Psmc1, Psma3, Psma4, Ube3a 
Plasma membrane raft 3 6.50E-03 Cdh2, Myo1d, Prkar1a 
Fascia adherens 3 7.70E-03 Cdh2, Des, Tln2 
Axonal growth cone 3 3.40E-02 Fkbp4, Dbn1, Kif5b 
Cytoplasmic ribonucleoprotein granule 3 3.40E-02 Rps4x, Rplp0, Tubb5 
Cop9 signalosome 3 4.50E-02 Hspa5, Hsp90ab1, Myh9 
Tubulin complex 2 4.10E-02 Tubb5, Tpt1 
Axonal spine 2 4.10E-02 Dbn1, Eea1 
Enriched terms connected to biological process and cellular component are presented for upregulated and downregulated proteins, together with the p-value and the number of annotated 
proteins. Proteins are presented as gene symbols. *In the category of upregulated proteins, enriched terms that contained mostly blood-derived proteins and keratins were excluded from 
the analysis. These proteins were: haptoglobin (Hp), fibrinogen beta chain (Fgb), fibrinogen gamma chain (Fgg), kininogen 1 (Kng1), histidine-rich glycoprotein (Hrg), spectrin alpha, 
erythrocytic 1 (Spta1), spectrin beta, erythrocytic (Sptb), hemoglobin Z, beta-like embryonic chain (Hbb-bh1), keratin 2 (Krt2), keratin 7 (Krt7), keratin 8 (Krt8), keratin 18 (Krt18), serine (or 
cysteine) peptidase inhibitor, clade A, member 3K (Serpina3k), natriuretic peptide type A (Nppa), solute carrier family 4 (anion exchanger), member 1 (Slc4a1), cytoglobin (Cygb), glutathione 
peroxidase 3 (Gpx3), C-type lectin domain family 3, member b (Clec3b), dipeptidase 1 (renal) (Dpep1), lymphocyte cytosolic protein 1 (Lcp1). 
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Appendix 4. Electrophoretic mobility of lamin A/C in the heart from late-symptomatic SMA mice (P8). Western 
blot showing lamin A and lamin C levels in the heart tissue extracts from SMA mice (n=5) and age-matched 
healthy controls (n=5). Coomassie stained gel was used as internal, total protein loading control. Odd numbers 
indicate control samples, and even numbers SMA samples.  
 
